"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Operator","Good day, ladies and gentlemen and welcome to the Fourth Quarter and Full Year 2009 Life Technologies Corporation Earnings Conference Call. (Operator Instructions).I will now turn the conference over to your host for today, Eileen Pattinson, Head of Inv",43,"Good day, ladies and gentlemen and welcome to the Fourth Quarter and Full Year 2009 Life Technologies Corporation Earnings Conference Call. (Operator Instructions).
I will now turn the conference over to your host for today, Eileen Pattinson, Head of Investor Relations. Please proceed.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, operator and good morning, everyone. Welcome to Life Technologies' Fourth Quarter and Full Year 2009 Earnings Conference Call.Joining me on the call today are Greg Lucier, our Chairman and CEO; Mark Stevenson, President and Chief Operating Of",192,"Thank you, operator and good morning, everyone. Welcome to Life Technologies' Fourth Quarter and Full Year 2009 Earnings Conference Call.
Joining me on the call today are Greg Lucier, our Chairman and CEO; Mark Stevenson, President and Chief Operating Officer; and David Hoffmeister, Chief Financial Officer. In addition, Bernd Brust, our Chief Commercial Officer is available during the Q&A portion of the call.
If you haven't received a copy of today's press release, you may obtain one from our website at lifetechnologies.com.
I want to remind our listeners that our discussion today will include forward-looking statements including, but not limited to, statements about future expectations, plans and prospects for the company. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated. It is our intent that these forward-looking statements be protected under the Safe Harbor created by the Private Securities Litigation Reform Act of 1995.
Additionally, we will be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP can be found in today's press release or on our website.
I will now hand the call over to Greg Lucier.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Eileen and thank you all for joining us. I hope you've had a chance to review the press release we put out this morning.During today's call, I will cover our achievements for the year and our recent product announcements and our outlook for 2010",1481,"Thanks, Eileen and thank you all for joining us. I hope you've had a chance to review the press release we put out this morning.
During today's call, I will cover our achievements for the year and our recent product announcements and our outlook for 2010. Mark Stevenson will talk about our integration progress over the past year and also provide some color on divisional performance. Finally, David will then cover more specifics on our financials for the quarter and the year as well as provide additional details on our view for 2010.
We had a terrific fourth quarter with 11% organic growth, which rounded out a strong year for Life Technologies. 2009 was our first full year after the Applied Biosystems and Invitrogen merger, and our teams around the world performed in an exceptional manner.
We ended the year with 7% organic growth, 300 basis points of operating margin expansion and $534 million in free cash flow. This performance was the result of a lot of hard work and executing on our three strategic imperatives; delivering on the integration, realizing the potential of the new company and investing for future growth.
Our first strategic imperative, delivering on the integration, is critical to our success. We methodically executed upon our integration plans, which enabled us to deliver over 100 million in synergies, considerably higher than our original expectations. In addition to the sizable synergies realized, we were able to merge the two companies into truly one company with a solid foundation of processes and systems.
We still have integrations in place to realize more synergies, but in 2009 we were able to complete all the basic actions necessary to operate as one company. In terms of synergy capture in 2010, by the end of this year we'll have taken actions for both revenue acceleration and cost reductions that will generate 175 million in synergies on an annual basis in 2011, one full year ahead of the original three-year integration schedule.
Beyond the accelerated integration efforts, 2009 was a strong year on a number of measures including organic growth, new product launches and productivity gains. As we announced yesterday, our development efforts last year set us up for an impressive line of new sequencing products to be launched in the next several months, which I'll speak about in a moment.
As you know, next-generation sequencing represents less than 5% of our revenues, and as such we also had numerous new products launched in other areas of our business, the most notable of which is our new flow cytometer, Attune. This product launched in December at the American Society of Cell Biology Conference to outstanding reviews from customers and industry experts alike.
Attune will begin shipping at the beginning of the second quarter and we already have customers lined up. The launch of this product represents our entry into the $1.4 billion flow cytometry market. In the next five years, we anticipate sales will exceed $100 million from our flow cytometry products.
In addition to the new instruments introduced this year, 2009 was another year of rapid releases for new reagent products and benchtop devices, and 2010 is shaping up to be even better.
I want to now take a moment to talk about our sequencing business and a number of new and very exciting products we'll be launching this year. You'll hear more about some of these products in February at the annual AGBT meeting, but today let me focus on the press release we issued yesterday.
As we announced, we are launching our new SOLiD 4 next-generation sequencing system this quarter, a system that we believe will deliver the highest quality genome on the market. It's important to understand that as sequencing becomes more of a clinical tool, meaning that as doctors begin to look at a person's genomic data as a basis for diagnosing and treating disease, it's critical that this data be as accurate as possible.
When you're talking about three billion base pairs, an error rate of even 1% will add up to 30 million mistakes. That's just not good enough when it comes to making decisions that affect peoples' health. That's why we're so excited about SOLiD 4. It will generate up to 100 gigabases of mappable sequence data per run, but more importantly it will deliver unparalleled accuracy.
In fact, by the second half of this year when the SOLiD 4hq package, an upgrade to SOLiD 4, will be available, researchers will be able to generate 300 gigabases of mappable data at 99.99% accuracy. Four nines. This is a remarkable achievement, and given that the system will lower the cost of sequencing a genome to about $3,000 later this year, we now have an instrument that delivers such accuracy and cost as to truly replace array-based technology.
We have already gotten tremendously positive feedback from our customers about what SOLiD 4 will help them achieve. Of course, one collaboration involving the SOLiD 4 System that we're particularly excited about is the one we announced this morning with the Ignite Institute for Individualized Health. As we announced in our release this morning, Ignite will acquire 100 SOLiD 4 Systems, creating the largest next-generation genome sequencing facility in North America.
Ignite is a unique organization, one that is focused on integrating R&D, commercialization and clinical care to create medical solutions fit for the 21st century, solutions based on personalized medicine. We're proud that Life Technologies will partner with such an innovative organization that is truly focused on translational research. As I said earlier, we're now at a stage where we need to look beyond the technological innovations to how the application of these technologies can be used to improve human health.
As sequencing becomes more rapid, accurate and cost effective, we also need to devote attention and resources to other factors. That's why we also announced yesterday that we will dedicate approximately $100 million over the next few years to solve the major challenges related to interpreting and understanding the data generated by sequencing. Our foundation will dedicate $5 million over the next two years to educating physicians on how to use this data to truly help their patients. I'm proud that Life Technologies has the drive and the capability to not just create the best sequencing technologies, but help the community use those technologies to make a difference in ways that really affect peoples' lives.
The use of life science tools and technologies in medical applications is already happening today, of course, specifically in molecular diagnostics, which is a $3 billion market growing at 15% annually. In 2009, we had over 300 million of sales related to molecular diagnostics, so we're already having a strong presence in this high growth market.
Our product offerings in this fast growing business range from reagents and OEM components to products that are cleared for diagnostic use in the U.S. and Europe. To further our participation in the molecular diagnostics arena, we will make investments in developing diagnostic content for our 7500 Fast Dx RT PCR instrument and our 3500 Dx capillary electrophoresis systems, as well as create new tools and components for research in this field.
In addition, we recently announced the acquisition of AcroMetrix, a provider of diagnostic quality control products. This acquisition allows us to further expand our diagnostic capabilities and also expand our direct channel to molecular diagnostics clients. The focus and investment we're putting on moving sequencing technologies into the clinic and making ever more molecular diagnostic tools that will fuel our revenue growth in the long term.
Now for our 2010 expectations. We expect that organic revenue growth will grow in the mid to high single digits. Including the impact of the previously announced mass spectrometry divestiture, earnings per share will grow 10 to 15%. I'll let David get more into the specifics about our expectations, but clearly we are anticipating another solid year of financial performance and value creation for our shareholders.
Beyond 2010, our outlook is equally compelling, with even more new products on the horizon and investments in markets such as food testing, molecular diagnostics and biofuels research adding to our growth rates. In the meanwhile, each and every day we remain focused on execution.
Since 2006, after we transformed the operating rhythm of the organization, we set out to be a company that could prioritize better than any and reliably complete those basic but essential tasks that make up great performance. Our results speak for themselves. Since that time, our earnings per share have grown from $1.46 per share to $3.04 per share 2009, in spite of the worst economic downturn in 60 years and a very large transformative acquisition. In 2010, we will continue to deliver this reliable performance.
I'll now hand it over to Mark Stevenson, who will provide some color on the integration and each of the divisions.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Greg. As Greg mentioned, one of our strategic imperatives is delivering on the integration. Now that Life Technologies has been operating for one full year as a combined company, I thought it fitting to make a few comments on the integration an",885,"Thank you, Greg. As Greg mentioned, one of our strategic imperatives is delivering on the integration. Now that Life Technologies has been operating for one full year as a combined company, I thought it fitting to make a few comments on the integration and the incredible company that is being created in the process.
Over the last year, we have worked diligently to extract the best attributes from both companies and create really a unique business with substantial scale and scope. The integration team made significant progress in 2009. However, there is still a lot of hard work to be done, and we remain focused on executing our integration plans.
With that said, I'll tell you a little bit about the progress we have made so far. Life Technologies has retained an incredibly talented workforce. Our sales teams were recently ranked number one by our customers in both instruments and reagents. Our extensive service and support teams are focused on providing the highest service level to our customers.
Our R&D teams manage the most comprehensive offering of technologies available, and in 2009 Life Technologies launched over 1,000 new product SKUs, and we will accelerate that pace in 2010 and beyond. We are making significant investments in research and development, so that we will remain on the cutting edge of science and technology. By doing this, we can not only meet the evolving needs of our customers, but actually accelerate scientific advancement by bringing relevant and innovative technologies to market.
The scope of Life Technologies is broader than either company could have achieved on a stand-alone basis. As a combined company, we serve over 160 countries around the world, we process 11,000 orders a day and distribute more than 8,000 shipments every single day. Our geographic presence and large volume of orders allows us to drive down the costs and become ever more efficient in our operations. The combination of Invitrogen and Applied Biosystems' strengths is really proving out to be a true competitive advantage that will sustain us into the future.
With that said, I'll move on to provide some specifics on the divisional performance. In the fourth quarter, Molecular Biology Systems grew approximately 15% organically to 422 million in revenue. The majority of H1N1-related products reside within this group and accounted for approximately four points of growth for the division. While we continue to partner with the CDC and other global health organizations to ensure H1N1 public health monitoring, we expect minimal revenue from H1N1-related products in 2010.
Organic growth was also positively impacted by the continued strength in the TaqMan arrays business, in addition to strong demand for qPCR instrumentation and reagents. Additionally, we saw an uptake in the sale of PCR instruments and consumables, a direct result of stimulus funding. For the year, Molecular Biology Systems grew 9% organically to 1.58 billion. Double-digit growth in the genomic assays and high single digit growth in PCR systems was offset by the expected decline in PCR royalties.
Cell Systems had revenues of 211 million in the quarter or 4% organic growth. Strong growth in many of the business areas, such as our magnetic beads and stem cell technologies, was slightly offset by a year-over-year decline in our Bioproduction business. The decline in Bioproduction this year can be mostly attributed to customer-specific issues. We expect that this business will return to a more robust growth in 2010. Total year revenue for Cell Systems was 789 million or 4% organic growth.
Genetic Systems had revenue of 234 million in the quarter, representing 13% organic growth. For the full year, Genetic Systems had revenue of 907 million or 9% organic growth, after accounting for the LIMS divestiture. Revenue for CE systems and consumables sold into the research market was flat in the fourth quarter and for the full year.
This result performance is of particular note since we expected the market would decline in the high single to low double digits as genome centers decommission CE systems in favor of next-generation sequencing systems. We now believe that the decommissioning process is largely complete, and going forward we expect this business to be relatively stable. CE systems and kits sold into applied markets, such as forensics and environmental testing, grew double digits in the quarter, and we expect that this business will continue to grow at a similar rate in the coming year.
Finally, next-generation sequencing continues to gain traction in the market with strong double digit growth in the quarter. We expect that the full suite of next-generation sequencing platforms that Greg spoke about earlier will continue to drive strong growth in the years to come.
Finally, in our Mass Spectrometry division, our joint venture with MDS, revenue growth 7% organically to 130 million. All geographies contributed to growth year-over-year, with Japan growing in the double digits. On a full year basis, this division declined 1%, in line with our expectation of flat to down 10% for the year.
As you are aware, we are in the process of selling our stake in this business to Danaher Corporation. We are in the final stages of this process and now expect the transaction to close shortly.
Now I will turn it over to David Hoffmeister for a full description of the 2009 results and our outlook for 2010.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Mark and good morning, everyone. I'll now take you through the financial details of the fourth quarter and the full year 2009 results.This quarter, revenue grew 14% to $874 million. Excluding the impact from currency and divestitures, revenue",2137,"Thank you, Mark and good morning, everyone. I'll now take you through the financial details of the fourth quarter and the full year 2009 results.
This quarter, revenue grew 14% to $874 million. Excluding the impact from currency and divestitures, revenue grew 11% organically. This was a strong quarter for organic growth with good performance across all our businesses and geographies.
For the full year, revenue grew 5% to 3.3 billion. Excluding the impact from currency and divestitures, revenue grew 7% organically. We're very pleased with these results, especially in the face of a large integration and a tough economic environment.
Let me briefly highlight a couple of items that we have mentioned in the past that contributed to growth again this quarter. Demand for our H1N1-related products was approximately 15 million for the quarter, resulting in full year revenues of about 45 million. Also, an order in the Japanese police force outfitting them with our 3130xl CE sequencer and sample preparation kits, totaling 20 million for the year, contributed nine million in the quarter. These are two good examples of how the broader capabilities of Life Technologies better position us to capitalize on these types of opportunities as they arise.
In terms of organic growth by region, excluding the mass spec division the Americas grew 9% in the fourth quarter, Europe grew 11%, Asia Pacific 23% and Japan 9%. Currency this quarter contributed approximately 4% to revenue growth, net of our hedging program. The positive impact to EPS was approximately $0.06 of earnings per share, including foreign currency impacts accounted for in revenue, other income and the mass spec joint venture.
On a full year basis, currency decreased revenue growth by approximately 2%, net of our hedging program. This impacted EPS negatively by approximately $0.19. The divestiture of the LIMS business had a negative one point effect on reported revenue growth in the fourth quarter and half a point impact on the full year.
Moving on to other items, fourth quarter non-GAAP gross margin was 65%, an increase of approximately 130 basis points over prior year. Positive price realization across the portfolio, positive currency impact, synergies and lower royalty expense all contributed to the gross margin improvements, offset slightly by the negative impact of lower royalty revenue.
On a sequential basis, gross margins declined as expected by 200 basis points as a result of lower price, a higher mix of instruments and OEM orders and the recognition of higher manufacturing expenses as we drew down inventory at year-end. As a reminder, gross margins in the fourth quarter are typically lower for these reasons.
For the full year, gross margins equaled 66.3%, an improvement of 70 basis points over prior year. Positive price, lower royalty expense and synergies from the merger drove the increase, which was partially offset by the negative impact of lower royalty revenue and currencies.
As expected, fourth quarter operating expenses of 342 million were higher than the previous quarter and the prior year. The increase resulted from investments in the commercial organization, in marketing programs aimed at capturing the stimulus and other opportunities, R&D programs for benchtop instrumentation and sequencing and depreciation as investments ramped up over the year. In addition, we entered into several collaborative R&D partnerships in the quarter.
Total operating expenses for 2009 equaled 1.3 billion, a $7 million decline year-over-year. Fourth quarter operating income was 226 million, an increase of 30% over prior year, including the impact of currency and 19% excluding currency. Our operating margin was 25.8%, representing the 300 basis points of improvement year-over-year including the impact from currency. This operating margin expansion primarily resulted from higher gross margin and decreases in head count-related expenses as a result of the merger. As expected, operating margins declined on a sequential basis due to lower gross margins.
For the full year, operating income equaled 879 million, an increase of 18% over the prior year including the impact of currency and 22% excluding currency. Operating margin expanded 300 basis points for the full year to 26.6% including the impact of currency, and 27% excluding currency. Full year operating margin expansion was a result of improved gross margins and decreased head count expenses due to synergies, partially offset by increases in depreciation and purchased services.
In terms of other income line items in the quarter, we had two million of interest income and approximately 16 million of income from our mass spec joint venture. Other income for the full year consisted of five million of interest income and 46 million of income from mass spec. Interest expense for the quarter was 36 million and 150 million for the full year.
Our non-GAAP tax rate for the fourth quarter was 26.2%, resulting in a full year tax rate of 28.5%. The tax rate in the fourth quarter was lower than in previous quarters due to higher income in lower tax rate jurisdictions. Specifically, we had increased sales of instruments manufactured in Singapore where we have a significantly lower tax rate.
Our diluted share count for the quarter was 187.3 million shares and 181.4 million for the full year. As you'll recall, our share count is impacted by our stock price due to our convertible debt and employee stock options.
GAAP diluted earnings per share for the quarter were $0.26, which includes $0.29 per share of acquisition-related amortization expense, $0.04 per share of non-cash interest expense associated with the adoption of APB14-1 and $0.19 per share of business integration costs and other items, and $0.02 per share of accelerated amortization of debt issuance costs resulting from the early repayment of term loans. On a non-GAAP basis which excludes these items, diluted earnings per were $0.80 for the quarter.
For the full year, GAAP diluted earnings per share were $0.80, which includes $1.43 per share of acquisition-related amortization expense, $0.17 per share of non-cash interest expense associated with APB14-1, $0.59 per share of business integration costs and other items; and $0.05 per share of accelerated amortization of debt issuance cost. On a non-GAAP basis, diluted earnings per share for the year were $3.04.
As a reminder, there is a full reconciliation between GAAP and non-GAAP measures in today's press release and on our website.
Moving on to the balance sheet and cash flow, our ending cash and short-term investments were 648 million, including approximately 41 million held as restricted cash. For the quarter, cash from operating activities was 264 million, capital expenditures were 77 million and free cash flow was $187 million, resulting in full year free cash flow of $534 million.
We repaid 150 million of term loan B during the fourth quarter and 425 million of term loans A and B for the full year. We ended the year with approximately 3.1 million of debt. The balance is made up of our convertible debt of 1.1 billion, in addition to term loans of two billion. As a reminder, 350 million of convertible debt is classified as short term with a put call date of August 1 of this year.
I'll now move on to our outlook for 2010. Before I get started, you should note that all guidance I'm providing today assumes we close the mass spec divestiture in the next few days.
As Greg mentioned earlier, we expect to grow revenue organically in the mid to high single digits. Due to the high volatility of currency rates in 2009, we are providing a range for the possible impact on revenue from currency in 2010. The effect on revenue is expected to be in the range of one to two points of additional growth, including the impact of our hedging program. The low end of the range is calculated using the 2009 average rates and the high end is calculated using year-end rates. For modeling purposes, you can choose the rates that you feel are most appropriate.
Non-GAAP earnings per share are expected to be in the range of $3.30 to $3.50. We expect free cash flow to be in the range of 575 to 600 million. Capital expenditures are expected to be 150 to 175 million, including approximately 30 million of integration-related capital.
Our free cash flow forecast also includes approximately 100 million of one-time expenses related to the integration. These costs will be excluded from pro forma earnings, but they're nonetheless cash, so they will lower free cash flow in 2010.
Additional items impacting free cash flow during 2010 include the full-year impact of cash bonuses paid to Applied Biosystems employees versus 2009 when bonuses covered only half the year, and cash impact from the divestiture of the mass spec business. It's important to note that as in the past our free cash flow will be back end loaded in the year due to normal working capital fluctuations throughout the year and the payout of annual bonuses in the first quarter.
A few other items related to our expectations in the coming year include the following. We've included the impact from the stimulus in our forecast. As we've stated in the past, we expect to receive in excess of $100 million in revenue over the life of the program. The exact size and timing of this is difficult to predict since the funds are just beginning to flow.
In the last half of 2009, we had approximately 50 million of revenue as a result of stimulus funding and we expect stimulus-related revenues to slowly ramp up in the first half of the year with the majority of the benefit realized in the latter half of 2010 and into 2011.
As these benefits materialize in 2010, we plan to take the opportunity to reinvest approximately half of the operating profit impact back into the core business to drive future organic growth. We will focus the investment in several areas, including sequencing technologies, which Greg mentioned earlier and accelerating the expansion of our commercial organization in some of our faster growing markets such as China.
Synergy savings for 2009 were 95 million, and we exited the year at a run rate of over 100 million on an annual basis. In 2010, we will put actions in place to achieve additional 70 million in synergy savings on an annual basis. You can expect that the annualized run rate exiting 2010 will be $175 million.
Royalty revenue is no longer expected to decline in 2010. Due to the efforts of our licensing team, the previously announced decline of 10 to 15 million has been offset with revenue from new license agreements. At this point, we still expect royalties to decline by 20 million in 2011.
We expect operating margins to expand between 100 and 125 basis points. This improvement will largely result from capturing additional synergies.
The pro forma tax rate will be approximately 29.0 to 29.5% depending on the geographical mix of income throughout the year. Interest income will fluctuate depending on our cash balance. Our average interest rate on investments is approximately 50 to 60 basis points.
Interest expense is expected to be in the range of 120 to $130 million, depending on the timing of debt repayment and interest rate fluctuations. Inclusive in this number are any changes in capital structure which may come as a result of the waiver we filed yesterday. The waiver seeks agreement from our current lenders to permit the issuance of debt securities, the proceeds of which would be used to repay the term loans. The waiver is effective for up to six months.
Also included in interest expense guidance is the expectation that we would make the following debt repayments during 2010 to reach our target leverage ratio of 2.0 to 2.5 times EBITDA. We anticipate making 140 million of mandatory debt repayments on the term loans and approximately 290 million utilizing the proceeds from the mass spec divestiture.
Our diluted share count is approximately 190 million at today's stock price, but it will increase if our stock price increases due to dilution from our convertible debt, as well as stock options. Assuming an average share price between 52 and $55, the share count would range between 192 and 194 million shares.
Finally, here are a couple of other variables that may further help in modeling the business. First, you can assume that every point of organic growth contributes about $0.07 of earnings per share and every 10 million in operating expenses equals $0.03 per share. Second, in order to help estimate the effect of currency, we've calculated the impact on earnings per share if all currencies moved against the dollar by 5% and our mix of foreign currencies stayed the same. In this scenario, the impact on earnings per share would be $0.10.
With that, I'll hand the call back over to Eileen so we can answer any questions that you may have. Eileen?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, David. Operator, we are now ready for the Q&A portion of the call.",15,"Thank you, David. Operator, we are now ready for the Q&A portion of the call.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Operator","(Operator Instructions). Our first question comes from the line of Quintin Lai with Robert W. Baird. Please proceed.",18,"(Operator Instructions). Our first question comes from the line of Quintin Lai with Robert W. Baird. Please proceed.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Hi, good morning and congratulations on a nice year-end.",9,"Hi, good morning and congratulations on a nice year-end.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Quintin.",3,"Thank you, Quintin.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","On the third quarter call, you kind of gave out a 2010 outlook of mid-single digit organic. Now here we go into 2010 now and you're looking at mid to high single digits and minimal expectations for H1N1. So could you tell me a little bit about what do you",77,"On the third quarter call, you kind of gave out a 2010 outlook of mid-single digit organic. Now here we go into 2010 now and you're looking at mid to high single digits and minimal expectations for H1N1. So could you tell me a little bit about what do you see incrementally better since then? Then as a follow-up, any outlook on the potential for NIH funding 2011 and onward based on what President Obama's been talking?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Sure. Thanks. I think one of the primary drivers for the higher organic growth in 2010 would be the timing of the stimulus. It's clear now most of it will fall into 2010 versus our earlier thinking that some more of it would have fallen into 2009 per the",164,"Sure. Thanks. I think one of the primary drivers for the higher organic growth in 2010 would be the timing of the stimulus. It's clear now most of it will fall into 2010 versus our earlier thinking that some more of it would have fallen into 2009 per the proclamations from the politicians. So again, I think that's the primary driver for higher organic growth in 2010.
The second part of your question was relating to the NIH. As you know, the NIH ex-stimulus got approximately 2% increase in the current fiscal budget 2010. In our current discussions, at least we have heard, is that the NIH will probably get another increase in fiscal year 2011. We don't think it will be held flat, but obviously it's subject to a lot of negotiation yet to be had. We're actually encouraged that the NIH in this current environment of potentially flat discretionary spending will actually be one of the budgets that does get an increase.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","All right. Thanks. I know you've got a lot of questions, so I'll jump back into the queue.",18,"All right. Thanks. I know you've got a lot of questions, so I'll jump back into the queue.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Operator","Our next question comes from the line of Tycho Peterson with JPMorgan. Please proceed.",14,"Our next question comes from the line of Tycho Peterson with JPMorgan. Please proceed.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Hey, good morning and congrats on the nice quarter.",9,"Hey, good morning and congrats on the nice quarter.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Thank you.",2,"Thank you.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Tycho.",2,"Thanks, Tycho.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe just start off on the new product introduction. Can you talk a little bit about the go-to-market strategy for SOLiD 4, how you approach your current installed base and maybe just any color on pricing, consumables? Then also with Ignite, it looks lik",76,"Maybe just start off on the new product introduction. Can you talk a little bit about the go-to-market strategy for SOLiD 4, how you approach your current installed base and maybe just any color on pricing, consumables? Then also with Ignite, it looks like you're getting payments over three years. So if you could talk a little bit about whether there's a change in the payment terms for your customers going forward that would be helpful.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Yeah, Tycho. This is Mark. So we started discussing with our customers SOLiD 4 over the last couple of weeks. We're excited to accelerate that. I mean, some of the investments you saw us make during Q4 was really accelerating the R&D. The customers have b",221,"Yeah, Tycho. This is Mark. So we started discussing with our customers SOLiD 4 over the last couple of weeks. We're excited to accelerate that. I mean, some of the investments you saw us make during Q4 was really accelerating the R&D. The customers have been very positive in the response we've got. Really going to our installed base, new customers; we've always said we felt this had the highest potential to upgrade our existing customer base. So we've really been going to them, explaining the roadmap and how we've accelerated that. So they're very excited about that and particularly on the accuracy. They're beginning to see the difference it makes in the results to really ensure that they're not getting any false positives in that. So very positive response as we've gone to those customers and we upgrade and outlaid the path for the year.
We expect payment terms will be as normal for customers that we deal with, no change in that policy. We were very excited to the partnership we announced this morning with Ignite, really in line with our strategic priorities about how do we translate this closer to the clinic. Ignite, with its capabilities and its vision is really all about taking that much closer and translating these discoveries we're making really into a clinical practice.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Then can you comment on your assumptions for consumables on the new instrument?",13,"Then can you comment on your assumptions for consumables on the new instrument?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","So we would expect the consumables to ramp up in a normal way. With the capacity now to go to the $6,000 genome and then 3,000 at the end of the year, we'll expect the pull-through to be very high during the usage of that as people replace other technolog",56,"So we would expect the consumables to ramp up in a normal way. With the capacity now to go to the $6,000 genome and then 3,000 at the end of the year, we'll expect the pull-through to be very high during the usage of that as people replace other technologies now to ramp up on that.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. Then Greg, in your comments you talked about trying to kind of accelerate I think the pace of product introductions. Are we going to see kind of a big bolus in the next couple years from some of these R&D efforts, and can you talk a little bit about",80,"Okay. Then Greg, in your comments you talked about trying to kind of accelerate I think the pace of product introductions. Are we going to see kind of a big bolus in the next couple years from some of these R&D efforts, and can you talk a little bit about how we should be thinking about R&D spend? Then if you can also include any comments on M&A and your appetite for smaller tuck-in deals right now that'd be helpful.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Sure. Well, I think you've started to see early signs of what has been a very aggressive innovation agenda by the company. So, the development and now launch of the flow cytometer product, which is very disruptive, very proprietary technology, now with SO",194,"Sure. Well, I think you've started to see early signs of what has been a very aggressive innovation agenda by the company. So, the development and now launch of the flow cytometer product, which is very disruptive, very proprietary technology, now with SOLiD 4 continuing to show and demonstrate that it is in our belief the most accurate chemistry to read the genome, and you'll hear more in the coming month at AGBT of some other major breakthroughs. You can expect that pace of innovation to continue coming out of the company. As Mark was mentioning, one of the primary motives for bringing these two companies together was to drive the scale around R&D, to really create ever more innovation in life sciences. You're seeing the very early stages of that.
In terms of the overall spend on R&D, we hover around 10, 10.5%. As we accelerate our organic growth, we think the R&D spend will stay in and around that percentage. Now we're dealing with some very large numbers, and numbers that are far larger than our competitors that allow us to have this scale of innovation that we hope will be unmatched.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Then...",2,"Then...
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Acquisitions, sorry.",2,"Acquisitions, sorry.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Your appetite for tuck-in M&A and...",7,"Your appetite for tuck-in M&A and...
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Yes. We're very, very comfortable with the current portfolio inside the company. Invitrogen did a lot of acquisitions to build up a platform, AB did a few. The combination of the two, we believe has a very strong portfolio as it is. Therefore, we don't ha",93,"Yes. We're very, very comfortable with the current portfolio inside the company. Invitrogen did a lot of acquisitions to build up a platform, AB did a few. The combination of the two, we believe has a very strong portfolio as it is. Therefore, we don't have to do any large acquisitions to add to this. However, we do have a good sense of paranoia that sometimes the best ideas are outside our company, and so we will continue to do smaller tuck-in, primarily oriented around technology acquisitions to bring it into the family.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. Then just a last one, a clarification on the royalties. Can you give us a sense as to whether your ability to kind of offset there was a function of going back to customers and getting paid what you were owed? Or was it adding the digital PCR patent",63,"Okay. Then just a last one, a clarification on the royalties. Can you give us a sense as to whether your ability to kind of offset there was a function of going back to customers and getting paid what you were owed? Or was it adding the digital PCR patents to the estate and being able to leverage that a little bit more?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Really all of the above. As I mentioned to some folks at your conference, we have reformulated the licensing team. It's a very capable group of people. They've gone back to existing licensees. They've looked back into our portfolio and gone out to license",71,"Really all of the above. As I mentioned to some folks at your conference, we have reformulated the licensing team. It's a very capable group of people. They've gone back to existing licensees. They've looked back into our portfolio and gone out to license other technologies. This year they achieved, I think, nice progress to mitigate the decline we were expecting. They've got their work cut out to start for 2011.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. Thank you very much.",5,"Okay. Thank you very much.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Operator","Our next question comes from the line of Doug Schenkel with Cowen and Company. Please proceed.",16,"Our next question comes from the line of Doug Schenkel with Cowen and Company. Please proceed.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Hi. Good morning and thanks for taking my questions.",9,"Hi. Good morning and thanks for taking my questions.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","You bet.",2,"You bet.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","It sounds like you guys had a pretty good solid quarter, maybe even picking up some momentum. Could you talk about whether or not there was any notable change in competitive win rates, maybe talk a little bit about stimulus impact to that business and how",52,"It sounds like you guys had a pretty good solid quarter, maybe even picking up some momentum. Could you talk about whether or not there was any notable change in competitive win rates, maybe talk a little bit about stimulus impact to that business and how things are differing across different geographies?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Let me take the first part of the question. So what we said was we saw some impact of the stimulus in the quarter, about eight to 10 million in the quarter. We think it's now starting to come through the pipeline. In terms of win rates, we believe that th",152,"Let me take the first part of the question. So what we said was we saw some impact of the stimulus in the quarter, about eight to 10 million in the quarter. We think it's now starting to come through the pipeline. In terms of win rates, we believe that the creation of the organization is allowing us to pick up increased market share at key accounts around the world on key areas of technology, whether it's customers wanting to consolidate their purchases into one vendor and save a lot of processing costs or in other areas like qPCR instrumentation where we had a very robust fourth quarter. So we feel good about our win rates and we think in the coming years that we'll be able to actually increase the market share in this industry.
Bernd, do you want to add any color commentary to maybe some of the emerging markets?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Sure. I mean, first I think in general on the selling organizations around the world, the combined organization, you really now have the reagent or consumables sales force have now focused on both the AB and Invitrogen portfolios, which gives you a tremen",123,"Sure. I mean, first I think in general on the selling organizations around the world, the combined organization, you really now have the reagent or consumables sales force have now focused on both the AB and Invitrogen portfolios, which gives you a tremendous pull-through and allows the traditional legacy AB team to focus more on instrumentation and get a bigger footprint on that side. We're seeing some tremendous payoffs happening on that end.
Emerging markets around the world, we continue to see tremendous growth in Latin America, China, Middle East and other countries. Along those lines, we continue to invest in those areas to capture share and be as close to those customers as we can, and those investments will continue to happen.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","That's helpful. Then David, you were really clear in providing background on why gross margin pulls back sequentially as it always does in the fourth quarter. Despite that, the Street was actually a little bit higher with our forecast. So that's probably",75,"That's helpful. Then David, you were really clear in providing background on why gross margin pulls back sequentially as it always does in the fourth quarter. Despite that, the Street was actually a little bit higher with our forecast. So that's probably just a function of poor modeling, but I just want to be clear. Was gross margin about where you expected it to be, and what was the FX impact in the quarter?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Gross margin was where we expected it to be. If you look back on last year, the pattern is almost identical on a relative basis. In total on an EPS level, gross margin was or I mean currency had a $0.06 impact.",42,"Gross margin was where we expected it to be. If you look back on last year, the pattern is almost identical on a relative basis. In total on an EPS level, gross margin was or I mean currency had a $0.06 impact.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. One last question, it's probably best for Greg. Your stock performance has lagged the group a little bit in the early part of 2010, recognizing that you guys just outgrew the group in the year by about 700 basis points and generated 300 basis points",151,"Okay. One last question, it's probably best for Greg. Your stock performance has lagged the group a little bit in the early part of 2010, recognizing that you guys just outgrew the group in the year by about 700 basis points and generated 300 basis points of operating leverage. Some of the reasons I've heard from some of the bears thrown around have been concerns about your long-term growth outlook and how much leverage there's going to be in the model, not just this year but beyond. So I want to give you an opportunity to address these concerns. Could you maybe talk a little bit about what you think the long-term targeted rate of organic growth is beyond 2010? Could you talk a little bit about whether or not it's right to think that operating margin could exceed maybe the historical peak for Invitrogen, which I believe was about 30%?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Thanks for the question. I think there seems to be a disconnect between the enthusiasm and confidence inside the company and some voices that you describe outside the company. We actually have never been more bullish on the future of the business. I don't",184,"Thanks for the question. I think there seems to be a disconnect between the enthusiasm and confidence inside the company and some voices that you describe outside the company. We actually have never been more bullish on the future of the business. I don't know why there would be any even justification for why our growth rates would somehow go down after 2010. Whether it's just the increased pace of innovation, the innovation that can allow us to enter very big markets like flow cytometry and molecular diagnostics that we're now talking about, or our enhanced global footprint where we can be closer to customers than any other company in life sciences and grow our share, to just new emerging opportunities even beyond the current consideration of what we were even doing as independent companies two years ago, such as biofuels research. There is just a enormous amount of opportunities for this new platform company to grow. So I would just say that there's a big disconnect between how we feel and the confidence we see in the future to the voices you describe.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","I'll just, I guess get to the second part of that and then I'll get back into the queue. From a margin standpoint, are we anywhere close to where you guys think you can be over the next few years?",41,"I'll just, I guess get to the second part of that and then I'll get back into the queue. From a margin standpoint, are we anywhere close to where you guys think you can be over the next few years?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","What we've said is that we can grow operating margins 50 basis points per year. In the past, we sometimes were asked the question, is there a limit at, let's say, 30% operating margin? We said we don't know. I guess my answer today would be, I don't see a",122,"What we've said is that we can grow operating margins 50 basis points per year. In the past, we sometimes were asked the question, is there a limit at, let's say, 30% operating margin? We said we don't know. I guess my answer today would be, I don't see any reason why that represents a ceiling on the growth of the profitability of the company. As we increase our investment in proprietary technologies, we should be able to extract higher margins in the company. So I don't see any reason why we can't continue to drive 50 basis points improvement each and every year for several years to come. So I don't see a ceiling on that profitability of the company.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. Thanks a lot. I appreciate you taking the questions.",10,"Okay. Thanks a lot. I appreciate you taking the questions.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","You bet.",2,"You bet.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Operator","Our next question comes from the line of Derik De Bruin with UBS. You may proceed",16,"Our next question comes from the line of Derik De Bruin with UBS. You may proceed
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Hey, good morning.",3,"Hey, good morning.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Good morning.",2,"Good morning.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Just a couple of questions then I'll jump back in the queue on this. So on looking at the Cell Systems business, it was about 4% organic growth in 2009. I guess, how much of this do you attribute to changes in the cell culture process in the sense that cu",84,"Just a couple of questions then I'll jump back in the queue on this. So on looking at the Cell Systems business, it was about 4% organic growth in 2009. I guess, how much of this do you attribute to changes in the cell culture process in the sense that customers are starting to get higher yields from some of their cell culture stuff and this is a volume decrease? Just talk about where you see trends in the Cell Systems business going.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","As Mark mentioned, we think that this is an area that was impacted by some economic factors in 2009. We see it returning to historical growth rates of high single digits, low double digits here in 2010 for Bioproduction. There is no question that there is",102,"As Mark mentioned, we think that this is an area that was impacted by some economic factors in 2009. We see it returning to historical growth rates of high single digits, low double digits here in 2010 for Bioproduction. There is no question that there is increased efficiencies taking place. At the same time, we believe our share of the molecules on the market is increasing as well. Now the other point I would say is that our guidance for Cell Systems in 2010 is mid to high single digits. So we see it returning to its historical growth patterns this year.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","That's helpful. Thanks. Going to the SOLiD 4, can you tell us what the cost of the upgrade is and how much of your installed SOLiD base would you expect to upgrade? I guess also the question, is what is the installed base of SOLiD?",46,"That's helpful. Thanks. Going to the SOLiD 4, can you tell us what the cost of the upgrade is and how much of your installed SOLiD base would you expect to upgrade? I guess also the question, is what is the installed base of SOLiD?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Well, with regard to the upgrade, we're making it very affordable for our customers to upgrade to the system. So it'll be $10,000 to upgrade from the customers that are 3 Plus now to upgrade to 4. We expect that the majority of customers will upgrade that",171,"Well, with regard to the upgrade, we're making it very affordable for our customers to upgrade to the system. So it'll be $10,000 to upgrade from the customers that are 3 Plus now to upgrade to 4. We expect that the majority of customers will upgrade that installed base and will continue to expand out on that. Then they'll also want to add in the EZ Bead System, which is $50,000 into that, which as we explained in the press release will cut their hands-on time by about 90%. Also improve the efficiency of that upfront ePCR process.
So the installed base is growing bigger and bigger. We're not giving specific numbers, but we've made a lot of traction in the progress in the market and we think this will continue to reinforce the great roadmap we have by laying out what we're going to do to the end of the year. We've consistently beat and accelerated where we said we'll be on our platform, and now delivering on the platform.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Great. Just one final question. You alluded to investing in your own molecular diagnostic content. Would you care to elaborate?",20,"Great. Just one final question. You alluded to investing in your own molecular diagnostic content. Would you care to elaborate?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Well, we're doing that in several ways. So one, we're doing it in partners. So we announced, for example, the partner earlier in the year with Asuragen, and we're developing that out, now going into clinical trials with BCR/ABL test. There are other partn",112,"Well, we're doing that in several ways. So one, we're doing it in partners. So we announced, for example, the partner earlier in the year with Asuragen, and we're developing that out, now going into clinical trials with BCR/ABL test. There are other partners that we're discussing with to bring proprietary content onto our platforms. We also see through these translational medicine collaborations that you see us setting up there'll be new and novel content discovered there that will come out again onto our platforms. So there are two ways that we see that coming through, both through partnerships and through the partnerships of taking this novel content onto our existing platforms.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Great. Thank you.",3,"Great. Thank you.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Operator","Our next question comes from the line of Marshall Urist with Morgan Stanley. You may proceed.",16,"Our next question comes from the line of Marshall Urist with Morgan Stanley. You may proceed.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Yeah, hey guys. Good morning. So first question just on the synergy opportunity in 2010. The incremental $75 million you guys talked about, can you give us just an idea of where that's coming from, price, cost realization, kind of what are the major drive",47,"Yeah, hey guys. Good morning. So first question just on the synergy opportunity in 2010. The incremental $75 million you guys talked about, can you give us just an idea of where that's coming from, price, cost realization, kind of what are the major drivers in 2010?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","It's 70 million. As you mentioned, it's a combination of revenue and costs. As we said when we kicked off the synergy discussion at the beginning of this year, that initially it was going to be predominantly cost. As time went on we would get more revenue",102,"It's 70 million. As you mentioned, it's a combination of revenue and costs. As we said when we kicked off the synergy discussion at the beginning of this year, that initially it was going to be predominantly cost. As time went on we would get more revenue synergies and that's what we expect to happen. So there's going to be a greater mix of revenues.
As far as costs go, we're going to continue to get synergies from purchasing. We identified earlier plant consolidations, other manufacturing opportunities. We expect to get those, as well as some consolidations and efficiencies in distribution.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, great. So sort of following on that, how should we be thinking about gross margin in 2010?",18,"Okay, great. So sort of following on that, how should we be thinking about gross margin in 2010?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","What we've commented on is at the operating margin level, you can expect operating margins to expand by 100 to 125 basis points.",24,"What we've commented on is at the operating margin level, you can expect operating margins to expand by 100 to 125 basis points.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Given some of the investments you guys have talked about in R&D and SG&A, should we assume that the leverage there is coming on the gross margin front given you've talked about some of these manufacturing synergies?",38,"Given some of the investments you guys have talked about in R&D and SG&A, should we assume that the leverage there is coming on the gross margin front given you've talked about some of these manufacturing synergies?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Yes, you can assume that we will get significant expansion or leverage in our margins, gross margins.",17,"Yes, you can assume that we will get significant expansion or leverage in our margins, gross margins.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, great. Thanks. Just one other follow-up question on SOLiD, just to follow-up on a previous question. When you guys talked about the price of the genome coming down, is there any change in how you're pricing consumables? Or is this an accuracy, decre",61,"Okay, great. Thanks. Just one other follow-up question on SOLiD, just to follow-up on a previous question. When you guys talked about the price of the genome coming down, is there any change in how you're pricing consumables? Or is this an accuracy, decreasing the coverage that you need sort of per genome to get to the same level of data?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Yeah, it's really technological advances that we're making in this. The first advance that we're making in SOLiD 4 is a combination of new reagents, these total precision reagents that we've increased, and also the EZ Bead. That allows us to reduce the co",105,"Yeah, it's really technological advances that we're making in this. The first advance that we're making in SOLiD 4 is a combination of new reagents, these total precision reagents that we've increased, and also the EZ Bead. That allows us to reduce the cost down for our customers down to $6,000. Then as we go to SOLiD hq, that upgrade will come from greater density from smaller beads. So it's a very straightforward upgrade for our customers also later in the year, and that'll get us up to the 300 gigabases and allow our customers to do runs of $3,000 to get a genome done.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, great. Just to be clear, there's no change in the pricing policy on consumables?",15,"Okay, great. Just to be clear, there's no change in the pricing policy on consumables?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","There's no change in that, no.",7,"There's no change in that, no.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, great. All right, I'll get back in the queue. Thanks a lot, guys.",14,"Okay, great. All right, I'll get back in the queue. Thanks a lot, guys.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","You bet.",2,"You bet.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Operator","Our next question comes from the line of Jonathan Groberg with Macquarie Capital. You may proceed.",16,"Our next question comes from the line of Jonathan Groberg with Macquarie Capital. You may proceed.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Hi, good morning. Just a couple questions. I was most interested in the comments, at least around the business and the outlook that you made, Mark on the research CE market that you think the decommissioning is done and that you actually expect stable rev",86,"Hi, good morning. Just a couple questions. I was most interested in the comments, at least around the business and the outlook that you made, Mark on the research CE market that you think the decommissioning is done and that you actually expect stable revenues going forward. Can you just maybe describe kind of what you're hearing, why you're willing to say that and what you're assuming in terms of additional advances that are made in other kind of longer read, lower cost technologies going forward?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Well, we see most of the high throughput applications have already actually switched to next-generation sequencing. I mean just the tremendous progress that has been made in the short run technologies as they got longer both in comparative sequencing and",239,"Well, we see most of the high throughput applications have already actually switched to next-generation sequencing. I mean just the tremendous progress that has been made in the short run technologies as they got longer both in comparative sequencing and de novo sequencing, that switch has already occurred. So the decommissioning that we're seeing and the transfer out of those experiments has actually occurred already.
What we see in the research market is where people want to do a single experiment and perhaps look at a part of a genome and just do one run, instruments like the 3500 that we introduced that run into smaller labs, into smaller clinics is a very cost efficient way to run that out, to validate that sequence and then translate that into a clinical setting. So that's where we're seeing research applications and good pickup continue in that CE market and continuing to run CE instruments in that space. So that's why we feel comfortable about, as we've seen this year, the stabilization of that business. We're aware obviously of the long run technologies. Again, we'll talk about our single molecule technology coming in at the AGBT conference. We see a good place for that in the market, but it's complementary to other next-generation sequencing tools. We think it's also complementary to CE. We'll be able to have the full breadth across CE short and long runs as we go forward here.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","So if I take what you've said in the past about the CE research business, it's maybe somewhere around a 430, $450 million business for you, which is a pretty substantial business. You're saying that regardless of newer technologies, advances, you think th",60,"So if I take what you've said in the past about the CE research business, it's maybe somewhere around a 430, $450 million business for you, which is a pretty substantial business. You're saying that regardless of newer technologies, advances, you think that's about the rate at which that market will stay, the CE research market, using CE technology?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Yeah. What you have to keep in mind with your numbers in the market is as we see the CE applications continue to get used into more clinical applications, that validation like we've done on the 3500 to get a CE-IVD mark and now in discussions to take the",93,"Yeah. What you have to keep in mind with your numbers in the market is as we see the CE applications continue to get used into more clinical applications, that validation like we've done on the 3500 to get a CE-IVD mark and now in discussions to take the CE into a 510(k), those applications continue to get into more translational applications into the clinic, and that's when CE is a robust and proven technology. Particularly for a quick experiment, that's exactly what you want to use, the right fit for that application.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. Thanks for clarifying the view there. Then just one more on sequencing if I can. On the SOLiD, can you maybe describe two things; one, you've had you and your competitor both introducing systems that are going to make significant advancements here.",131,"Okay. Thanks for clarifying the view there. Then just one more on sequencing if I can. On the SOLiD, can you maybe describe two things; one, you've had you and your competitor both introducing systems that are going to make significant advancements here. A lot of promises more towards the back half of the year, I guess. How does that dynamic play in the near term in terms of how you think customers are going to go about purchasing instruments? Does this delay purchases towards the back half of the year? You described what entailed going from the 3 to the 4. Can you maybe just describe as you go from the 4 to the hq what kind of upgrades you need to go to these smaller beads that you described?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Well, we don't see the market slowing down here in the first half of 2010. I think our announcement here with Ignite is a good example that this is a very robust market. In terms of what's driving it, for us the message is really around accuracy, that the",169,"Well, we don't see the market slowing down here in the first half of 2010. I think our announcement here with Ignite is a good example that this is a very robust market. In terms of what's driving it, for us the message is really around accuracy, that the technology is now taking us to a point where you can do really important translational research and accuracy is the key element when you're doing this sequencing. So we see that opportunity opening up here in 2010 for our organization.
In terms of the upgrade to hq, I'll defer to my colleagues here. Again, it's not a very expensive upgrade once you're into SOLiD 4, which as you heard from SOLiD 3 Plus to 4 is only about $10,000. So we've tried to make this very economical for our installed base. We've continued to tell our customers that the SOLiD platform, the SOLiD technology has still lots of runway from here. As they invest in us, we invest in them.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","Yeah. I think that I'd just add that what you're not seeing here is any discontinuance of a platform, the switch. So the customers don't feel as they move up that they need any switch. So they continue to invest. They'll invest in SOLiD 4, and later in th",84,"Yeah. I think that I'd just add that what you're not seeing here is any discontinuance of a platform, the switch. So the customers don't feel as they move up that they need any switch. So they continue to invest. They'll invest in SOLiD 4, and later in the year, they can add this upgrade which will add the extra smaller beads on. So they see a path and they just want to get going. They feel now is the time to get sequencing.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Like on the smaller beads, when you talk about an upgrade, do they have to replace a camera or anything like that in terms of the optic side of things? I'm just curious what exactly they upgraded.",37,"Like on the smaller beads, when you talk about an upgrade, do they have to replace a camera or anything like that in terms of the optic side of things? I'm just curious what exactly they upgraded.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","There may be smaller engineering upgrades that go as we've done in the past with SOLiD 3 to 3 Plus, but there's nothing significant that they'll need to upgrade in this.",32,"There may be smaller engineering upgrades that go as we've done in the past with SOLiD 3 to 3 Plus, but there's nothing significant that they'll need to upgrade in this.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. Then, lastly and I'll jump in the queue. On pricing, can you maybe talk about what you've realized in 2009, kind of on average for the year? If that was any different than previous years, given the merger here with AB? Then whether or not you expect",52,"Okay. Then, lastly and I'll jump in the queue. On pricing, can you maybe talk about what you've realized in 2009, kind of on average for the year? If that was any different than previous years, given the merger here with AB? Then whether or not you expect anything different in 2010?
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","In previous years we've said we've realized somewhere between one to 2% in net price, and that's about what we got this year. We were very pleased with the pricing impact we were able to get on the AB side of the business. We're going to continue that goi",63,"In previous years we've said we've realized somewhere between one to 2% in net price, and that's about what we got this year. We were very pleased with the pricing impact we were able to get on the AB side of the business. We're going to continue that going forward. Our outlook for 2010 is another one to 2% in realized price.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Analysts","Great. Thanks a million for the detail.",7,"Great. Thanks a million for the detail.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Executives","All right. Thank you. We've run out of time, and this concludes our Fourth Quarter and Full Year 2009 Earnings Conference Call. This webcast will be available via a replay on our website for three weeks.As a reminder, we will be hosting a follow-up Q&A",82,"All right. Thank you. We've run out of time, and this concludes our Fourth Quarter and Full Year 2009 Earnings Conference Call. This webcast will be available via a replay on our website for three weeks.
As a reminder, we will be hosting a follow-up Q&A call for investors and analysts at 11:00 Eastern Standard Time. You can find dial-in information on the Investor Relations website and in the press release issued this morning.
Thank you again for joining us this morning.
"
30253,84148556,47365,"Life Technologies Corporation, Q4 2009 Earnings Call, Jan-28-2010",2010-01-28,"Earnings Calls","Life Technologies Corporation","Operator","This concludes today's presentation. You may now disconnect. Good day.",11,"This concludes today's presentation. You may now disconnect. Good day.

"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Good day, ladies and gentlemen, and welcome to the Q1 2010 Life Technologies Corporation earnings conference call. My name is Tamina [ph] and I will be your operator for today. At this time all participants are in listen-only mode. Later we will conduct a",83,"Good day, ladies and gentlemen, and welcome to the Q1 2010 Life Technologies Corporation earnings conference call. My name is Tamina [ph] and I will be your operator for today. At this time all participants are in listen-only mode. Later we will conduct a question-and-answer session. (Operator instructions) As a reminder this conference is being recorded for replay purposes. I would now like to turn the conference over to your host for today, Ms. Eileen Pattinson, Head of Investor Relations. Please proceed, maam.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Tamina, and good afternoon everyone. Welcome to Life Technologies' First Quarter 2010 Earnings Conference Call.Joining me on the call today are Greg Lucier, our Chairman and CEO and David Hoffmeister, Chief Financial Officer. In addition, Mar",189,"Thank you, Tamina, and good afternoon everyone. Welcome to Life Technologies' First Quarter 2010 Earnings Conference Call.
Joining me on the call today are Greg Lucier, our Chairman and CEO and David Hoffmeister, Chief Financial Officer. In addition, Mark Stevenson, our Chief Operating Officer and Bernd Brust, our Chief Commercial Officer are available during the Q&A portion of the call.
If you haven't received a copy of today's press release, you may obtain one from our website at lifetechnologies.com.
I want to remind our listeners that our discussion today will include forward-looking statements including, but not limited to, statements about future expectations, plans and prospects for the Company. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated. It is our intent that these forward-looking statements be protected under the Safe Harbor created by the Private Securities Litigation Reform Act of 1995.
Additionally, we will be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP can be found in today's press release or on our website.
I will now hand the call over to Greg Lucier.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Eileen, and thanks to all of you for joining us. I hope youve had a chance to review the press release we put out this afternoon. As you can see from our results, we delivered another quarter of strong top and bottom line growth and we are plea",1442,"Thanks, Eileen, and thanks to all of you for joining us. I hope youve had a chance to review the press release we put out this afternoon. As you can see from our results, we delivered another quarter of strong top and bottom line growth and we are pleased with how we have started 2010.
Revenue grew 10% organically to $887 million, a result of terrific growth in both instruments and consumables. Operating margins expanded by 330 basis points to hit a record 29.5%. And earnings per share grew 21% to $0.87 for the quarter. This quarter marks the 14th quarter in a row that this Company has met or exceeded its financial targets on both the top and the bottom line. This milestone demonstrates how seriously we take our commitments to our shareholders. Our teams around the world have proven that they know how to put their heads down and get the work done, driving above market revenue growth with a relentless focus on execution.
As I do every quarter, I will take a few moments now to talk about these results in the context of our strategic imperatives delivering on the integration, realizing the potential of this new Company, and investing for the future. First, we made significant progress on our integration goals for the year. The sales force reorganization is complete and our reps are hitting the street with a singular purpose of adding value for our customers. Our ultimate goal is to become their partner of choice by providing unparalled customer service, and offering an expansive portfolio of innovative products that simplify and streamline entire workflows.
In addition, we announced the closure of two manufacturing site in Camarillo, California, and Bromborough, UK. The work to consolidate these operations into our facilities in Frederick, Maryland and Warrington in the UK is well underway and going successfully. These initiatives, as well as many others will generate an additional $20 million in annualized synergies. This brings us one step closer to our goal of putting action plans in place that will generate an additional $70 million in annualized savings by the end of this year.
Our diligence [ph] approach to the integration has not only paid off from a near term synergy perspective, but has set us up for success in other important ways. In particular, weve made great strides in realizing the potential of the new Company, which is our second strategic imperative. Let me now share with you some ways in which we optimize the value of our combined Company in the first quarter.
As I mentioned, we grew revenue 10% organically. Regionally, Japan was a standup performer with 23% growth for the quarter. Throughout 2009 our team in Japan executed on a strategy to optimize our commercial structure in the region. Among other actions, we increased the number of sales reps in the field and implemented a new dealer strategy that more closely aligned incentives with performance. These efforts position us well to take advantage of the additional research funding that the Japanese government released in the first quarter of 2010. As a result, we had strong sales across all of our businesses in Japan with a notable increase in sales of the new 3500 Genetic Analyzer and the Neon Transfection system.
Growth in Japan was also positively impacted from a lift in realized price and recognition of the last installment from the landmark police forensics deal. We are very pleased with this performance and recognize the tremendous efforts that our team in Japan is putting forth. However, this remains a very challenging region, and we expect growth to be in the low-single digits for the balance of the year now.
The Americas region grew 8% in the quarter with stimulus-related revenues contributing approximately 3% of this growth. While we did not see a significant ramp up in stimulus revenues for the fourth quarter, we are still confident - from the fourth quarter, we are still confident in our estimate of greater than $100 million over the life of this federal program. However, because of the slow ramp up in stimulus related spending, we believe that more of this revenue might now push into 2011 than we had originally anticipated
Id like to now talk a bit about our last strategic priority, investing for future growth. As Ive stated in the past, we expect to grow revenue one to two points faster than the market for the foreseeable future. One of the ways in which we will achieve this goal is the consistent introduction of new and innovative products. It is critical to have an eye on the future and anticipate the areas that will drive growth in the months and the years to come.
To that end, we have spent considerable efforts fine-tuning our innovation techniques over the last 24 months and focus our efforts on several key areas, including genetic sequencing, synthetic biology, flow cytometry, benchtop devices, and PCR. In addition to meeting the needs of our research customers, investments in these areas will increasingly move us into higher growth in commercial and clinical realms.
We will go into more detail about our investment strategies at our upcoming investor day in June, but I will give you a few highlights of some of our recent product introductions now.
Yesterday, we issued a press release about the debut of the industrys first benchtop proteomic and epigenetic sample preparation system, the MAGic Sample Processor. In line with our strategy of offering innovative products that simplify and streamline workflows, this new device cuts protocol times in half and dramatically reduces experimental errors by automating manual processes. MAGic utilizes microfluidics, thermal controls, and integrated magnetic separation technology, which enables researchers to more easily perform technically challenging experiments in protein purification and epigenetics.
We are particularly excited about this launch as it is another product in a growing line of innovative, productivity-enhancing benchtop devices. And I might add, it combines the very best of Life Technologies engineering, Dynal bead technology, and our consumables channel [ph]. It is a product that couldnt have been created without the creating of Life Technologies.
In addition to the launch of MAGic, last week at the America Association for Cancer Research, we unveiled several new technologies, including research only KRAS and BRAF mutation analysis reagents that can be analyzed using the 3500 Genetic Analyzer.
We also announced our newest innovation in real-time PCR, the ViiA 7 Real-Time PCR System. The ViiA 7 System offers maximum productivity, ease of use, and instrument to instrument consistency. While the ViiA 7 System is currently for research use only, it was designed with clinical applications in mind. We expect to get a CE IVD mark later in the year and ultimately plan for 510(k) in the U.S. Gaining these clearances will extend the application of the ViiA 7 System beyond research lab and into clinical and diagnostic markets. The launch of the ViiA 7 System is part of our broader strategy to extend our leadership position in PCR by setting new technology standards. We began executing upon this strategy in 2009 when we acquired Cytonix for intellectual property related to digital PCR technology and then followed that with the acquisition of BioTrove for its OpenArray platform, enabling high throughput traditional genotyping into PCR as well as digital PCR reads.
Today, I am pleased to announce the acquisition of Stokespile [ph] whose ground-breaking technology redefines the current play-safe paradigm for the PCR process, generating orders of magnitude more date in less time. Stokespile has developed the microfluidics based system for high throughput, highly flexible genotyping, gene expression analysis, and digital PCR. This technology is well-suited to meet the ever-growing demand for higher throughput genomic analysis in agriculture, drug discovery, translational research, and other applications being fuelled by the rapid rate of discovery from next generation sequencing systems such as ours. The acquisition of Stokespile is another very exciting step forward as we continue to build out and redefine the PCR industry.
These combined assets will enable our vision of delivering (inaudible) performance and quality, fast, easy, and configured for customer throughput and flexibility needs. Building out our PCR franchise through both internal development and the acquisition of technologies is just one example of how we are investing in our future. We have programs in place that will ultimately drive our business forward and its a smart and efficient allocation of resources to these programs that will set us up for success in the years to come.
With that, I will turn it over to David who will provide a little more color on our divisional performance and overall financial results. David?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Greg. This quarter we grew revenue 13% to $887 million. Currency had a positive four point impact on reported revenue growth and acquisitions and divestitures had a negative one point impact. Excluding the effect of currency, acquisitions, and div",1785,"Thanks, Greg. This quarter we grew revenue 13% to $887 million. Currency had a positive four point impact on reported revenue growth and acquisitions and divestitures had a negative one point impact. Excluding the effect of currency, acquisitions, and divestitures, revenue grew 10% organically.
This performance was the result of strong volume growth and better pricing in most areas of the business. In addition, growth was positively impacted by three items in particular. As Greg mentioned before, we recognized $8 million in revenue from the last installment of the Japanese police order. We also benefited from spending related to the supplemental budget in Japan which added $4 million in revenues.
And finally, revenue associated with the NIH stimulus totaled $10 million. These three items added about 3% to the overall growth rate.
Before I walk through some of divisional highlights, Id like to point out a relatively small change in our division structure that went into effect at the beginning of the year. In order to better align certain technologies within our divisions, we created a new business unit called Applied Molecular Testing, which is now part of the Molecular Biology Systems division. Going forward, all of our animal, biosecurity, food, and environmental testing products will be accounted for in this new business unit.
In addition to this change, we moved certain products associated with our pharma analytics business from Genetic Systems to Cell Systems to more closely align our product offerings for pharmaceutical and biological production. As a result, product lines totaling approximately $50 million in revenue were moved between divisions. For year-over-year comparison purposes, weve posted a worksheet on our website that restates divisional revenue for 2009. In addition, we will be providing more detail during the post earnings Q&A call later this afternoon.
Now, I will get into the divisional highlights. Molecular Biology Systems grew approximately 10% organically to $432 million in revenue. Our PCR business grew in the teens, driven by particularly strong demand for instruments in the Americas and Asia as well as the Japanese police order that I referenced earlier. Genomic Assays also performed well with double-digit growth in the Americas, Asia-Pacific, and Japan. Lastly, the Molecular Biology Reagent business benefited from strong sales for reagents in all regions.
Genetic Systems grew 12% organically to $238 million. CE, our largest technology group in this division grew mid-single digits for the quarter, driven by growth in both consumables and instruments. Consumables continued to experience solid growth in research and applied applications. Instrument growth was driven by strong sales in clinical research, particularly for the newly launched 3500 Genetic Analyzer, partially offset by a year-over-year decline in instruments sold into applied markets due to a large sale in the first quarter of last year.
And finally, we continue to gain traction in next generation sequencing as we improve the ease-of-use and the performance of the SOLiD platform. Ongoing improvements in the technology, new product launches such as the SOLiD PI system, along with investments in our field support sales teams and marketing are paying off. A good example of this is the British Columbia Cancer Agencys purchase of 10 SOLiD 4 units for their research. The accuracy of the SOLiD system is increasingly recognized by thought leaders as critical for cancer related research.
Cell systems had revenues of $214 million, representing 8% organic growth. Growth in this division increased compared to prior quarters as pharmaceutical and biotech end markets started to improve. This quarter saw a double-digit growth in bioproduction, driven by new drug introductions, and the timing of large customer orders.
Primary and stem cell systems also posted strong growth in the quarter, driven by demand for both media and reagents.
And lastly, our Dynal beads based business grew in the double digits on large orders from molecular diagnostic customers.
In terms of organic growth by region, the Americas grew 8%; Europe grew 5%, Asia-Pacific 25%, and Japan 23%.
As I mentioned earlier, currency added four points of growth to revenue for the quarter, net of our hedging program. The positive impact to EPS was approximately 7% or $0.07 including foreign currency impacts accounted for in revenue and other income.
First quarter non-GAAP gross margin was 68.3%, an increase of approximately 160 basis points over prior year. This improvement was primarily due to price, currency, synergies, and manufacturing productivity. On a sequential basis, gross margins increased by 330 basis points due to increases in price and royalty revenue and higher productivity in our plants. Keep in mind that gross margins in the fourth quarter are typically lower, so sequential increase was expected.
First quarter operating expenses were $343 million, an increase over prior year levels of 8% with currency, and 6% without currency. Operating expenses increased due to increases in R&D, depreciation, and cost associated with employee stock options. Sequentially, operating expenses were relatively flat, mainly due to delaying some investments until we had a better understanding of how stimulus related revenues would flow in the quarter.
Operating income was $262 million, an increase of 27% over prior year including the impact of currency, and 20% excluding currency. Operating margin was 29.5%, representing 330 basis points of improvement year-over-year, including the impact from currency. This level of operating margin expansion resulted from improved gross margins, synergies and other operating expense reductions. As weve said before, our goal over the next several years is to consistently deliver 50 plus basis points of operating margin improvements.
In terms of other income, we had $1 million of interest income, $3 million from currency gain, and $1 million of expense from our mass spec joint venture. Interest expense for the quarter was $30 million.
Our non-GAAP tax rate was 30%, slightly higher than guidance due to the expiration of the federal R&D tax credit. We believe that this tax credit will be renewed at some time during the year. If renewed, the credit will reduce our full year tax rate by approximately one percentage point. Therefore, we expect our full year tax rate to be between 29% and 29.5%.
Our diluted share count for the quarter was 190 million shares. As you will recall, our share count is impacted by our stock price due to our convertible debt and employee stock options. We continue to expect a full year diluted share count of 192 million to 194 million shares, assuming an average stock price for the year between $52 and $55 per share.
GAAP diluted earnings per share were $0.48, which includes the gain of $0.14 per share on the sale of the mass spec division, $0.25 of acquisition related amortization expense, $0.03 per share of non-cash interest expense associated with the adoption of APB 14-1, $0.08 per share of business integration cost and other items, and $0.17 per share of accelerated amortization of debt issuance cost resulting from the early repayment of debt.
On a non-GAAP basis, which excludes these items, diluted earnings per share were $0.87, a 21% increase over last year.
Moving on to the balance sheet and cash flow, our ending cash and short term investments were $642 million. This compares to last years balance of $648 million. Cash from operating activities was $71 million, capital expenditures were $30 million, and free cash flow was $41 million. As a reminder, free cash flow is lower in the first quarter due to the payout of annual employee bonuses.
Return on invested capital increased 0.5% to 8.6%. We are making good progress towards our goal of a 10% return on invested capital in the next couple of years.
Paying down debt continues to be our top priority. To that end, we use the proceeds from the sale of the mass spec joint venture and the bond offering, as well as cash on hand to pay off term loans amounting to $1.97 billion. As a result, our ending debt as of March 31st was $2.64 billion. This balance is made up of our convertible debt of $1.15 billion and senior notes of $1.5 billion.
Our leverage ratio is approximately 2.7 times, and we still expect to be between 2.0 and 2.5 times by the end of the year. Since the merger of Invitrogen and Applied Biosystems, weve paid off $900 million in debt.
Ill now move on to our expectations for the rest of the year. Our full year guidance is unchanged. Revenue growth is expected to be in the mid-to-high single digits and EPS is expected to be in the range of $3.30 to $3.50. As we stated in our Q4 call, the impact from the NIH stimulus is the main driver between the mid- and the high-single digit revenue growth.
As Greg mentioned earlier, the impact from the stimulus was approximately the same as we saw in the fourth quarter of last year, $10 million. At this point, we expect that the impact of stimulus funding will be spread over a longer period of time with more of the spending now pushed into 2011. Well keep you updated on the impact of the stimulus funding as we move through the year.
As is our practice, I will also give you a few specific items to take into consideration for the coming quarter. First, in regard to the stimulus, as we stated on the Q4 call, we intend to reinvest approximately half of the operating profit from the stimulus back into the business to fund future growth opportunities. These reinvestments will begin in the second quarter and will be primarily focused on R&D and commercial projects in emerging markets such as China and India.
Gross margins are expected to decrease sequentially as price is normally strongest in the first quarter. Additionally, in the second quarter we expect to sell a higher mix of instruments, which are lower margin than our consumables.
Operating expenses are expected to increase sequentially due to increases in investment in emerging markets and R&D as well as the full quarter impact of new hires and merit increases that went into effect at the beginning of April. Our currency guidance is unchanged. We continue to expect the impact on revenue will be one to two points of additional growth for the year, including the impact of our hedging programs.
And lastly, weve received questions on the impact to our business of the eruption of the volcano in Iceland, and we are pleased to report there has been no material impact on revenue. Delivery times did increase slightly due to a switch to - a switch from air to ground freight. However, we were able to supply our customers from stock at our European distribution centers.
And with that, I will now hand the call over to Eileen for Q&A.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, David. Because of time constraints, Id like to ask everyone to limit themselves to one question and one followup question. If you have additional questions after that and you would like to ask please get back in the queue and we can take any",69,"Thank you, David. Because of time constraints, Id like to ask everyone to limit themselves to one question and one followup question. If you have additional questions after that and you would like to ask please get back in the queue and we can take any remaining questions on the post call scheduled for later this afternoon.
Operator, we are now ready for the Q&A portion of the call.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","(Operator instructions) Our first question comes from the line of Quintin Lai with Robert Baird. Please proceed.",17,"(Operator instructions) Our first question comes from the line of Quintin Lai with Robert Baird. Please proceed.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Hi, good afternoon. Nice start to the year, guys.",9,"Hi, good afternoon. Nice start to the year, guys.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thank you.",2,"Thank you.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","First question, Greg. With respect to the NIH stimulus and its getting - it looks like its going to be spread out a little bit further, could you tell us a little bit about what are your customers doing, is it just being more cautious? And then with",69,"First question, Greg. With respect to the NIH stimulus and its getting - it looks like its going to be spread out a little bit further, could you tell us a little bit about what are your customers doing, is it just being more cautious? And then with respect to your reaffirmed guidance, is it that other markets or new products will help make up for that little push-out?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, Quintin, I think the first quarter shows that even with a lower stimulus spending than perhaps we all envisioned we still grew organically at 10%. And so I think it shows that the teams are executing and that we may be perhaps gaining share, and so",97,"Well, Quintin, I think the first quarter shows that even with a lower stimulus spending than perhaps we all envisioned we still grew organically at 10%. And so I think it shows that the teams are executing and that we may be perhaps gaining share, and so as we look at now stimulus being spread out over more quarters than we originally thought, I think what we are counting on and weve demonstrated it that we can execute, we can grow, and still achieve the financial estimates that weve given you and others for the 2010 year.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And then just a quick followup, what percent of your sales are being generated by new products over like the last two years?",23,"And then just a quick followup, what percent of your sales are being generated by new products over like the last two years?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Eileen may be I will turn that to you in terms of that particular fact.",15,"Eileen may be I will turn that to you in terms of that particular fact.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","We actually havent given out that level of details in terms of new - revenue generated by new products, but well get into more detail, Quintin, at the analyst day in June.",33,"We actually havent given out that level of details in terms of new - revenue generated by new products, but well get into more detail, Quintin, at the analyst day in June.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Super, thank you, guys.",4,"Super, thank you, guys.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Tycho Peterson with JPMorgan. Please proceed.",11,"Our following question comes from Tycho Peterson with JPMorgan. Please proceed.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Hey thanks for taking the question. David, in your comments a minute ago, you just talked about some of the commercial investments in China and India. Can you elaborate a little bit on what that entails?",36,"Hey thanks for taking the question. David, in your comments a minute ago, you just talked about some of the commercial investments in China and India. Can you elaborate a little bit on what that entails?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Why dont I hand that over to Bernd.",9,"Why dont I hand that over to Bernd.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Hi, Tycho, how are you. In China and India, I mean the focus really continues to be for us to get closer and closer to our customers, that really that means a couple of things. We continue to invest in our IT infrastructure, making sure our websites are i",73,"Hi, Tycho, how are you. In China and India, I mean the focus really continues to be for us to get closer and closer to our customers, that really that means a couple of things. We continue to invest in our IT infrastructure, making sure our websites are in local language and has accessibility to local markets that way as well as continuing to invest in direct sales forces for both those countries.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. And then with regards to the flow cytometry business, youve talked about that being a pretty large market; I think $1.7 billion or so. Can you talk a little bit about how the early reception to Attune has been and how you are approaching the go-t",48,"Okay. And then with regards to the flow cytometry business, youve talked about that being a pretty large market; I think $1.7 billion or so. Can you talk a little bit about how the early reception to Attune has been and how you are approaching the go-to-market strategy?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Mark, you want to grab that one?",7,"Mark, you want to grab that one?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Yes, I can add to that. So, yes, we see its a big opportunity, actually $1.4 billion was the number we put out for the size of the market. Weve just started shipping our first early access units to customers here in the U.S. and shipped our first un",92,"Yes, I can add to that. So, yes, we see its a big opportunity, actually $1.4 billion was the number we put out for the size of the market. Weve just started shipping our first early access units to customers here in the U.S. and shipped our first units into Europe. The reaction has been very positive, particularly around the ability to detect rare events, so the ability to slow the flow down and to do something that other systems can't do in traditional flow has been well received by the market.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, and then, Mark, just one last one on the enhancements to SOLiD that you highlighted at EasyBead. Can you talk a little bit about how EasyBead has done and what the customer reception has been to SOLiD 4?",39,"Okay, and then, Mark, just one last one on the enhancements to SOLiD that you highlighted at EasyBead. Can you talk a little bit about how EasyBead has done and what the customer reception has been to SOLiD 4?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","The customer reception on EasyBead has been very positive. I mean really that was one of the major bottlenecks they were finding. And so just being able to automate that front end is a big relief for many of those customers who wanted to get into the accu",113,"The customer reception on EasyBead has been very positive. I mean really that was one of the major bottlenecks they were finding. And so just being able to automate that front end is a big relief for many of those customers who wanted to get into the accuracy, but needed that automation up front.
And then on SOLiD 4, really the combination of the new pricing and the roll out of the new software and system in there has been well received. Weve been very active in this quarter in rolling that out and a good update on the SOLiD 4; we had our best quarter ever as you saw in our results.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, thank you very much.",5,"Okay, thank you very much.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Doug Schenkel with Cowen and Company. Please proceed, sir.",14,"Our following question comes from Doug Schenkel with Cowen and Company. Please proceed, sir.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Hi, good afternoon.",3,"Hi, good afternoon.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Hi.",1,"Hi.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","So, first question, I believe you said that there were some signs the biopharma end market is starting to improve. Could you just provide a little bit more color in terms of exactly what you are seeing and would you be willing to tell us what biopharma sa",54,"So, first question, I believe you said that there were some signs the biopharma end market is starting to improve. Could you just provide a little bit more color in terms of exactly what you are seeing and would you be willing to tell us what biopharma sales growth is incorporated into your guidance?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, in the latter part, I dont think we are willing to disclose that level of detail, but on the first part of your comment, as we look at the first quarter of 2009 and then compare it to the first quarter of 2010 there clearly has been a recovery in",93,"Well, in the latter part, I dont think we are willing to disclose that level of detail, but on the first part of your comment, as we look at the first quarter of 2009 and then compare it to the first quarter of 2010 there clearly has been a recovery in research spending across the biopharma customer base for us. Now, its still not having returned to 2008 levels, but its coming back quarter-by-quarter nicely and that type of incremental return is what we have thought about and included in our 2010 estimate.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And any chance you would be willing to speak to whether you are seeing demand across all areas of pharma spending, meaning is it more an early-stage or its late-stage, do you have that level of detail available?",38,"And any chance you would be willing to speak to whether you are seeing demand across all areas of pharma spending, meaning is it more an early-stage or its late-stage, do you have that level of detail available?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, screening campaigns as an example greatly dropped off when the economic crisis hit. We are starting to see screening campaigns return again. And we are also seeing more spending back into the basic research areas as well. And so Id say there is j",59,"Well, screening campaigns as an example greatly dropped off when the economic crisis hit. We are starting to see screening campaigns return again. And we are also seeing more spending back into the basic research areas as well. And so Id say there is just overall a better tone and tenor to the research spending in that customer base.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And one more question, Greg, I think you were over at the GET conference today at Boston or was that I think you were scheduled to be there. You know there is a decent focus I mean the focus of that meeting was on personalized genomes. One of your challen",101,"And one more question, Greg, I think you were over at the GET conference today at Boston or was that I think you were scheduled to be there. You know there is a decent focus I mean the focus of that meeting was on personalized genomes. One of your challenges in second generation sequencing has been the fact that you were second to the market. Do you expect this challenge that youve had over the last couple of years with SOLiD to be different in this area of sequencing, I mean do you think you are better positioned at personalized medicine?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, I think as Mark referenced, we believe SOLiD has a distinct accuracy advantage versus other platforms, and customers that are discriminating are starting to understand that and we think that really allows SOLiD to be a preferred platform for medical",104,"Well, I think as Mark referenced, we believe SOLiD has a distinct accuracy advantage versus other platforms, and customers that are discriminating are starting to understand that and we think that really allows SOLiD to be a preferred platform for medical applications. And thats where all our efforts really ever more are focused is this move more towards the clinical application of sequencing. So, that is, as Mark said, why we had one of our best quarters ever in SOLiD and why we feel that while we may have been second, we might just be first in terms of the medical application of sequencing.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, thats great. And actually, if can slip one more, and, Mark -",13,"Okay, thats great. And actually, if can slip one more, and, Mark -
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Doug, you need to get back in the queue.",9,"Doug, you need to get back in the queue.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","You got to catch on, okay. Alright, I will get back in the queue. Sorry about that and thanks for taking my question.",23,"You got to catch on, okay. Alright, I will get back in the queue. Sorry about that and thanks for taking my question.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thanks.",1,"Thanks.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Marshall Urist with Morgan Stanley. Please proceed, sir.",13,"Our following question comes from Marshall Urist with Morgan Stanley. Please proceed, sir.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Yes, hey guys, good afternoon. So, first question, if we just cut the business as consumables growth versus instruments in the quarter, can you tell us kind of what the relative organic growth rates were?",35,"Yes, hey guys, good afternoon. So, first question, if we just cut the business as consumables growth versus instruments in the quarter, can you tell us kind of what the relative organic growth rates were?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","So, Greg, I can take that. We actually grew low-double digits in both areas of the business.",17,"So, Greg, I can take that. We actually grew low-double digits in both areas of the business.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, great. And then just I mean I realize that you may be pushing out some of the stimulus into next year, but maybe talking about - so are expecting kind of this $10 million level to continue over the next few quarters? Do we still see some incremental",69,"Okay, great. And then just I mean I realize that you may be pushing out some of the stimulus into next year, but maybe talking about - so are expecting kind of this $10 million level to continue over the next few quarters? Do we still see some incremental growth off of that and kind of is that making you comfortable still with organic growth guidance for the year.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, we feel comfortable about the organic growth guidance for the year. Weve reaffirmed that. But in terms of particular amount of stimulus in the ensuing quarters, I will defer it to you, Eileen, in terms of disclosure.",38,"Well, we feel comfortable about the organic growth guidance for the year. Weve reaffirmed that. But in terms of particular amount of stimulus in the ensuing quarters, I will defer it to you, Eileen, in terms of disclosure.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, I think (inaudible) Greg, this is David, if I can add, in our guidance, in our revenue guidance weve said a growth for the year of mid-to-high single digits. And that basically covers that range of stimulus. So if we get more stimulus well mov",99,"Well, I think (inaudible) Greg, this is David, if I can add, in our guidance, in our revenue guidance weve said a growth for the year of mid-to-high single digits. And that basically covers that range of stimulus. So if we get more stimulus well move towards that high-single digit growth. Lower level of stimulus that we have well be closer to mid-single digits. And I think no one knows. You know we are watching it very closely. Bernd has a dedicated team thats following it, but its really beyond our control. Well just see how it flows out.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, great, thanks.",3,"Okay, great, thanks.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Jon Groberg with Macquarie Capital. Please proceed, sir.",13,"Our following question comes from Jon Groberg with Macquarie Capital. Please proceed, sir.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Hi, thanks a million for taking the question. Just two questions. The first is you mentioned on the Genetic Systems and CE that you continue to see some growth and I am curious one of the labs that reported last week was saying that even though people are",109,"Hi, thanks a million for taking the question. Just two questions. The first is you mentioned on the Genetic Systems and CE that you continue to see some growth and I am curious one of the labs that reported last week was saying that even though people are very interested, states are very interested in forensics and human identification, that given the budget situation that many of these are there, just not able to do what perhaps they would like to do. And I am just curious if you are seeing any of that impact or expect to see some of that impact as you go throughout the year?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Mark, you want to handle that one?",7,"Mark, you want to handle that one?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Yes, I mean so far our demand for the forensic sample analysis far outstretches both capabilities of lab and to some extend funding. So to the extent there is more funding available, I mean this year we were fortunate The Debbie Smith Act here in the U.S.",118,"Yes, I mean so far our demand for the forensic sample analysis far outstretches both capabilities of lab and to some extend funding. So to the extent there is more funding available, I mean this year we were fortunate The Debbie Smith Act here in the U.S. was reauthorized fully at $151 million and that gets trickled down to the states. Clearly, the states are under some pressure, but mostly we see the political pressure and will always still to fund the increased DNA testing both here in the U.S. and as weve seen internationally with Japan coming on board and strong growth in other countries around the world. It still is a double-digit growing market for us.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. And then, Greg, one of the aspects of the story that was very interesting about in vitro and maybe its gotten lost a little bit is your e-commerce channel. And just I noticed that you are doing pretty good 18% in the quarter. Maybe you can just t",72,"Okay. And then, Greg, one of the aspects of the story that was very interesting about in vitro and maybe its gotten lost a little bit is your e-commerce channel. And just I noticed that you are doing pretty good 18% in the quarter. Maybe you can just talk about any initiatives you have there kind of where thats falling and the relative importance of where you look to invest looking forward?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, we have a goal internally to try to surpass the $1 billion of e-commerce across both the Invitrogen site and the AB.com site, which you know a billion dollars of e-commerce I think in any industry there is probably only a handful that are doing that",136,"Well, we have a goal internally to try to surpass the $1 billion of e-commerce across both the Invitrogen site and the AB.com site, which you know a billion dollars of e-commerce I think in any industry there is probably only a handful that are doing that level of sales. When we combined the two companies, we combined the two e-commerce teams and actually added to them and so weve got a very large team and infrastructure now. And as Bernd said, the real work is to add what maybe as some sophisticated features in other industries into this one, and more importantly in some way is to localize the sites into China, into Japan, into other languages to really drive that revenue growth and its been very successful for us and so we continue it.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Thanks a million.",3,"Thanks a million.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Operator?",1,"Operator?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from the line of Steven Lichtman with JMP Securities. Please proceed.",15,"Our following question comes from the line of Steven Lichtman with JMP Securities. Please proceed.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Thank you. Good afternoon. First question I had was, did this quarter include any placements of SOLiD to Ignite and if not when is that expected to start this year?",30,"Thank you. Good afternoon. First question I had was, did this quarter include any placements of SOLiD to Ignite and if not when is that expected to start this year?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Bernd, I will turn that to you.",7,"Bernd, I will turn that to you.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Hi, Steven. No SOLiD units were placed with Ignite yet. As you know, Ignite is still finalizing its business plans. We are all set to continue to partner with them as they finalize how they will get to commercialize soon here. So, at this point, now SOLiD",51,"Hi, Steven. No SOLiD units were placed with Ignite yet. As you know, Ignite is still finalizing its business plans. We are all set to continue to partner with them as they finalize how they will get to commercialize soon here. So, at this point, now SOLiD units have been place.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. And then just the follow-up on foreign currency, may be just a little bit more details on the hedging program, just given the strengthening of the dollar, we are still keeping it in that 1% to 2% range. How are you keeping it still in that positive",77,"Okay. And then just the follow-up on foreign currency, may be just a little bit more details on the hedging program, just given the strengthening of the dollar, we are still keeping it in that 1% to 2% range. How are you keeping it still in that positive 1% to 2% impact of the top line and do you expect the bottom line impact to be the same as you thought a couple of months back? Thanks.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Yes, at this point we dont see any significant change in our projection.",13,"Yes, at this point we dont see any significant change in our projection.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","(inaudible)",1,"(inaudible)
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","No, again either the top line or the bottom line should still be covered by our guidance.",17,"No, again either the top line or the bottom line should still be covered by our guidance.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, great. Alright, thank you.",5,"Okay, great. Alright, thank you.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Derik De Bruin with UBS Capital. Please proceed.",13,"Our following question comes from Derik De Bruin with UBS Capital. Please proceed.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Hi, good afternoon.",3,"Hi, good afternoon.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Good afternoon.",2,"Good afternoon.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Hey, I jumped on the call late, so my apologies if you have asked this, but I am curious just on the Cell Systems strength, I am curious just like have you seen a real boost from the stem cell initiatives for that funding was from - coming from California",132,"Hey, I jumped on the call late, so my apologies if you have asked this, but I am curious just on the Cell Systems strength, I am curious just like have you seen a real boost from the stem cell initiatives for that funding was from - coming from California. They had to build (inaudible) has any real meaningful funds come from that or have you seen - as that tied up the budget? And I also kind of want to take that on just a followup on the Cell Systems, so its like what are you seeing in terms of bioproduction, picked up yet? Have some of the recent contamination issues at some of the big companies, have that had an impact on your customers getting more concerned about quality control?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well - I mean this is Greg. Overall, Cell Systems had a very good quarter and as you referenced bioproduction had in particular a good quarter. And the contamination issues you referenced didnt impact us, but as you say I think further stimulates anoth",135,"Well - I mean this is Greg. Overall, Cell Systems had a very good quarter and as you referenced bioproduction had in particular a good quarter. And the contamination issues you referenced didnt impact us, but as you say I think further stimulates another part of our business, which is - use of PCR technology and quality control. So, we see a very robust future of applying that technology to bioproduction.
On the stem cell side, as you know we started that business several years ago and brought in some real strong leadership and thats a business now that continues to grow at very strong double digits spurred on by NIH work, California, overseas, and just the general move towards primary cell usage. So, its been a great business for us and continues to do so.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And just one quick followup question. I just jumped on late, but the R&D spend was a little bit below where I thought it was going to be tracking for this quarter. Are you still expecting that to ramp up specifically towards the back half as you move forw",51,"And just one quick followup question. I just jumped on late, but the R&D spend was a little bit below where I thought it was going to be tracking for this quarter. Are you still expecting that to ramp up specifically towards the back half as you move forward the year?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, as we said in our guidance, in the second quarter, we do plan incremental investments in R&D and so you will see the R&D line tick up going forward here.",31,"Well, as we said in our guidance, in the second quarter, we do plan incremental investments in R&D and so you will see the R&D line tick up going forward here.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Great. Thanks.",2,"Great. Thanks.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from the Jon Wood with Jefferies. Please proceed, sir.",13,"Our following question comes from the Jon Wood with Jefferies. Please proceed, sir.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Hey, thanks a lot. So, it looks like you will be with - I mean I had you below your - within your target leverage ratios, but I think I heard David say 2.7. It looks like you will be well within that in the second quarter. Is it reasonable to assume there",65,"Hey, thanks a lot. So, it looks like you will be with - I mean I had you below your - within your target leverage ratios, but I think I heard David say 2.7. It looks like you will be well within that in the second quarter. Is it reasonable to assume there are some share repurchases that could begin here in the second quarter?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, I think our use of capital hasnt changed. So, number one use is pay down the debt and you are right, Jon, we want to get between 2.0 to 2.5 times and that we have said well certainly be there by the end of the year. I dont know if well b",152,"Well, I think our use of capital hasnt changed. So, number one use is pay down the debt and you are right, Jon, we want to get between 2.0 to 2.5 times and that we have said well certainly be there by the end of the year. I dont know if well be there in the second quarter. We also, in terms of paying down the debt, we have a convert thats callable in August. Thats $350 million. And at the current level of stock we would call that at that point in time.
Once we are within our range, and we have been, second use of our cash is to look at acquisitions, primarily tuck-in and key technologies. And then our philosophy still is to return excess cash to shareholders. So, at that point we would look at share buybacks, but that will probably be end of the year or 2011.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. And are you willing to disclose anything, I mean I know you announced a tuck-in today, and then I saw on the tape about a month ago a German Company, (inaudible) disclose what in terms of invested capital to assume from these deals in the second qua",48,"Okay. And are you willing to disclose anything, I mean I know you announced a tuck-in today, and then I saw on the tape about a month ago a German Company, (inaudible) disclose what in terms of invested capital to assume from these deals in the second quarter.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","So, Jon, we havent released any information around those two acquisitions in terms of more than what youve already got.",20,"So, Jon, we havent released any information around those two acquisitions in terms of more than what youve already got.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay. And the only way you can pay down debt at this point right is the convert, right, because I think you are fixed on the senior notes side at this point. Is that correct, David?",36,"Okay. And the only way you can pay down debt at this point right is the convert, right, because I think you are fixed on the senior notes side at this point. Is that correct, David?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Yes, thats correct. We have the $1.2 billion roughly of converts outstanding that are - have put call dates over the next three years.",24,"Yes, thats correct. We have the $1.2 billion roughly of converts outstanding that are - have put call dates over the next three years.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, thanks a lot.",4,"Okay, thanks a lot.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Jeff Ares with Leerink Swann. Please proceed, sir.",13,"Our following question comes from Jeff Ares with Leerink Swann. Please proceed, sir.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Hey guys, thanks for taking the question. Going off of the earlier question about SOLiD and TGen, I remember when that was announced at the time you said there were more potential deals like that in the pipeline. I am wondering if you can provide us with",51,"Hey guys, thanks for taking the question. Going off of the earlier question about SOLiD and TGen, I remember when that was announced at the time you said there were more potential deals like that in the pipeline. I am wondering if you can provide us with an update on that.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Mark and Bernd?",3,"Mark and Bernd?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Yes, you will see in the coming pipeline more focus as Greg mentioned where we see these interests in the translational medicine group and TGen is a great example of actually taking what we are discovering about cancer and applying that. And an example ag",94,"Yes, you will see in the coming pipeline more focus as Greg mentioned where we see these interests in the translational medicine group and TGen is a great example of actually taking what we are discovering about cancer and applying that. And an example again, you saw this last quarter and was in our numbers was the group in BC Kansa [ph] which is really taking a discovery to translational medicine approach. There will be more of those during the coming year and you will see that is announced as we do those deals.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, great, thanks. And as a followup, could you provide us a little bit of an update on how project Starlight is going and if you guys still target again early access customers by the end of the year?",39,"Okay, great, thanks. And as a followup, could you provide us a little bit of an update on how project Starlight is going and if you guys still target again early access customers by the end of the year?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","So, we got very good reception from the technical data that we showed at the scientific meeting, the AGBT, just tremendous interest in some of the features of the system particularly in its ability to do recursive sequencing to go back over and improve bo",84,"So, we got very good reception from the technical data that we showed at the scientific meeting, the AGBT, just tremendous interest in some of the features of the system particularly in its ability to do recursive sequencing to go back over and improve both the accuracy and the read length. We are beginning now to talk with the early access customers that saw some of these presentations and would expect to more fully engage with them at the end of this calendar year.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","All right. And one - I mean you talked at the time at AGBT that you would be seeing some other data later this year. Any idea of timing for that like may be (inaudible) spring or-?",37,"All right. And one - I mean you talked at the time at AGBT that you would be seeing some other data later this year. Any idea of timing for that like may be (inaudible) spring or-?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","We will release some of that data as we go through. We havent targeted since its not a commercial product particularly in meetings but there will be clear experiments well do and continue to share that with the community.",39,"We will release some of that data as we go through. We havent targeted since its not a commercial product particularly in meetings but there will be clear experiments well do and continue to share that with the community.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","All right. Thanks a lot.",5,"All right. Thanks a lot.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from the line of Dan Leonard with First Analysis. Please proceed, sir.",16,"Our following question comes from the line of Dan Leonard with First Analysis. Please proceed, sir.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Hi, thank you. My first question is on the revenue guidance. Besides what you mentioned in Japan as well as tougher year-over-year comps, is there anything else that we should think about mitigating your revenue growth for the balance of the year?",42,"Hi, thank you. My first question is on the revenue guidance. Besides what you mentioned in Japan as well as tougher year-over-year comps, is there anything else that we should think about mitigating your revenue growth for the balance of the year?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","David?",1,"David?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","No, I think that you know the two things that we mentioned were Japan, which had just a phenomenal first quarter. As Greg pointed out, that team has done a great job. But we dont expect growth to continue at that rate in the subsequent quarters. And th",62,"No, I think that you know the two things that we mentioned were Japan, which had just a phenomenal first quarter. As Greg pointed out, that team has done a great job. But we dont expect growth to continue at that rate in the subsequent quarters. And then the other wild card is what weve talked about as well is the stimulus.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, thank you. And my followup, either Greg or David, could you walk me through the thought process in closing Camarillo and what steps youve taken to mitigate any disruption from that closure?",33,"Okay, thank you. And my followup, either Greg or David, could you walk me through the thought process in closing Camarillo and what steps youve taken to mitigate any disruption from that closure?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","You bet. Frederick, Maryland has become ever more of the R&D center for our Cell Systems business. And we have a lot of very talented R&D people there. And so we wanted to centralize the antibody piece of that overall portfolio into Frederick. I would als",138,"You bet. Frederick, Maryland has become ever more of the R&D center for our Cell Systems business. And we have a lot of very talented R&D people there. And so we wanted to centralize the antibody piece of that overall portfolio into Frederick. I would also say that by making it closer to our large distribution center there in Frederick, we can have much more rapid delivery times for the myriad of antibodies that we do provide.
Now, in terms of not having disruption, weve gotten pretty good at these transfers as weve brought together AB and Invitrogen and so the same team that transferred production out of Foster City in 2009 is on the job here in Camarillo and weve built up substantial inventories in Frederick ahead of time before we have phased out production in Camarillo.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, thank you.",3,"Okay, thank you.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Peter Lawson with Thomas Weisel Partners. Please proceed.",13,"Our following question comes from Peter Lawson with Thomas Weisel Partners. Please proceed.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Greg, I wonder if you could just talk to whats happened with the NIH, meaning whats the drug in force behind that delay.",23,"Greg, I wonder if you could just talk to whats happened with the NIH, meaning whats the drug in force behind that delay.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, I think thats more a speculation than anything if were to give you answers. I think people are generally being cautious. I think they are trying to use other monies first. And I think thats just how we are seeing this play out right now. Now,",76,"Well, I think thats more a speculation than anything if were to give you answers. I think people are generally being cautious. I think they are trying to use other monies first. And I think thats just how we are seeing this play out right now. Now, there is a deadline to this program. It has to all be spent by 2011 and so it will get spent. Its just a question of at what pace.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Thank you. And then just as a followup on the clinical market, you talked about that. Whats your strategy there for diagnostics and can you talk in any kind of revenue number over the next couple of years for that market?",41,"Thank you. And then just as a followup on the clinical market, you talked about that. Whats your strategy there for diagnostics and can you talk in any kind of revenue number over the next couple of years for that market?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, we already do in excess of $300 million a year in molecular diagnostics. We, as I have said to others, have a very strong franchise and the fundamental tools and technologies that go into other peoples diagnostics test. Secondly, we continue to g",126,"Well, we already do in excess of $300 million a year in molecular diagnostics. We, as I have said to others, have a very strong franchise and the fundamental tools and technologies that go into other peoples diagnostics test. Secondly, we continue to get our platforms, our interim [ph] platforms validated and certified. And as I had mentioned, with the new ViiA 7, thats certainly our goal with this new PCR platform. So, we will have ever more instruments for molecular diagnostics.
And then selectively we are making smaller acquisitions like we did with AcroMetrix around molecular diagnostic controls. So we like our strategy. We think its kind of a smart incremental way to build out from our core strength. And its giving us nice growth.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Okay, thank you so much.",5,"Okay, thank you so much.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Ross Muken with Deutsche Bank. Please proceed.",12,"Our following question comes from Ross Muken with Deutsche Bank. Please proceed.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Good evening. So, as we think about kind of the portfolio as you have evolved it, weve obviously had a great amount of new product introductions and youve set this sort of goal to grow above the market. I mean as we look out on kind of the longer te",100,"Good evening. So, as we think about kind of the portfolio as you have evolved it, weve obviously had a great amount of new product introductions and youve set this sort of goal to grow above the market. I mean as we look out on kind of the longer term basis, as you look at sort of the biopharma and academic markets, I mean is your view on sort of the growth trajectory there changed at all, whether its based on global mix or sort of whats gone on from recovery perspective broadly from - in terms of the economy?
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","You know, Ross, our view hasnt changed. We actually have remained confident that 2010, 11, and really as much as anybody can have a portal into the future of 2012 look pretty good for us. And so we think the next couple of years just due to our disc",81,"You know, Ross, our view hasnt changed. We actually have remained confident that 2010, 11, and really as much as anybody can have a portal into the future of 2012 look pretty good for us. And so we think the next couple of years just due to our disciplined execution, our international footprint, and all of these new products continuing to come out of the R&D labs, we feel we can continue to grow above the market, as we have demonstrated.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Thanks a million, Greg.",4,"Thanks a million, Greg.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Yes.",1,"Yes.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thank you. This concludes our first quarter earnings conference call. This webcast will be available via a replay on our website for three weeks. As a reminder, we will be hosting a followup Q&A call for investors and analyst at 7O Clock PM Eastern Tim",74,"Thank you. This concludes our first quarter earnings conference call. This webcast will be available via a replay on our website for three weeks. As a reminder, we will be hosting a followup Q&A call for investors and analyst at 7O Clock PM Eastern Time. You can find dial-in information on the Investor Relations page of our website and then in the press release we issued this morning. Thank you again for joining us.
"
30253,100477331,57967,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Ladies and gentlemen, that concludes todays conference. Thank you for your participation. You may now disconnect and have a wonderful day.",21,"Ladies and gentlemen, that concludes todays conference. Thank you for your participation. You may now disconnect and have a wonderful day. 

"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Good day, ladies and gentlemen, and welcome to the Q1 2010 Life Technologies Corporation Earnings Conference Call. My name is Tamina, and I will be your operator for today. [Operator Instructions] I would now like to turn the conference over to your host",55,"Good day, ladies and gentlemen, and welcome to the Q1 2010 Life Technologies Corporation Earnings Conference Call. My name is Tamina, and I will be your operator for today. [Operator Instructions] I would now like to turn the conference over to your host for today, Ms. Eileen Pattinson, head of Investor Relations. Please proceed, ma'am."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Tamina, and good afternoon, everyone. Welcome to Life Technologies First Quarter Earnings Conference Call.  Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer. In addition, Mark St",187,"Thank you, Tamina, and good afternoon, everyone. Welcome to Life Technologies First Quarter Earnings Conference Call.  Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer. In addition, Mark Stevenson, our Chief Operating Officer; and Bernd Brust, our Chief Commercial Officer, are available during the Q&A portion of the call. If you haven't received a copy of today's press release, you may obtain one from our website at lifetechnologies.com.
I want to remind our listeners that our discussion today will include forward-looking statements including, but not limited to, statements about future expectations, plans and prospects for the company. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated. It is our intent that these forward-looking statements be protected under the Safe Harbor created by the Private Securities Litigation Reform Act of 1995. Additionally, we'll be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP can be found in today's press release or on our website. I will now hand the call over to Greg Lucier."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Eileen, and thanks to all of you for joining us. I hope you've had a chance to review the press release we put out this afternoon. As you can see from our results, we delivered another quarter of strong top and bottom line growth, and we are pleas",1424,"Thanks, Eileen, and thanks to all of you for joining us. I hope you've had a chance to review the press release we put out this afternoon. As you can see from our results, we delivered another quarter of strong top and bottom line growth, and we are pleased with how we have started in 2010.
Revenue grew 10% organically to $887 million, a result of terrific growth in both instruments and consumables. Operating margins expanded by 330 basis points to hit a record 29.5%. And earnings per share grew 21% to $0.87 for the quarter. This quarter marks the 14th quarter in a row that this company has met or exceeded its financial targets on both the top and the bottom line. This milestone demonstrates how seriously we take our commitment to our shareholders. Our teams around the world have proven that they know how to put their heads down and get the work done, driving above market revenue growth with a relentless focus on execution.
As I do every quarter, I'll take a few moments now to talk about these results in the context of our strategic imperatives: Delivering on the integration, realizing the potential of this new company and investing for the future.
First, we made significant progress on our integration goals for the year. The sales force reorganization is complete and our reps are hitting the street with a singular purpose of adding value for our customers. Our ultimate goal is to become their partner of choice by providing unparalleled customer service and offering an expansive portfolio of innovative products that simplify and streamline entire workflows. 
In addition, we announced the closure of two manufacturing sites in Camarillo, California and Bromborough, U.K. The work to consolidate these operations into our facilities in Frederick, Maryland and Warrington, in the U.K. is well underway and going successfully. These initiatives, as well as many others, will generate an additional $20 million in annualized synergies. This brings us one step closer to our goal of putting action plans in place that will generate an additional $70 million in annualized savings by the end of this year.
Our diligent approach to the integration has not only paid off from a near-term synergy perspective, but has set us up for success in other important ways. In particular, we've made great strides in realizing the potential of the new company, which is our second strategic imperative. Let me now share with you some ways in which we optimize the value of our combined company in the first quarter.
As I mentioned, we grew revenue 10% organically. Regionally, Japan was a stand up performer with 23% growth for the quarter. Throughout 2009, our team in Japan executed on a strategy to optimize our commercial structure in the region. Among other actions, we increased the number of sales reps in the field and implemented a new dealer strategy that more closely align incentives with performance. These efforts position us well to take advantage of the additional research funding that the Japanese government released in the first quarter of 2010. As a result, we had strong sales across all of our businesses in Japan with a notable increase in sales of the new 3500 Genetic Analyzer and the Neon Transfection system.
Growth in Japan was also positively impacted from a list in realized priced in recognition of the last installment from the landmark police forensics deal. We are very pleased with this performance and recognize the tremendous efforts that our team in Japan is putting forth. However, this remains a very challenging region, and we expect growth to be in the low single digits for the balance of the year now.
The Americas region grew 8% in the quarter, with stimulus-related revenues contributing approximately 3% of this growth. While we did not see a significant ramp up in stimulus revenues from the fourth quarter, we are still confident in our estimate of greater than $100 million over the life of this federal program. However, because of the slow ramp up in stimulus-related spending, we believe that more of this revenue might now push into 2011 than we had originally anticipated.
I'd like to now talk a bit about our last strategic priority, investing for future growth. As I've stated in the past, we expect to grow revenue one to two points faster than the market for the foreseeable future. One of the ways in which we will achieve this goal is the consistent introduction of new and innovative products. It is critical to have an eye on the future and anticipate the areas that will drive growth in the months and the years to come. To that end, we have spent considerable efforts fine-tuning our innovation techniques over the last 24 months and focused our efforts on several key areas, including genetic sequencing, synthetic biology, flow cytometry, benchtop devices and PCR. In addition to meeting the needs of our research customers, investments in these areas will increasingly move us into higher growth, commercial and clinical realms.
We will go into more detail about our investment strategies at our upcoming Investor Day in June, but I'll give you a few highlights of some of our recent product introductions now.
Yesterday, we issued a press release about the debut of the industry's first benchtop proteomic and epigenetic sample preparation system, the MAGic Sample Processor. In line with our strategy of offering innovative products that simplify and streamline workflows, this new device cuts protocol times in half and dramatically reduces experimental errors by automating manual processes. MAGic utilizes microfluidics, thermal controls and integrated magnetic separation technology, which enables researchers to more easily perform technically challenging experiments in protein purification and epigenetics.
We are particularly excited about this launch as it is another product in a growing line of innovative, productivity-enhancing benchtop devices. And I might add, it combines the very best of Life Technologies' engineering, Dynabead technology and our consumables channel. It is a product that couldn't  have been created without the creation of Life Technologies.
In addition to the launch of MAGic, last week at the American Association for Cancer Research, we unveiled several new technologies, including research-only KRAS and BRAF mutation analysis reagents that can be analyzed using the 3500 Genetic Analyzer. We also announced our newest innovation in realtime PCR, the ViiA 7 Real-Time PCR system. The ViiA 7 system offers maximum productivity, ease of use and instrument-to-instrument consistency. While the ViiA 7 system is currently for research-use only, it was designed with clinical applications in mind. We expect to get a CE-IVD mark later in the year and ultimately plan for 510(k) clearance in the U.S.  Gaining these clearances will extend the application of the ViiA 7 system beyond research labs and into clinical and diagnostic markets.
The launch of the ViiA 7 system is part of our broader strategy to extend our leadership position in PCR by setting new technology standards. We began executing upon this strategy in 2009 when we acquired Cytonix for intellectual-property related to digital PCR technology, and then followed that with the acquisition of BioTrove for its OpenArray platform, enabling high throughput traditional genotyping into PCR as well as digital PCR reads.
Today, I'm pleased to announce the acquisition of Stokes Bio, whose ground-breaking technology redefines the current play-safe paradigm for the PCR process, generating orders of magnitude more data in less time. Stokes Bio has developed the microfluidic-base system for high throughput, highly flexible genotyping, gene expression analysis and digital PCR. This technology is well suited to meet the ever growing demand for higher throughput genomic analysis in agriculture, drug discovery, translational research and other applications being fueled by the rapid rate of discovery from next-generation sequencing systems such as ours.  The acquisition of Stokes Bio is another very exciting step forward as we continue to build out and redefine the PCR industry.  These combined assets will enable our vision of delivering TaqMan's performance in quality: Fast, easy and configured for customer throughput and flexibility needs.
Building out our PCR franchise through both internal development and the acquisition of technologies is just one example of how we are investing in our future. We have many programs in place that will ultimately drive our business forward and it's a smart and efficient allocation of resources to these programs that will set us up for success in the years to come.
With that, I'll turn it over to David who will provide a little more color on our divisional performance and overall financial results. David?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Greg. This quarter, we grew revenue 13% to $887 million. Currency had a positive four-point impact on reported revenue growth, and acquisitions and divestitures had a negative one-point impact. Excluding the effect of currency, acquisitions and di",1767,"Thanks, Greg. This quarter, we grew revenue 13% to $887 million. Currency had a positive four-point impact on reported revenue growth, and acquisitions and divestitures had a negative one-point impact. Excluding the effect of currency, acquisitions and divestitures, revenue grew 10% organically.
This performance was the result of strong volume growth and better pricing in most areas of the business. In addition, growth was positively impacted by three items in particular. As Greg mentioned before, we recognized $8 million in revenue from the last installment of the Japanese police order. We also benefited from spending related to the supplemental budget in Japan, which added $4 million in revenues. And finally, revenue associated with the NIH stimulus totaled $10 million. These three items added about 3% to the overall growth rate.
Before I walk through some of the divisional highlights, I'd like to point out a relatively small change in our division structure that went into effect at the beginning of the year. In order to better align certain technologies within our divisions, we created a new business unit called Applied Molecular Testing, which is now part of the Molecular Biology Systems division.
Going forward, all of our animal, biosecurity, food and environmental testing products will be accounted for in this new business unit. In addition to this change, we moved certain products associate with our Pharma-Analytics business from Genetic Systems to Cell Systems to more closely align our product offerings for pharmaceutical and biological production.
As a result, product lines totaling approximately $50 million in revenue were moved between divisions. For year-over-year comparison purposes, we've posted a worksheet on our website that restates divisional revenue for 2009. In addition, we will be providing more detail during the post earnings Q&A call later this afternoon.
Now, I'll get into the divisional highlights. Molecular Biology Systems grew approximately 10% organically to $432 million in revenue. Our PCR business grew in the teens, driven by a particularly strong demand for instruments in the Americas and Asia, as well as the Japanese police order that I referenced earlier.  Genomic Assays also performed well with double-digit growth in the Americas, Asia-Pacific and Japan. Lastly, the Molecular Biology Reagent business benefited from strong sales of reagents in all regions.
Genetic Systems grew 12% organically to $238 million. CE, our largest technology group in this division grew mid-single digits for the quarter, driven by growth in both consumables and instruments. Consumables continue to experience solid growth in research and applied applications. Instrument growth was driven by strong sales in clinical research, particularly for the newly launched 3500 Genetic Analyzer, partially offset by a year-over-year decline in instruments sold into applied markets due to a large sale in the first quarter of last year.
And finally, we continue to gain traction in next-generation sequencing as we improved the ease-of-use and the performance of the SOLiD platform, ongoing improvements in the technology, new product launches such as the SOLiD PI system, along with investments in our field support, sales teams and marketing are paying off. A good example of this is the British Columbia Cancer Agency's purchase of 10 SOLiD 4 units for their research. The accuracy of the SOLiD System is increasingly recognized by thought leaders as critical for cancer-related research.
Cell Systems had revenues of $214 million, representing 8% organic growth. Growth in this division increased compared to prior quarters as pharmaceutical and biotech end markets started to improve. This quarter saw a double-digit growth in Bioproduction driven by new drug introductions, and the timing of large customer orders.
Primary and Stem Cell Systems also posted strong growth in the quarter driven by demand for both media and reagents. And lastly, our Dynabeads-based business grew in the double digits on large orders from molecular diagnostic customers.
In terms of organic growth by region, the Americas grew 8%, Europe grew 5%; Asia-Pacific, 25%; and Japan, 23%. As I mentioned earlier, currency added four points of growth to revenue for the quarter, net of our hedging program. The positive impact to EPS was approximately 7% or $0.07, including foreign currency impacts accounted for in revenue and other income.
First quarter non-GAAP gross margin was 68.3%, an increase of approximately 160 basis points over prior year. This improvement was primarily due to price, currency, synergies and manufacturing productivity.  On a sequential basis, gross margins increased by 330 basis points due to increases in price and royalty revenue, and higher productivity in our plants.  Keep in mind that gross margins in the fourth quarter are typically lower, so a sequential increase was expected. 
First quarter operating expenses were $343 million, an increase over prior year levels of 8% with currency and 6% without currency. Operating expenses increased due to increases in R&D, depreciation and cost associated with employee stock options. Sequentially, operating expenses were relatively flat, mainly due to delaying some investments until we had a better understanding of how stimulus-related revenues would flow in the quarter. Operating income was $262 million, an increase of 27% over prior year, including the impact of currency, and 20% excluding currency. Operating margin was 29.5%, representing 330 basis points of improvement year-over-year, including the impact from currency.
This level of operating margin expansion resulted from improved gross margins, synergies and other operating expense reductions. As we've said before, our goal over the next several years is to consistently deliver 50 plus basis points of operating margin improvements.
In terms of other income, we had $1 million of interest income, $3 million from currency gain and $1 million of expense from our mass spec joint venture. Interest expense for the quarter was $30 million.
Our non-GAAP tax rate was 30%, slightly higher than guidance due to the expiration of the federal R&D tax credit. We believe that this tax credit will be renewed at some point during the year. If renewed, the credit will reduce our full year tax rate by approximately one percentage point. Therefore, we expect our full year tax rate to be between 29% and 29.5%. Our diluted share count for the quarter was $190 million shares. As you will recall, our share count is impacted our stock price due to our convertible debt and employee stock options.  We continue to expect a full year diluted share count of 192 million to 194 million shares, assuming an average stock price for the year between $52 and $55 per share.
GAAP diluted earnings per share were $0.48, which includes a gain of $0.14 per share on the sale of the mass spec division, $0.25 of acquisition-related amortization expense, $0.03 per share of non-cash interest expense associated with the adoption of APB 14-1, $0.08 per share of business integration cost and other items, and $0.17 per share of accelerated amortization of debt issuance cost resulting from the early repayment of debt. On a non-GAAP basis, which exclude these items, diluted earnings per share were $0.87, a 21% increase over last year.
Moving on to the balance sheet and cash flow, our ending cash and short-term investments were $642 million. This compares to last year's balance of $648 million. Cash from operating activities was $71 million, capital expenditures were $30 million, and free cash flow was $41 million. As a reminder, free cash flow is lower in the first quarter due to the payout of annual employee bonuses.
Return on invested capital increased 0.5% to 8.6%. We're making good progress towards our goal of a 10% return on invested capital in the next couple of years.
Paying down debt continues to be our top priority. To that end, we used the proceeds from the sale of the mass spec joint venture and the bond offering, as well as cash on hand, to pay off term loans amounting to $1.97 billion. As a result, our ending debt as of March 31 was $2.64 billion. This balance is made up of our convertible debt of $1.15 billion and senior notes of $1.5 billion.  Our leverage ratio is approximately 2.7x, and we still expect to be between 2x and 2.5x by the end of the year. Since the merger of Invitrogen and Applied Biosystems, we paid off $900 million in debt. 
I'll now move on to our expectations for the rest of the year. Our full year guidance is unchanged. Revenue growth is expected to be in the mid to high single digits, and EPS is expected to be in the range of $3.30 to $3.50.
As we stated in our Q4 call, the impact from the NIH stimulus is the Main driver between the mid and high single-digit revenue growth. As Greg mentioned earlier, the impact from the stimulus was approximately the same as we saw in the fourth quarter of last year, $10 million. At this point, we expect that the impact of stimulus funding will be spread over a longer period of time with more of the spending now pushed into 2011. We'll keep you updated on the impact of the stimulus funding as we move through the year.
As is our practice, I will also give you a few specific items to take into consideration for the coming quarter. First, in regard to the stimulus, as we stated on the Q4 call, we intend to reinvest approximately half of the operating profit from the stimulus back into the business to fund future growth opportunities. These reinvestments will begin in the second quarter and will be primarily focused on R&D and commercial projects in emerging markets such as China and India. Gross margins are expected to decrease sequentially as price is normally strongest in the first quarter. Additionally, in the second quarter, we expect to sell a higher mix of instruments which are lower margin than our consumables.
Operating expenses are expected to increase sequentially due to increases in investments in emerging markets and R&D, as well as the full quarter impact of new hires and merit increases that went into effect at the beginning of April. Our currency guidance is unchanged. We continue to expect the impact on revenue will be one to two points of additional growth for the year including the impact of our hedging programs.
And lastly, we received questions on the impact to our business of the eruption of the volcano in Iceland, and we're pleased to report there's been no material impact on revenue. Delivery times did increase slightly due to a switch from air to ground freight. However, we were able to supply our customers from stock at our European distribution centers.
And with that, I'll now hand the call over to Eileen for Q&A."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, David. Because of time constraints, I'd like to ask everyone to limit themselves to one question and one follow-up question. If you have additional questions after that, and you would like to ask, please get back in the queue, and we can take a",69,"Thank you, David. Because of time constraints, I'd like to ask everyone to limit themselves to one question and one follow-up question. If you have additional questions after that, and you would like to ask, please get back in the queue, and we can take any remaining questions on the post call scheduled for later this afternoon. Operator, we are now ready for the Q&A portion of the call."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","[Operator Instructions] Our first question comes from the line of Quintin Lai with Robert Baird.***",16,"[Operator Instructions] Our first question comes from the line of Quintin Lai with Robert Baird.
***"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","First question, Greg, with respect to the NIH stimulus and it's getting -- looks like it's going to be spread out a little bit further, could you tell us a little bit about what are your customers doing, is it just being more cautious? And then with respe",69,"First question, Greg, with respect to the NIH stimulus and it's getting -- looks like it's going to be spread out a little bit further, could you tell us a little bit about what are your customers doing, is it just being more cautious? And then with respect to your reaffirmed guidance, is it that other markets or new products will help make up for that little push out?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, Quintin, I think the first quarter shows that even with a lower stimulus spending than perhaps we all envisioned, we still grew organically at 10%. And so I think it shows that the teams are executing and that we maybe perhaps gaining share. And so",95,"Well, Quintin, I think the first quarter shows that even with a lower stimulus spending than perhaps we all envisioned, we still grew organically at 10%. And so I think it shows that the teams are executing and that we maybe perhaps gaining share. And so as we look at now stimulus being spread out over more quarters than we originally thought, I think what we're counting on and we've demonstrated it, that we can execute, we can grow and still achieve the financial estimates that we've given you and others for the 2010 year."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And then just a quick follow-up, what percent of your sales are being generated by new products over, like, the last two years?",24,"And then just a quick follow-up, what percent of your sales are being generated by new products over, like, the last two years?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Eileen, maybe I'll turn that to you in terms of that particular fact.",13,"Eileen, maybe I'll turn that to you in terms of that particular fact."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","We actually haven't giving out that level of detail in terms of new revenue generated by new products. But we'll probably get into more detail, Quintin, at the Analyst Day in June.",33,"We actually haven't giving out that level of detail in terms of new revenue generated by new products. But we'll probably get into more detail, Quintin, at the Analyst Day in June."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Tycho Peterson with JPMorgan.",9,"Our following question comes from Tycho Peterson with JPMorgan."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","David, in your comments a minute ago, you just talked about some of the commercial investments in China and India. Can you elaborate a little bit on what that entails?",30,"David, in your comments a minute ago, you just talked about some of the commercial investments in China and India. Can you elaborate a little bit on what that entails?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Why don't I hand that over to Bernd?",9,"Why don't I hand that over to Bernd?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Tycho, in China and India, I mean, the focus really continues to be for us to get closer and closer to our customers. That's really that means [ph] and a couple of things. We continue to invest in our IT infrastructure, making sure our websites are in loc",71,"Tycho, in China and India, I mean, the focus really continues to be for us to get closer and closer to our customers. That's really that means [ph] and a couple of things. We continue to invest in our IT infrastructure, making sure our websites are in local language and has accessibility to local markets that way, as well as continuing to invest in direct sales forces for both those countries."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And then with regards to the Flow Cytometry business, you've talked about that being a pretty large market, I think $1.7 billion or so. Can you talk a little bit about how the early reception to Attune has been and how you're approaching the go-to-market",46,"And then with regards to the Flow Cytometry business, you've talked about that being a pretty large market, I think $1.7 billion or so. Can you talk a little bit about how the early reception to Attune has been and how you're approaching the go-to-market strategy?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Mark, you want to grab that one?",7,"Mark, you want to grab that one?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Yes, I can add to [ph] that. So yes, we think it's a big opportunity. Actually $1.4 billion was the number we've put out for the size of the market. We've just started shipping our first early access units to customers here in the U.S. and shipped our fir",93,"Yes, I can add to [ph] that. So yes, we think it's a big opportunity. Actually $1.4 billion was the number we've put out for the size of the market. We've just started shipping our first early access units to customers here in the U.S. and shipped our first unit into Europe. The reaction has been very positive, particular around the ability to detect rare events. So the ability to slow the flow down and to do something that other systems can't do in traditional flow has been well received by the market."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And then Mark, just one last one on the enhancements to SOLiD that you highlighted at AGBT, can you talk a little bit about how EZ Bead has done and what the customer reception has been to SOLiD 4?",39,"And then Mark, just one last one on the enhancements to SOLiD that you highlighted at AGBT, can you talk a little bit about how EZ Bead has done and what the customer reception has been to SOLiD 4?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","The customer reception on EZ Bead has been very positive. I mean, really that was one of the major bottlenecks they were finding. And so just being able to automate that front end is a big relief for many of those customers who wanted to get into the accu",112,"The customer reception on EZ Bead has been very positive. I mean, really that was one of the major bottlenecks they were finding. And so just being able to automate that front end is a big relief for many of those customers who wanted to get into the accuracy, but needed that automation upfront. And then on SOLiD 4, really, the combination of the new pricing and the rollout of the new software and system in there has been well received. We've been very active in this quarter in rolling that out and have good update on the SOLiD 4. We had our best quarter ever as you saw in our results."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Doug Schenkel with Cowen and Company.",11,"Our following question comes from Doug Schenkel with Cowen and Company."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","So first question, I believe you said that there were some signs the biopharma end market is starting to improve. Could you just provide a little bit more color in terms of exactly what you're seeing? And would you be willing to tell us what biopharma sal",53,"So first question, I believe you said that there were some signs the biopharma end market is starting to improve. Could you just provide a little bit more color in terms of exactly what you're seeing? And would you be willing to tell us what biopharma sales growth is incorporated into your guidance?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, in the latter part, I don't think we're willing to disclose that level of detail. But on the first part of your comment, as we look at the first quarter of 2009 and then compare it to the first quarter of 2010, there clearly has been a recovery in r",94,"Well, in the latter part, I don't think we're willing to disclose that level of detail. But on the first part of your comment, as we look at the first quarter of 2009 and then compare it to the first quarter of 2010, there clearly has been a recovery in research spending across the biopharma customer base for us. Now it's still not having returned to 2008 levels, but it's coming back quarter by quarter nicely. And that type of incremental return is what we have thought about and included in our 2010 estimate."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And any chance you'd be willing to speak to whether you're seeing demand across all areas of pharma spending? Meaning, is it more on early stage or late stage, do you have that level of detail available?",38,"And any chance you'd be willing to speak to whether you're seeing demand across all areas of pharma spending? Meaning, is it more on early stage or late stage, do you have that level of detail available?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, screening campaigns as an example, greatly dropped off when the economic crisis hit. We're starting to see screening campaigns return again, and we're also seeing more spending back into the basic research areas as well. And so I'd say there is just",57,"Well, screening campaigns as an example, greatly dropped off when the economic crisis hit. We're starting to see screening campaigns return again, and we're also seeing more spending back into the basic research areas as well. And so I'd say there is just, overall, a better tone and tenor to the research spending in that customer base."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And one more question, Greg, I think you were over at the GET [Genomes Environments Traits] Conference today in Boston, or at least, I think you were scheduled to be there. There's a decent focus -- I mean, the focus of that meeting was on personalized ge",99,"And one more question, Greg, I think you were over at the GET [Genomes Environments Traits] Conference today in Boston, or at least, I think you were scheduled to be there. There's a decent focus -- I mean, the focus of that meeting was on personalized genomes. One of your challenges in second-generation sequencing has been the fact that you were second to the market. Do you expect this challenge that you've had over the last couple of years with SOLiD to be different in this area of sequencing? I mean, do think you're better positioned at personalized medicine?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, I think, as Mark referenced, we believe SOLiD has a distinct accuracy advantage versus other platforms, and customers that are discriminating are starting to understand that. And we think that really allows SOLiD to be a preferred platform for medic",103,"Well, I think, as Mark referenced, we believe SOLiD has a distinct accuracy advantage versus other platforms, and customers that are discriminating are starting to understand that. And we think that really allows SOLiD to be a preferred platform for medical applications. And that's where all our efforts really, ever more, are focused is this move more towards the clinical application of sequencing. So that's, as Mark said, why we had one of our best quarters ever in SOLiD and why we feel that, while we may have been second, we might just be first in terms of the medical application of sequencing."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Marshall Urist with Morgan Stanley.",10,"Our following question comes from Marshall Urist with Morgan Stanley."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","If we just cut the business as consumables growth versus instruments in the quarter, can you tell us what the relative organic growth rates were?",25,"If we just cut the business as consumables growth versus instruments in the quarter, can you tell us what the relative organic growth rates were?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","So Greg, I can take that. We actually grew low double digits in both areas of the business.",18,"So Greg, I can take that. We actually grew low double digits in both areas of the business."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And then I realize that you may be pushing out some of stimulus into next year, but maybe talk about, so are you expecting kind of the $10 million level to continue over the next few quarters, or we still see some incremental growth off of that and kind o",63,"And then I realize that you may be pushing out some of stimulus into next year, but maybe talk about, so are you expecting kind of the $10 million level to continue over the next few quarters, or we still see some incremental growth off of that and kind of is that making you comfortable still with organic growth guidance for the year?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, we feel comfortable about the organic growth guidance for the year. We've reaffirmed that. But in terms of particular amount of stimulus in the ensuing quarters, I'll defer to you, Eileen, in terms of disclosure.",36,"Well, we feel comfortable about the organic growth guidance for the year. We've reaffirmed that. But in terms of particular amount of stimulus in the ensuing quarters, I'll defer to you, Eileen, in terms of disclosure."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Greg, this is David. If I can add, in our guidance, in our revenue guidance, we've said growth for the year of mid to high single digits. And that basically covers that range of stimulus. So if we get more stimulus, we'll move towards that high single-dig",95,"Greg, this is David. If I can add, in our guidance, in our revenue guidance, we've said growth for the year of mid to high single digits. And that basically covers that range of stimulus. So if we get more stimulus, we'll move towards that high single-digit growth. The lower level of stimulus that we have will be closer to mid single digits. And I think no one knows, we're watching it very closely. Bernd has a dedicated team that's following it, but it's really beyond our control. We'll just see how it flows out."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Jon Groberg with Macquarie.",9,"Our following question comes from Jon Groberg with Macquarie."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Just two questions. The first is, you mentioned on the Genetic Systems and CE that you continue to see some growth. And I'm curious, one of the labs that reported last week was saying that even though people are very interested, states are very interested",98,"Just two questions. The first is, you mentioned on the Genetic Systems and CE that you continue to see some growth. And I'm curious, one of the labs that reported last week was saying that even though people are very interested, states are very interested in forensics and human identification, that given the budget situations of many of these, that they're just not able to do what perhaps they would like to do. And I'm just curious if you're seeing any of that impact or expect to see some of that impact as you go throughout the year?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Mark, you want to want to handle that one?",9,"Mark, you want to want to handle that one?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Yes, I mean, so far our demand for the forensic sample analysis far outstretch both capabilities of lab. And to some extent, funding -- so to the extent, there is more funding available, I mean, this year, we were fortunate the Debbie Smith Act here in th",118,"Yes, I mean, so far our demand for the forensic sample analysis far outstretch both capabilities of lab. And to some extent, funding -- so to the extent, there is more funding available, I mean, this year, we were fortunate the Debbie Smith Act here in the U.S. was reauthorized fully at $151 million, and that gets trickled down to the states. Clearly, the states under some pressure, but mostly we see the political pressure and will restore [ph] to fund increased DNA testing. But here in the U.S. and as we've seen internationally, with Japan coming on board and strong growth in other countries around the world, it still is a double digit growing market for us."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And then Greg, one of the aspects of the story that was very interesting about Invitrogen, and maybe it's gotten lost a little bit, is your eCommerce channel. And just I noticed that you, I think, sort of grew 18% in the quarter. Maybe you can just talk a",72,"And then Greg, one of the aspects of the story that was very interesting about Invitrogen, and maybe it's gotten lost a little bit, is your eCommerce channel. And just I noticed that you, I think, sort of grew 18% in the quarter. Maybe you can just talk about any initiatives you have there, kind of where that's falling on the relative importance and where you look to invest with the firm?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, we have a goal internally to try to surpass the $1 billion mark of eCommerce across both the invitrogen.com site and the ab.com (sic) [appliedbiosystems.com] site, which $1 billion of eCommerce, I think, in any industry there's probably only a handf",137,"Well, we have a goal internally to try to surpass the $1 billion mark of eCommerce across both the invitrogen.com site and the ab.com (sic) [appliedbiosystems.com] site, which $1 billion of eCommerce, I think, in any industry there's probably only a handful that are doing that level of sales. When we combine the two companies, we combine the two eCommerce teams and actually added to them, and so we've got a very large team in infrastructure now. And as Bernd said, the real work is to add what maybe we see as some sophisticated features in other industries into this one. And more importantly, in some ways is, to localize the sites into China, into Japan, into other languages to really drive that revenue growth. And it's been very successful for us, and so we continue it."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from the line of Steven Lichtman with JMP Securities.",13,"Our following question comes from the line of Steven Lichtman with JMP Securities."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Did this quarter include any placements of SOLiD to Ignite? And if not, when is that expected to start this year?",21,"Did this quarter include any placements of SOLiD to Ignite? And if not, when is that expected to start this year?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Bernd, I'll turn that to you.",6,"Bernd, I'll turn that to you."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Steve, no SOLiD units were placed with Ignite yet. As you know, Ignite is still finalizing its business plans. We are all set to continue to partner with them as they finalize how they will get to commercialize soon here. So at this point, no SOLiD units",50,"Steve, no SOLiD units were placed with Ignite yet. As you know, Ignite is still finalizing its business plans. We are all set to continue to partner with them as they finalize how they will get to commercialize soon here. So at this point, no SOLiD units have been placed."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And then just the follow-up on foreign currency, if you could, maybe just a little bit more details on the hedging program. Just given the strengthening of the dollar, we're still keeping it in that 1% to 2% range. How are you keeping it still in that pos",77,"And then just the follow-up on foreign currency, if you could, maybe just a little bit more details on the hedging program. Just given the strengthening of the dollar, we're still keeping it in that 1% to 2% range. How are you keeping it still in that positive 1% to 2% impact to the top line? And do you expect the bottom line impact to be the same as you thought a couple of months back?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Yes, at this point, we don't see any significant change in our projection.",13,"Yes, at this point, we don't see any significant change in our projection."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","On the bottom?",3,"On the bottom?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","No, neither at [ph] the top line or the bottom line, should still be covered by our guidance.",18,"No, neither at [ph] the top line or the bottom line, should still be covered by our guidance."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Derik De Bruin with UBS Capital.",11,"Our following question comes from Derik De Bruin with UBS Capital."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","But I'm curious just on the Cell Systems strength, I'm curious, have you seen a real boost from the stem cell initiatives throughout [ph] that funding was coming from California? They had to build bundle [ph] a couple of years ago. Has any real meaningful",122,"But I'm curious just on the Cell Systems strength, I'm curious, have you seen a real boost from the stem cell initiatives throughout [ph] that funding was coming from California? They had to build bundle [ph] a couple of years ago. Has any real meaningful funds come from that or have you seen, as that get tied up the budgets -- and I also kind of want to take that on just as a follow-up on the whole Cell Systems specifically. Like, what have you seen in terms of Bioproduction, it's picked up yet? Have some of the recent contamination issues in some of the big companies, have that had an impact on your customers getting more concerned about quality control?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","This is Greg. Overall, Cell Systems had a very good quarter. And as you referenced, Bioproduction had, in particular, a good quarter. And the contamination issues you referenced didn't impact us, but as you say, I think further stimulates another part of",132,"This is Greg. Overall, Cell Systems had a very good quarter. And as you referenced, Bioproduction had, in particular, a good quarter. And the contamination issues you referenced didn't impact us, but as you say, I think further stimulates another part of our business, which is the use of PCR technology in quality control. So we see a very robust future of applying that technology at the Bioproduction. On the stem cell side, as you know, we started that business several years ago and brought in some real strong leadership. That's the business now that continues to grow at very strong double digits, spurred on by NIH work, California, overseas and just the general move towards primary cell usage. So it's been a great business for us and continues to do so."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","But the R&D spend was a little bit below where I thought it was going to be tracking for this quarter. Are you still expecting that to ramp up significantly and towards the back half as we move for [ph] the year?",43,"But the R&D spend was a little bit below where I thought it was going to be tracking for this quarter. Are you still expecting that to ramp up significantly and towards the back half as we move for [ph] the year?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","As we said in our guidance, in the second quarter, we do plan incremental investments in R&D, and so you will see the R&D line pick up going forward here.",30,"As we said in our guidance, in the second quarter, we do plan incremental investments in R&D, and so you will see the R&D line pick up going forward here."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Jon Wood with Jefferies.",9,"Our following question comes from Jon Wood with Jefferies."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","So it looks like you'll be with -- I mean, I have you below within your target leverage ratios. But I think I heard David say 2.7. It looks like you'll be well within that in the second quarter. Is it reasonable to assume there's some share repurchases th",57,"So it looks like you'll be with -- I mean, I have you below within your target leverage ratios. But I think I heard David say 2.7. It looks like you'll be well within that in the second quarter. Is it reasonable to assume there's some share repurchases that could begin here in the second quarter?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, I think our use of capital hasn't changed. So number one use is to pay down the debt. And you're right, John, we want to get between 2x to 2.5x, and that we have said we'll certainly be there by the end of the year. I don't know if we'll be there in",148,"Well, I think our use of capital hasn't changed. So number one use is to pay down the debt. And you're right, John, we want to get between 2x to 2.5x, and that we have said we'll certainly be there by the end of the year. I don't know if we'll be there in the second quarter. We also, in terms of paying down the debt, we have convert that's callable in August. That's $350 million, and at the current level of stock, we would call that at that point in time. Once we're within our range, and we have been, second use of our cash is to look at acquisitions, primarily tuck-in and key technologies. And then, our philosophy still is to return excess cash to shareholders. So at that point, we would look at share buybacks, but that would probably be end of the year 2011."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Are you willing to disclose anything? I mean, you've announced a tuck-in today, and then I saw on the tape about a month ago, a German company, GENEART. Disclose what in terms of invested capital to assume from these deals in the second quarter?",44,"Are you willing to disclose anything? I mean, you've announced a tuck-in today, and then I saw on the tape about a month ago, a German company, GENEART. Disclose what in terms of invested capital to assume from these deals in the second quarter?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","So Jon, we haven't released any information around those two acquisitions in terms of more than what you've already got.",20,"So Jon, we haven't released any information around those two acquisitions in terms of more than what you've already got."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And the only way you can pay down debt at this point is the convert, right? Because I think you're fixed on the senior notes side at this point, is that correct, David?",33,"And the only way you can pay down debt at this point is the convert, right? Because I think you're fixed on the senior notes side at this point, is that correct, David?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Yes, that's correct. We have the $1.2 billion roughly of converts outstanding that have put-call dates over the next three years.",21,"Yes, that's correct. We have the $1.2 billion roughly of converts outstanding that have put-call dates over the next three years."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Jeff Ares with Leerink Swann.",10,"Our following question comes from Jeff Ares with Leerink Swann."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Going off of the other question about SOLiD and TGen, I remember when that was announced at the time, you said there were more potential deals like that in the pipeline. I'm wondering if you can provide us with an update on that --",44,"Going off of the other question about SOLiD and TGen, I remember when that was announced at the time, you said there were more potential deals like that in the pipeline. I'm wondering if you can provide us with an update on that --"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Mark and Bernd?",3,"Mark and Bernd?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Yes, you'll see in the coming pipeline, more focus, as Greg mentioned, where we see these interest in the translational medicine group, and TGen is a great example of actually taking what we're discovering about cancer and applying that. And an example, a",87,"Yes, you'll see in the coming pipeline, more focus, as Greg mentioned, where we see these interest in the translational medicine group, and TGen is a great example of actually taking what we're discovering about cancer and applying that. And an example, again, you saw this last quarter and within our numbers was the group in BC Cancer, which is really taking a discovery to translational medicine approach. There'll be more of those during the coming year, and you'll see those announced as we do those deals."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Could you provide us with a little update on how Project Starlight is going and if you guys are still targeting early access customers by the end of the year?",30,"Could you provide us with a little update on how Project Starlight is going and if you guys are still targeting early access customers by the end of the year?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","So we got very good reception from the technical data that we showed at the scientific meeting, the AGBT, just tremendous interest in some of the features of the system, particularly in its ability to do recursive sequencing, to go back over and improve b",83,"So we got very good reception from the technical data that we showed at the scientific meeting, the AGBT, just tremendous interest in some of the features of the system, particularly in its ability to do recursive sequencing, to go back over and improve both the accuracy and the relent [ph]. We're beginning now to talk with the early access customers that saw some of these presentations, and would expect to more fully engage with them at the end of this calendar year."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","You talked a time [ph] at AGBT that we'd be seeing some other data later this year. Any idea of timing for that, like, maybe Colorado [ph] spring or?",29,"You talked a time [ph] at AGBT that we'd be seeing some other data later this year. Any idea of timing for that, like, maybe Colorado [ph] spring or?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","We'll release some of the data as we go through the year. We haven't targeted, since it's not a commercial product, particular meetings. But there'll be key experiments we'll do and continue to share that with the community.",39,"We'll release some of the data as we go through the year. We haven't targeted, since it's not a commercial product, particular meetings. But there'll be key experiments we'll do and continue to share that with the community."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from the line of Dan Leonard with First Analysis.",13,"Our following question comes from the line of Dan Leonard with First Analysis."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","My first question is on the revenue guidance. Besides what you mentioned in Japan, as well as tougher year-over-year comps, is there anything else that we should think about mitigating your revenue growth through the balance of the year?",39,"My first question is on the revenue guidance. Besides what you mentioned in Japan, as well as tougher year-over-year comps, is there anything else that we should think about mitigating your revenue growth through the balance of the year?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","David?",1,"David?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","No, I think that you know the two things that we mentioned were Japan, which had just a phenomenal first quarter. As Greg pointed out, that team's done a great job, but we don't expect growth to continue at that rate in the subsequent quarters. And then t",60,"No, I think that you know the two things that we mentioned were Japan, which had just a phenomenal first quarter. As Greg pointed out, that team's done a great job, but we don't expect growth to continue at that rate in the subsequent quarters. And then the other wildcard is what we've talked about as well as the stimulus."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","Either Greg or David, could you walk me through the thought process in closing Camarillo and what steps you've taken to mitigate any disruption from that closure?",27,"Either Greg or David, could you walk me through the thought process in closing Camarillo and what steps you've taken to mitigate any disruption from that closure?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","You bet. Frederick, Maryland has become ever more of the R&D center for our Cell Systems business, and we have a lot of very talented R&D people there. And so we wanted to centralize the antibody piece of that overall portfolio into Frederick. I would als",140,"You bet. Frederick, Maryland has become ever more of the R&D center for our Cell Systems business, and we have a lot of very talented R&D people there. And so we wanted to centralize the antibody piece of that overall portfolio into Frederick. I would also say that by making it closer to our large distribution center there in Frederick, we can have much more rapid delivery times or the myriad of antibodies that we do provide. Now in terms of not having disruption, we've gotten pretty good at these transfers as we've brought together AB [Applied Biosystems] and Invitrogen. And so the same team that transferred production out of Foster City in 2009 is on the job here in Camarillo, and we've built up substantial inventories in Frederick ahead of time before we have phased out production in Camarillo."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Peter Lawson with Thomas Weisel Partners.",11,"Our following question comes from Peter Lawson with Thomas Weisel Partners."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","I wonder if you could just talk through what's happening with the NIH; meaning, what's the driving force behind that delay?",22,"I wonder if you could just talk through what's happening with the NIH; meaning, what's the driving force behind that delay?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Well, I think that's more speculation than anything if I was to give you answers. I think people are generally being cautious. I think they are trying to use other monies first. And I think that's just how we're seeing this play out right now. Now there i",76,"Well, I think that's more speculation than anything if I was to give you answers. I think people are generally being cautious. I think they are trying to use other monies first. And I think that's just how we're seeing this play out right now. Now there is a deadline for this program. It does have to all be spent by 2011, and so it will get spent. It's just a question of at what pace."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","And then just as a follow-up on the clinical market, you talked about that, what's your strategy there for diagnostics and have you talked any kind of revenue number over the next couple of years for that market?",39,"And then just as a follow-up on the clinical market, you talked about that, what's your strategy there for diagnostics and have you talked any kind of revenue number over the next couple of years for that market?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","We already do in excess of $300 million a year in molecular diagnostics. We, as I've said to others, have a very strong franchise in the fundamental tools and technologies that go into other people's diagnostics test. Secondly, we continue to get our plat",120,"We already do in excess of $300 million a year in molecular diagnostics. We, as I've said to others, have a very strong franchise in the fundamental tools and technologies that go into other people's diagnostics test. Secondly, we continue to get our platforms, our interim platforms, validated and certified. And as I'd mentioned, with the new ViiA 7, that's certainly our goal with this new PCR platform. So we'll have ever more instruments for molecular diagnostics. And then selectively, we're making smaller acquisitions like we did with AcroMetrix around molecular diagnostic controls. So we like our strategy, we think it's kind of a smart incremental way to build out from our core strength and it's giving us nice growth."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Our following question comes from Ross Muken with Deutsche Bank.",10,"Our following question comes from Ross Muken with Deutsche Bank."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Analysts","So as we think about kind of the portfolio as you've evolved it, we've obviously had a great amount of new product introductions, and you've set this sort of goal to grow above the market. I mean, as we look out on kind of a longer-term basis, as you look",96,"So as we think about kind of the portfolio as you've evolved it, we've obviously had a great amount of new product introductions, and you've set this sort of goal to grow above the market. I mean, as we look out on kind of a longer-term basis, as you look at sort of the biopharma and academic markets, has your view on the sort of the growth trajectory there changed at all, whether it's based on global mix or sort of what's gone on from a recovery perspective broadly from in terms of the economy?"
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Ross, our view hasn't changed, and we actually have remained confident that 2010, '11 and really, as much as anybody can have a portal into the future of 2012, look pretty good for us. And so we think the next couple of years, just due to our disciplined",80,"Ross, our view hasn't changed, and we actually have remained confident that 2010, '11 and really, as much as anybody can have a portal into the future of 2012, look pretty good for us. And so we think the next couple of years, just due to our disciplined execution, our international footprint and all of these new products continuing to come out of the R&D labs, we feel we can continue to grow above the market, as we have demonstrated."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Executives","Thank you. This concludes our First Quarter Earnings Conference Call. This webcast will be available via a replay on our website for three weeks. As a reminder, we will be hosting a follow-up Q&A call for investors and analysts at 7:00 p.m. Eastern Standa",73,"Thank you. This concludes our First Quarter Earnings Conference Call. This webcast will be available via a replay on our website for three weeks. As a reminder, we will be hosting a follow-up Q&A call for investors and analysts at 7:00 p.m. Eastern Standard Time. You can find dial-in information on the Investor Relations page of our website and in the press release we issued this morning. Thank you again for joining us."
30253,100477331,59141,"Life Technologies Corporation, Q1 2010 Earnings Call, Apr 27, 2010",2010-04-27,"Earnings Calls","Life Technologies Corporation","Operator","Ladies and gentlemen, that concludes today's conference. Thank you for your participation. You may now disconnect, and have a wonderful day.",21,"Ladies and gentlemen, that concludes today's conference. Thank you for your participation. You may now disconnect, and have a wonderful day."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Good day, ladies and gentlemen, and welcome to the Second Quarter 2010 Life Technologies Corporation Earnings Conference Call. My name is Diana, and I'll be your operator for today. [Operator Instructions] I would now like to turn the conference over to y",54,"Good day, ladies and gentlemen, and welcome to the Second Quarter 2010 Life Technologies Corporation Earnings Conference Call. My name is Diana, and I'll be your operator for today. [Operator Instructions] I would now like to turn the conference over to your host for today, Ms. Eileen Pattinson, Head of Investor Relations. Please proceed."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Diana, and good morning, everyone. Welcome to Life Technologies Second Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer. In addition, Mark Steve",187,"Thank you, Diana, and good morning, everyone. Welcome to Life Technologies Second Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer. In addition, Mark Stevenson, our Chief Operating Officer; and Bernd Brust, our Chief Commercial Officer, are available during the Q&A portion of the call. If you haven't received a copy of today's press release, you may obtain one from our website at lifetechnologies.com.
I want to remind our listeners that our discussion today will include forward-looking statements, including, but not limited to, statements about future expectations, plans and prospects for the company. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated. It is our intent that these forward-looking statements be protected under the Safe Harbor, created by the Private Securities Litigation Reform Act of 1995. Additionally, we will be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP can be found in today's press release or on our website. 
I'll now hand the call over to Greg Lucier."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Eileen, and thank you, all for joining us. Coming off the heels of our Investor Day just a few weeks ago, we are going to keep our prepared comments short this morning. So let's get started. As you can see from our results, we delivered another",1092,"Thanks, Eileen, and thank you, all for joining us. Coming off the heels of our Investor Day just a few weeks ago, we are going to keep our prepared comments short this morning. 
So let's get started. As you can see from our results, we delivered another quarter of strong top and bottom line growth. Revenue grew 6% organically to $906 million, 8% excluding the impact of H1N1 sales in 2009. Operating margins expanded by 290 basis points to reach a record 30.1%, and earnings per share grew 15% to $0.91 for the quarter.
We are pleased with our results for the second quarter in the first half of the year, which are a reflection of the fundamental strength of the business and the essential nature of our product offering. I'd like to extend my thanks to our teams around the world for their commitment to excellence and relentless focus on execution.
As I do every quarter, I'll take a few moments to talk about these results, give you an update on the integration and provide some color on the strength of our end markets. First, we continue to be very focused on the integration, and I'm pleased to report good progress towards our goal of putting actions in place that will generate $175 million in annual synergies by the end of 2010. 
In the second quarter, we continue to execute on an integration plan, including the placement of over 50 dual-branded supply centers around the world and further optimization of our combined eBusiness platforms. We are seeing good traction from these efforts and achieve new records for the number of the total transactions, both in North America and globally, that will process through eCommerce channels.
In terms of synergy capture, these actions, as well as many others, will generate another $15 million in annualized synergies, getting it halfway to our full year goal. Looking ahead in the second half of the year, we will continue to optimize the programs already started, as well as implement new initiatives, including additional site consolidations and cities where we have multiple offices, continuing to build out the combined eBusiness platforms and optimizing our distribution network.
Now beyond these integration activities, Life Technologies is well positioned to capture opportunities that will continue to drive strong revenue growth. Commercial execution, coupled with a broad product offering of innovative tools ensures that our products are an essential part of our customers' workflows. Recent launches have gone very well. Customer response to Attune, our flow cytometry offering and the ViiA 7 PCR instrument have been very positive, and the sales of our latest CE instrumentation, the 3500, have reinvigorated that business. Since the launch of the 3500 in Q4 of last year, we have placed approximately 400 instruments and demand continues to be very robust.
I'll take a moment now to walk you through more notable points on Q2 performance and give some color on what we're seeing on our end markets. The Americas delivered 7% organic growth in the quarter, 10% without the impact of H1N1. End markets in the Americas remain strong, with pharma and biotech continuing to pick up steam. Evidenced by the strong demand for our discovery and assay services business and double-digit growth in bioproduction. On the research side, stimulus-related revenues for the quarter were approximately $10 million, about the same as we've seen in prior quarters.
Our outlook for the stimulus is unchanged. We continue to estimate that we will generate more than $100 million in stimulus-related revenue over the life of this program. However, since we have not observed the material ramp-up in spending since the third quarter of last year, we estimate that stimulus-related revenues will be around $10 million per quarter in the second half of the year, with the rest of the benefit realized in 2011.
Europe grew 4% organically in the quarter. Growth for the quarter is slightly less than in recent periods due to the uncertainty about future government funding levels. At this time, we have no reason to believe that there will be declining government funding for our research in major European markets, such as U.K., Germany and France. However, some of our customers have reported that there have been delays in the release of funds from the institutions to researchers. In addition, researchers seem to be cautious in their spending due to fears that future funding may be curtailed. As a result, spending in these countries on both consumables and instruments softened towards the end of the quarter.
The situation in some of our smaller markets, such as Italy and Spain is slightly different. Funding in these countries have been negatively impacted to some degree as a result of the current economic environment. Revenue growth in these countries was flat during the second quarter. Looking forward to the second half, we expect that for the European region as a whole, revenue growth will be in the low-single digits or mid-single digits, excluding H1N1.
Moving on to other markets, Asia-Pacific had another strong quarter, growing 19% organically. End markets in the Asia Pacific region remain healthy, particularly in India and greater China, which grew an excess of 30% in the quarter. We were well positioned in these markets to continue to drive robust growth.
There's no change in our outlook for Japan. In the second quarter, Japan declined 4% organically as a result of a very difficult year-over-year comparison. As a reminder, Q2 of last year included revenue from a large police order, as well as H1N1. Excluding these items, Japan grew 3%, in line with expectations.
Now before I hand it over to David, I'm pleased to announce earlier this week, our Board of Directors approved a two-year $350 million share repurchase program, which is consistent with our strategy of balanced capital deployment. We intend to begin repurchasing shares in the fourth quarter after we have redeemed the 2% convertible notes in August, and we are within our target leverage ratio of 2x to 2.5x EBITDA. In general, the timing and amount of purchases would depend on quarterly fluctuations in cash associated with operating cash flow, capital expenditures and further debt prepayment. 
We remain committed to the financial goals we've outlined previously, and our priorities for cash remain the same. We will continue to pay down debt to keep our leverage within 2x to 2.5x EBITDA, as well as make investments in the business that will drive future growth and then return excess cash to shareholders. 
And with that, I'll turn it over to David."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Greg. This quarter, revenue grew 8% to $906 million. Currency had a positive impact of 1.5 percentage points on reported revenue growth. And acquisitions and divestitures contributed half a point to growth. Excluding the impact from currency, acqu",1414,"Thanks, Greg. This quarter, revenue grew 8% to $906 million. Currency had a positive impact of 1.5 percentage points on reported revenue growth. And acquisitions and divestitures contributed half a point to growth. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6% organically.
Genetic Systems had revenue of $235 million, representing 7% organic growth. Sales of CE instruments, including the new 3500 Genetic Analyzer and sales of CE consumables to research and clinical labs, grew in the mid-single digits. This was partially offset by a year-over-year decline in CE instruments and consumables sold into the applied markets, as this business experienced a difficult year-over-year comparison due to the Japanese police order received in 2009.
Customer feedback on the SOLiD 4 and ECB platforms continues to be very positive. As a result, the Next-Generation Sequencing business demonstrated strong double-digit growth during the quarter. At this point, approximately half of the installed base of SOLiD 3.5 instruments has been upgraded to the SOLiD 4 platform.
Molecular Biology Systems grew 2% organically to $434 million in revenue. Excluding H1N1-related revenue, organic growth was approximately 6%. Growth was driven by strong results in the Genomic Assays and Molecular Biology Reagents businesses. Demand for Genomic Assay products grew in the high-single digits. The Molecular Biology Reagents business grew in the mid-single digits and benefited from strong double-digit growth in Asia-Pacific, particularly China.
Cell Systems had revenue of $230 million representing 13% organic growth with strong demand across the portfolio. Double-digit growth in bioproduction was driven by continued improvement in demand from European and North American pharmaceutical customers, as well as the timing of large orders.
The Dynal Beads business also benefited from an improvement in pharma, biotech and clinical diagnostic end markets, resulting in double-digit growth for the quarter. And lastly, our Primary and Stem Cell business grew in the mid-teens, driven by worldwide demand for both media and reagents --
As I mentioned earlier, currency added 1.5 points of growth to revenue for the quarter, including the impact of our hedging program. The positive impact to EPS was approximately $0.04, including foreign currency effects accounted for in revenue and other income.
Moving on to other items. Second quarter non-GAAP gross margin was 67.7%, an increase of approximately 100 basis points over the prior-year quarter. This improvement was primarily due to positive price realization, synergies, manufacturing productivity and an increase in royalty revenue, partially offset by a mix, particularly increased sales of bioproduction and instruments. On a sequential basis, gross margin decreased by 60 basis points due to currency and increased sales of lower margin bioproduction products. 
Second quarter non-GAAP operating expenses increased 3% over prior year's levels to $341 million. This was as a result of headcount additions related to acquisitions and increase in depreciation resulting from capital expenditures associated with the AB and Invitrogen integration and currency. Sequentially, operating expenses declined 1%, mainly due to currency.
Non-GAAP operating income was $272 million, an increase of 19% over prior year, including the impact of currency, and 17% excluding currency. This quarter, operating margins reached a record level of 30.1% representing 290 basis points of improvement year-over-year. This operating margin expansion primarily resulted from improved gross margins and synergies.
In terms of other income line items, we had $1 million of interest income, $1 million from currency gains and interest expense for the quarter was $28 million. Our non-GAAP tax rate was 29.5%. Our diluted share count for the quarter was 191 million shares. As you will recall, our share count is impacted by our stock price in the quarter due to our convertible debt and employee stock options.
GAAP diluted earnings per share were $0.58, which includes $0.21 per share of acquisition-related amortization expense, $0.03 per share of non-cash interest expense associated with the adoption of APB 14-1 and $0.09 per share of business integration costs and other items. On a non-GAAP basis, which excludes these items, diluted earnings per share was $0.91.
Moving on to the balance sheet and cash flow, our ending cash and short-term investments were $706 million. This compares to last quarter's balance of $642 million. Cash from operating activities was $228 million, capital expenditures were $25 million and free cash flow was $203 million. Included in our cash flow from operations is approximately $25 million of favorability associated with hedges on inter-company loans as a result of increased volatility and currency rates. Return on invested capital increased 40 basis points to 9%.
Our ending debt as of June 30 was approximately $2.64 billion. This balance is made up of our convertible debt of $1.1 billion and our senior notes of $1.5 billion. For the first half of 2010, revenue increased 8% organically, gross margins expanded 130 basis points and operating margins expanded 310 basis points. We feel good about our results thus far and are focused on continued execution in the second half of the year.
With that, I'll now move on to our expectations for the rest of this year. EPS is now expected to be in the range of $3.35 to $3.50. Our full year guidance for organic revenue growth is unchanged and is still expected to be in the mid to high-single digits.
Given Greg's commentary on stimulus and end markets, I'll provide a bit more color on second half of  expectations. As a reminder, when we provided guidance in the beginning of the year, we stated that the difference between mid and high-single digit organic revenue growth was dependent on the amount of stimulus-related revenue that would be recognized during the year. We've not seen a notable increase in quarterly stimulus-related revenues since the third quarter of last year.  As a result, we expect second half organic revenue growth to be in the mid-single digits. Revenue from prior acquisitions will add approximately one point to growth in each quarter. 
In terms of year-over-year comparables, keep in mind that in the second half of 2009, we had $15 million of H1N1 revenue per quarter, approximately $8 million to $9 million per quarter from the Japanese police order and stimulus revenues of $15 million.
Due to the volatility of currency rates over the last couple of months, I'll provide some detail on the expected impact of currency on our results. With rates as of June 30 and including the impact from our hedging programs, currency is expected to have a small negative impact on revenue, and no impact on EPS in the third quarter.
In the fourth quarter, currency is expected to have a negative three-point impact to revenue growth, and EPS is expected to be negatively impacted by $0.04 to $0.05. Q3 gross margins are expected to be lower sequentially due to lower fixed cost absorption as a result of lower volume in the quarter and a decline in royalty revenue. Operating expenses in Q3 are expected to be approximately the same as in Q2. 
As we indicated on the last earnings call, we are reinvesting a portion of the operating-income impact from stimulus back into the business to fund future growth opportunities. These investments, which are primarily focused on R&D and commercial projects in emerging markets, began late in the second quarter and will continue through Q3. As a result, R&D expense as a percentage of sales in the third quarter will be slightly higher than our full year guidance. We continue to expect full year R&D expense to be 10% to 10.5% of revenue.
Q3 operating margins are expected to be approximately the same level as last year. For the full year, operating margin expansion is still expected to be within 175 to 225 basis points. We expect the average diluted share count for the second half of the year to be $192 million to $194 million shares assuming an average stock price between $45 and $50.
And finally, we've received a number of questions on our hedging programs as it relates to next year. Because of the continued uncertainty about the global economy and the resulting impact on exchange rates, we opted in June to continue with our currency hedging program in 2011. At this point, we have currency hedges in place for the first seven months of 2011 and intend to execute additional hedges each month until we are hedged for the full 12 months. Share repurchase program will be used to help mitigate the impact of currency on EPS.
And with that, I'll now hand the call back over to Eileen for Q&A."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, David. A quick note before we get started. Recently we've received feedback from a number of you that one-on-one calls are preferable to the post earnings Q&A call. For this reason, we will not be holding a post call today. If you have question",105,"Thank you, David. A quick note before we get started. Recently we've received feedback from a number of you that one-on-one calls are preferable to the post earnings Q&A call. For this reason, we will not be holding a post call today. If you have questions following this call, please contact me directly. We have about 30 minutes for Q&A, so I would like to ask everyone to limit themselves to one question and one follow-up question. If you have additional questions that you'd like to ask, please get back in the queue. Operator, we are now ready for the Q&A portion of the call."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","[Operator Instructions] And the first question will come from the line of Quintin Lai, Robert W. Baird.",17,"[Operator Instructions] And the first question will come from the line of Quintin Lai, Robert W. Baird."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Greg, could you give a little bit more color on what you're seeing, I guess, in Europe? I mean, it sounds like the spending slowed as delay of release of funds. What kind of visibility do your customers get in terms of when some of those funds will be rel",79,"Greg, could you give a little bit more color on what you're seeing, I guess, in Europe? I mean, it sounds like the spending slowed as delay of release of funds. What kind of visibility do your customers get in terms of when some of those funds will be released? And then, kind of, what's the long-term forecast for Europe, given the fact that those are big research mandate that was just put forward in terms of 2011 budgets?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think what we saw in the second quarter was a reaction to the heightened sensitivity around the whole European fiscal crisis. And so that seemingly had a ripple effect through spending at the bench level on a company like ours towards the end of that se",206,"I think what we saw in the second quarter was a reaction to the heightened sensitivity around the whole European fiscal crisis. And so that seemingly had a ripple effect through spending at the bench level on a company like ours towards the end of that second quarter. Now that's kind of a short-term reaction, and that's why our comments are that, perhaps that could persist a bit through the second half of the year. On long term, the second half of your question, it's unclear, but our opinion is that this side of government funding will probably remain intact. And it centers around what you said in that, the larger countries are committed to a agenda of innovation. And therefore, at least in their public pronouncements that we can understand, they have said they're going to ring fence innovation funding, and so again, we rely on that to say that over the next couple of years, the European business should do okay. So that's what we know at this point. We're not predicting dire consequences, and yet at the same time, we think the robust growth we saw in the last couple of years may be modulated a bit over the next couple of years."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","The improvement that you're seeing in U.S. pharma, is it broad-based or are you seeing maybe increased growth from companies that have completed some of their recent M&A activity?",30,"The improvement that you're seeing in U.S. pharma, is it broad-based or are you seeing maybe increased growth from companies that have completed some of their recent M&A activity?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","What we've always seen in that pharma sector is an account-by-account variability. And so our top accounts are not always our top accounts year-over-year. It just changes depending on their own particular spending or situation they find themselves that ma",72,"What we've always seen in that pharma sector is an account-by-account variability. And so our top accounts are not always our top accounts year-over-year. It just changes depending on their own particular spending or situation they find themselves that may be due to an integration. So overall, we're certainly seeing, in aggregate, a nice recovery. But the individual companies and their respective growth rates has changed this year versus last year."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Next question will come from the line of Doug Schenkel, Cowen.",11,"Next question will come from the line of Doug Schenkel, Cowen."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First, in Molecular Biology Systems, that seems to be an area that some folks are pointing to as a blemish on an otherwise good quarter. By my math, when you strip out the impact of H1 [H1N1] in Japan, and I think you highlighted this, you did 6% organic",138,"First, in Molecular Biology Systems, that seems to be an area that some folks are pointing to as a blemish on an otherwise good quarter. By my math, when you strip out the impact of H1 [H1N1] in Japan, and I think you highlighted this, you did 6% organic growth in the quarter. I just want to make sure that this was consistent with your expectations given the comps and make sure that nothing is changed regarding competitive landscape or the environment relative to where you were in Q1. And then the second question kind of related to organic growth, David, if you mentioned this I missed it, but could you just talk about how H1 versus H2 compares organically when you strip out all the one-timers that you mentioned for the first half and the second half?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Doug, on the first part of your question, your math is correct. The Molecular Biology business had organic growth around 6%, and you have to remember that's a very large franchise. So that's 6% on a big number. So actually, I think the results were very r",133,"Doug, on the first part of your question, your math is correct. The Molecular Biology business had organic growth around 6%, and you have to remember that's a very large franchise. So that's 6% on a big number. So actually, I think the results were very robust actually, and I think it also is indicative that we continue to invest in Molecular Biology. Respective in one of those segments in the PCR franchise, we have the broadest product offering by far. We have millions of assays available on demand, and it really is the standard that people continue to come to more and more. So we feel very good actually about the Molecular Biology results, so I'm glad you clarified that. David, on to you in terms of the second question Doug asked."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes. So Doug, so just let me repeat in terms of what was the impact on H1N1 and the other onetime items on our results for last year and our second half results. So H1N1, we had $15 million of revenue per quarter last year. Another major item was the Japa",99,"Yes. So Doug, so just let me repeat in terms of what was the impact on H1N1 and the other onetime items on our results for last year and our second half results. So H1N1, we had $15 million of revenue per quarter last year. Another major item was the Japanese Police order, and that was approximately $8 million to $9 million per quarter last year. And then finally, we had stimulus revenues in the second half of $15 million, and that was $5 million in the third quarter and $10 million in the fourth. That answer your question?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Yes, it does. I mean, I guess part of the reason I asked this is there has been some concern in the quarter with some other companies that organic growth optics don't look good and that organic growth is actually slowing down in the second half. I'm just",145,"Yes, it does. I mean, I guess part of the reason I asked this is there has been some concern in the quarter with some other companies that organic growth optics don't look good and that organic growth is actually slowing down in the second half. I'm just doing a quick math based on those headwinds, which frankly, you did outline last quarter as well, so those are nothing new. And I want to make sure my math is correct that when you strip the headwinds out of the first half and then you strip headwinds out of the second half, it actually looks like, even though you're guiding organic growth to mid single digits in the second half, that it actually looks like things are accelerating in the second half if you strip everything out. Is that the right way to think about things?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","That is correct. We don't anticipate any significant change between the first half and the second half.",17,"That is correct. We don't anticipate any significant change between the first half and the second half."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","The next question will come from the line of Tycho Peterson, JPMorgan.",12,"The next question will come from the line of Tycho Peterson, JPMorgan."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe just first question for David on kind of the margin improvement, and understanding your comments about kind of the third quarter and how you're going to be reinvesting. Well, can you talk a little bit about how much of what you're seeing here is sus",119,"Maybe just first question for David on kind of the margin improvement, and understanding your comments about kind of the third quarter and how you're going to be reinvesting. Well, can you talk a little bit about how much of what you're seeing here is sustainable? And I asked because I know at your analyst day, you highlighted a lot of productivity initiatives and you highlighted things like non-refrigerated TaqMan reagent and things that seemingly should have a nice impact on margins going forward. So can you talk about kind of the sustainability of manufacturing productivity? And I don't know if you can quantify how much this quarter came from price versus royalty versus some of those productivity enhancements."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes. Yes, I mean, you're absolutely right, Tycho. We did talk at Investor Day a lot about this. Nothing is changed. We continue to expect to get 50-plus basis points of operating margin improvement over the next several years. So we believe that the chang",121,"Yes. Yes, I mean, you're absolutely right, Tycho. We did talk at Investor Day a lot about this. Nothing is changed. We continue to expect to get 50-plus basis points of operating margin improvement over the next several years. So we believe that the changes that we make are sustainable, and that we've got further improvements that we can make. In terms of the impact of price, we continue to get price improvement that is in line with what we've had in the past, and we're averaging one to two percentage points of price. And it has, through the upheaval in the economy over the last couple of years, not changed, and we're seeing that same type of improvement this year."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","I mean, from this quarter, the 100 basis points you saw, can you break out how much was from price versus other factors?",23,"I mean, from this quarter, the 100 basis points you saw, can you break out how much was from price versus other factors?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I can't do that right off the top of my head at this point.",15,"I can't do that right off the top of my head at this point."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe then just a follow-up for Greg on SOLiD. As we think about the launch of hq later this year and then obviously the PI at the lower end, could you talk a little bit about where you're seeing interest from customers in terms of core academic centers a",56,"Maybe then just a follow-up for Greg on SOLiD. As we think about the launch of hq later this year and then obviously the PI at the lower end, could you talk a little bit about where you're seeing interest from customers in terms of core academic centers and then the non-traditional markets for SOLiD?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","You bet, Tycho. I have Mark Stevenson here with me. I'll let Mark answer that in more detail.",18,"You bet, Tycho. I have Mark Stevenson here with me. I'll let Mark answer that in more detail."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes, Tycho. So we continue to see uptake of genome centers, the smaller genome centers that are getting into this, particularly in the area of cancer where we see the accuracy that we get with the SOLiD System, really an uptake in that one. People want to",166,"Yes, Tycho. So we continue to see uptake of genome centers, the smaller genome centers that are getting into this, particularly in the area of cancer where we see the accuracy that we get with the SOLiD System, really an uptake in that one. People want to do those kind of experiments. You saw some of the announcements we've made and some of the uptake in some of the cancer centers both here in North America and in Europe during the last quarter. And we expect, as we launch the SOLiD PI, we'll broaden that base and with the hq, bring the cost of the genome down even further and so continue to see good progress into the market with the SOLiD technology. We also mentioned in the script a very good feedback on the EZ Bead, which is taking away. One other thing important to our customer and the workflow is much more simple and straightforward upfront sample preparation now with that EZ Bead System."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Can you talk about Bioproduction? You called that out as being strong. How sustainable are the trends there, and kind of what you're visibility to the back half of the year for that business?",34,"Can you talk about Bioproduction? You called that out as being strong. How sustainable are the trends there, and kind of what you're visibility to the back half of the year for that business?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","We feel good about the Bioproduction business. Again, it's account-specific. But the macro environment for us, we continue to see uptake across that, and have actually broaden our portfolio there with the introduction of more assays and products into the",53,"We feel good about the Bioproduction business. Again, it's account-specific. But the macro environment for us, we continue to see uptake across that, and have actually broaden our portfolio there with the introduction of more assays and products into the Bioproduction area as they continue to see that's a good market for us."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Derik De Bruin, UBS Securities.",5,"Derik De Bruin, UBS Securities."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So just to follow up on some of Quintin's questions on the funding environment. There's also, obviously, been a lot of concern from amongst people about what happens in the U.S. following the midterm elections. And I guess, what are you looking at now in",79,"So just to follow up on some of Quintin's questions on the funding environment. There's also, obviously, been a lot of concern from amongst people about what happens in the U.S. following the midterm elections. And I guess, what are you looking at now in terms of what are you hearing on the NIH budget in fiscal 2011 and the initial take on fiscal 2012? And I guess, what are your embedded expectations in terms of budget increasing?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Here's what we currently believe, that the NIH budget in 2011 will probably be up by about $1 billion if the House Appropriations recommendations hold. So over the next 12, 18 months, funding should be pretty good. Into 2012, I think it's a bit more uncer",172,"Here's what we currently believe, that the NIH budget in 2011 will probably be up by about $1 billion if the House Appropriations recommendations hold. So over the next 12, 18 months, funding should be pretty good. Into 2012, I think it's a bit more uncertain. But potentially, the NIH could be flat to slightly down. Inside of that though I will tell you that a lot of our work is preparing around where the money would be spent, because it won't just be everything 5% or 3% or flat. There will be changes in how the funding actually gets spent, and we certainly saw this earlier in the Bush administration and I think we learned pretty smartly on how to navigate that. So again, the next couple of years then because of, at least stimulus, the 2011 NIH budget being probably okay and growing, and then the changing and funding towards where we see real strength in our portfolio, the next couple of years should be okay in United States."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Thanks for the color on the FX impact for next year. I guess when we start thinking about where your hedges are in place, what's the euro-dollar number that you kind of got -- the exchange you kind of have the hedging blend [ph] so we can kind of watch th",51,"Thanks for the color on the FX impact for next year. I guess when we start thinking about where your hedges are in place, what's the euro-dollar number that you kind of got -- the exchange you kind of have the hedging blend [ph] so we can kind of watch that?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","You're talking about next year?",6,"You're talking about next year?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Next year, yes.",3,"Next year, yes."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Well, I think we need to go through the second half of the year before we know what our rate is going to be. But we'll provide that, obviously, when we talk about our outlook for next year.",38,"Well, I think we need to go through the second half of the year before we know what our rate is going to be. But we'll provide that, obviously, when we talk about our outlook for next year."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And you had given some general rules of thumb. I'm looking at the impact of currencies on EPS for this year, a 10% move has you -- I think you said it was a $0.06 impact or something like that. It's like, I guess, would those same types of rule of thumb h",64,"And you had given some general rules of thumb. I'm looking at the impact of currencies on EPS for this year, a 10% move has you -- I think you said it was a $0.06 impact or something like that. It's like, I guess, would those same types of rule of thumb hold for these next hedges, or is it that bar has reset?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Bar has reset.",3,"Bar has reset."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And the next question will come from the line of Marshall Urist, Morgan Stanley.",14,"And the next question will come from the line of Marshall Urist, Morgan Stanley."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First question, just more -- I know there's been a lot of questions about this, but maybe to take a step back and just kind of talk about how does Life grow and what are the strategies for growth if, given the exposure to academic, market and government f",91,"First question, just more -- I know there's been a lot of questions about this, but maybe to take a step back and just kind of talk about how does Life grow and what are the strategies for growth if, given the exposure to academic, market and government funding broadly as we think about that for the long term, if it is a flattish funding environment. How do you guys think about growth opportunities? Do you deploy capital differently? Sort of what's the strategy, and how are you thinking about that?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Well, first of all, about 30% of our portfolio is in what we call the broadly applied biology segment. So Forensics, Bioproduction, Animal Health, and those segments are growing very fast, and we see them continuing to grow as a percentage of the portfoli",273,"Well, first of all, about 30% of our portfolio is in what we call the broadly applied biology segment. So Forensics, Bioproduction, Animal Health, and those segments are growing very fast, and we see them continuing to grow as a percentage of the portfolio. So that's a good thing. Second, in terms of academic funding over the next couple of years, I think if you take my earlier comment, we think it's going to be okay. It's probably more of the funding environment we saw in the 2003 and '04 type of time frame, and we actually grew okay through that period by really focusing the portfolio on where the money would be spent. And I think that a very important point to be made is that all products aren't equal, and the funding does get directed then in a certain way and you just simply have to have the portfolio to capture it. So I think we're feeling pretty good that we'll be able to do well in the overall funding environment in the U.S. and Europe. And then lastly, importantly, is the geographic aspect, which is, we have built a very robust infrastructure across Asia. And I think you can see the benefits of that investment by our continued very strong growth across Asia. We are direct in a lot of the main countries. We're going ever more direct in all of the countries. We're building logistics centers across the region. And so geographically, we're exposed to where higher growth will be. So when you couple all of that together, Life Technologies will do fine over the next couple of years."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","I know you guys had talked about, with the convert out of the way, starting a buyback program. And obviously, free cash flow will start to inflect in 2011. So would just be curious as we kind of move past this, maybe you could give your kind of updated hi",96,"I know you guys had talked about, with the convert out of the way, starting a buyback program. And obviously, free cash flow will start to inflect in 2011. So would just be curious as we kind of move past this, maybe you could give your kind of updated high-level thoughts on -- are buybacks likely to be the major use of capital in this $350 million over two years. So is that how you guys are thinking? So is that going to be the major strategy, or is there more opportunities on product tuck-in acquisitions?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think our philosophy and our plans for use of cash are unchanged. Our number one priority is to pay down our debt. And as we've said many times before, target is to get and remain within a leverage ratio of 2 to 2.5x EBITDA. Second point that you bring",96,"I think our philosophy and our plans for use of cash are unchanged. Our number one priority is to pay down our debt. And as we've said many times before, target is to get and remain within a leverage ratio of 2 to 2.5x EBITDA. Second point that you bring out is we're going to continue to invest in the business organically and inorganically. And then third, our philosophy on excess cash also remains the same. We intend to return that to shareholders. A primary vehicle that we've used is share repurchases, and we will continue."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Your next question will come from the line of Jon Wood, Jefferies & Co.",14,"Your next question will come from the line of Jon Wood, Jefferies & Co."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So David, you will be within your target leverage ratio next week, correct, when you pay out the convert?",19,"So David, you will be within your target leverage ratio next week, correct, when you pay out the convert?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Actually, there are a variety of ways of calculating the leverage ratio. So the one we've most often use is our credit agreement, but each of the rating agencies also have a calculation. Moody's, for example, is slightly different than ours. That's why we",83,"Actually, there are a variety of ways of calculating the leverage ratio. So the one we've most often use is our credit agreement, but each of the rating agencies also have a calculation. Moody's, for example, is slightly different than ours. That's why we're saying that by the end of the third quarter, we will be within our target leverage ratio for all of the rating agencies on all of the calculations and anticipate to begin the buyback then in the fourth quarter."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And then on the cash flow statement, can you just disclose the divestiture proceeds from the mass spec [mass spectrometry] JV, and then talk about whether you've paid the taxes yet on that proceed number?",35,"And then on the cash flow statement, can you just disclose the divestiture proceeds from the mass spec [mass spectrometry] JV, and then talk about whether you've paid the taxes yet on that proceed number?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","That's a good question, Jon. Why don't we get the answer to that, and we'll have a follow-up conversation with you on it.",24,"That's a good question, Jon. Why don't we get the answer to that, and we'll have a follow-up conversation with you on it."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Your next question will come from the line of Jon Groberg, Macquarie Capital.",13,"Your next question will come from the line of Jon Groberg, Macquarie Capital."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So just one quick question for you Greg. You've often talked about one of the strengths of the portfolio is that it's not that price-sensitive, and in terms of when you tried lowering prices, it hasn't really stimulated a lot of demand and that's why you",107,"So just one quick question for you Greg. You've often talked about one of the strengths of the portfolio is that it's not that price-sensitive, and in terms of when you tried lowering prices, it hasn't really stimulated a lot of demand and that's why you get some price -- a lot of good pricing ability. Then I'm just curious, specifically within the PCR portfolio, have you tried that overtime? I'm just curious, there's been some, obviously, a lot of announcements around people trying to get more into that business. I'm curious just you view of how effective price is as a mechanism in the PCR space."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think what gets highlighted is in that particular space, there's a lot of the very low end reagents and otherwise. And actually, they've always been around, at least for the last several years, kind of the low end of that segment. We have products from",118,"I think what gets highlighted is in that particular space, there's a lot of the very low end reagents and otherwise. And actually, they've always been around, at least for the last several years, kind of the low end of that segment. We have products from that segment as well. So my comments really still pertain globally to this business, that the relationship between price and volume is not a direct connection. And that's due to a lot of the friction of publications, previous experiments. There's just inertia to switching. And when you have market leadership like we certainly do in the PCR business, people are inclined to stay with their products, and so we benefited from that."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Your next question will come from the line of Steven Lichtman, Oppenheimer & Co.",14,"Your next question will come from the line of Steven Lichtman, Oppenheimer & Co."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First, I was wondering the update on single molecule, still expecting to have a beta launch here towards year end?",20,"First, I was wondering the update on single molecule, still expecting to have a beta launch here towards year end?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes, we still, as we updated at the Investor Day, making good progress in developing the system and continuing to engage with customers around the early access and discussing the experiments and applications that they see for single molecule sequencing.",40,"Yes, we still, as we updated at the Investor Day, making good progress in developing the system and continuing to engage with customers around the early access and discussing the experiments and applications that they see for single molecule sequencing."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And then on CE, certainly seemed like it's picked its head up here a bit more than expected. Is it really driven by the launch of the 3500? Anything else in the sort of end markets you can comment on relative to CE?",43,"And then on CE, certainly seemed like it's picked its head up here a bit more than expected. Is it really driven by the launch of the 3500? Anything else in the sort of end markets you can comment on relative to CE?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","The CE, as we expected with the launch of the 3500, that really goes into markets such as the clinical testing market. We have the CE-IVD mark. Recently, we launched assays that start to go into that like a  BRAF assay. And so we see that uptake falls for",100,"The CE, as we expected with the launch of the 3500, that really goes into markets such as the clinical testing market. We have the CE-IVD mark. Recently, we launched assays that start to go into that like a  BRAF assay. And so we see that uptake falls forward into that CE space. In addition in the Forensics space, launching more kits, more geographic expansion. And they see franchise is robust in that segment, continues to be the right technology choice for those applications where you have a couple of genes that are very variable that you want to analyze."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And the last question will come from the line of Tony Butler, Barclays Capital.",14,"And the last question will come from the line of Tony Butler, Barclays Capital."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","David, is there any way to characterize the revenue synergies in the quarter that you may be seeing with the combination of the companies?",24,"David, is there any way to characterize the revenue synergies in the quarter that you may be seeing with the combination of the companies?"
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Would you like to talk about some of the -- I think sources of revenue synergies would be helpful.",19,"Would you like to talk about some of the -- I think sources of revenue synergies would be helpful."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Sure. In the revenue synergy sources, we touched on a few in the earlier comments around combined supply centers, leveraging our combined website. When you look today at the portfolio, where many of these types of sources were purely tied to one of the co",112,"Sure. In the revenue synergy sources, we touched on a few in the earlier comments around combined supply centers, leveraging our combined website. When you look today at the portfolio, where many of these types of sources were purely tied to one of the companies, they're now combined. Our selling organization has been restructured where commercial teams we have consumables, sales reps have carried both the AB [Applied Biosystems] consumables as well as former Invitrogen consumables. It gives our instrument teams more time to focused on -- focusing on instrument placements. And so all of those combined, they have driven many of the synergies that we have indicated in our earlier calls."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And this concludes the question-and-answer session. I'd like to turn the call back to Eileen Pattinson for closing remarks.",20,"And this concludes the question-and-answer session. I'd like to turn the call back to Eileen Pattinson for closing remarks."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you. This concludes our second quarter earnings conference call. If there are any additional questions, please feel free to contact me. This webcast will be available via a replay on our website for three weeks. Thank you again for joining us this m",44,"Thank you. This concludes our second quarter earnings conference call. If there are any additional questions, please feel free to contact me. This webcast will be available via a replay on our website for three weeks. Thank you again for joining us this morning."
30253,109039325,70382,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And ladies and gentlemen, again, this does conclude today's conference call. Thank you for your participation. You may now disconnect, and have a great day.",25,"And ladies and gentlemen, again, this does conclude today's conference call. Thank you for your participation. You may now disconnect, and have a great day."
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Good day, ladies and gentlemen, and welcome to the Second Quarter 2010 Life Technologies Corporation Earnings Conference Call. My name is Diana, and I'll be your operator for today. [Operator Instructions] I would now like to turn the conference over to y",54,"Good day, ladies and gentlemen, and welcome to the Second Quarter 2010 Life Technologies Corporation Earnings Conference Call. My name is Diana, and I'll be your operator for today. [Operator Instructions] I would now like to turn the conference over to your host for today, Ms. Eileen Pattinson, Head of Investor Relations. Please proceed.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Diana, and good morning, everyone. Welcome to Life Technologies Second Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer. In addition, Mark Steve",187,"Thank you, Diana, and good morning, everyone. Welcome to Life Technologies Second Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer. In addition, Mark Stevenson, our Chief Operating Officer; and Bernd Brust, our Chief Commercial Officer, are available during the Q&A portion of the call. If you haven't received a copy of today's press release, you may obtain one from our website at lifetechnologies.com.
I want to remind our listeners that our discussion today will include forward-looking statements, including, but not limited to, statements about future expectations, plans and prospects for the company. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated. It is our intent that these forward-looking statements be protected under the Safe Harbor, created by the Private Securities Litigation Reform Act of 1995. Additionally, we will be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP can be found in today's press release or on our website. 
I'll now hand the call over to Greg Lucier.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Eileen, and thank you, all for joining us. Coming off the heels of our Investor Day just a few weeks ago, we are going to keep our prepared comments short this morning. So let's get started. As you can see from our results, we delivered another",1092,"Thanks, Eileen, and thank you, all for joining us. Coming off the heels of our Investor Day just a few weeks ago, we are going to keep our prepared comments short this morning. 
So let's get started. As you can see from our results, we delivered another quarter of strong top and bottom line growth. Revenue grew 6% organically to $906 million, 8% excluding the impact of H1N1 sales in 2009. Operating margins expanded by 290 basis points to reach a record 30.1%, and earnings per share grew 15% to $0.91 for the quarter.
We are pleased with our results for the second quarter in the first half of the year, which are a reflection of the fundamental strength of the business and the essential nature of our product offering. I'd like to extend my thanks to our teams around the world for their commitment to excellence and relentless focus on execution.
As I do every quarter, I'll take a few moments to talk about these results, give you an update on the integration and provide some color on the strength of our end markets. First, we continue to be very focused on the integration, and I'm pleased to report good progress towards our goal of putting actions in place that will generate $175 million in annual synergies by the end of 2010. 
In the second quarter, we continue to execute on an integration plan, including the placement of over 50 dual-branded supply centers around the world and further optimization of our combined eBusiness platforms. We are seeing good traction from these efforts and achieve new records for the number of the total transactions, both in North America and globally, that will process through eCommerce channels.
In terms of synergy capture, these actions, as well as many others, will generate another $15 million in annualized synergies, getting it halfway to our full year goal. Looking ahead in the second half of the year, we will continue to optimize the programs already started, as well as implement new initiatives, including additional site consolidations and cities where we have multiple offices, continuing to build out the combined eBusiness platforms and optimizing our distribution network.
Now beyond these integration activities, Life Technologies is well positioned to capture opportunities that will continue to drive strong revenue growth. Commercial execution, coupled with a broad product offering of innovative tools ensures that our products are an essential part of our customers' workflows. Recent launches have gone very well. Customer response to Attune, our flow cytometry offering and the ViiA 7 PCR instrument have been very positive, and the sales of our latest CE instrumentation, the 3500, have reinvigorated that business. Since the launch of the 3500 in Q4 of last year, we have placed approximately 400 instruments and demand continues to be very robust.
I'll take a moment now to walk you through more notable points on Q2 performance and give some color on what we're seeing on our end markets. The Americas delivered 7% organic growth in the quarter, 10% without the impact of H1N1. End markets in the Americas remain strong, with pharma and biotech continuing to pick up steam. Evidenced by the strong demand for our discovery and assay services business and double-digit growth in bioproduction. On the research side, stimulus-related revenues for the quarter were approximately $10 million, about the same as we've seen in prior quarters.
Our outlook for the stimulus is unchanged. We continue to estimate that we will generate more than $100 million in stimulus-related revenue over the life of this program. However, since we have not observed the material ramp-up in spending since the third quarter of last year, we estimate that stimulus-related revenues will be around $10 million per quarter in the second half of the year, with the rest of the benefit realized in 2011.
Europe grew 4% organically in the quarter. Growth for the quarter is slightly less than in recent periods due to the uncertainty about future government funding levels. At this time, we have no reason to believe that there will be declining government funding for our research in major European markets, such as U.K., Germany and France. However, some of our customers have reported that there have been delays in the release of funds from the institutions to researchers. In addition, researchers seem to be cautious in their spending due to fears that future funding may be curtailed. As a result, spending in these countries on both consumables and instruments softened towards the end of the quarter.
The situation in some of our smaller markets, such as Italy and Spain is slightly different. Funding in these countries have been negatively impacted to some degree as a result of the current economic environment. Revenue growth in these countries was flat during the second quarter. Looking forward to the second half, we expect that for the European region as a whole, revenue growth will be in the low-single digits or mid-single digits, excluding H1N1.
Moving on to other markets, Asia-Pacific had another strong quarter, growing 19% organically. End markets in the Asia Pacific region remain healthy, particularly in India and greater China, which grew an excess of 30% in the quarter. We were well positioned in these markets to continue to drive robust growth.
There's no change in our outlook for Japan. In the second quarter, Japan declined 4% organically as a result of a very difficult year-over-year comparison. As a reminder, Q2 of last year included revenue from a large police order, as well as H1N1. Excluding these items, Japan grew 3%, in line with expectations.
Now before I hand it over to David, I'm pleased to announce earlier this week, our Board of Directors approved a two-year $350 million share repurchase program, which is consistent with our strategy of balanced capital deployment. We intend to begin repurchasing shares in the fourth quarter after we have redeemed the 2% convertible notes in August, and we are within our target leverage ratio of 2x to 2.5x EBITDA. In general, the timing and amount of purchases would depend on quarterly fluctuations in cash associated with operating cash flow, capital expenditures and further debt prepayment. 
We remain committed to the financial goals we've outlined previously, and our priorities for cash remain the same. We will continue to pay down debt to keep our leverage within 2x to 2.5x EBITDA, as well as make investments in the business that will drive future growth and then return excess cash to shareholders. 
And with that, I'll turn it over to David.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Greg. This quarter, revenue grew 8% to $906 million. Currency had a positive impact of 1.5 percentage points on reported revenue growth. And acquisitions and divestitures contributed half a point to growth. Excluding the impact from currency, acqu",1414,"Thanks, Greg. This quarter, revenue grew 8% to $906 million. Currency had a positive impact of 1.5 percentage points on reported revenue growth. And acquisitions and divestitures contributed half a point to growth. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6% organically.
Genetic Systems had revenue of $235 million, representing 7% organic growth. Sales of CE instruments, including the new 3500 Genetic Analyzer and sales of CE consumables to research and clinical labs, grew in the mid-single digits. This was partially offset by a year-over-year decline in CE instruments and consumables sold into the applied markets, as this business experienced a difficult year-over-year comparison due to the Japanese police order received in 2009.
Customer feedback on the SOLiD 4 and ECB platforms continues to be very positive. As a result, the Next-Generation Sequencing business demonstrated strong double-digit growth during the quarter. At this point, approximately half of the installed base of SOLiD 3.5 instruments has been upgraded to the SOLiD 4 platform.
Molecular Biology Systems grew 2% organically to $434 million in revenue. Excluding H1N1-related revenue, organic growth was approximately 6%. Growth was driven by strong results in the Genomic Assays and Molecular Biology Reagents businesses. Demand for Genomic Assay products grew in the high-single digits. The Molecular Biology Reagents business grew in the mid-single digits and benefited from strong double-digit growth in Asia-Pacific, particularly China.
Cell Systems had revenue of $230 million representing 13% organic growth with strong demand across the portfolio. Double-digit growth in bioproduction was driven by continued improvement in demand from European and North American pharmaceutical customers, as well as the timing of large orders.
The Dynal Beads business also benefited from an improvement in pharma, biotech and clinical diagnostic end markets, resulting in double-digit growth for the quarter. And lastly, our Primary and Stem Cell business grew in the mid-teens, driven by worldwide demand for both media and reagents --
As I mentioned earlier, currency added 1.5 points of growth to revenue for the quarter, including the impact of our hedging program. The positive impact to EPS was approximately $0.04, including foreign currency effects accounted for in revenue and other income.
Moving on to other items. Second quarter non-GAAP gross margin was 67.7%, an increase of approximately 100 basis points over the prior-year quarter. This improvement was primarily due to positive price realization, synergies, manufacturing productivity and an increase in royalty revenue, partially offset by a mix, particularly increased sales of bioproduction and instruments. On a sequential basis, gross margin decreased by 60 basis points due to currency and increased sales of lower margin bioproduction products. 
Second quarter non-GAAP operating expenses increased 3% over prior year's levels to $341 million. This was as a result of headcount additions related to acquisitions and increase in depreciation resulting from capital expenditures associated with the AB and Invitrogen integration and currency. Sequentially, operating expenses declined 1%, mainly due to currency.
Non-GAAP operating income was $272 million, an increase of 19% over prior year, including the impact of currency, and 17% excluding currency. This quarter, operating margins reached a record level of 30.1% representing 290 basis points of improvement year-over-year. This operating margin expansion primarily resulted from improved gross margins and synergies.
In terms of other income line items, we had $1 million of interest income, $1 million from currency gains and interest expense for the quarter was $28 million. Our non-GAAP tax rate was 29.5%. Our diluted share count for the quarter was 191 million shares. As you will recall, our share count is impacted by our stock price in the quarter due to our convertible debt and employee stock options.
GAAP diluted earnings per share were $0.58, which includes $0.21 per share of acquisition-related amortization expense, $0.03 per share of non-cash interest expense associated with the adoption of APB 14-1 and $0.09 per share of business integration costs and other items. On a non-GAAP basis, which excludes these items, diluted earnings per share was $0.91.
Moving on to the balance sheet and cash flow, our ending cash and short-term investments were $706 million. This compares to last quarter's balance of $642 million. Cash from operating activities was $228 million, capital expenditures were $25 million and free cash flow was $203 million. Included in our cash flow from operations is approximately $25 million of favorability associated with hedges on inter-company loans as a result of increased volatility and currency rates. Return on invested capital increased 40 basis points to 9%.
Our ending debt as of June 30 was approximately $2.64 billion. This balance is made up of our convertible debt of $1.1 billion and our senior notes of $1.5 billion. For the first half of 2010, revenue increased 8% organically, gross margins expanded 130 basis points and operating margins expanded 310 basis points. We feel good about our results thus far and are focused on continued execution in the second half of the year.
With that, I'll now move on to our expectations for the rest of this year. EPS is now expected to be in the range of $3.35 to $3.50. Our full year guidance for organic revenue growth is unchanged and is still expected to be in the mid to high-single digits.
Given Greg's commentary on stimulus and end markets, I'll provide a bit more color on second half of  expectations. As a reminder, when we provided guidance in the beginning of the year, we stated that the difference between mid and high-single digit organic revenue growth was dependent on the amount of stimulus-related revenue that would be recognized during the year. We've not seen a notable increase in quarterly stimulus-related revenues since the third quarter of last year.  As a result, we expect second half organic revenue growth to be in the mid-single digits. Revenue from prior acquisitions will add approximately one point to growth in each quarter. 
In terms of year-over-year comparables, keep in mind that in the second half of 2009, we had $15 million of H1N1 revenue per quarter, approximately $8 million to $9 million per quarter from the Japanese police order and stimulus revenues of $15 million.
Due to the volatility of currency rates over the last couple of months, I'll provide some detail on the expected impact of currency on our results. With rates as of June 30 and including the impact from our hedging programs, currency is expected to have a small negative impact on revenue, and no impact on EPS in the third quarter.
In the fourth quarter, currency is expected to have a negative three-point impact to revenue growth, and EPS is expected to be negatively impacted by $0.04 to $0.05. Q3 gross margins are expected to be lower sequentially due to lower fixed cost absorption as a result of lower volume in the quarter and a decline in royalty revenue. Operating expenses in Q3 are expected to be approximately the same as in Q2. 
As we indicated on the last earnings call, we are reinvesting a portion of the operating-income impact from stimulus back into the business to fund future growth opportunities. These investments, which are primarily focused on R&D and commercial projects in emerging markets, began late in the second quarter and will continue through Q3. As a result, R&D expense as a percentage of sales in the third quarter will be slightly higher than our full year guidance. We continue to expect full year R&D expense to be 10% to 10.5% of revenue.
Q3 operating margins are expected to be approximately the same level as last year. For the full year, operating margin expansion is still expected to be within 175 to 225 basis points. We expect the average diluted share count for the second half of the year to be $192 million to $194 million shares assuming an average stock price between $45 and $50.
And finally, we've received a number of questions on our hedging programs as it relates to next year. Because of the continued uncertainty about the global economy and the resulting impact on exchange rates, we opted in June to continue with our currency hedging program in 2011. At this point, we have currency hedges in place for the first seven months of 2011 and intend to execute additional hedges each month until we are hedged for the full 12 months. Share repurchase program will be used to help mitigate the impact of currency on EPS.
And with that, I'll now hand the call back over to Eileen for Q&A.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, David. A quick note before we get started. Recently we've received feedback from a number of you that one-on-one calls are preferable to the post earnings Q&A call. For this reason, we will not be holding a post call today. If you have question",105,"Thank you, David. A quick note before we get started. Recently we've received feedback from a number of you that one-on-one calls are preferable to the post earnings Q&A call. For this reason, we will not be holding a post call today. If you have questions following this call, please contact me directly. We have about 30 minutes for Q&A, so I would like to ask everyone to limit themselves to one question and one follow-up question. If you have additional questions that you'd like to ask, please get back in the queue. Operator, we are now ready for the Q&A portion of the call.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","[Operator Instructions] And the first question will come from the line of Quintin Lai, Robert W. Baird.",17,"[Operator Instructions] And the first question will come from the line of Quintin Lai, Robert W. Baird.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Greg, could you give a little bit more color on what you're seeing, I guess, in Europe? I mean, it sounds like the spending slowed as delay of release of funds. What kind of visibility do your customers get in terms of when some of those funds will be rel",79,"Greg, could you give a little bit more color on what you're seeing, I guess, in Europe? I mean, it sounds like the spending slowed as delay of release of funds. What kind of visibility do your customers get in terms of when some of those funds will be released? And then, kind of, what's the long-term forecast for Europe, given the fact that those are big research mandate that was just put forward in terms of 2011 budgets?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think what we saw in the second quarter was a reaction to the heightened sensitivity around the whole European fiscal crisis. And so that seemingly had a ripple effect through spending at the bench level on a company like ours towards the end of that se",206,"I think what we saw in the second quarter was a reaction to the heightened sensitivity around the whole European fiscal crisis. And so that seemingly had a ripple effect through spending at the bench level on a company like ours towards the end of that second quarter. Now that's kind of a short-term reaction, and that's why our comments are that, perhaps that could persist a bit through the second half of the year. On long term, the second half of your question, it's unclear, but our opinion is that this side of government funding will probably remain intact. And it centers around what you said in that, the larger countries are committed to a agenda of innovation. And therefore, at least in their public pronouncements that we can understand, they have said they're going to ring fence innovation funding, and so again, we rely on that to say that over the next couple of years, the European business should do okay. So that's what we know at this point. We're not predicting dire consequences, and yet at the same time, we think the robust growth we saw in the last couple of years may be modulated a bit over the next couple of years.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","The improvement that you're seeing in U.S. pharma, is it broad-based or are you seeing maybe increased growth from companies that have completed some of their recent M&A activity?",30,"The improvement that you're seeing in U.S. pharma, is it broad-based or are you seeing maybe increased growth from companies that have completed some of their recent M&A activity?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","What we've always seen in that pharma sector is an account-by-account variability. And so our top accounts are not always our top accounts year-over-year. It just changes depending on their own particular spending or situation they find themselves that ma",72,"What we've always seen in that pharma sector is an account-by-account variability. And so our top accounts are not always our top accounts year-over-year. It just changes depending on their own particular spending or situation they find themselves that may be due to an integration. So overall, we're certainly seeing, in aggregate, a nice recovery. But the individual companies and their respective growth rates has changed this year versus last year.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Next question will come from the line of Doug Schenkel, Cowen.",11,"Next question will come from the line of Doug Schenkel, Cowen.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First, in Molecular Biology Systems, that seems to be an area that some folks are pointing to as a blemish on an otherwise good quarter. By my math, when you strip out the impact of H1 [H1N1] in Japan, and I think you highlighted this, you did 6% organic",138,"First, in Molecular Biology Systems, that seems to be an area that some folks are pointing to as a blemish on an otherwise good quarter. By my math, when you strip out the impact of H1 [H1N1] in Japan, and I think you highlighted this, you did 6% organic growth in the quarter. I just want to make sure that this was consistent with your expectations given the comps and make sure that nothing is changed regarding competitive landscape or the environment relative to where you were in Q1. And then the second question kind of related to organic growth, David, if you mentioned this I missed it, but could you just talk about how H1 versus H2 compares organically when you strip out all the one-timers that you mentioned for the first half and the second half?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Doug, on the first part of your question, your math is correct. The Molecular Biology business had organic growth around 6%, and you have to remember that's a very large franchise. So that's 6% on a big number. So actually, I think the results were very r",133,"Doug, on the first part of your question, your math is correct. The Molecular Biology business had organic growth around 6%, and you have to remember that's a very large franchise. So that's 6% on a big number. So actually, I think the results were very robust actually, and I think it also is indicative that we continue to invest in Molecular Biology. Respective in one of those segments in the PCR franchise, we have the broadest product offering by far. We have millions of assays available on demand, and it really is the standard that people continue to come to more and more. So we feel very good actually about the Molecular Biology results, so I'm glad you clarified that. David, on to you in terms of the second question Doug asked.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes. So Doug, so just let me repeat in terms of what was the impact on H1N1 and the other onetime items on our results for last year and our second half results. So H1N1, we had $15 million of revenue per quarter last year. Another major item was the Japa",99,"Yes. So Doug, so just let me repeat in terms of what was the impact on H1N1 and the other onetime items on our results for last year and our second half results. So H1N1, we had $15 million of revenue per quarter last year. Another major item was the Japanese Police order, and that was approximately $8 million to $9 million per quarter last year. And then finally, we had stimulus revenues in the second half of $15 million, and that was $5 million in the third quarter and $10 million in the fourth. That answer your question?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Yes, it does. I mean, I guess part of the reason I asked this is there has been some concern in the quarter with some other companies that organic growth optics don't look good and that organic growth is actually slowing down in the second half. I'm just",145,"Yes, it does. I mean, I guess part of the reason I asked this is there has been some concern in the quarter with some other companies that organic growth optics don't look good and that organic growth is actually slowing down in the second half. I'm just doing a quick math based on those headwinds, which frankly, you did outline last quarter as well, so those are nothing new. And I want to make sure my math is correct that when you strip the headwinds out of the first half and then you strip headwinds out of the second half, it actually looks like, even though you're guiding organic growth to mid single digits in the second half, that it actually looks like things are accelerating in the second half if you strip everything out. Is that the right way to think about things?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","That is correct. We don't anticipate any significant change between the first half and the second half.",17,"That is correct. We don't anticipate any significant change between the first half and the second half.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","The next question will come from the line of Tycho Peterson, JPMorgan.",12,"The next question will come from the line of Tycho Peterson, JPMorgan.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe just first question for David on kind of the margin improvement, and understanding your comments about kind of the third quarter and how you're going to be reinvesting. Well, can you talk a little bit about how much of what you're seeing here is sus",119,"Maybe just first question for David on kind of the margin improvement, and understanding your comments about kind of the third quarter and how you're going to be reinvesting. Well, can you talk a little bit about how much of what you're seeing here is sustainable? And I asked because I know at your analyst day, you highlighted a lot of productivity initiatives and you highlighted things like non-refrigerated TaqMan reagent and things that seemingly should have a nice impact on margins going forward. So can you talk about kind of the sustainability of manufacturing productivity? And I don't know if you can quantify how much this quarter came from price versus royalty versus some of those productivity enhancements.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes. Yes, I mean, you're absolutely right, Tycho. We did talk at Investor Day a lot about this. Nothing is changed. We continue to expect to get 50-plus basis points of operating margin improvement over the next several years. So we believe that the chang",121,"Yes. Yes, I mean, you're absolutely right, Tycho. We did talk at Investor Day a lot about this. Nothing is changed. We continue to expect to get 50-plus basis points of operating margin improvement over the next several years. So we believe that the changes that we make are sustainable, and that we've got further improvements that we can make. In terms of the impact of price, we continue to get price improvement that is in line with what we've had in the past, and we're averaging one to two percentage points of price. And it has, through the upheaval in the economy over the last couple of years, not changed, and we're seeing that same type of improvement this year.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","I mean, from this quarter, the 100 basis points you saw, can you break out how much was from price versus other factors?",23,"I mean, from this quarter, the 100 basis points you saw, can you break out how much was from price versus other factors?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I can't do that right off the top of my head at this point.",15,"I can't do that right off the top of my head at this point.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe then just a follow-up for Greg on SOLiD. As we think about the launch of hq later this year and then obviously the PI at the lower end, could you talk a little bit about where you're seeing interest from customers in terms of core academic centers a",56,"Maybe then just a follow-up for Greg on SOLiD. As we think about the launch of hq later this year and then obviously the PI at the lower end, could you talk a little bit about where you're seeing interest from customers in terms of core academic centers and then the non-traditional markets for SOLiD?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","You bet, Tycho. I have Mark Stevenson here with me. I'll let Mark answer that in more detail.",18,"You bet, Tycho. I have Mark Stevenson here with me. I'll let Mark answer that in more detail.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes, Tycho. So we continue to see uptake of genome centers, the smaller genome centers that are getting into this, particularly in the area of cancer where we see the accuracy that we get with the SOLiD System, really an uptake in that one. People want to",166,"Yes, Tycho. So we continue to see uptake of genome centers, the smaller genome centers that are getting into this, particularly in the area of cancer where we see the accuracy that we get with the SOLiD System, really an uptake in that one. People want to do those kind of experiments. You saw some of the announcements we've made and some of the uptake in some of the cancer centers both here in North America and in Europe during the last quarter. And we expect, as we launch the SOLiD PI, we'll broaden that base and with the hq, bring the cost of the genome down even further and so continue to see good progress into the market with the SOLiD technology. We also mentioned in the script a very good feedback on the EZ Bead, which is taking away. One other thing important to our customer and the workflow is much more simple and straightforward upfront sample preparation now with that EZ Bead System.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Can you talk about Bioproduction? You called that out as being strong. How sustainable are the trends there, and kind of what you're visibility to the back half of the year for that business?",34,"Can you talk about Bioproduction? You called that out as being strong. How sustainable are the trends there, and kind of what you're visibility to the back half of the year for that business?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","We feel good about the Bioproduction business. Again, it's account-specific. But the macro environment for us, we continue to see uptake across that, and have actually broaden our portfolio there with the introduction of more assays and products into the",53,"We feel good about the Bioproduction business. Again, it's account-specific. But the macro environment for us, we continue to see uptake across that, and have actually broaden our portfolio there with the introduction of more assays and products into the Bioproduction area as they continue to see that's a good market for us.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Derik De Bruin, UBS Securities.",5,"Derik De Bruin, UBS Securities.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So just to follow up on some of Quintin's questions on the funding environment. There's also, obviously, been a lot of concern from amongst people about what happens in the U.S. following the midterm elections. And I guess, what are you looking at now in",79,"So just to follow up on some of Quintin's questions on the funding environment. There's also, obviously, been a lot of concern from amongst people about what happens in the U.S. following the midterm elections. And I guess, what are you looking at now in terms of what are you hearing on the NIH budget in fiscal 2011 and the initial take on fiscal 2012? And I guess, what are your embedded expectations in terms of budget increasing?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Here's what we currently believe, that the NIH budget in 2011 will probably be up by about $1 billion if the House Appropriations recommendations hold. So over the next 12, 18 months, funding should be pretty good. Into 2012, I think it's a bit more uncer",172,"Here's what we currently believe, that the NIH budget in 2011 will probably be up by about $1 billion if the House Appropriations recommendations hold. So over the next 12, 18 months, funding should be pretty good. Into 2012, I think it's a bit more uncertain. But potentially, the NIH could be flat to slightly down. Inside of that though I will tell you that a lot of our work is preparing around where the money would be spent, because it won't just be everything 5% or 3% or flat. There will be changes in how the funding actually gets spent, and we certainly saw this earlier in the Bush administration and I think we learned pretty smartly on how to navigate that. So again, the next couple of years then because of, at least stimulus, the 2011 NIH budget being probably okay and growing, and then the changing and funding towards where we see real strength in our portfolio, the next couple of years should be okay in United States.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Thanks for the color on the FX impact for next year. I guess when we start thinking about where your hedges are in place, what's the euro-dollar number that you kind of got -- the exchange you kind of have the hedging blend [ph] so we can kind of watch th",51,"Thanks for the color on the FX impact for next year. I guess when we start thinking about where your hedges are in place, what's the euro-dollar number that you kind of got -- the exchange you kind of have the hedging blend [ph] so we can kind of watch that?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","You're talking about next year?",6,"You're talking about next year?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Next year, yes.",3,"Next year, yes.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Well, I think we need to go through the second half of the year before we know what our rate is going to be. But we'll provide that, obviously, when we talk about our outlook for next year.",38,"Well, I think we need to go through the second half of the year before we know what our rate is going to be. But we'll provide that, obviously, when we talk about our outlook for next year.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And you had given some general rules of thumb. I'm looking at the impact of currencies on EPS for this year, a 10% move has you -- I think you said it was a $0.06 impact or something like that. It's like, I guess, would those same types of rule of thumb h",64,"And you had given some general rules of thumb. I'm looking at the impact of currencies on EPS for this year, a 10% move has you -- I think you said it was a $0.06 impact or something like that. It's like, I guess, would those same types of rule of thumb hold for these next hedges, or is it that bar has reset?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Bar has reset.",3,"Bar has reset.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And the next question will come from the line of Marshall Urist, Morgan Stanley.",14,"And the next question will come from the line of Marshall Urist, Morgan Stanley.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First question, just more -- I know there's been a lot of questions about this, but maybe to take a step back and just kind of talk about how does Life grow and what are the strategies for growth if, given the exposure to academic, market and government f",91,"First question, just more -- I know there's been a lot of questions about this, but maybe to take a step back and just kind of talk about how does Life grow and what are the strategies for growth if, given the exposure to academic, market and government funding broadly as we think about that for the long term, if it is a flattish funding environment. How do you guys think about growth opportunities? Do you deploy capital differently? Sort of what's the strategy, and how are you thinking about that?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Well, first of all, about 30% of our portfolio is in what we call the broadly applied biology segment. So Forensics, Bioproduction, Animal Health, and those segments are growing very fast, and we see them continuing to grow as a percentage of the portfoli",273,"Well, first of all, about 30% of our portfolio is in what we call the broadly applied biology segment. So Forensics, Bioproduction, Animal Health, and those segments are growing very fast, and we see them continuing to grow as a percentage of the portfolio. So that's a good thing. Second, in terms of academic funding over the next couple of years, I think if you take my earlier comment, we think it's going to be okay. It's probably more of the funding environment we saw in the 2003 and '04 type of time frame, and we actually grew okay through that period by really focusing the portfolio on where the money would be spent. And I think that a very important point to be made is that all products aren't equal, and the funding does get directed then in a certain way and you just simply have to have the portfolio to capture it. So I think we're feeling pretty good that we'll be able to do well in the overall funding environment in the U.S. and Europe. And then lastly, importantly, is the geographic aspect, which is, we have built a very robust infrastructure across Asia. And I think you can see the benefits of that investment by our continued very strong growth across Asia. We are direct in a lot of the main countries. We're going ever more direct in all of the countries. We're building logistics centers across the region. And so geographically, we're exposed to where higher growth will be. So when you couple all of that together, Life Technologies will do fine over the next couple of years.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","I know you guys had talked about, with the convert out of the way, starting a buyback program. And obviously, free cash flow will start to inflect in 2011. So would just be curious as we kind of move past this, maybe you could give your kind of updated hi",96,"I know you guys had talked about, with the convert out of the way, starting a buyback program. And obviously, free cash flow will start to inflect in 2011. So would just be curious as we kind of move past this, maybe you could give your kind of updated high-level thoughts on -- are buybacks likely to be the major use of capital in this $350 million over two years. So is that how you guys are thinking? So is that going to be the major strategy, or is there more opportunities on product tuck-in acquisitions?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think our philosophy and our plans for use of cash are unchanged. Our number one priority is to pay down our debt. And as we've said many times before, target is to get and remain within a leverage ratio of 2 to 2.5x EBITDA. Second point that you bring",96,"I think our philosophy and our plans for use of cash are unchanged. Our number one priority is to pay down our debt. And as we've said many times before, target is to get and remain within a leverage ratio of 2 to 2.5x EBITDA. Second point that you bring out is we're going to continue to invest in the business organically and inorganically. And then third, our philosophy on excess cash also remains the same. We intend to return that to shareholders. A primary vehicle that we've used is share repurchases, and we will continue.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Your next question will come from the line of Jon Wood, Jefferies & Co.",14,"Your next question will come from the line of Jon Wood, Jefferies & Co.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So David, you will be within your target leverage ratio next week, correct, when you pay out the convert?",19,"So David, you will be within your target leverage ratio next week, correct, when you pay out the convert?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Actually, there are a variety of ways of calculating the leverage ratio. So the one we've most often use is our credit agreement, but each of the rating agencies also have a calculation. Moody's, for example, is slightly different than ours. That's why we",83,"Actually, there are a variety of ways of calculating the leverage ratio. So the one we've most often use is our credit agreement, but each of the rating agencies also have a calculation. Moody's, for example, is slightly different than ours. That's why we're saying that by the end of the third quarter, we will be within our target leverage ratio for all of the rating agencies on all of the calculations and anticipate to begin the buyback then in the fourth quarter.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And then on the cash flow statement, can you just disclose the divestiture proceeds from the mass spec [mass spectrometry] JV, and then talk about whether you've paid the taxes yet on that proceed number?",35,"And then on the cash flow statement, can you just disclose the divestiture proceeds from the mass spec [mass spectrometry] JV, and then talk about whether you've paid the taxes yet on that proceed number?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","That's a good question, Jon. Why don't we get the answer to that, and we'll have a follow-up conversation with you on it.",24,"That's a good question, Jon. Why don't we get the answer to that, and we'll have a follow-up conversation with you on it.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Your next question will come from the line of Jon Groberg, Macquarie Capital.",13,"Your next question will come from the line of Jon Groberg, Macquarie Capital.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So just one quick question for you Greg. You've often talked about one of the strengths of the portfolio is that it's not that price-sensitive, and in terms of when you tried lowering prices, it hasn't really stimulated a lot of demand and that's why you",107,"So just one quick question for you Greg. You've often talked about one of the strengths of the portfolio is that it's not that price-sensitive, and in terms of when you tried lowering prices, it hasn't really stimulated a lot of demand and that's why you get some price -- a lot of good pricing ability. Then I'm just curious, specifically within the PCR portfolio, have you tried that overtime? I'm just curious, there's been some, obviously, a lot of announcements around people trying to get more into that business. I'm curious just you view of how effective price is as a mechanism in the PCR space.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think what gets highlighted is in that particular space, there's a lot of the very low end reagents and otherwise. And actually, they've always been around, at least for the last several years, kind of the low end of that segment. We have products from",118,"I think what gets highlighted is in that particular space, there's a lot of the very low end reagents and otherwise. And actually, they've always been around, at least for the last several years, kind of the low end of that segment. We have products from that segment as well. So my comments really still pertain globally to this business, that the relationship between price and volume is not a direct connection. And that's due to a lot of the friction of publications, previous experiments. There's just inertia to switching. And when you have market leadership like we certainly do in the PCR business, people are inclined to stay with their products, and so we benefited from that.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Your next question will come from the line of Steven Lichtman, Oppenheimer & Co.",14,"Your next question will come from the line of Steven Lichtman, Oppenheimer & Co.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First, I was wondering the update on single molecule, still expecting to have a beta launch here towards year end?",20,"First, I was wondering the update on single molecule, still expecting to have a beta launch here towards year end?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes, we still, as we updated at the Investor Day, making good progress in developing the system and continuing to engage with customers around the early access and discussing the experiments and applications that they see for single molecule sequencing.",40,"Yes, we still, as we updated at the Investor Day, making good progress in developing the system and continuing to engage with customers around the early access and discussing the experiments and applications that they see for single molecule sequencing.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And then on CE, certainly seemed like it's picked its head up here a bit more than expected. Is it really driven by the launch of the 3500? Anything else in the sort of end markets you can comment on relative to CE?",43,"And then on CE, certainly seemed like it's picked its head up here a bit more than expected. Is it really driven by the launch of the 3500? Anything else in the sort of end markets you can comment on relative to CE?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","The CE, as we expected with the launch of the 3500, that really goes into markets such as the clinical testing market. We have the CE-IVD mark. Recently, we launched assays that start to go into that like a  BRAF assay. And so we see that uptake falls for",100,"The CE, as we expected with the launch of the 3500, that really goes into markets such as the clinical testing market. We have the CE-IVD mark. Recently, we launched assays that start to go into that like a  BRAF assay. And so we see that uptake falls forward into that CE space. In addition in the Forensics space, launching more kits, more geographic expansion. And they see franchise is robust in that segment, continues to be the right technology choice for those applications where you have a couple of genes that are very variable that you want to analyze.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And the last question will come from the line of Tony Butler, Barclays Capital.",14,"And the last question will come from the line of Tony Butler, Barclays Capital.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","David, is there any way to characterize the revenue synergies in the quarter that you may be seeing with the combination of the companies?",24,"David, is there any way to characterize the revenue synergies in the quarter that you may be seeing with the combination of the companies?
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Would you like to talk about some of the -- I think sources of revenue synergies would be helpful.",19,"Would you like to talk about some of the -- I think sources of revenue synergies would be helpful.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Sure. In the revenue synergy sources, we touched on a few in the earlier comments around combined supply centers, leveraging our combined website. When you look today at the portfolio, where many of these types of sources were purely tied to one of the co",112,"Sure. In the revenue synergy sources, we touched on a few in the earlier comments around combined supply centers, leveraging our combined website. When you look today at the portfolio, where many of these types of sources were purely tied to one of the companies, they're now combined. Our selling organization has been restructured where commercial teams we have consumables, sales reps have carried both the AB [Applied Biosystems] consumables as well as former Invitrogen consumables. It gives our instrument teams more time to focused on -- focusing on instrument placements. And so all of those combined, they have driven many of the synergies that we have indicated in our earlier calls.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And this concludes the question-and-answer session. I'd like to turn the call back to Eileen Pattinson for closing remarks.",20,"And this concludes the question-and-answer session. I'd like to turn the call back to Eileen Pattinson for closing remarks.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you. This concludes our second quarter earnings conference call. If there are any additional questions, please feel free to contact me. This webcast will be available via a replay on our website for three weeks. Thank you again for joining us this m",44,"Thank you. This concludes our second quarter earnings conference call. If there are any additional questions, please feel free to contact me. This webcast will be available via a replay on our website for three weeks. Thank you again for joining us this morning.
"
30253,109039325,70394,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And ladies and gentlemen, again, this does conclude today's conference call. Thank you for your participation. You may now disconnect, and have a great day.",25,"And ladies and gentlemen, again, this does conclude today's conference call. Thank you for your participation. You may now disconnect, and have a great day.

"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Good day, ladies and gentlemen, and welcome to the Second Quarter 2010 Life Technologies Corporation Earnings Conference Call. My name is Diana, and I'll be your operator for today. [Operator Instructions] I would now like to turn the conference over to y",54,"Good day, ladies and gentlemen, and welcome to the Second Quarter 2010 Life Technologies Corporation Earnings Conference Call. My name is Diana, and I'll be your operator for today. [Operator Instructions] I would now like to turn the conference over to your host for today, Ms. Eileen Pattinson, Head of Investor Relations. Please proceed."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Diana, and good morning, everyone. Welcome to Life Technologies Second Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer. In addition, Mark Steve",187,"Thank you, Diana, and good morning, everyone. Welcome to Life Technologies Second Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer. In addition, Mark Stevenson, our Chief Operating Officer; and Bernd Brust, our Chief Commercial Officer, are available during the Q&A portion of the call. If you haven't received a copy of today's press release, you may obtain one from our website at lifetechnologies.com.
I want to remind our listeners that our discussion today will include forward-looking statements, including, but not limited to, statements about future expectations, plans and prospects for the company. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated. It is our intent that these forward-looking statements be protected under the Safe Harbor, created by the Private Securities Litigation Reform Act of 1995. Additionally, we will be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP can be found in today's press release or on our website. 
I'll now hand the call over to Greg Lucier."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Eileen, and thank you, all for joining us. Coming off the heels of our Investor Day just a few weeks ago, we are going to keep our prepared comments short this morning. So let's get started. As you can see from our results, we delivered another",1094,"Thanks, Eileen, and thank you, all for joining us. Coming off the heels of our Investor Day just a few weeks ago, we are going to keep our prepared comments short this morning. 
So let's get started. As you can see from our results, we delivered another quarter of strong top and bottom line growth. Revenue grew 6% organically to $906 million, 8% excluding the impact of H1N1 sales in 2009. Operating margins expanded by 290 basis points to reach a record 30.1%, and earnings per share grew 15% to $0.91 for the quarter.
We are pleased with our results for the second quarter in the first half of the year, which are a reflection of the fundamental strength of the business and the essential nature of our product offering. I'd like to extend my thanks to our teams around the world for their commitment to excellence and relentless focus on execution.
As I do every quarter, I'll take a few moments to talk about these results, give you an update on the integration and provide some color on the strength of our end markets. First, we continue to be very focused on the integration, and I'm pleased to report good progress towards our goal of putting actions in place that will generate $175 million in annual synergies by the end of 2010. 
In the second quarter, we continue to execute on an integration plan, including the placement of over 50 dual-branded supply centers around the world and further optimization of our combined eBusiness platforms. We are seeing good traction from these efforts and achieve new records for the number of the total transactions, both in North America and globally, that will process through eCommerce channels.
In terms of synergy capture, these actions, as well as many others, will generate another $15 million in annualized synergies, getting it halfway to our full year goal. Looking ahead in the second half of the year, we will continue to optimize the programs already started, as well as implement new initiatives, including additional site consolidations and cities where we have multiple offices, continuing to build out the combined eBusiness platforms and optimizing our distribution network.
Now beyond these integration activities, Life Technologies is well positioned to capture opportunities that will continue to drive strong revenue growth. Commercial execution, coupled with a broad product offering of innovative tools ensures that our products are an essential part of our customers' workflows. Recent launches have gone very well. Customer response to Attune, our flow cytometry offering and the ViiA 7 PCR instrument have been very positive, and the sales of our latest CE instrumentation, the 3500, have reinvigorated that business. Since the launch of the 3500 in Q4 of last year, we have placed approximately 400 instruments and demand continues to be very robust.
I'll take a moment now to walk you through more notable points on Q2 performance and give some color on what we're seeing on our end markets. The Americas delivered 7% organic growth in the quarter, 10% without the impact of H1N1. End markets in the Americas remain strong, with pharma and biotech continuing to pick up steam. Evidenced by the strong demand for our discovery and assay services business and double-digit growth in bioproduction. On the research side, stimulus-related revenues for the quarter were approximately $10 million, about the same as we've seen in prior quarters.
Our outlook for the stimulus is unchanged. We continue to estimate that we will generate more than $100 million in stimulus-related revenue over the life of this program. However, since we have not observed the material ramp up in spending since the third quarter of last year, we estimate that stimulus-related revenues will be around $10 million per quarter in the second half of the year, with the rest of the benefit realized in 2011.
Europe grew 4% organically in the quarter. Growth for the quarter is slightly less than in recent periods due to the uncertainty about future government funding levels. At this time, we have no reason to believe that there will be declining government funding for our research in major European markets, such as U.K., Germany and France. However, some of our customers have reported that there have been delays in the release of funds from the institutions to researchers. In addition, researchers seem to be cautious in their spending due to fears that future funding may be curtailed. As a result, spending in these countries on both consumables and instruments softened towards the end of the quarter.
The situation in some of our smaller markets, such as Italy and Spain is slightly different. Funding in these countries have been negatively impacted to some degree as a result of the current economic environment. Revenue growth in these countries was flat during the second quarter. Looking forward to the second half, we expect that for the European region as a whole, revenue growth will be in the low-single digits or mid-single digits, excluding H1N1.
Moving on to other markets, Asia Pacific had another strong quarter, growing 19% organically. End markets in the Asia Pacific region remain healthy, particularly in India and greater China, which grew an excess of 30% in the quarter. We were well positioned in these markets to continue to drive robust growth.
There's no change in our outlook for Japan. In the second quarter, Japan declined 4% organically as a result of a very difficult year-over-year comparison. As a reminder, Q2 of last year included revenue from a large police order, as well as H1N1. Excluding these items, Japan grew 3%, in line with expectations.
Now before I hand it over to David, I'm pleased to announce earlier this week, our Board of Directors approved a two-year $350 million share repurchase program, which is consistent with our strategy of balanced capital deployment. We intend to begin repurchasing shares in the fourth quarter after we have redeemed the 2% convertible notes in August, and we are within our target leverage ratio of 2x to 2.5x EBITDA. In general, the timing and amount of purchases would depend on quarterly fluctuations in cash associated with operating cash flow, capital expenditures and further debt repayment. 
We remain committed to the financial goals we've outlined previously, and our priorities for cash remain the same. We will continue to pay down debt to keep our leverage within 2x to 2.5x EBITDA, as well as make investments in the business that will drive future growth, and then return excess cash to shareholders. 
And with that, I'll turn it over to David."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Greg. This quarter, revenue grew 8% to $906 million. Currency had a positive impact of 1.5 percentage points on reported revenue growth. And acquisitions and divestitures contributed 0.5 to growth. Excluding the impact from currency, acquisitions",1418,"Thanks, Greg. This quarter, revenue grew 8% to $906 million. Currency had a positive impact of 1.5 percentage points on reported revenue growth. And acquisitions and divestitures contributed 0.5 to growth. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6% organically.
Genetic Systems had revenue of $235 million, representing 7% organic growth. Sales of CE instruments, including the new 3500 Genetic Analyzer, and sales of CE consumables to research and clinical labs grew in the mid single digits. This was partially offset by a year-over-year decline in CE instruments and consumables sold into the applied markets, as this business experienced a difficult year-over-year comparison due to the Japanese police order received in 2009.
Customer feedback on the SOLiD 4 and EZ Bead platforms continues to be very positive. As a result, the Next-Generation Sequencing business demonstrated strong double-digit growth during the quarter. At this point, approximately half of the installed base of SOLiD 3.5 instruments has been upgraded to the SOLiD 4 platform.
Molecular Biology Systems grew 2% organically to $434 million in revenue. Excluding H1N1-related revenue, organic growth was approximately 6%. Growth was driven by strong results in the Genomic Assays and Molecular Biology Reagents businesses. Demand for Genomic Assay products grew in the high single digits. The Molecular Biology Reagents business grew in the mid single digits and benefited from strong double-digit growth in Asia Pacific, particularly China.
Cell Systems had revenue of $230 million, representing 13% organic growth with strong demand across the portfolio. Double-digit growth in bioproduction was driven by continued improvement in demand from European and North American pharmaceutical customers, as well as the timing of large orders. The Dynal Beads business also benefited from an improvement in pharma, biotech and clinical diagnostic end markets, resulting in double-digit growth for the quarter. 
And lastly, our Primary and Stem Cell business grew in the midteens, driven by worldwide demand for both media and reagents. 
As I mentioned earlier, currency added 1.5 points of growth to revenue for the quarter, including the impact of our hedging program. The positive impact to EPS was approximately $0.04, including foreign currency effects accounted for in revenue and other income.
Moving on to other items. Second quarter non-GAAP gross margin was 67.7%, an increase of approximately 100 basis points over the prior-year quarter. This improvement was primarily due to positive price realization, synergies, manufacturing productivity and an increase in royalty revenue, partially offset by a mix, particularly, increased sales of bioproduction and instruments. On a sequential basis, gross margin decreased by 60 basis points due to currency and increased sales of lower margin bioproduction products. 
Second quarter non-GAAP operating expenses increased 3% over prior year's levels to $341 million. This was as a result of headcount additions related to acquisitions and increase in depreciation resulting from capital expenditures associated with the AB and Invitrogen integration and currency. Sequentially, operating expenses declined 1%, mainly due to currency.
Non-GAAP operating income was $272 million, an increase of 19% over prior year including the impact of currency and 17% excluding currency. This quarter, operating margins reached a record level of 30.1% representing 290 basis points of improvement year-over-year. This operating margin expansion primarily resulted from improved gross margins and synergies.
In terms of other income line items, we had $1 million of interest income, $1 million from currency gains and interest expense for the quarter was $28 million. Our non-GAAP tax rate was 29.5%. 
Our diluted share count for the quarter was 191 million shares. As you will recall, our share count is impacted by our stock price in the quarter due to our convertible debt and employee stock options. GAAP diluted earnings per share were $0.58, which includes $0.21 per share of acquisition-related amortization expense, $0.03 per share of noncash interest expense associated with the adoption of APB 14-1 and $0.09 per share of business integration costs and other items. On a non-GAAP basis, which excludes these items, diluted earnings per share was $0.91.
Moving on to the balance sheet and cash flow. Our ending cash and short-term investments were $706 million. This compares to last quarter's balance of $642 million. Cash from operating activities was $228 million, capital expenditures were $25 million and free cash flow was $203 million. Included in our cash flow from operations is approximately $25 million of favorability associated with hedges on inter-company loans as a result of increased volatility and currency rates. Return on invested capital increased 40 basis points to 9%. Our ending debt as of June 30 was approximately $2.64 billion. This balance is made up of our convertible debt of $1.1 billion and our senior notes of $1.5 billion. 
For the first half of 2010, revenue increased 8% organically, gross margins expanded 130 basis points and operating margins expanded 310 basis points. We feel good about our results thus far and are focused on continued execution in the second half of the year.
With that, I'll now move on to our expectations for the rest of this year. EPS is now expected to be in the range of $3.35 to $3.50. Our full year guidance for organic revenue growth is unchanged and is still expected to be in the mid to high single digits.
Given Greg's commentary on stimulus and end markets, I'll provide a bit more color on second half of  expectations. As a reminder, when we provided guidance in the beginning of the year, we stated that the difference between mid and high single-digit organic revenue growth was dependent on the amount of stimulus-related revenue that would be recognized during the year. 
We've not seen a notable increase in quarterly stimulus-related revenues since the third quarter of last year. As a result, we expect second half organic revenue growth to be in the mid single digits. Revenue from prior acquisitions will add approximately one point to growth in each quarter. In terms of year-over-year comparables, keep in mind that in the second half of 2009, we had $15 million of H1N1 revenue per quarter, approximately $8 million to $9 million per quarter from the Japanese police order and stimulus revenues of $15 million.
Due to the volatility of currency rates over the last couple of months, I'll provide some detail on the expected impact of currency on our results. With rates as of June 30 and including the impact from our hedging programs, currency is expected to have a small negative impact on revenue, and no impact on EPS in the third quarter. In the fourth quarter, currency is expected to have a negative three-point impact to revenue growth, and EPS is expected to be negatively impacted by $0.04 to $0.05. 
Q3 gross margins are expected to be lower sequentially due to lower fixed cost absorption as a result of lower volume in the quarter and a decline in royalty revenue. Operating expenses in Q3 are expected to be approximately the same as in Q2. 
As we indicated on the last earnings call, we are reinvesting a portion of the operating-income impact from stimulus back into the business to fund future growth opportunities. These investments, which are primarily focused on R&D and commercial projects in emerging markets, began late in the second quarter and will continue through Q3. As a result, R&D expense as a percentage of sales in the third quarter will be slightly higher than our full year guidance. We continue to expect full year R&D expense to be 10% to 10.5% of revenue.
Q3 operating margins are expected to be approximately the same level as last year. For the full year, operating margin expansion is still expected to be within 175 to 225 basis points. We expect the average diluted share count for the second half of the year to be $192 million to $194 million shares assuming an average stock price between $45 and $50.
And finally, we've received a number of questions on our hedging programs as it relates to next year. Because of the continued uncertainty about the global economy and the resulting impact on exchange rates, we opted in June to continue with our currency hedging program in 2011. At this point, we have currency hedges in place for the first seven months of 2011 and intend to execute additional hedges each month until we are hedged for the full 12 months. Share repurchase program will be used to help mitigate the impact of currency on EPS.
And with that, I'll now hand the call back over to Eileen for Q&A."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, David. A quick note before we get started. Recently we've received feedback from a number of you that one-on-one calls are preferable to the post earnings Q&A call. For this reason, we will not be holding a post call today. If you have question",105,"Thank you, David. A quick note before we get started. Recently we've received feedback from a number of you that one-on-one calls are preferable to the post earnings Q&A call. For this reason, we will not be holding a post call today. If you have questions following this call, please contact me directly. 
We have about 30 minutes for Q&A, so I would like to ask everyone to limit themselves to one question and one follow-up question. If you have additional questions that you'd like to ask, please get back in the queue. 
Operator, we are now ready for the Q&A portion of the call."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","[Operator Instructions] And the first question will come from the line of Quintin Lai, Robert W. Baird.",17,"[Operator Instructions] And the first question will come from the line of Quintin Lai, Robert W. Baird."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Greg, could you give a little bit more color on what you're seeing, I guess, in Europe? I mean, it sounds like the spending slowed as delay of release of funds. What kind of visibility do your customers get in terms of when some of those funds will be rel",79,"Greg, could you give a little bit more color on what you're seeing, I guess, in Europe? I mean, it sounds like the spending slowed as delay of release of funds. What kind of visibility do your customers get in terms of when some of those funds will be released? And then, kind of, what's the long-term forecast for Europe, given the fact that those are big research mandate that was just put forward in terms of 2011 budgets?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think what we saw in the second quarter was a reaction to the heightened sensitivity around the whole European fiscal crisis. And so that seemingly had a ripple effect through spending at the bench level on a company like ours towards the end of that se",206,"I think what we saw in the second quarter was a reaction to the heightened sensitivity around the whole European fiscal crisis. And so that seemingly had a ripple effect through spending at the bench level on a company like ours towards the end of that second quarter. Now that's kind of a short-term reaction, and that's why our comments are that, perhaps that could persist a bit through the second half of the year. On long term, the second half of your question, it's unclear, but our opinion is that this side of government funding will probably remain intact. And it centers around what you said in that, the larger countries are committed to a agenda of innovation. And therefore, at least in their public pronouncements that we can understand, they have said they're going to ring fence innovation funding, and so again, we rely on that to say that over the next couple of years, the European business should do okay. So that's what we know at this point. We're not predicting dire consequences, and yet at the same time, we think the robust growth we saw in the last couple of years may be modulated a bit over the next couple of years."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","The improvement that you're seeing in U.S. pharma, is it broad-based or are you seeing maybe increased growth from companies that have completed some of their recent M&A activity?",30,"The improvement that you're seeing in U.S. pharma, is it broad-based or are you seeing maybe increased growth from companies that have completed some of their recent M&A activity?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","What we've always seen in that pharma sector is an account-by-account variability. And so our top accounts are not always our top accounts year-over-year. It just changes depending on their own particular spending or situation they find themselves that ma",72,"What we've always seen in that pharma sector is an account-by-account variability. And so our top accounts are not always our top accounts year-over-year. It just changes depending on their own particular spending or situation they find themselves that may be due to an integration. So overall, we're certainly seeing, in aggregate, a nice recovery. But the individual companies and their respective growth rates has changed this year versus last year."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Next question will come from the line of Doug Schenkel, Cowen.",11,"Next question will come from the line of Doug Schenkel, Cowen."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First, in Molecular Biology Systems, that seems to be an area that some folks are pointing to as a blemish on an otherwise good quarter. By my math, when you strip out the impact of H1 [H1N1] in Japan, and I think you highlighted this, you did 6% organic",138,"First, in Molecular Biology Systems, that seems to be an area that some folks are pointing to as a blemish on an otherwise good quarter. By my math, when you strip out the impact of H1 [H1N1] in Japan, and I think you highlighted this, you did 6% organic growth in the quarter. I just want to make sure that this was consistent with your expectations given the comps and make sure that nothing is changed regarding competitive landscape or the environment relative to where you were in Q1. And then the second question kind of related to organic growth, David, if you mentioned this I missed it, but could you just talk about how H1 versus H2 compares organically when you strip out all the one-timers that you mentioned for the first half and the second half?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Doug, on the first part of your question, your math is correct. The Molecular Biology business had organic growth around 6%, and you have to remember that's a very large franchise. So that's 6% on a big number. So actually, I think the results were very r",133,"Doug, on the first part of your question, your math is correct. The Molecular Biology business had organic growth around 6%, and you have to remember that's a very large franchise. So that's 6% on a big number. So actually, I think the results were very robust actually, and I think it also is indicative that we continue to invest in Molecular Biology. Respective in one of those segments in the PCR franchise, we have the broadest product offering by far. We have millions of assays available on demand, and it really is the standard that people continue to come to more and more. So we feel very good actually about the Molecular Biology results, so I'm glad you clarified that. David, on to you in terms of the second question Doug asked."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes. So Doug, so just let me repeat in terms of what was the impact on H1N1 and the other onetime items on our results for last year and our second half results. So H1N1, we had $15 million of revenue per quarter last year. Another major item was the Japa",99,"Yes. So Doug, so just let me repeat in terms of what was the impact on H1N1 and the other onetime items on our results for last year and our second half results. So H1N1, we had $15 million of revenue per quarter last year. Another major item was the Japanese Police order, and that was approximately $8 million to $9 million per quarter last year. And then finally, we had stimulus revenues in the second half of $15 million, and that was $5 million in the third quarter and $10 million in the fourth. That answer your question?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Yes, it does. I mean, I guess part of the reason I asked this is there has been some concern in the quarter with some other companies that organic growth optics don't look good and that organic growth is actually slowing down in the second half. I'm just",145,"Yes, it does. I mean, I guess part of the reason I asked this is there has been some concern in the quarter with some other companies that organic growth optics don't look good and that organic growth is actually slowing down in the second half. I'm just doing a quick math based on those headwinds, which frankly, you did outline last quarter as well, so those are nothing new. And I want to make sure my math is correct that when you strip the headwinds out of the first half and then you strip headwinds out of the second half, it actually looks like, even though you're guiding organic growth to mid single digits in the second half, that it actually looks like things are accelerating in the second half if you strip everything out. Is that the right way to think about things?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","That is correct. We don't anticipate any significant change between the first half and the second half.",17,"That is correct. We don't anticipate any significant change between the first half and the second half."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","The next question will come from the line of Tycho Peterson, JPMorgan.",12,"The next question will come from the line of Tycho Peterson, JPMorgan."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe just first question for David on kind of the margin improvement, and understanding your comments about kind of the third quarter and how you're going to be reinvesting. Well, can you talk a little bit about how much of what you're seeing here is sus",119,"Maybe just first question for David on kind of the margin improvement, and understanding your comments about kind of the third quarter and how you're going to be reinvesting. Well, can you talk a little bit about how much of what you're seeing here is sustainable? And I asked because I know at your analyst day, you highlighted a lot of productivity initiatives and you highlighted things like non-refrigerated TaqMan reagent and things that seemingly should have a nice impact on margins going forward. So can you talk about kind of the sustainability of manufacturing productivity? And I don't know if you can quantify how much this quarter came from price versus royalty versus some of those productivity enhancements."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes. Yes, I mean, you're absolutely right, Tycho. We did talk at Investor Day a lot about this. Nothing is changed. We continue to expect to get 50-plus basis points of operating margin improvement over the next several years. So we believe that the chang",121,"Yes. Yes, I mean, you're absolutely right, Tycho. We did talk at Investor Day a lot about this. Nothing is changed. We continue to expect to get 50-plus basis points of operating margin improvement over the next several years. So we believe that the changes that we make are sustainable, and that we've got further improvements that we can make. In terms of the impact of price, we continue to get price improvement that is in line with what we've had in the past, and we're averaging one to two percentage points of price. And it has, through the upheaval in the economy over the last couple of years, not changed, and we're seeing that same type of improvement this year."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","I mean, from this quarter, the 100 basis points you saw, can you break out how much was from price versus other factors?",23,"I mean, from this quarter, the 100 basis points you saw, can you break out how much was from price versus other factors?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I can't do that right off the top of my head at this point.",15,"I can't do that right off the top of my head at this point."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe then just a follow-up for Greg on SOLiD. As we think about the launch of hq later this year and then obviously the PI at the lower end, could you talk a little bit about where you're seeing interest from customers in terms of core academic centers a",56,"Maybe then just a follow-up for Greg on SOLiD. As we think about the launch of hq later this year and then obviously the PI at the lower end, could you talk a little bit about where you're seeing interest from customers in terms of core academic centers and then the non-traditional markets for SOLiD?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","You bet, Tycho. I have Mark Stevenson here with me. I'll let Mark answer that in more detail.",18,"You bet, Tycho. I have Mark Stevenson here with me. I'll let Mark answer that in more detail."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes, Tycho. So we continue to see uptake of genome centers, the smaller genome centers that are getting into this, particularly in the area of cancer where we see the accuracy that we get with the SOLiD System, really an uptake in that one. People want to",166,"Yes, Tycho. So we continue to see uptake of genome centers, the smaller genome centers that are getting into this, particularly in the area of cancer where we see the accuracy that we get with the SOLiD System, really an uptake in that one. People want to do those kind of experiments. You saw some of the announcements we've made and some of the uptake in some of the cancer centers both here in North America and in Europe during the last quarter. And we expect, as we launch the SOLiD PI, we'll broaden that base and with the hq, bring the cost of the genome down even further and so continue to see good progress into the market with the SOLiD technology. We also mentioned in the script a very good feedback on the EZ Bead, which is taking away. One other thing important to our customer and the workflow is much more simple and straightforward upfront sample preparation now with that EZ Bead System."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Can you talk about Bioproduction? You called that out as being strong. How sustainable are the trends there, and kind of what you're visibility to the back half of the year for that business?",34,"Can you talk about Bioproduction? You called that out as being strong. How sustainable are the trends there, and kind of what you're visibility to the back half of the year for that business?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","We feel good about the Bioproduction business. Again, it's account-specific. But the macro environment for us, we continue to see uptake across that, and have actually broaden our portfolio there with the introduction of more assays and products into the",53,"We feel good about the Bioproduction business. Again, it's account-specific. But the macro environment for us, we continue to see uptake across that, and have actually broaden our portfolio there with the introduction of more assays and products into the Bioproduction area as they continue to see that's a good market for us."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Derik De Bruin, UBS Securities.",5,"Derik De Bruin, UBS Securities."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So just to follow up on some of Quintin's questions on the funding environment. There's also, obviously, been a lot of concern from amongst people about what happens in the U.S. following the midterm elections. And I guess, what are you looking at now in",79,"So just to follow up on some of Quintin's questions on the funding environment. There's also, obviously, been a lot of concern from amongst people about what happens in the U.S. following the midterm elections. And I guess, what are you looking at now in terms of what are you hearing on the NIH budget in fiscal 2011 and the initial take on fiscal 2012? And I guess, what are your embedded expectations in terms of budget increasing?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Here's what we currently believe, that the NIH budget in 2011 will probably be up by about $1 billion if the House Appropriations recommendations hold. So over the next 12, 18 months, funding should be pretty good. Into 2012, I think it's a bit more uncer",172,"Here's what we currently believe, that the NIH budget in 2011 will probably be up by about $1 billion if the House Appropriations recommendations hold. So over the next 12, 18 months, funding should be pretty good. Into 2012, I think it's a bit more uncertain. But potentially, the NIH could be flat to slightly down. Inside of that though I will tell you that a lot of our work is preparing around where the money would be spent, because it won't just be everything 5% or 3% or flat. There will be changes in how the funding actually gets spent, and we certainly saw this earlier in the Bush administration and I think we learned pretty smartly on how to navigate that. So again, the next couple of years then because of, at least stimulus, the 2011 NIH budget being probably okay and growing, and then the changing and funding towards where we see real strength in our portfolio, the next couple of years should be okay in United States."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Thanks for the color on the FX impact for next year. I guess when we start thinking about where your hedges are in place, what's the euro-dollar number that you kind of got -- the exchange you kind of have the hedging blend [ph] so we can kind of watch th",51,"Thanks for the color on the FX impact for next year. I guess when we start thinking about where your hedges are in place, what's the euro-dollar number that you kind of got -- the exchange you kind of have the hedging blend [ph] so we can kind of watch that?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","You're talking about next year?",6,"You're talking about next year?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Next year, yes.",3,"Next year, yes."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Well, I think we need to go through the second half of the year before we know what our rate is going to be. But we'll provide that, obviously, when we talk about our outlook for next year.",38,"Well, I think we need to go through the second half of the year before we know what our rate is going to be. But we'll provide that, obviously, when we talk about our outlook for next year."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And you had given some general rules of thumb. I'm looking at the impact of currencies on EPS for this year, at 10% move has you -- I think what you said was a $0.06 impact or something like that. It's like, I guess, would those same types of rule of thum",64,"And you had given some general rules of thumb. I'm looking at the impact of currencies on EPS for this year, at 10% move has you -- I think what you said was a $0.06 impact or something like that. It's like, I guess, would those same types of rule of thumb hold for these next hedges? Or is it that bar gets reset?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Bar gets reset.",3,"Bar gets reset."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And the next question will come from the line of Marshall Urist, Morgan Stanley.",14,"And the next question will come from the line of Marshall Urist, Morgan Stanley."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First question, just more -- I know there's been a lot of questions about this, but maybe to take a step back and just kind of talk about how does Life grow? And what are the strategies for growth if, given the exposure to academic, market and government",91,"First question, just more -- I know there's been a lot of questions about this, but maybe to take a step back and just kind of talk about how does Life grow? And what are the strategies for growth if, given the exposure to academic, market and government funding broadly as we think about that for the long term, if it is a flattish funding environment? How do you guys think about growth opportunities? Do you deploy capital differently? Sort of what's the strategy? And how are you thinking about that?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Well, first of all, about 30% of our portfolio is in what we call the broadly applied biology segment. So Forensics, Bioproduction, Animal Health, and those segments are growing very fast, and we see them continuing to grow as a percentage of the portfoli",273,"Well, first of all, about 30% of our portfolio is in what we call the broadly applied biology segment. So Forensics, Bioproduction, Animal Health, and those segments are growing very fast, and we see them continuing to grow as a percentage of the portfolio. So that's a good thing. Second, in terms of academic funding over the next couple of years, I think if you take my earlier comment, we think it's going to be okay. It's probably more of the funding environment we saw in the 2003 and '04 type of time frame, and we actually grew okay through that period by really focusing the portfolio on where the money would be spent. And I think that's a very important point to be made is that all products aren't equal, and the funding does get directed then in a certain way and you just simply have to have the portfolio to capture it. So I think we're feeling pretty good that we'll be able to do well in the overall funding environment in the U.S. and Europe. And then lastly, importantly, is the geographic aspect, which is, we have built a very robust infrastructure across Asia, and I think you can see the benefits of that investment by our continued very strong growth across Asia. We are direct in a lot of the main countries. We're going ever more direct in all of the countries. We're building logistics centers across the region, and so geographically, we're exposed to where higher growth will be. So when you couple all of that together, Life Technologies will do fine over the next couple of years."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","I know you guys had talked about, with the convert out of the way, starting a buyback program, and obviously, free cash flow will start to inflect in 2011. So would just be curious as we kind of move past this, maybe you could get your kind of updated hig",96,"I know you guys had talked about, with the convert out of the way, starting a buyback program, and obviously, free cash flow will start to inflect in 2011. So would just be curious as we kind of move past this, maybe you could get your kind of updated high-level thoughts on -- are buybacks likely to be the major use of capital in this $350 million over two years? So is that how you guys are thinking? So is that going to be the major strategy? Or is there more opportunities on product tuck-in acquisitions?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think our philosophy and our plans for use of cash are unchanged. Our number one priority is to pay down our debt. And as we've said many times before, target is to get and remain within a leverage ratio of 2 to 2.5x EBITDA. Second point that you bring",96,"I think our philosophy and our plans for use of cash are unchanged. Our number one priority is to pay down our debt. And as we've said many times before, target is to get and remain within a leverage ratio of 2 to 2.5x EBITDA. Second point that you bring out is we're going to continue to invest in the business, organically and inorganically. And then third, our philosophy on excess cash also remains the same. We intend to return that to shareholders. A primary vehicle that we've used is share repurchases, and we will continue."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Your next question will come from the line of Jon Wood, Jefferies & Co.",14,"Your next question will come from the line of Jon Wood, Jefferies & Co."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So David, you will be within your target leverage ratio next week, correct, when you pay out the convert?",19,"So David, you will be within your target leverage ratio next week, correct, when you pay out the convert?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Actually, there are a variety of ways of calculating the leverage ratio. So one we've most often use is our credit agreement, but each of the rating agencies also have a calculation. Moody's, for example, is slightly different than ours. That's why we're",82,"Actually, there are a variety of ways of calculating the leverage ratio. So one we've most often use is our credit agreement, but each of the rating agencies also have a calculation. Moody's, for example, is slightly different than ours. That's why we're saying that by the end of the third quarter, we will be within our target leverage ratio for all of the rating agencies on all of the calculations and anticipate to begin the buyback then in the fourth quarter."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And then on the cash flow statement, can you just disclose the divestiture proceeds from the mass spec [mass spectrometry] JV? And then talk about whether you've paid the taxes yet on that proceed number?",35,"And then on the cash flow statement, can you just disclose the divestiture proceeds from the mass spec [mass spectrometry] JV? And then talk about whether you've paid the taxes yet on that proceed number?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","That's a good question, Jon. Why don't we get the answer to that, and we'll have a follow-up conversation with you on it.",24,"That's a good question, Jon. Why don't we get the answer to that, and we'll have a follow-up conversation with you on it."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Your next question will come from the line of Jon Groberg, Macquarie Capital.",13,"Your next question will come from the line of Jon Groberg, Macquarie Capital."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So just one quick question for you Greg. You've often talked about one of the strengths of the portfolio is that it's not that price sensitive. In terms of when you tried lowering prices, it hasn't really stimulated a lot of demand, and that's why you get",108,"So just one quick question for you Greg. You've often talked about one of the strengths of the portfolio is that it's not that price sensitive. In terms of when you tried lowering prices, it hasn't really stimulated a lot of demand, and that's why you get some price -- a lot of good pricing ability. And I'm just curious, specifically within the PCR portfolio, have you tried that over time? I'm just curious, there's been some, obviously, a lot of announcements around people trying to get more into that business. I'm curious just your view of how effective price is as a mechanism in the PCR space."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think what gets highlighted is in that particular space, there's a lot of the very low-end reagents and otherwise. And actually, they've always been around, at least for the last several years, kind of the low end of that segment. We have products from",117,"I think what gets highlighted is in that particular space, there's a lot of the very low-end reagents and otherwise. And actually, they've always been around, at least for the last several years, kind of the low end of that segment. We have products from that segment as well. So my comments really, still pertain globally to this business, that the relationship between price and volume is not a direct connection, and that's due to a lot of the friction of publications, previous experiments. There's just inertia to switching. And when you have market leadership like we certainly do in the PCR business, people are inclined to stay with their products, and so we benefited from that."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Latest question will come from the line of Steven Lichtman, Oppenheimer & Co.",13,"Latest question will come from the line of Steven Lichtman, Oppenheimer & Co."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First, I was wondering the update on single molecule, still expecting to have a beta launch here towards year end?",20,"First, I was wondering the update on single molecule, still expecting to have a beta launch here towards year end?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes, we still, as we updated at the Investor Day, making good progress in developing the system and continuing to engage with customers around the early access and discussing the experiments and applications that they see for single molecule sequencing.",40,"Yes, we still, as we updated at the Investor Day, making good progress in developing the system and continuing to engage with customers around the early access and discussing the experiments and applications that they see for single molecule sequencing."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And then on CE, it certainly seemed like it's picked its head up here a bit more than expected. Is it really driven by the launch of the 3500? Anything else in the sort of end markets you can comment on relative to CE?",44,"And then on CE, it certainly seemed like it's picked its head up here a bit more than expected. Is it really driven by the launch of the 3500? Anything else in the sort of end markets you can comment on relative to CE?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","The CE, as we expected, with the launch of the 3500, really goes into markets, such as the clinical testing market. We have the CE-IVD mark. Recently, we launched assays that start to go into that like a  BRAF assay, and so we see that uptake falls forwar",99,"The CE, as we expected, with the launch of the 3500, really goes into markets, such as the clinical testing market. We have the CE-IVD mark. Recently, we launched assays that start to go into that like a  BRAF assay, and so we see that uptake falls forward into that CE space. In addition, in the Forensics space, launching more kits, more geographic expansion. And they see franchise is robust in that segment, continues to be the right technology choice for those applications where you have a couple of genes that are very variable that you want to analyze."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And the last question will come from the line of Tony Butler, Barclays Capital.",14,"And the last question will come from the line of Tony Butler, Barclays Capital."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","David, is there any way to characterize the revenue synergies in the quarter that you may be seeing with the combination of the companies?",24,"David, is there any way to characterize the revenue synergies in the quarter that you may be seeing with the combination of the companies?"
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Would you like to talk about some of the -- I think sources of revenue synergies would be helpful.",19,"Would you like to talk about some of the -- I think sources of revenue synergies would be helpful."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Sure. In the revenue synergy sources, we touched on a few in the earlier comments around combined supply centers, leveraging our combined website. When you look today at the portfolio, where many of these types of sources were purely tied to one of the co",112,"Sure. In the revenue synergy sources, we touched on a few in the earlier comments around combined supply centers, leveraging our combined website. When you look today at the portfolio, where many of these types of sources were purely tied to one of the companies, they're now combined. Our selling organization has been restructured where commercial teams we have consumables, sales reps have carried both the AB [Applied Biosystems] consumables as well as former Invitrogen consumables. It gives our instrument teams more time to focused on -- focusing on instrument placements. And so all of those combined, they have driven many of the synergies that we have indicated in our earlier calls."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And this concludes the question-and-answer session. I'd like to turn the call back to Eileen Pattinson for closing remarks.",20,"And this concludes the question-and-answer session. I'd like to turn the call back to Eileen Pattinson for closing remarks."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you. This concludes our second quarter earnings conference call. If there are any additional questions, please feel free to contact me. This webcast will be available via a replay on our website for three weeks. Thank you again for joining us this m",44,"Thank you. This concludes our second quarter earnings conference call. If there are any additional questions, please feel free to contact me. This webcast will be available via a replay on our website for three weeks. Thank you again for joining us this morning."
30253,109039325,70540,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And ladies and gentlemen, again, this does conclude today's conference call. Thank you for your participation. You may now disconnect, and have a great day.",25,"And ladies and gentlemen, again, this does conclude today's conference call. Thank you for your participation. You may now disconnect, and have a great day."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Good day, ladies and gentlemen, and welcome to the Second Quarter 2010 Life Technologies Corporation Earnings Conference Call. My name is Diana, and I'll be your operator for today. [Operator Instructions] I would now like to turn the conference over to y",54,"Good day, ladies and gentlemen, and welcome to the Second Quarter 2010 Life Technologies Corporation Earnings Conference Call. My name is Diana, and I'll be your operator for today. [Operator Instructions] I would now like to turn the conference over to your host for today, Ms. Eileen Pattinson, Head of Investor Relations. Please proceed."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Diana, and good morning, everyone. Welcome to Life Technologies Second Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer. In addition, Mark Steve",187,"Thank you, Diana, and good morning, everyone. Welcome to Life Technologies Second Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer. In addition, Mark Stevenson, our Chief Operating Officer; and Bernd Brust, our Chief Commercial Officer, are available during the Q&A portion of the call. If you haven't received a copy of today's press release, you may obtain one from our website at lifetechnologies.com.
I want to remind our listeners that our discussion today will include forward-looking statements, including, but not limited to, statements about future expectations, plans and prospects for the company. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated. It is our intent that these forward-looking statements be protected under the Safe Harbor, created by the Private Securities Litigation Reform Act of 1995. Additionally, we will be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP can be found in today's press release or on our website. 
I'll now hand the call over to Greg Lucier."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Eileen, and thank you, all for joining us. Coming off the heels of our Investor Day just a few weeks ago, we are going to keep our prepared comments short this morning. So let's get started. As you can see from our results, we delivered another",1094,"Thanks, Eileen, and thank you, all for joining us. Coming off the heels of our Investor Day just a few weeks ago, we are going to keep our prepared comments short this morning. 
So let's get started. As you can see from our results, we delivered another quarter of strong top and bottom line growth. Revenue grew 6% organically to $906 million, 8% excluding the impact of H1N1 sales in 2009. Operating margins expanded by 290 basis points to reach a record 30.1%, and earnings per share grew 15% to $0.91 for the quarter.
We are pleased with our results for the second quarter in the first half of the year, which are a reflection of the fundamental strength of the business and the essential nature of our product offering. I'd like to extend my thanks to our teams around the world for their commitment to excellence and relentless focus on execution.
As I do every quarter, I'll take a few moments to talk about these results, give you an update on the integration and provide some color on the strength of our end markets. First, we continue to be very focused on the integration, and I'm pleased to report good progress towards our goal of putting actions in place that will generate $175 million in annual synergies by the end of 2010. 
In the second quarter, we continue to execute on an integration plan, including the placement of over 50 dual-branded supply centers around the world and further optimization of our combined eBusiness platforms. We are seeing good traction from these efforts and achieve new records for the number of the total transactions, both in North America and globally, that will process through eCommerce channels.
In terms of synergy capture, these actions, as well as many others, will generate another $15 million in annualized synergies, getting it halfway to our full year goal. Looking ahead in the second half of the year, we will continue to optimize the programs already started, as well as implement new initiatives, including additional site consolidations and cities where we have multiple offices, continuing to build out the combined eBusiness platforms and optimizing our distribution network.
Now beyond these integration activities, Life Technologies is well positioned to capture opportunities that will continue to drive strong revenue growth. Commercial execution, coupled with a broad product offering of innovative tools ensures that our products are an essential part of our customers' workflows. Recent launches have gone very well. Customer response to Attune, our flow cytometry offering and the ViiA 7 PCR instrument have been very positive, and the sales of our latest CE instrumentation, the 3500, have reinvigorated that business. Since the launch of the 3500 in Q4 of last year, we have placed approximately 400 instruments and demand continues to be very robust.
I'll take a moment now to walk you through more notable points on Q2 performance and give some color on what we're seeing on our end markets. The Americas delivered 7% organic growth in the quarter, 10% without the impact of H1N1. End markets in the Americas remain strong, with pharma and biotech continuing to pick up steam. Evidenced by the strong demand for our discovery and assay services business and double-digit growth in bioproduction. On the research side, stimulus-related revenues for the quarter were approximately $10 million, about the same as we've seen in prior quarters.
Our outlook for the stimulus is unchanged. We continue to estimate that we will generate more than $100 million in stimulus-related revenue over the life of this program. However, since we have not observed the material ramp up in spending since the third quarter of last year, we estimate that stimulus-related revenues will be around $10 million per quarter in the second half of the year, with the rest of the benefit realized in 2011.
Europe grew 4% organically in the quarter. Growth for the quarter is slightly less than in recent periods due to the uncertainty about future government funding levels. At this time, we have no reason to believe that there will be declining government funding for our research in major European markets, such as U.K., Germany and France. However, some of our customers have reported that there have been delays in the release of funds from the institutions to researchers. In addition, researchers seem to be cautious in their spending due to fears that future funding may be curtailed. As a result, spending in these countries on both consumables and instruments softened towards the end of the quarter.
The situation in some of our smaller markets, such as Italy and Spain is slightly different. Funding in these countries have been negatively impacted to some degree as a result of the current economic environment. Revenue growth in these countries was flat during the second quarter. Looking forward to the second half, we expect that for the European region as a whole, revenue growth will be in the low-single digits or mid-single digits, excluding H1N1.
Moving on to other markets, Asia Pacific had another strong quarter, growing 19% organically. End markets in the Asia Pacific region remain healthy, particularly in India and greater China, which grew an excess of 30% in the quarter. We were well positioned in these markets to continue to drive robust growth.
There's no change in our outlook for Japan. In the second quarter, Japan declined 4% organically as a result of a very difficult year-over-year comparison. As a reminder, Q2 of last year included revenue from a large police order, as well as H1N1. Excluding these items, Japan grew 3%, in line with expectations.
Now before I hand it over to David, I'm pleased to announce earlier this week, our Board of Directors approved a two-year $350 million share repurchase program, which is consistent with our strategy of balanced capital deployment. We intend to begin repurchasing shares in the fourth quarter after we have redeemed the 2% convertible notes in August, and we are within our target leverage ratio of 2x to 2.5x EBITDA. In general, the timing and amount of purchases would depend on quarterly fluctuations in cash associated with operating cash flow, capital expenditures and further debt repayment. 
We remain committed to the financial goals we've outlined previously, and our priorities for cash remain the same. We will continue to pay down debt to keep our leverage within 2x to 2.5x EBITDA, as well as make investments in the business that will drive future growth, and then return excess cash to shareholders. 
And with that, I'll turn it over to David."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Greg. This quarter, revenue grew 8% to $906 million. Currency had a positive impact of 1.5 percentage points on reported revenue growth. And acquisitions and divestitures contributed 0.5 to growth. Excluding the impact from currency, acquisitions",1418,"Thanks, Greg. This quarter, revenue grew 8% to $906 million. Currency had a positive impact of 1.5 percentage points on reported revenue growth. And acquisitions and divestitures contributed 0.5 to growth. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6% organically.
Genetic Systems had revenue of $235 million, representing 7% organic growth. Sales of CE instruments, including the new 3500 Genetic Analyzer, and sales of CE consumables to research and clinical labs grew in the mid single digits. This was partially offset by a year-over-year decline in CE instruments and consumables sold into the applied markets, as this business experienced a difficult year-over-year comparison due to the Japanese police order received in 2009.
Customer feedback on the SOLiD 4 and EZ Bead platforms continues to be very positive. As a result, the Next-Generation Sequencing business demonstrated strong double-digit growth during the quarter. At this point, approximately half of the installed base of SOLiD 3.5 instruments has been upgraded to the SOLiD 4 platform.
Molecular Biology Systems grew 2% organically to $434 million in revenue. Excluding H1N1-related revenue, organic growth was approximately 6%. Growth was driven by strong results in the Genomic Assays and Molecular Biology Reagents businesses. Demand for Genomic Assay products grew in the high single digits. The Molecular Biology Reagents business grew in the mid single digits and benefited from strong double-digit growth in Asia Pacific, particularly China.
Cell Systems had revenue of $230 million, representing 13% organic growth with strong demand across the portfolio. Double-digit growth in bioproduction was driven by continued improvement in demand from European and North American pharmaceutical customers, as well as the timing of large orders. The Dynal Beads business also benefited from an improvement in pharma, biotech and clinical diagnostic end markets, resulting in double-digit growth for the quarter. 
And lastly, our Primary and Stem Cell business grew in the midteens, driven by worldwide demand for both media and reagents. 
As I mentioned earlier, currency added 1.5 points of growth to revenue for the quarter, including the impact of our hedging program. The positive impact to EPS was approximately $0.04, including foreign currency effects accounted for in revenue and other income.
Moving on to other items. Second quarter non-GAAP gross margin was 67.7%, an increase of approximately 100 basis points over the prior-year quarter. This improvement was primarily due to positive price realization, synergies, manufacturing productivity and an increase in royalty revenue, partially offset by a mix, particularly, increased sales of bioproduction and instruments. On a sequential basis, gross margin decreased by 60 basis points due to currency and increased sales of lower margin bioproduction products. 
Second quarter non-GAAP operating expenses increased 3% over prior year's levels to $341 million. This was as a result of headcount additions related to acquisitions and increase in depreciation resulting from capital expenditures associated with the AB and Invitrogen integration and currency. Sequentially, operating expenses declined 1%, mainly due to currency.
Non-GAAP operating income was $272 million, an increase of 19% over prior year including the impact of currency and 17% excluding currency. This quarter, operating margins reached a record level of 30.1% representing 290 basis points of improvement year-over-year. This operating margin expansion primarily resulted from improved gross margins and synergies.
In terms of other income line items, we had $1 million of interest income, $1 million from currency gains and interest expense for the quarter was $28 million. Our non-GAAP tax rate was 29.5%. 
Our diluted share count for the quarter was 191 million shares. As you will recall, our share count is impacted by our stock price in the quarter due to our convertible debt and employee stock options. GAAP diluted earnings per share were $0.58, which includes $0.21 per share of acquisition-related amortization expense, $0.03 per share of noncash interest expense associated with the adoption of APB 14-1 and $0.09 per share of business integration costs and other items. On a non-GAAP basis, which excludes these items, diluted earnings per share was $0.91.
Moving on to the balance sheet and cash flow. Our ending cash and short-term investments were $706 million. This compares to last quarter's balance of $642 million. Cash from operating activities was $228 million, capital expenditures were $25 million and free cash flow was $203 million. Included in our cash flow from operations is approximately $25 million of favorability associated with hedges on inter-company loans as a result of increased volatility and currency rates. Return on invested capital increased 40 basis points to 9%. Our ending debt as of June 30 was approximately $2.64 billion. This balance is made up of our convertible debt of $1.1 billion and our senior notes of $1.5 billion. 
For the first half of 2010, revenue increased 8% organically, gross margins expanded 130 basis points and operating margins expanded 310 basis points. We feel good about our results thus far and are focused on continued execution in the second half of the year.
With that, I'll now move on to our expectations for the rest of this year. EPS is now expected to be in the range of $3.35 to $3.50. Our full year guidance for organic revenue growth is unchanged and is still expected to be in the mid to high single digits.
Given Greg's commentary on stimulus and end markets, I'll provide a bit more color on second half of  expectations. As a reminder, when we provided guidance in the beginning of the year, we stated that the difference between mid and high single-digit organic revenue growth was dependent on the amount of stimulus-related revenue that would be recognized during the year. 
We've not seen a notable increase in quarterly stimulus-related revenues since the third quarter of last year. As a result, we expect second half organic revenue growth to be in the mid single digits. Revenue from prior acquisitions will add approximately one point to growth in each quarter. In terms of year-over-year comparables, keep in mind that in the second half of 2009, we had $15 million of H1N1 revenue per quarter, approximately $8 million to $9 million per quarter from the Japanese police order and stimulus revenues of $15 million.
Due to the volatility of currency rates over the last couple of months, I'll provide some detail on the expected impact of currency on our results. With rates as of June 30 and including the impact from our hedging programs, currency is expected to have a small negative impact on revenue, and no impact on EPS in the third quarter. In the fourth quarter, currency is expected to have a negative three-point impact to revenue growth, and EPS is expected to be negatively impacted by $0.04 to $0.05. 
Q3 gross margins are expected to be lower sequentially due to lower fixed cost absorption as a result of lower volume in the quarter and a decline in royalty revenue. Operating expenses in Q3 are expected to be approximately the same as in Q2. 
As we indicated on the last earnings call, we are reinvesting a portion of the operating-income impact from stimulus back into the business to fund future growth opportunities. These investments, which are primarily focused on R&D and commercial projects in emerging markets, began late in the second quarter and will continue through Q3. As a result, R&D expense as a percentage of sales in the third quarter will be slightly higher than our full year guidance. We continue to expect full year R&D expense to be 10% to 10.5% of revenue.
Q3 operating margins are expected to be approximately the same level as last year. For the full year, operating margin expansion is still expected to be within 175 to 225 basis points. We expect the average diluted share count for the second half of the year to be $192 million to $194 million shares assuming an average stock price between $45 and $50.
And finally, we've received a number of questions on our hedging programs as it relates to next year. Because of the continued uncertainty about the global economy and the resulting impact on exchange rates, we opted in June to continue with our currency hedging program in 2011. At this point, we have currency hedges in place for the first seven months of 2011 and intend to execute additional hedges each month until we are hedged for the full 12 months. Share repurchase program will be used to help mitigate the impact of currency on EPS.
And with that, I'll now hand the call back over to Eileen for Q&A."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, David. A quick note before we get started. Recently we've received feedback from a number of you that one-on-one calls are preferable to the post earnings Q&A call. For this reason, we will not be holding a post call today. If you have question",105,"Thank you, David. A quick note before we get started. Recently we've received feedback from a number of you that one-on-one calls are preferable to the post earnings Q&A call. For this reason, we will not be holding a post call today. If you have questions following this call, please contact me directly. 
We have about 30 minutes for Q&A, so I would like to ask everyone to limit themselves to one question and one follow-up question. If you have additional questions that you'd like to ask, please get back in the queue. 
Operator, we are now ready for the Q&A portion of the call."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","[Operator Instructions] And the first question will come from the line of Quintin Lai, Robert W. Baird.",17,"[Operator Instructions] And the first question will come from the line of Quintin Lai, Robert W. Baird."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Greg, could you give a little bit more color on what you're seeing, I guess, in Europe? I mean, it sounds like the spending slowed as delay of release of funds. What kind of visibility do your customers get in terms of when some of those funds will be rel",79,"Greg, could you give a little bit more color on what you're seeing, I guess, in Europe? I mean, it sounds like the spending slowed as delay of release of funds. What kind of visibility do your customers get in terms of when some of those funds will be released? And then, kind of, what's the long-term forecast for Europe, given the fact that those are big research mandate that was just put forward in terms of 2011 budgets?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think what we saw in the second quarter was a reaction to the heightened sensitivity around the whole European fiscal crisis. And so that seemingly had a ripple effect through spending at the bench level on a company like ours towards the end of that se",206,"I think what we saw in the second quarter was a reaction to the heightened sensitivity around the whole European fiscal crisis. And so that seemingly had a ripple effect through spending at the bench level on a company like ours towards the end of that second quarter. Now that's kind of a short-term reaction, and that's why our comments are that, perhaps that could persist a bit through the second half of the year. On long term, the second half of your question, it's unclear, but our opinion is that this side of government funding will probably remain intact. And it centers around what you said in that, the larger countries are committed to a agenda of innovation. And therefore, at least in their public pronouncements that we can understand, they have said they're going to ring fence innovation funding, and so again, we rely on that to say that over the next couple of years, the European business should do okay. So that's what we know at this point. We're not predicting dire consequences, and yet at the same time, we think the robust growth we saw in the last couple of years may be modulated a bit over the next couple of years."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","The improvement that you're seeing in U.S. pharma, is it broad-based or are you seeing maybe increased growth from companies that have completed some of their recent M&A activity?",30,"The improvement that you're seeing in U.S. pharma, is it broad-based or are you seeing maybe increased growth from companies that have completed some of their recent M&A activity?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","What we've always seen in that pharma sector is an account-by-account variability. And so our top accounts are not always our top accounts year-over-year. It just changes depending on their own particular spending or situation they find themselves that ma",72,"What we've always seen in that pharma sector is an account-by-account variability. And so our top accounts are not always our top accounts year-over-year. It just changes depending on their own particular spending or situation they find themselves that may be due to an integration. So overall, we're certainly seeing, in aggregate, a nice recovery. But the individual companies and their respective growth rates has changed this year versus last year."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Next question will come from the line of Doug Schenkel, Cowen.",11,"Next question will come from the line of Doug Schenkel, Cowen."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First, in Molecular Biology Systems, that seems to be an area that some folks are pointing to as a blemish on an otherwise good quarter. By my math, when you strip out the impact of H1 [H1N1] in Japan, and I think you highlighted this, you did 6% organic",138,"First, in Molecular Biology Systems, that seems to be an area that some folks are pointing to as a blemish on an otherwise good quarter. By my math, when you strip out the impact of H1 [H1N1] in Japan, and I think you highlighted this, you did 6% organic growth in the quarter. I just want to make sure that this was consistent with your expectations given the comps and make sure that nothing is changed regarding competitive landscape or the environment relative to where you were in Q1. And then the second question kind of related to organic growth, David, if you mentioned this I missed it, but could you just talk about how H1 versus H2 compares organically when you strip out all the one-timers that you mentioned for the first half and the second half?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Doug, on the first part of your question, your math is correct. The Molecular Biology business had organic growth around 6%, and you have to remember that's a very large franchise. So that's 6% on a big number. So actually, I think the results were very r",133,"Doug, on the first part of your question, your math is correct. The Molecular Biology business had organic growth around 6%, and you have to remember that's a very large franchise. So that's 6% on a big number. So actually, I think the results were very robust actually, and I think it also is indicative that we continue to invest in Molecular Biology. Respective in one of those segments in the PCR franchise, we have the broadest product offering by far. We have millions of assays available on demand, and it really is the standard that people continue to come to more and more. So we feel very good actually about the Molecular Biology results, so I'm glad you clarified that. David, on to you in terms of the second question Doug asked."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes. So Doug, so just let me repeat in terms of what was the impact on H1N1 and the other onetime items on our results for last year and our second half results. So H1N1, we had $15 million of revenue per quarter last year. Another major item was the Japa",99,"Yes. So Doug, so just let me repeat in terms of what was the impact on H1N1 and the other onetime items on our results for last year and our second half results. So H1N1, we had $15 million of revenue per quarter last year. Another major item was the Japanese Police order, and that was approximately $8 million to $9 million per quarter last year. And then finally, we had stimulus revenues in the second half of $15 million, and that was $5 million in the third quarter and $10 million in the fourth. That answer your question?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Yes, it does. I mean, I guess part of the reason I asked this is there has been some concern in the quarter with some other companies that organic growth optics don't look good and that organic growth is actually slowing down in the second half. I'm just",145,"Yes, it does. I mean, I guess part of the reason I asked this is there has been some concern in the quarter with some other companies that organic growth optics don't look good and that organic growth is actually slowing down in the second half. I'm just doing a quick math based on those headwinds, which frankly, you did outline last quarter as well, so those are nothing new. And I want to make sure my math is correct that when you strip the headwinds out of the first half and then you strip headwinds out of the second half, it actually looks like, even though you're guiding organic growth to mid single digits in the second half, that it actually looks like things are accelerating in the second half if you strip everything out. Is that the right way to think about things?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","That is correct. We don't anticipate any significant change between the first half and the second half.",17,"That is correct. We don't anticipate any significant change between the first half and the second half."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","The next question will come from the line of Tycho Peterson, JPMorgan.",12,"The next question will come from the line of Tycho Peterson, JPMorgan."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe just first question for David on kind of the margin improvement, and understanding your comments about kind of the third quarter and how you're going to be reinvesting. Well, can you talk a little bit about how much of what you're seeing here is sus",119,"Maybe just first question for David on kind of the margin improvement, and understanding your comments about kind of the third quarter and how you're going to be reinvesting. Well, can you talk a little bit about how much of what you're seeing here is sustainable? And I asked because I know at your analyst day, you highlighted a lot of productivity initiatives and you highlighted things like non-refrigerated TaqMan reagent and things that seemingly should have a nice impact on margins going forward. So can you talk about kind of the sustainability of manufacturing productivity? And I don't know if you can quantify how much this quarter came from price versus royalty versus some of those productivity enhancements."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes. Yes, I mean, you're absolutely right, Tycho. We did talk at Investor Day a lot about this. Nothing is changed. We continue to expect to get 50-plus basis points of operating margin improvement over the next several years. So we believe that the chang",121,"Yes. Yes, I mean, you're absolutely right, Tycho. We did talk at Investor Day a lot about this. Nothing is changed. We continue to expect to get 50-plus basis points of operating margin improvement over the next several years. So we believe that the changes that we make are sustainable, and that we've got further improvements that we can make. In terms of the impact of price, we continue to get price improvement that is in line with what we've had in the past, and we're averaging one to two percentage points of price. And it has, through the upheaval in the economy over the last couple of years, not changed, and we're seeing that same type of improvement this year."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","I mean, from this quarter, the 100 basis points you saw, can you break out how much was from price versus other factors?",23,"I mean, from this quarter, the 100 basis points you saw, can you break out how much was from price versus other factors?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I can't do that right off the top of my head at this point.",15,"I can't do that right off the top of my head at this point."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe then just a follow-up for Greg on SOLiD. As we think about the launch of hq later this year and then obviously the PI at the lower end, could you talk a little bit about where you're seeing interest from customers in terms of core academic centers a",56,"Maybe then just a follow-up for Greg on SOLiD. As we think about the launch of hq later this year and then obviously the PI at the lower end, could you talk a little bit about where you're seeing interest from customers in terms of core academic centers and then the non-traditional markets for SOLiD?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","You bet, Tycho. I have Mark Stevenson here with me. I'll let Mark answer that in more detail.",18,"You bet, Tycho. I have Mark Stevenson here with me. I'll let Mark answer that in more detail."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes, Tycho. So we continue to see uptake of genome centers, the smaller genome centers that are getting into this, particularly in the area of cancer where we see the accuracy that we get with the SOLiD System, really an uptake in that one. People want to",166,"Yes, Tycho. So we continue to see uptake of genome centers, the smaller genome centers that are getting into this, particularly in the area of cancer where we see the accuracy that we get with the SOLiD System, really an uptake in that one. People want to do those kind of experiments. You saw some of the announcements we've made and some of the uptake in some of the cancer centers both here in North America and in Europe during the last quarter. And we expect, as we launch the SOLiD PI, we'll broaden that base and with the hq, bring the cost of the genome down even further and so continue to see good progress into the market with the SOLiD technology. We also mentioned in the script a very good feedback on the EZ Bead, which is taking away. One other thing important to our customer and the workflow is much more simple and straightforward upfront sample preparation now with that EZ Bead System."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Can you talk about Bioproduction? You called that out as being strong. How sustainable are the trends there, and kind of what you're visibility to the back half of the year for that business?",34,"Can you talk about Bioproduction? You called that out as being strong. How sustainable are the trends there, and kind of what you're visibility to the back half of the year for that business?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","We feel good about the Bioproduction business. Again, it's account-specific. But the macro environment for us, we continue to see uptake across that, and have actually broaden our portfolio there with the introduction of more assays and products into the",53,"We feel good about the Bioproduction business. Again, it's account-specific. But the macro environment for us, we continue to see uptake across that, and have actually broaden our portfolio there with the introduction of more assays and products into the Bioproduction area as they continue to see that's a good market for us."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Derik De Bruin, UBS Securities.",5,"Derik De Bruin, UBS Securities."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So just to follow up on some of Quintin's questions on the funding environment. There's also, obviously, been a lot of concern from amongst people about what happens in the U.S. following the midterm elections. And I guess, what are you looking at now in",79,"So just to follow up on some of Quintin's questions on the funding environment. There's also, obviously, been a lot of concern from amongst people about what happens in the U.S. following the midterm elections. And I guess, what are you looking at now in terms of what are you hearing on the NIH budget in fiscal 2011 and the initial take on fiscal 2012? And I guess, what are your embedded expectations in terms of budget increasing?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Here's what we currently believe, that the NIH budget in 2011 will probably be up by about $1 billion if the House Appropriations recommendations hold. So over the next 12, 18 months, funding should be pretty good. Into 2012, I think it's a bit more uncer",172,"Here's what we currently believe, that the NIH budget in 2011 will probably be up by about $1 billion if the House Appropriations recommendations hold. So over the next 12, 18 months, funding should be pretty good. Into 2012, I think it's a bit more uncertain. But potentially, the NIH could be flat to slightly down. Inside of that though I will tell you that a lot of our work is preparing around where the money would be spent, because it won't just be everything 5% or 3% or flat. There will be changes in how the funding actually gets spent, and we certainly saw this earlier in the Bush administration and I think we learned pretty smartly on how to navigate that. So again, the next couple of years then because of, at least stimulus, the 2011 NIH budget being probably okay and growing, and then the changing and funding towards where we see real strength in our portfolio, the next couple of years should be okay in United States."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Thanks for the color on the FX impact for next year. I guess when we start thinking about where your hedges are in place, what's the euro-dollar number that you kind of got -- the exchange you kind of have the hedging blend [ph] so we can kind of watch th",51,"Thanks for the color on the FX impact for next year. I guess when we start thinking about where your hedges are in place, what's the euro-dollar number that you kind of got -- the exchange you kind of have the hedging blend [ph] so we can kind of watch that?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","You're talking about next year?",6,"You're talking about next year?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","Next year, yes.",3,"Next year, yes."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Well, I think we need to go through the second half of the year before we know what our rate is going to be. But we'll provide that, obviously, when we talk about our outlook for next year.",38,"Well, I think we need to go through the second half of the year before we know what our rate is going to be. But we'll provide that, obviously, when we talk about our outlook for next year."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And you had given some general rules of thumb. I'm looking at the impact of currencies on EPS for this year, at 10% move has you -- I think what you said was a $0.06 impact or something like that. It's like, I guess, would those same types of rule of thum",64,"And you had given some general rules of thumb. I'm looking at the impact of currencies on EPS for this year, at 10% move has you -- I think what you said was a $0.06 impact or something like that. It's like, I guess, would those same types of rule of thumb hold for these next hedges? Or is it that bar gets reset?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Bar gets reset.",3,"Bar gets reset."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And the next question will come from the line of Marshall Urist, Morgan Stanley.",14,"And the next question will come from the line of Marshall Urist, Morgan Stanley."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First question, just more -- I know there's been a lot of questions about this, but maybe to take a step back and just kind of talk about how does Life grow? And what are the strategies for growth if, given the exposure to academic, market and government",91,"First question, just more -- I know there's been a lot of questions about this, but maybe to take a step back and just kind of talk about how does Life grow? And what are the strategies for growth if, given the exposure to academic, market and government funding broadly as we think about that for the long term, if it is a flattish funding environment? How do you guys think about growth opportunities? Do you deploy capital differently? Sort of what's the strategy? And how are you thinking about that?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Well, first of all, about 30% of our portfolio is in what we call the broadly applied biology segment. So Forensics, Bioproduction, Animal Health, and those segments are growing very fast, and we see them continuing to grow as a percentage of the portfoli",273,"Well, first of all, about 30% of our portfolio is in what we call the broadly applied biology segment. So Forensics, Bioproduction, Animal Health, and those segments are growing very fast, and we see them continuing to grow as a percentage of the portfolio. So that's a good thing. Second, in terms of academic funding over the next couple of years, I think if you take my earlier comment, we think it's going to be okay. It's probably more of the funding environment we saw in the 2003 and '04 type of time frame, and we actually grew okay through that period by really focusing the portfolio on where the money would be spent. And I think that's a very important point to be made is that all products aren't equal, and the funding does get directed then in a certain way and you just simply have to have the portfolio to capture it. So I think we're feeling pretty good that we'll be able to do well in the overall funding environment in the U.S. and Europe. And then lastly, importantly, is the geographic aspect, which is, we have built a very robust infrastructure across Asia, and I think you can see the benefits of that investment by our continued very strong growth across Asia. We are direct in a lot of the main countries. We're going ever more direct in all of the countries. We're building logistics centers across the region, and so geographically, we're exposed to where higher growth will be. So when you couple all of that together, Life Technologies will do fine over the next couple of years."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","I know you guys had talked about, with the convert out of the way, starting a buyback program, and obviously, free cash flow will start to inflect in 2011. So would just be curious as we kind of move past this, maybe you could get your kind of updated hig",96,"I know you guys had talked about, with the convert out of the way, starting a buyback program, and obviously, free cash flow will start to inflect in 2011. So would just be curious as we kind of move past this, maybe you could get your kind of updated high-level thoughts on -- are buybacks likely to be the major use of capital in this $350 million over two years? So is that how you guys are thinking? So is that going to be the major strategy? Or is there more opportunities on product tuck-in acquisitions?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think our philosophy and our plans for use of cash are unchanged. Our number one priority is to pay down our debt. And as we've said many times before, target is to get and remain within a leverage ratio of 2 to 2.5x EBITDA. Second point that you bring",96,"I think our philosophy and our plans for use of cash are unchanged. Our number one priority is to pay down our debt. And as we've said many times before, target is to get and remain within a leverage ratio of 2 to 2.5x EBITDA. Second point that you bring out is we're going to continue to invest in the business, organically and inorganically. And then third, our philosophy on excess cash also remains the same. We intend to return that to shareholders. A primary vehicle that we've used is share repurchases, and we will continue."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Your next question will come from the line of Jon Wood, Jefferies & Co.",14,"Your next question will come from the line of Jon Wood, Jefferies & Co."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So David, you will be within your target leverage ratio next week, correct, when you pay out the convert?",19,"So David, you will be within your target leverage ratio next week, correct, when you pay out the convert?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Actually, there are a variety of ways of calculating the leverage ratio. So one we've most often use is our credit agreement, but each of the rating agencies also have a calculation. Moody's, for example, is slightly different than ours. That's why we're",82,"Actually, there are a variety of ways of calculating the leverage ratio. So one we've most often use is our credit agreement, but each of the rating agencies also have a calculation. Moody's, for example, is slightly different than ours. That's why we're saying that by the end of the third quarter, we will be within our target leverage ratio for all of the rating agencies on all of the calculations and anticipate to begin the buyback then in the fourth quarter."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And then on the cash flow statement, can you just disclose the divestiture proceeds from the mass spec [mass spectrometry] JV? And then talk about whether you've paid the taxes yet on that proceed number?",35,"And then on the cash flow statement, can you just disclose the divestiture proceeds from the mass spec [mass spectrometry] JV? And then talk about whether you've paid the taxes yet on that proceed number?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","That's a good question, Jon. Why don't we get the answer to that, and we'll have a follow-up conversation with you on it.",24,"That's a good question, Jon. Why don't we get the answer to that, and we'll have a follow-up conversation with you on it."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Your next question will come from the line of Jon Groberg, Macquarie Capital.",13,"Your next question will come from the line of Jon Groberg, Macquarie Capital."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","So just one quick question for you Greg. You've often talked about one of the strengths of the portfolio is that it's not that price sensitive. In terms of when you tried lowering prices, it hasn't really stimulated a lot of demand, and that's why you get",108,"So just one quick question for you Greg. You've often talked about one of the strengths of the portfolio is that it's not that price sensitive. In terms of when you tried lowering prices, it hasn't really stimulated a lot of demand, and that's why you get some price -- a lot of good pricing ability. And I'm just curious, specifically within the PCR portfolio, have you tried that over time? I'm just curious, there's been some, obviously, a lot of announcements around people trying to get more into that business. I'm curious just your view of how effective price is as a mechanism in the PCR space."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","I think what gets highlighted is in that particular space, there's a lot of the very low-end reagents and otherwise. And actually, they've always been around, at least for the last several years, kind of the low end of that segment. We have products from",117,"I think what gets highlighted is in that particular space, there's a lot of the very low-end reagents and otherwise. And actually, they've always been around, at least for the last several years, kind of the low end of that segment. We have products from that segment as well. So my comments really, still pertain globally to this business, that the relationship between price and volume is not a direct connection, and that's due to a lot of the friction of publications, previous experiments. There's just inertia to switching. And when you have market leadership like we certainly do in the PCR business, people are inclined to stay with their products, and so we benefited from that."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","Latest question will come from the line of Steven Lichtman, Oppenheimer & Co.",13,"Latest question will come from the line of Steven Lichtman, Oppenheimer & Co."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","First, I was wondering the update on single molecule, still expecting to have a beta launch here towards year end?",20,"First, I was wondering the update on single molecule, still expecting to have a beta launch here towards year end?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Yes, we still, as we updated at the Investor Day, making good progress in developing the system and continuing to engage with customers around the early access and discussing the experiments and applications that they see for single molecule sequencing.",40,"Yes, we still, as we updated at the Investor Day, making good progress in developing the system and continuing to engage with customers around the early access and discussing the experiments and applications that they see for single molecule sequencing."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","And then on CE, it certainly seemed like it's picked its head up here a bit more than expected. Is it really driven by the launch of the 3500? Anything else in the sort of end markets you can comment on relative to CE?",44,"And then on CE, it certainly seemed like it's picked its head up here a bit more than expected. Is it really driven by the launch of the 3500? Anything else in the sort of end markets you can comment on relative to CE?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","The CE, as we expected, with the launch of the 3500, really goes into markets, such as the clinical testing market. We have the CE-IVD mark. Recently, we launched assays that start to go into that like a  BRAF assay, and so we see that uptake falls forwar",99,"The CE, as we expected, with the launch of the 3500, really goes into markets, such as the clinical testing market. We have the CE-IVD mark. Recently, we launched assays that start to go into that like a  BRAF assay, and so we see that uptake falls forward into that CE space. In addition, in the Forensics space, launching more kits, more geographic expansion. And they see franchise is robust in that segment, continues to be the right technology choice for those applications where you have a couple of genes that are very variable that you want to analyze."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And the last question will come from the line of Tony Butler, Barclays Capital.",14,"And the last question will come from the line of Tony Butler, Barclays Capital."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Analysts","David, is there any way to characterize the revenue synergies in the quarter that you may be seeing with the combination of the companies?",24,"David, is there any way to characterize the revenue synergies in the quarter that you may be seeing with the combination of the companies?"
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Would you like to talk about some of the -- I think sources of revenue synergies would be helpful.",19,"Would you like to talk about some of the -- I think sources of revenue synergies would be helpful."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Sure. In the revenue synergy sources, we touched on a few in the earlier comments around combined supply centers, leveraging our combined website. When you look today at the portfolio, where many of these types of sources were purely tied to one of the co",112,"Sure. In the revenue synergy sources, we touched on a few in the earlier comments around combined supply centers, leveraging our combined website. When you look today at the portfolio, where many of these types of sources were purely tied to one of the companies, they're now combined. Our selling organization has been restructured where commercial teams we have consumables, sales reps have carried both the AB [Applied Biosystems] consumables as well as former Invitrogen consumables. It gives our instrument teams more time to focused on -- focusing on instrument placements. And so all of those combined, they have driven many of the synergies that we have indicated in our earlier calls."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And this concludes the question-and-answer session. I'd like to turn the call back to Eileen Pattinson for closing remarks.",20,"And this concludes the question-and-answer session. I'd like to turn the call back to Eileen Pattinson for closing remarks."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Executives","Thank you. This concludes our second quarter earnings conference call. If there are any additional questions, please feel free to contact me. This webcast will be available via a replay on our website for three weeks. Thank you again for joining us this m",44,"Thank you. This concludes our second quarter earnings conference call. If there are any additional questions, please feel free to contact me. This webcast will be available via a replay on our website for three weeks. Thank you again for joining us this morning."
30253,109039325,70543,"Life Technologies Corporation, Q2 2010 Earnings Call, Jul-29-2010",2010-07-29,"Earnings Calls","Life Technologies Corporation","Operator","And ladies and gentlemen, again, this does conclude today's conference call. Thank you for your participation. You may now disconnect, and have a great day.",25,"And ladies and gentlemen, again, this does conclude today's conference call. Thank you for your participation. You may now disconnect, and have a great day."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Good day, ladies and gentlemen, and welcome to the Life Technologies Third Quarter Earnings Conference Call. My name is Tony, and I'll be your coordinator for today. [Operator Instructions] I would now like to hand the call over to your host for today, Ms",52,"Good day, ladies and gentlemen, and welcome to the Life Technologies Third Quarter Earnings Conference Call. My name is Tony, and I'll be your coordinator for today. [Operator Instructions] I would now like to hand the call over to your host for today, Ms. Eileen Pattinson, Head of Investor Relations. Please proceed."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Tony, and good afternoon, everyone. Welcome to Life Technologies' Third Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer.In addition, Mark Ste",188,"Thank you, Tony, and good afternoon, everyone. Welcome to Life Technologies' Third Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer.
In addition, Mark Stevenson, our Chief Operating Officer; and Bernd Brust, our Chief Commercial Officer, will be available during the Q&A portion of the call. If you haven't received a copy of today's press release, you may obtain one from our website at lifetechnologies.com.
I want to remind our listeners that our discussion today will include forward-looking statements, including, but not limited to, statements about future expectations, plans and prospects for the company. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated. It is our intent that these forward-looking statements be protected under the Safe Harbor created by the Private Securities Litigation Reform Act of 1995. Additionally, we will be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP can be found in today's press release or on our website.
I'll now hand the call over to Greg Lucier."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Eileen, and thank you all for joining us. I hope you had a chance to review the press release that we issued earlier today. As you can see from our results, we delivered another quarter of strong top and bottom line growth.Revenue grew 6% organi",1305,"Thanks, Eileen, and thank you all for joining us. I hope you had a chance to review the press release that we issued earlier today. As you can see from our results, we delivered another quarter of strong top and bottom line growth.
Revenue grew 6% organically to $869 million. And excluding the impact from the H1N1 pandemic, as well as the very large forensics deal for the Japanese police, organic revenue grew 9% for the quarter, driven by strong demand for both instruments and consumables across all of our customer end markets. Operating margins expanded by 170 basis points to reach 29%, and earnings per share grew 19% to $0.87 for the quarter.
On a year-to-date basis, organic revenue has grown 7.5% over prior year, 9.5% excluding H1N1 and that Japanese police forensics deal. Operating margins have expanded by 270 basis points. These are terrific results for the third quarter and for the year-to-date and is a testament to the execution mindset of our teams from around the world.
Now this quarter marks the 16th quarter in a row that we have exceeded expectations on both the top and bottom line. I'm particularly proud of this achievement as it demonstrates ability and commitment to deliver consistent, strong financial results to our shareholders.
Since 2007, EPS has grown at a compounded annual rate of 19% from $2.03 to the current consensus of $3.43, and free cash flow has more than doubled. Looking forward, you can expect the same focus on execution and commitment to great results as you've seen in the past.
This management team has built an incredibly unique business that is proven to be resilient enough to manage through the ups and the downs of the market that naturally occur over the years. With opportunities for both revenue growth and margin expansion that we see in the horizon, there's just no reason to believe that we will do anything but strengthen our position, allowing us to deliver double-digit organic earnings growth per share in 2011 and the foreseeable future.
Let me share with you our thinking about how we will deliver on this promise by walking you through a little bit of history. Over the last two years, we've been taking very deliberate average action to set the stage for our future. The planning process began actually several years ago when we set out to create optimal portfolio products. Today, we believe we had the best mix by far in the Life Science tools industry. 20% of our revenue is derived from proprietary instruments, which drive demand for the higher-margin consumables that make up the remaining 80% of our revenue stream. The consumables portion of our portfolio provides stability and add to the resiliency of the company over time. In addition, specific investments we've made over the last few years have refreshened certain aspects of our portfolio, such as PCR, and laid the groundwork for Life Technologies to build leading positions in areas such as synthetic biology and genomic medicine. With the recent close of the Ion Torrent deal, our portfolio optimization is largely now complete. The stage is set for us to leverage this industry-leading portfolio for significant growth.
The balance of our product portfolio is only part of the story. Our revenues are also diversified by region, affording us a certain level of protection in periods where weakness in any one region could negatively impact a less resilient business. As a result, we've been able to grow to some relatively challenging periods in the last few years.
Since 2007, Life Technologies has grown organic revenues each and every quarter between 5% and 11%, even during some very difficult funding environment and when the overall market was flat or declining for our competitors. In order to manage regional expansion and the overall growth in volume we have experienced, we have reinvested in the business to build a scalable infrastructure so that new products and technologies could be easily incorporated into our network.
Since 2007, we have consolidated eight ERPs into two main systems and grown our e-commerce platforms to the point where over 50% of our global transactions are processed through this high-margin channel of the web b2b connection in automated supply centers. Our investment in emerging markets, such as China and India, have enabled us to build out direct sales channels and distribution networks to build and meet the needs of these customers and their growing supply demands.
As a result of this effort, Life Technologies' unparalleled scale and scope in its commercial, manufacturing distribution capabilities around the globe.
So with the infrastructure now in place, we look to refine and optimize their operations. Again, since 2007, operating margins have increased 390 basis points from 24.9% to the 2010 consensus estimate of 28.8%. But there is still a lot of room for improvement here. Over the next three years, we will continue to drive significant margin expansion to very specific programs, designed to capture productivity in manufacturing, distribution and our supply chain.
The creation of multi-mix manufacturing site is a very good example of the programs we're working on. Our substantial expansion of the Frederick, Maryland  Campus and the continued growth of our Singaporean operations this year are key to this trust. Through these efforts and others like them, we can maximize operational productivity and expect to be able to deliver margins in excess of 31% in 2013.
While we are executing on the strategies that I have described to you today, we are also laying the groundwork for future revenue growth. Researchers in every field of science use our products to perform the fundamental research that advances scientific discovery. Over the next few years, we will leverage our strength in R&D and manufacturing to launch thousands of innovative products in the fastest-growing areas of research.
We also see a very bright future in applied markets, where for a relatively low cost, we can adapt the technologies used in biological research for use in fast-growing industries, such as forensics, and food and water testing. Over the next few years, we will be focused on building out industry-leading franchises in high-growth technology areas, applied markets and emerging geographies, all of which will be key drivers of growth for the company going forward.
One of the greatest benefits of our portfolio is that our product mix heavily weighted towards high-volume, higher-margin consumables allows us to generate significant free cash flow on a very consistent and predictable basis. Since the acquisition of Applied Biosystems, our priorities for the deployment of this cash have been to pay down debt, invest in the business and then return any excess cash to shareholders.
At the end of Q3, we reached our target debt levels, and with the recent acquisition of Ion Torrent, we believe our product portfolio is where it needs to be to drive significant future growth. In keeping with our philosophy of balanced capital deployment, the level of investment to acquire technologies will now come down in the next 24 months to approximately $100 million or so per year. After we have serviced our debt requirement, excess cash will be returned to shareholders.
So I've given you a little insight on what we've been working towards and more importantly, some thoughts in the future and what we can achieve. We'll go into more detail of our specific plans in the Q4 call in February, but suffice it to say, we are very optimistic about the future and confident in our ability to deliver on our financial goals in the very same consistent fashion that we have now done in the past. The track record is proven. 
Thanks. And with that, I'll hand it over to David to give you an update on the integration and more details on our  financial results for the third quarter."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Greg. This quarter, revenue grew 8% to $869 million. Currency had a positive 0.5 impact on reported revenue growth, and acquisitions added 1.5 points. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6%, and grew 9%",1542,"Thanks, Greg. This quarter, revenue grew 8% to $869 million. Currency had a positive 0.5 impact on reported revenue growth, and acquisitions added 1.5 points. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6%, and grew 9% also excluding the impact of H1N1 and the Japanese police deal.
Moving on to the divisional results, the Genetic Systems division had revenues of $227 million, representing 12% organic growth. Overall, sales of CE instruments and consumables grew 5% for the quarter, driven by high-single digit growth in consumables and continued strong demand for our recently launched 3500 Genetic Analyzer.
Growth in this business was negatively impacted by a difficult year-over-year comparison, resulting from last year's Japanese police order. Excluding the impact of this order, overall sales of CE instruments and consumables grew 9% for the quarter.
The CE business has proven to be incredibly resilient and continues to be the gold standard for many sequencing applications, not only in research, but increasingly in forensics and other applied markets.
Sales of CE consumables and instruments into hospital clinics and labs for diagnostic testing are particularly strong and have been a major driver of growth for the 3500 instrument. 
Lastly, the Next Generation Sequencing business demonstrated very strong double-digit growth during the quarter, driven by record sales of the SOLiD 4 system. Molecular Biology Systems had revenue of $415 million, flat to last year. However, excluding H1N1-related revenue, organic growth was approximately 4%, driven by strong demand for Genomic Assays and the recently launched ViiA 7 PCR instrument.
Customer reaction to the ViiA 7 has been very positive, and this is the first of several innovations that will refresh our entire qPCR franchise.
Shelf systems had revenue of $221 million, representing 15% organic growth. Growth was driven by strong demand across the portfolio. The Bioproduction, Dynal Beads and Stem Cell businesses all delivered double-digit growth in the quarter.
Organic growth by region in the quarter was as follows: The Americas grew 8%; Europe 5%; Asia-Pacific 7%; and Japan declined 1%. Excluding the impact of H1N1 and the Japanese police order, the Americas grew 10%, Europe 6%, Japan 13% and Asia-Pacific 11%.
Revenue growth in the Asia-Pacific region is slightly lower than in the past due to the timing of orders and a slowdown in order processing associated with an information systems implementation. This is similar to what we experienced when we implemented systems in Europe and the U.S. The project is now largely complete, and we expect fourth quarter growth for the region to return to historical levels.
In line with expectations, stimulus-related revenues for the third quarter were approximately $10 million. We also expect $10 million of stimulus-related revenue in the fourth quarter, the same level as prior year.
Moving on to other items. Third quarter non-GAAP gross margin was 66.8%, largely unchanged from the same period last year. Higher price and synergies were offset by mix, particularly increased sales of bioproduction and instruments.
On a sequential basis, gross margin declined by 90 basis points, primarily due to lower fixed cost absorption as a result of lower volume in the quarter.
Third quarter non-GAAP operating expenses increased 3% over prior year levels to $328 million. The increase was a result of acquisition-related headcount additions and an increase in depreciation, resulting from integration-related capital expenditures. Sequentially, operating expenses declined 4% as a result of cost controls implemented in the quarter, including a slowdown in spending on some commercial projects in our emerging markets.
These projects, such as building out our e-commerce platforms in Asia, are expected to ramp back up in the fourth quarter.
Non-GAAP operating income was $252 million, an increase of 15% over prior year, including the impact of currency, and 12% excluding currency. Third quarter operating margins were 29.0%, representing 170 basis points of improvement year-over-year. Operating margin expansion, primarily resulted from synergies and other operating expense reductions.
In terms of other income line items, we had $1 million of interest income, a loss of $5 million from currency, and interest expense for the quarter was $27 million.
Our non-GAAP tax rate was 25.8%. The tax rate is lower in the quarter due to the benefit of a one-time savings associated with the consolidation of foreign entities. This contributed approximately $0.02 to EPS.
Other items contributing to the lower tax rate are the settlement of prior year IRS audits and an adjustment to account for a higher portion of earnings in lower tax rate jurisdictions. These other items contributed an additional $0.02 to earnings per share.
Our diluted share count for the quarter was $190.1 million. As you will recall, our share count is impacted by our stock price due to our convertible debt and employee stock options.
GAAP diluted earnings per share were $0.56, which includes $0.22 per share of acquisition-related amortization expense, $0.03 per share of non-cash interest expense associated with the adoption of APB14-1 and $0.06 per share of business integration costs and other items. On a non-GAAP basis, which excludes these items, diluted earnings per share was $0.87.
Moving onto the balance sheet and cash flow. Our ending cash and short-term investments were $537 million. This compares to last quarter's balance of $706 million. Cash from operating activities was $215 million. Capital expenditures were $28 million, and free cash flow was $187 million.
Return on invested capital increased 20 basis points to 9.2%. We remain on track to achieve our goal of 10% ROIC by 2012.
Our ending debt as of September 30 was approximately $2.3 billion. This balance is made up of our convertible debt of $800 million and senior notes of $1.5 billion. During the quarter, we retired $350 million of convertible debt.
As for our ongoing integration efforts, during the quarter, we executed plans to generate an additional $25 million in annualized synergies. Specific actions included the completion of the European back-office consolidation, site consolidations in Asia and the placement of approximately 90 dual-branded supply centers worldwide.
At this point, we're on track to meet our goal of $175 million in annualized run rate synergies by the end of the fourth quarter, a year ahead of schedule.
Looking ahead to the fourth quarter, we expect organic revenue growth to be in the mid-single digits, but slightly lower than the third quarter due to a difficult year-over-year comparison. As a reminder, organic growth in the fourth quarter of last year was 11% as a result of several large one-time items. Revenue from acquisitions will add approximately 1.5 points to growth in the quarter. 
Due to the volatility of currency rates over the last couple of months, our estimate of the impact of currency on fourth quarter results has changed. As of September 30 rates, currency is expected to be neutral to the fourth quarter revenue growth and EPS.
Q4 gross margins are expected to be lower sequentially due to the impact of mix and lower price realization. Operating expenses in Q4 are expected to increase sequentially due to projects and activities that were delayed in the third quarter, acquisition-related expenses and increased depreciation from integration-related capital expenditures. Operating margins for the quarter are expected to expand approximately 150 basis points year-over-year.
The fourth quarter effective tax rate is expected to be approximately 29.5%, and the full year effective tax rate is expected to be approximately 29%, excluding any impact from the R&D tax credit. If the R&D tax credit is extended, then the full year tax rate will be reduced by approximately a point to 28%, and that would add $0.02 to earnings per share.  Our full year EPS guidance does not include any benefit from the tax credit.
Average diluted shares in the fourth quarter are expected to range from 191 million to 192 million, assuming an average stock price of between $46 and $50 a share. To date, we've repurchased 2.7 million shares at a cost of approximately $128 million, and are on track to complete the $350 million repurchase authorization and the repurchase of shares associated with the Ion Torrent transaction by the end of the year.
As Greg mentioned earlier, we're proud of our results so far this year and feel good about our ability to deliver on our financial goals. We are nearing the end of a successful integration, and despite minimal impact from the stimulus, we are on track to deliver between $3.48 and $3.52 earnings per share for the year.
And finally, since the dollar has weakened considerably over the last few months, I'll give you an update on the expected impact from currency on our 2011 results. As a reminder, we have currency hedges in place for the first seven months of 2011. We do not intend to hedge the remaining five months of the year.
As of September month-end rates, EPS is expected to be negatively impacted by approximately $0.12. In order to help you estimate the effect of currency for 2011, we've calculated the impact on earnings per share if all currencies moved by 5% versus the dollar. And our mix of foreign currencies stayed the same. In this case, the impact on earnings per share would be plus or minus $0.11.
And with that, I'll now hand the call back over to Eileen. Eileen?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, David. We have about 20 minutes for Q&A, so I'd like everyone to limit themselves to one question and one follow-up question. If you have additional questions after that, please get back in the queueu. Tony, we are now ready for the Q&A portion of",48,"Thanks, David. We have about 20 minutes for Q&A, so I'd like everyone to limit themselves to one question and one follow-up question. If you have additional questions after that, please get back in the queueu. Tony, we are now ready for the Q&A portion of the call."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","[Operator Instructions] And your first question comes from the line of Quintin Lai. [Robert W. Baird]",16,"[Operator Instructions] And your first question comes from the line of Quintin Lai. [Robert W. Baird]"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Looks like that it did get a little better from you from last quarter. So kindly give us a little color on what you're seeing now in terms of the market demand, given what you saw in Q2? And then as a quick follow-up, you put out a press release earlier t",79,"Looks like that it did get a little better from you from last quarter. So kindly give us a little color on what you're seeing now in terms of the market demand, given what you saw in Q2? And then as a quick follow-up, you put out a press release earlier this morning about the single-read accuracy for the SOLiD. Could you give us a little update or maybe a preview of what you're going to show next week?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, Quintin, we actually missed the first part of your question. Could you repeat the first part of that?",19,"Yes, Quintin, we actually missed the first part of your question. Could you repeat the first part of that?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","No problem. So the first part was really just Europe, that was one of the issues that came up on the last call. It looks like they may have been trailing down. And then this quarter, it looked like that you got back on schedule with 5% growth and then 6%",69,"No problem. So the first part was really just Europe, that was one of the issues that came up on the last call. It looks like they may have been trailing down. And then this quarter, it looked like that you got back on schedule with 5% growth and then 6% excluding H1N1. So just kind of a discussion of just how the trends have been going in Europe."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","This is Bernd. On the European market, as we shared in our last earnings call, we saw some changes in buying behavior. We also thought they were fairly short term, funding already at that point have stabilized in two to three core markets, being Germany a",113,"This is Bernd. On the European market, as we shared in our last earnings call, we saw some changes in buying behavior. We also thought they were fairly short term, funding already at that point have stabilized in two to three core markets, being Germany and France. Now with the U.K. funding announcement from lastly, I think we have the full picture in place again. So when you look at the European market, I think our outlook of low to mid-single digit growth, the execution is good. The portfolio is holding up against that well. The performance is there, and we see no change in that performance coming in the next foreseeable future."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","And just a follow up, Quintin, it's Mark here. on the second part of your question. So yes, we're very excited. As David mentioned, we had a record quarter with SOLiD. A lot of that traction was in contour applications where it matters with the accuracy.",85,"And just a follow up, Quintin, it's Mark here. on the second part of your question. So yes, we're very excited. As David mentioned, we had a record quarter with SOLiD. A lot of that traction was in contour applications where it matters with the accuracy. And so what we've made a great improvement of the level of accuracy to get [4,9] accuracy in a single-read, with new modification to our ligation chemistry and we're showing that data next week at the SHD [ph] meeting."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And is that something that can be immediately implementable now on SOLiD?",12,"And is that something that can be immediately implementable now on SOLiD?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","That will be implemented on SOLiD and we'll start shipping that new Chemistry with the systems, and we'll talk more about that at ASHG.",25,"That will be implemented on SOLiD and we'll start shipping that new Chemistry with the systems, and we'll talk more about that at ASHG."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Doug Schenkel. [Cowen and Company]",14,"And your next question comes from the line of Doug Schenkel. [Cowen and Company]"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","You guided operating margin flat year-over-year in Q3, I think, to about 27.3%. You came in at 29%. I was just hoping you would be willing to tease out really what changed. Was it better than you expected and maybe how much of it is attributable to some o",106,"You guided operating margin flat year-over-year in Q3, I think, to about 27.3%. You came in at 29%. I was just hoping you would be willing to tease out really what changed. Was it better than you expected and maybe how much of it is attributable to some of the projects that you referred to as being delayed? And then I guess the second question, kind of building off of a bit, my recollection is you talked about Q4 margin and growth being better than Q3. It sounds like that's no longer the case. So I was just hoping you can maybe explain what's changed."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Let me start, Doug, this is David. You're right about Q3. I think in terms of our guidance on Q3, I think what changed is it goes back to Quintin's question. When we look at Q3 at the end of Q2, there were some concerns about weakness in Europe, what the",186,"Let me start, Doug, this is David. You're right about Q3. I think in terms of our guidance on Q3, I think what changed is it goes back to Quintin's question. When we look at Q3 at the end of Q2, there were some concerns about weakness in Europe, what the impact would be in terms of sales elsewhere around the world. So we were cautious in terms of what our spending was. And we actually put some of the projects that we intended to begin on hold to get a better idea of what the revenue outlook was going to be. Good news is that revenues came in as we expected or better. And that, combined with lower spending, drove up our margins. What we're saying about Q4 is we're pretty confident in the outlook at this point. I think the markets and the funding around the world has stabilized from what it was at the end of Q2. And we plan to ramp back up some of those programs, particularly, some of the spending in commercial areas and on the web in emerging markets."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Your next question comes from the line of Tycho Peterson. [JPMorgan]",11,"Your next question comes from the line of Tycho Peterson. [JPMorgan]"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe I just want to jump in with a question on Ion Torrent since this is the first call you've done since you've announced the deal. Can you just talk a little bit about the go-to-market strategy here for the Personal Genome Machine, how we think about e",90,"Maybe I just want to jump in with a question on Ion Torrent since this is the first call you've done since you've announced the deal. Can you just talk a little bit about the go-to-market strategy here for the Personal Genome Machine, how we think about early access customers, if there are technical milestones that you'll be announcing along the way? And then are you to targeting kind of a mix at genome centers and in clinical markets initially or how do we think about the initial rollout?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Tycho, this is Greg, and I'll have Mark follow up  my point. As you know, we will be launching the Personal Genome Machine here in the fourth quarter. It has been in the hands of early access customers, working through the overall workflow and finishing u",110,"Tycho, this is Greg, and I'll have Mark follow up  my point. As you know, we will be launching the Personal Genome Machine here in the fourth quarter. It has been in the hands of early access customers, working through the overall workflow and finishing up the refinement of that. And that particular platform has lots of multi-generational growth in it as well. So it will be launched at a certain throughput, and then it will go up over time in basically the same box. In terms of the target customers, Mark, I'll let you give some a color commentary on how we see it being introduced in the market."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, so we really see, across that range of customers, the applications fit. So I think some of the genome centers are certainly seeing interest to QC some of their application work and do some smaller genomes with it. We'll certainly see it in the decent",152,"Yes, so we really see, across that range of customers, the applications fit. So I think some of the genome centers are certainly seeing interest to QC some of their application work and do some smaller genomes with it. We'll certainly see it in the decentralized application and some of the smaller genome centers or hospitals and application there is that will light the turnaround time and speech, just a number of experiments that you can do. And so really be quite a broad go-to-market approach for us. We're initially starting, we started taking orders across that breadth of customer base. And we'll be talking more again next week during SHD with that customer set and also at the Association Molecular Pathology meeting, one of the early access customers who we're presenting some data. So we'll begin to see more data here as we start shipping units at the end of December."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question will come from the line of John Wood. [Jefferies & Company]",15,"And your next question will come from the line of John Wood. [Jefferies & Company]"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","I think just probably for Mark. This might be too early as well, but talking to your customers last couple of weeks since the Europe budgets were announced. Is there a sense of relief or incremental concern versus their expectations going into those budge",44,"I think just probably for Mark. This might be too early as well, but talking to your customers last couple of weeks since the Europe budgets were announced. Is there a sense of relief or incremental concern versus their expectations going into those budgets."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","John, it's Bernd. No, I think to the sense of relief, obviously the only new one in recent history is the U.K. They both, Germany and France, they have announced some time ago in the U.K. the doomsday numbers were significantly worsened. I think, actually",81,"John, it's Bernd. No, I think to the sense of relief, obviously the only new one in recent history is the U.K. They both, Germany and France, they have announced some time ago in the U.K. the doomsday numbers were significantly worsened. I think, actually it was the best case scenario that was announced. And so I think in general, there's relief and people are feeling good about what the next few years hold from a research funding point of view."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And Bernd, do you think that there's been any pent-up demand just as people kind of held back in front of those numbers or is that a stretch at this point?",31,"And Bernd, do you think that there's been any pent-up demand just as people kind of held back in front of those numbers or is that a stretch at this point?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","I think it's been a stretch. I think, materially, there won't be much change there. I think what you will see is much more consistency, right, as we saw in Q2 last time, a result in changes in volume toward the end of the quarter and I think you're going",58,"I think it's been a stretch. I think, materially, there won't be much change there. I think what you will see is much more consistency, right, as we saw in Q2 last time, a result in changes in volume toward the end of the quarter and I think you're going to see that balance out more now."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Derik De Bruin. [UBS Investment Bank]",15,"And your next question comes from the line of Derik De Bruin. [UBS Investment Bank]"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","So first kind of a housekeeping. So what's the interest expense forecast for 2010? I guess, could you talk about -- I think you have some converts coming up in 2011, can you just talk about the debt claim plans and what you're expectations are for the con",48,"So first kind of a housekeeping. So what's the interest expense forecast for 2010? I guess, could you talk about -- I think you have some converts coming up in 2011, can you just talk about the debt claim plans and what you're expectations are for the converts?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","The first part of your question was the interest expense?",10,"The first part of your question was the interest expense?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Yes, for 2010. I mean, another kind of pay downs of things. I'm just questioning where the expense numbers are coming out?",22,"Yes, for 2010. I mean, another kind of pay downs of things. I'm just questioning where the expense numbers are coming out?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","So the interest expense is $110 million to $120 million. And then in terms of the converts, it obviously depends on the share price, but assuming the share price continues to rise, we would expect to retire or call those converts when they're due.",44,"So the interest expense is $110 million to $120 million. And then in terms of the converts, it obviously depends on the share price, but assuming the share price continues to rise, we would expect to retire or call those converts when they're due."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And I guess I'm a little bit -- I think I'm a little bit surprised and certainly, that I think some of the investors are going to be surprised the fact that you're reporting double-digit growth in your SOLiD franchise. And I guess a couple of questions. A",105,"And I guess I'm a little bit -- I think I'm a little bit surprised and certainly, that I think some of the investors are going to be surprised the fact that you're reporting double-digit growth in your SOLiD franchise. And I guess a couple of questions. Are you still on track throughout the SOLiD, the upgraded SOLiD, the hq, by the end of the year? Is the throughput commentary that you still have on that the same? I think it was a 200 g [ph] throughput per round there. And I guess, just where are those labs that you're placing new instruments in?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","First, just to confirm, actually it was a strong double-digit growth that we experienced in the quarter and it was the best quarter ever that we've have for SOLiD. So we've got great traction in that and saw that in the overall growth, actually like seque",233,"First, just to confirm, actually it was a strong double-digit growth that we experienced in the quarter and it was the best quarter ever that we've have for SOLiD. So we've got great traction in that and saw that in the overall growth, actually like sequencing brand franchise it's not only solid you see but also strong sales of CE of the 3500. It's really across a range of labs. I mean, with regard to SOLiD, as I've mentioned in the first question, the appreciation of the accuracy is there in terms of both finding these rare mutations as I've said in  the quote sort of needle in the haystack that accuracy matters. And so that's very much appreciated. That also translates into lower throughput cost when you're doing how much coverage you need. So that's one thing. On the second part of your question, we're very much on track to launch the systems. We'll give much more detail about that and our plans next week at ASHG and update you on where we are both on the platforms and throughput, and very much is an upgrade of old parts for all our customers. So they're coming with us on this journey. We've made tremendous improvement in the performance of the system, and they are coming with us on this journey as we carry on and get greater performance out of the system."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Marshall Urist. [Morgan Stanley]",13,"And your next question comes from the line of Marshall Urist. [Morgan Stanley]"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Just a big picture question on how you're kind of thinking about overall business trends. Typically, you guys talked about closing stronger sort of sequentially into the end of the year, both in terms of margin momentum and organic growth. So given the co",140,"Just a big picture question on how you're kind of thinking about overall business trends. Typically, you guys talked about closing stronger sort of sequentially into the end of the year, both in terms of margin momentum and organic growth. So given the commentary that you've had, I guess, is there no change in sort of the sequential momentum that you're thinking about it purely a function of the tougher comp from last year? And I guess, on the margin side, sort of a similar question but sort of asking given some of the spending that you delayed this quarter, is some of that going to get pushed in the next quarter so we can kind of think about underlying margin momentum sort of improving sequentially, if we kind of share some of that spend between the two quarters."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Right. So really, the commentary on the fourth quarter is nothing but the comparable issue. So as you know, fourth quarter is traditionally one of the larger ones of the overall year. It continues to be. And again, it just relates to the 2009 fourth quart",83,"Right. So really, the commentary on the fourth quarter is nothing but the comparable issue. So as you know, fourth quarter is traditionally one of the larger ones of the overall year. It continues to be. And again, it just relates to the 2009 fourth quarter comp that we have. The way you think about margins is right on. They will increase, but it will be modulated somewhat by the increased spending that we'll have in the quarter on some of these projects."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And then just one follow-up is just on the Molecular Biology Systems trends in the quarter, sort of flat organic, 4% without H1N1. Can you kind of talk about what the kind of biggest trends were there? And any sort of change from last quarter or over the",67,"And then just one follow-up is just on the Molecular Biology Systems trends in the quarter, sort of flat organic, 4% without H1N1. Can you kind of talk about what the kind of biggest trends were there? And any sort of change from last quarter or over the first half, in terms of the sort of excluding H1N1 benefit but kind of the core business there?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","I think the only commentary about that piece of the business was it was probably more than any other part of our company impacted by the information technology project we had in Asia and the overall -- a little slower growth we had in Asia in the quarter.",77,"I think the only commentary about that piece of the business was it was probably more than any other part of our company impacted by the information technology project we had in Asia and the overall -- a little slower growth we had in Asia in the quarter. So again, fourth quarter, we expect Asia to snap back into the high-double digits again, and you'll see that business snap back up to higher organic growth as well."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Charles Butler. [Barclays Capital]",13,"And your next question comes from the line of Charles Butler. [Barclays Capital]"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Greg, a strategy question. You recently hired a medical officer to come on board. I'm curious just exactly to whom would he actually interface? Or is he just providing advice to you all in the board? And moreover, is he actually on board now? Just a very",49,"Greg, a strategy question. You recently hired a medical officer to come on board. I'm curious just exactly to whom would he actually interface? Or is he just providing advice to you all in the board? And moreover, is he actually on board now? Just a very interesting decision."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Dr. Paul Billings is on board now. He interfaces with myself, with Mark, with Bernd in terms of customers and the board as well. It's the first several moves you'll see from us and that we will announce to continue to evolve the company to be not only ver",108,"Dr. Paul Billings is on board now. He interfaces with myself, with Mark, with Bernd in terms of customers and the board as well. It's the first several moves you'll see from us and that we will announce to continue to evolve the company to be not only very strong in research, but increasingly strong in medicine. As I've said in the past, all of these molecular tools are getting pulled into the medical environment, and we have to get the company ready to become more hospital oriented, more genomically medicine oriented, and this is the first of the several announcements that you'll here over the next year."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Your next question comes from the line of Jon Groberg. [Macquarie Research]",12,"Your next question comes from the line of Jon Groberg. [Macquarie Research]"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","So just one quick clarification, on the FX for '11, Dave, is that a net number in terms of all the other activities you had in place in for '11 as well or is that purely an FX number, the $0.12?",41,"So just one quick clarification, on the FX for '11, Dave, is that a net number in terms of all the other activities you had in place in for '11 as well or is that purely an FX number, the $0.12?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Just FX, but is net of our hedges.",8,"Just FX, but is net of our hedges."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Right, but not the buybacks, before you gave the number kind of bracket around some other things. So just FX right now is $0.12?",24,"Right, but not the buybacks, before you gave the number kind of bracket around some other things. So just FX right now is $0.12?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Correct, I understand your question. No, it does not include any buybacks, that's just foreign currency.",16,"Correct, I understand your question. No, it does not include any buybacks, that's just foreign currency."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And then, Greg, how are you going to go about evaluating the R&D that you've been spending and the money that you spent on Ion Torrent. Can you maybe just talk about one, obviously, there are a lot of new technologies that are percolating out there, compa",97,"And then, Greg, how are you going to go about evaluating the R&D that you've been spending and the money that you spent on Ion Torrent. Can you maybe just talk about one, obviously, there are a lot of new technologies that are percolating out there, companies trying to go public, a lot of people involved in the space. Can you maybe talk about one, how it is that you decided on Ion Torrent. And two, how you're going to kind of evaluate all of the spend that's been going on in the sequencing business, going forward?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Well, John, we have been evaluating the technologies associated with sequencing for the last several years. We've had, and we still have, a standing team that is fully 100% dedicated to that effort. And our major requirement for sequencing to really explo",241,"Well, John, we have been evaluating the technologies associated with sequencing for the last several years. We've had, and we still have, a standing team that is fully 100% dedicated to that effort. And our major requirement for sequencing to really explode the market was a turnaround time, the ability to get fast results. And as we looked at that, we just really came to the conclusion that the current generations of technology wouldn't get you to the measurement of hours in that regard versus the current days. And so Ion Torrent, as we got to understand it better, tested better, understand where it was going, really presented to us the technology that would enable this technology to move into the clinical realm, and that's why we made the acquisition of Ion Torrent. We continue to monitor all sorts of different paths to read the genome. But again, we're quite bullish that we have the right platform here to complement the very high accuracy -- even higher accuracy than it's even known today that Mark will talk about this next week of SOLiD. And yet, get to this turnaround time that I think will become quite essential to really unlock the big diagnostic markets. So that's why we did Ion Torrent. And, yet, I would just finish that we're not resting. We continue to monitor and watch, but we feel very confident that we have a great set of technologies here."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your final question comes from the line of Isaac Ro. [Goldman Sachs]",13,"And your final question comes from the line of Isaac Ro. [Goldman Sachs]"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","I want to ask some question about NIH funding. I understand the outlook here at a macroeconomic environment level is somewhat uncertain, but I'm just wondering what you guys are assuming for NIH funding growth over the next three to five years?",42,"I want to ask some question about NIH funding. I understand the outlook here at a macroeconomic environment level is somewhat uncertain, but I'm just wondering what you guys are assuming for NIH funding growth over the next three to five years?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Isaac, next year should be pretty good. We think it'll go up a couple of percentage points, and the stimulus continues to meander along through the course of the next several quarters, which will be okay. So I would tell investors the next year should be",175,"Isaac, next year should be pretty good. We think it'll go up a couple of percentage points, and the stimulus continues to meander along through the course of the next several quarters, which will be okay. So I would tell investors the next year should be fine. As we look to 2012 and beyond, those are the conversations that are taking place today. But as I've said in other settings, I'm actually hopeful that it will be okay. And I think it pertains back to an innovation agenda that a lot of our political leaders see is needed by the United States. And so there's not going to be a mad rush to balance the budget on the backs of the NIH. I mean, quite frankly, that's not where our overspending has been. And so the more of that message, I think, is appreciated and shared by more and more folks, the more I feel better about that NIH will come through this pretty well okay. So that's kind of our current outlook right now."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Second one would be on the PCR business, maybe, David, if you could outline sort of the kind of growth you've seen in that business year-to-date. And then you said switch pricing in PCR has helped drive that growth?",39,"Second one would be on the PCR business, maybe, David, if you could outline sort of the kind of growth you've seen in that business year-to-date. And then you said switch pricing in PCR has helped drive that growth?"
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Well, maybe Mark...",3,"Well, maybe Mark..."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, I mean, we still see good growth overall in that qPCR market. It's really a breadth of portfolios. So now as we've introduced the ViiA 7, we have a refresh of the high end of our price points in the instrument side and all the way down to the lower p",112,"Yes, I mean, we still see good growth overall in that qPCR market. It's really a breadth of portfolios. So now as we've introduced the ViiA 7, we have a refresh of the high end of our price points in the instrument side and all the way down to the lower price points on that system. And going forward, evermore, we're reinventing that game in terms of how we think about qPCR, both in terms of what you've seen us do in a couple of acquisitions in getting to higher throughput and also moving into the world of digital PCR, which we think is going to be really big going forward here."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Great. This concludes our third quarter earnings conference call. If there are any additional questions, please feel free to contact me. The webcast will be a available via a replay on our website for three weeks. Thank you, again, for joining us this aft",44,"Great. This concludes our third quarter earnings conference call. If there are any additional questions, please feel free to contact me. The webcast will be a available via a replay on our website for three weeks. Thank you, again, for joining us this afternoon."
30253,114142881,81912,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Thank you for your participation in today's presentation. You may now disconnect. Good day.",15,"Thank you for your participation in today's presentation. You may now disconnect. Good day."
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","So first kind of a housekeeping. So what's the interest expense forecast for 2010? I guess, could you talk about -- I think you have some converts coming up in 2011, can you just talk about the debt claim plans and what you're expectations are for the con",48,"So first kind of a housekeeping. So what's the interest expense forecast for 2010? I guess, could you talk about -- I think you have some converts coming up in 2011, can you just talk about the debt claim plans and what you're expectations are for the converts?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","The first part of your question was the interest expense?",10,"The first part of your question was the interest expense?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Yes, for 2010. I mean, another kind of pay downs of things. I'm just questioning where the expense numbers are coming out?",22,"Yes, for 2010. I mean, another kind of pay downs of things. I'm just questioning where the expense numbers are coming out?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","So the interest expense is $110 million to $120 million. And then in terms of the converts, it obviously depends on the share price, but assuming the share price continues to rise, we would expect to retire or call those converts when they're due.",44,"So the interest expense is $110 million to $120 million. And then in terms of the converts, it obviously depends on the share price, but assuming the share price continues to rise, we would expect to retire or call those converts when they're due.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And I guess I'm a little bit -- I think I'm a little bit surprised and certainly, that I think some of the investors are going to be surprised the fact that you're reporting double-digit growth in your SOLiD franchise. And I guess a couple of questions. A",105,"And I guess I'm a little bit -- I think I'm a little bit surprised and certainly, that I think some of the investors are going to be surprised the fact that you're reporting double-digit growth in your SOLiD franchise. And I guess a couple of questions. Are you still on track throughout the SOLiD, the upgraded SOLiD, the hq, by the end of the year? Is the throughput commentary that you still have on that the same? I think it was a 200 g [ph] throughput per round there. And I guess, just where are those labs that you're placing new instruments in?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","First, just to confirm, actually it was a strong double-digit growth that we experienced in the quarter and it was the best quarter ever that we've have for SOLiD. So we've got great traction in that and saw that in the overall growth, actually like seque",233,"First, just to confirm, actually it was a strong double-digit growth that we experienced in the quarter and it was the best quarter ever that we've have for SOLiD. So we've got great traction in that and saw that in the overall growth, actually like sequencing brand franchise it's not only solid you see but also strong sales of CE of the 3500. It's really across a range of labs. I mean, with regard to SOLiD, as I've mentioned in the first question, the appreciation of the accuracy is there in terms of both finding these rare mutations as I've said in  the quote sort of needle in the haystack that accuracy matters. And so that's very much appreciated. That also translates into lower throughput cost when you're doing how much coverage you need. So that's one thing. On the second part of your question, we're very much on track to launch the systems. We'll give much more detail about that and our plans next week at ASHG and update you on where we are both on the platforms and throughput, and very much is an upgrade of old parts for all our customers. So they're coming with us on this journey. We've made tremendous improvement in the performance of the system, and they are coming with us on this journey as we carry on and get greater performance out of the system.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Marshall Urist. [Morgan Stanley]",13,"And your next question comes from the line of Marshall Urist. [Morgan Stanley]
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Just a big picture question on how you're kind of thinking about overall business trends. Typically, you guys talked about closing stronger sort of sequentially into the end of the year, both in terms of margin momentum and organic growth. So given the co",140,"Just a big picture question on how you're kind of thinking about overall business trends. Typically, you guys talked about closing stronger sort of sequentially into the end of the year, both in terms of margin momentum and organic growth. So given the commentary that you've had, I guess, is there no change in sort of the sequential momentum that you're thinking about it purely a function of the tougher comp from last year? And I guess, on the margin side, sort of a similar question but sort of asking given some of the spending that you delayed this quarter, is some of that going to get pushed in the next quarter so we can kind of think about underlying margin momentum sort of improving sequentially, if we kind of share some of that spend between the two quarters.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Right. So really, the commentary on the fourth quarter is nothing but the comparable issue. So as you know, fourth quarter is traditionally one of the larger ones of the overall year. It continues to be. And again, it just relates to the 2009 fourth quart",83,"Right. So really, the commentary on the fourth quarter is nothing but the comparable issue. So as you know, fourth quarter is traditionally one of the larger ones of the overall year. It continues to be. And again, it just relates to the 2009 fourth quarter comp that we have. The way you think about margins is right on. They will increase, but it will be modulated somewhat by the increased spending that we'll have in the quarter on some of these projects.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And then just one follow-up is just on the Molecular Biology Systems trends in the quarter, sort of flat organic, 4% without H1N1. Can you kind of talk about what the kind of biggest trends were there? And any sort of change from last quarter or over the",67,"And then just one follow-up is just on the Molecular Biology Systems trends in the quarter, sort of flat organic, 4% without H1N1. Can you kind of talk about what the kind of biggest trends were there? And any sort of change from last quarter or over the first half, in terms of the sort of excluding H1N1 benefit but kind of the core business there?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","I think the only commentary about that piece of the business was it was probably more than any other part of our company impacted by the information technology project we had in Asia and the overall -- a little slower growth we had in Asia in the quarter.",77,"I think the only commentary about that piece of the business was it was probably more than any other part of our company impacted by the information technology project we had in Asia and the overall -- a little slower growth we had in Asia in the quarter. So again, fourth quarter, we expect Asia to snap back into the high-double digits again, and you'll see that business snap back up to higher organic growth as well.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Charles Butler. [Barclays Capital]",13,"And your next question comes from the line of Charles Butler. [Barclays Capital]
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Greg, a strategy question. You recently hired a medical officer to come on board. I'm curious just exactly to whom would he actually interface? Or is he just providing advice to you all in the board? And moreover, is he actually on board now? Just a very",49,"Greg, a strategy question. You recently hired a medical officer to come on board. I'm curious just exactly to whom would he actually interface? Or is he just providing advice to you all in the board? And moreover, is he actually on board now? Just a very interesting decision.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Dr. Paul Billings is on board now. He interfaces with myself, with Mark, with Bernd in terms of customers and the board as well. It's the first several moves you'll see from us and that we will announce to continue to evolve the company to be not only ver",108,"Dr. Paul Billings is on board now. He interfaces with myself, with Mark, with Bernd in terms of customers and the board as well. It's the first several moves you'll see from us and that we will announce to continue to evolve the company to be not only very strong in research, but increasingly strong in medicine. As I've said in the past, all of these molecular tools are getting pulled into the medical environment, and we have to get the company ready to become more hospital oriented, more genomically medicine oriented, and this is the first of the several announcements that you'll here over the next year.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Your next question comes from the line of Jon Groberg. [Macquarie Research]",12,"Your next question comes from the line of Jon Groberg. [Macquarie Research]
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","So just one quick clarification, on the FX for '11, Dave, is that a net number in terms of all the other activities you had in place in for '11 as well or is that purely an FX number, the $0.12?",41,"So just one quick clarification, on the FX for '11, Dave, is that a net number in terms of all the other activities you had in place in for '11 as well or is that purely an FX number, the $0.12?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Just FX, but is net of our hedges.",8,"Just FX, but is net of our hedges.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Right, but not the buybacks, before you gave the number kind of bracket around some other things. So just FX right now is $0.12?",24,"Right, but not the buybacks, before you gave the number kind of bracket around some other things. So just FX right now is $0.12?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Correct, I understand your question. No, it does not include any buybacks, that's just foreign currency.",16,"Correct, I understand your question. No, it does not include any buybacks, that's just foreign currency.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And then, Greg, how are you going to go about evaluating the R&D that you've been spending and the money that you spent on Ion Torrent. Can you maybe just talk about one, obviously, there are a lot of new technologies that are percolating out there, compa",97,"And then, Greg, how are you going to go about evaluating the R&D that you've been spending and the money that you spent on Ion Torrent. Can you maybe just talk about one, obviously, there are a lot of new technologies that are percolating out there, companies trying to go public, a lot of people involved in the space. Can you maybe talk about one, how it is that you decided on Ion Torrent. And two, how you're going to kind of evaluate all of the spend that's been going on in the sequencing business, going forward?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Well, John, we have been evaluating the technologies associated with sequencing for the last several years. We've had, and we still have, a standing team that is fully 100% dedicated to that effort. And our major requirement for sequencing to really explo",241,"Well, John, we have been evaluating the technologies associated with sequencing for the last several years. We've had, and we still have, a standing team that is fully 100% dedicated to that effort. And our major requirement for sequencing to really explode the market was a turnaround time, the ability to get fast results. And as we looked at that, we just really came to the conclusion that the current generations of technology wouldn't get you to the measurement of hours in that regard versus the current days. And so Ion Torrent, as we got to understand it better, tested better, understand where it was going, really presented to us the technology that would enable this technology to move into the clinical realm, and that's why we made the acquisition of Ion Torrent. We continue to monitor all sorts of different paths to read the genome. But again, we're quite bullish that we have the right platform here to complement the very high accuracy -- even higher accuracy than it's even known today that Mark will talk about this next week of SOLiD. And yet, get to this turnaround time that I think will become quite essential to really unlock the big diagnostic markets. So that's why we did Ion Torrent. And, yet, I would just finish that we're not resting. We continue to monitor and watch, but we feel very confident that we have a great set of technologies here.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your final question comes from the line of Isaac Ro. [Goldman Sachs]",13,"And your final question comes from the line of Isaac Ro. [Goldman Sachs]
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","I want to ask some question about NIH funding. I understand the outlook here at a macroeconomic environment level is somewhat uncertain, but I'm just wondering what you guys are assuming for NIH funding growth over the next three to five years?",42,"I want to ask some question about NIH funding. I understand the outlook here at a macroeconomic environment level is somewhat uncertain, but I'm just wondering what you guys are assuming for NIH funding growth over the next three to five years?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Isaac, next year should be pretty good. We think it'll go up a couple of percentage points, and the stimulus continues to meander along through the course of the next several quarters, which will be okay. So I would tell investors the next year should be",175,"Isaac, next year should be pretty good. We think it'll go up a couple of percentage points, and the stimulus continues to meander along through the course of the next several quarters, which will be okay. So I would tell investors the next year should be fine. As we look to 2012 and beyond, those are the conversations that are taking place today. But as I've said in other settings, I'm actually hopeful that it will be okay. And I think it pertains back to an innovation agenda that a lot of our political leaders see is needed by the United States. And so there's not going to be a mad rush to balance the budget on the backs of the NIH. I mean, quite frankly, that's not where our overspending has been. And so the more of that message, I think, is appreciated and shared by more and more folks, the more I feel better about that NIH will come through this pretty well okay. So that's kind of our current outlook right now.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Second one would be on the PCR business, maybe, David, if you could outline sort of the kind of growth you've seen in that business year-to-date. And then you said switch pricing in PCR has helped drive that growth?",39,"Second one would be on the PCR business, maybe, David, if you could outline sort of the kind of growth you've seen in that business year-to-date. And then you said switch pricing in PCR has helped drive that growth?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Well, maybe Mark...",3,"Well, maybe Mark...
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, I mean, we still see good growth overall in that qPCR market. It's really a breadth of portfolios. So now as we've introduced the ViiA 7, we have a refresh of the high end of our price points in the instrument side and all the way down to the lower p",112,"Yes, I mean, we still see good growth overall in that qPCR market. It's really a breadth of portfolios. So now as we've introduced the ViiA 7, we have a refresh of the high end of our price points in the instrument side and all the way down to the lower price points on that system. And going forward, evermore, we're reinventing that game in terms of how we think about qPCR, both in terms of what you've seen us do in a couple of acquisitions in getting to higher throughput and also moving into the world of digital PCR, which we think is going to be really big going forward here.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Great. This concludes our third quarter earnings conference call. If there are any additional questions, please feel free to contact me. The webcast will be a available via a replay on our website for three weeks. Thank you, again, for joining us this aft",44,"Great. This concludes our third quarter earnings conference call. If there are any additional questions, please feel free to contact me. The webcast will be a available via a replay on our website for three weeks. Thank you, again, for joining us this afternoon.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Thank you for your participation in today's presentation. You may now disconnect. Good day.",15,"Thank you for your participation in today's presentation. You may now disconnect. Good day.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Good day, ladies and gentlemen, and welcome to the Life Technologies Third Quarter Earnings Conference Call. My name is Tony, and I'll be your coordinator for today. [Operator Instructions] I would now like to hand the call over to your host for today, Ms",52,"Good day, ladies and gentlemen, and welcome to the Life Technologies Third Quarter Earnings Conference Call. My name is Tony, and I'll be your coordinator for today. [Operator Instructions] I would now like to hand the call over to your host for today, Ms. Eileen Pattinson, Head of Investor Relations. Please proceed.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Tony, and good afternoon, everyone. Welcome to Life Technologies' Third Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer.In addition, Mark Ste",188,"Thank you, Tony, and good afternoon, everyone. Welcome to Life Technologies' Third Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer.
In addition, Mark Stevenson, our Chief Operating Officer; and Bernd Brust, our Chief Commercial Officer, will be available during the Q&A portion of the call. If you haven't received a copy of today's press release, you may obtain one from our website at lifetechnologies.com.
I want to remind our listeners that our discussion today will include forward-looking statements, including, but not limited to, statements about future expectations, plans and prospects for the company. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated. It is our intent that these forward-looking statements be protected under the Safe Harbor created by the Private Securities Litigation Reform Act of 1995. Additionally, we will be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP can be found in today's press release or on our website.
I'll now hand the call over to Greg Lucier.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Eileen, and thank you all for joining us. I hope you had a chance to review the press release that we issued earlier today. As you can see from our results, we delivered another quarter of strong top and bottom line growth.Revenue grew 6% organi",1305,"Thanks, Eileen, and thank you all for joining us. I hope you had a chance to review the press release that we issued earlier today. As you can see from our results, we delivered another quarter of strong top and bottom line growth.
Revenue grew 6% organically to $869 million. And excluding the impact from the H1N1 pandemic, as well as the very large forensics deal for the Japanese police, organic revenue grew 9% for the quarter, driven by strong demand for both instruments and consumables across all of our customer end markets. Operating margins expanded by 170 basis points to reach 29%, and earnings per share grew 19% to $0.87 for the quarter.
On a year-to-date basis, organic revenue has grown 7.5% over prior year, 9.5% excluding H1N1 and that Japanese police forensics deal. Operating margins have expanded by 270 basis points. These are terrific results for the third quarter and for the year-to-date and is a testament to the execution mindset of our teams from around the world.
Now this quarter marks the 16th quarter in a row that we have exceeded expectations on both the top and bottom line. I'm particularly proud of this achievement as it demonstrates ability and commitment to deliver consistent, strong financial results to our shareholders.
Since 2007, EPS has grown at a compounded annual rate of 19% from $2.03 to the current consensus of $3.43, and free cash flow has more than doubled. Looking forward, you can expect the same focus on execution and commitment to great results as you've seen in the past.
This management team has built an incredibly unique business that is proven to be resilient enough to manage through the ups and the downs of the market that naturally occur over the years. With opportunities for both revenue growth and margin expansion that we see in the horizon, there's just no reason to believe that we will do anything but strengthen our position, allowing us to deliver double-digit organic earnings growth per share in 2011 and the foreseeable future.
Let me share with you our thinking about how we will deliver on this promise by walking you through a little bit of history. Over the last two years, we've been taking very deliberate average action to set the stage for our future. The planning process began actually several years ago when we set out to create optimal portfolio products. Today, we believe we had the best mix by far in the Life Science tools industry. 20% of our revenue is derived from proprietary instruments, which drive demand for the higher-margin consumables that make up the remaining 80% of our revenue stream. The consumables portion of our portfolio provides stability and add to the resiliency of the company over time. In addition, specific investments we've made over the last few years have refreshened certain aspects of our portfolio, such as PCR, and laid the groundwork for Life Technologies to build leading positions in areas such as synthetic biology and genomic medicine. With the recent close of the Ion Torrent deal, our portfolio optimization is largely now complete. The stage is set for us to leverage this industry-leading portfolio for significant growth.
The balance of our product portfolio is only part of the story. Our revenues are also diversified by region, affording us a certain level of protection in periods where weakness in any one region could negatively impact a less resilient business. As a result, we've been able to grow to some relatively challenging periods in the last few years.
Since 2007, Life Technologies has grown organic revenues each and every quarter between 5% and 11%, even during some very difficult funding environment and when the overall market was flat or declining for our competitors. In order to manage regional expansion and the overall growth in volume we have experienced, we have reinvested in the business to build a scalable infrastructure so that new products and technologies could be easily incorporated into our network.
Since 2007, we have consolidated eight ERPs into two main systems and grown our e-commerce platforms to the point where over 50% of our global transactions are processed through this high-margin channel of the web b2b connection in automated supply centers. Our investment in emerging markets, such as China and India, have enabled us to build out direct sales channels and distribution networks to build and meet the needs of these customers and their growing supply demands.
As a result of this effort, Life Technologies' unparalleled scale and scope in its commercial, manufacturing distribution capabilities around the globe.
So with the infrastructure now in place, we look to refine and optimize their operations. Again, since 2007, operating margins have increased 390 basis points from 24.9% to the 2010 consensus estimate of 28.8%. But there is still a lot of room for improvement here. Over the next three years, we will continue to drive significant margin expansion to very specific programs, designed to capture productivity in manufacturing, distribution and our supply chain.
The creation of multi-mix manufacturing site is a very good example of the programs we're working on. Our substantial expansion of the Frederick, Maryland  Campus and the continued growth of our Singaporean operations this year are key to this trust. Through these efforts and others like them, we can maximize operational productivity and expect to be able to deliver margins in excess of 31% in 2013.
While we are executing on the strategies that I have described to you today, we are also laying the groundwork for future revenue growth. Researchers in every field of science use our products to perform the fundamental research that advances scientific discovery. Over the next few years, we will leverage our strength in R&D and manufacturing to launch thousands of innovative products in the fastest-growing areas of research.
We also see a very bright future in applied markets, where for a relatively low cost, we can adapt the technologies used in biological research for use in fast-growing industries, such as forensics, and food and water testing. Over the next few years, we will be focused on building out industry-leading franchises in high-growth technology areas, applied markets and emerging geographies, all of which will be key drivers of growth for the company going forward.
One of the greatest benefits of our portfolio is that our product mix heavily weighted towards high-volume, higher-margin consumables allows us to generate significant free cash flow on a very consistent and predictable basis. Since the acquisition of Applied Biosystems, our priorities for the deployment of this cash have been to pay down debt, invest in the business and then return any excess cash to shareholders.
At the end of Q3, we reached our target debt levels, and with the recent acquisition of Ion Torrent, we believe our product portfolio is where it needs to be to drive significant future growth. In keeping with our philosophy of balanced capital deployment, the level of investment to acquire technologies will now come down in the next 24 months to approximately $100 million or so per year. After we have serviced our debt requirement, excess cash will be returned to shareholders.
So I've given you a little insight on what we've been working towards and more importantly, some thoughts in the future and what we can achieve. We'll go into more detail of our specific plans in the Q4 call in February, but suffice it to say, we are very optimistic about the future and confident in our ability to deliver on our financial goals in the very same consistent fashion that we have now done in the past. The track record is proven. 
Thanks. And with that, I'll hand it over to David to give you an update on the integration and more details on our  financial results for the third quarter.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Greg. This quarter, revenue grew 8% to $869 million. Currency had a positive 0.5 impact on reported revenue growth, and acquisitions added 1.5 points. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6%, and grew 9%",1542,"Thanks, Greg. This quarter, revenue grew 8% to $869 million. Currency had a positive 0.5 impact on reported revenue growth, and acquisitions added 1.5 points. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6%, and grew 9% also excluding the impact of H1N1 and the Japanese police deal.
Moving on to the divisional results, the Genetic Systems division had revenues of $227 million, representing 12% organic growth. Overall, sales of CE instruments and consumables grew 5% for the quarter, driven by high-single digit growth in consumables and continued strong demand for our recently launched 3500 Genetic Analyzer.
Growth in this business was negatively impacted by a difficult year-over-year comparison, resulting from last year's Japanese police order. Excluding the impact of this order, overall sales of CE instruments and consumables grew 9% for the quarter.
The CE business has proven to be incredibly resilient and continues to be the gold standard for many sequencing applications, not only in research, but increasingly in forensics and other applied markets.
Sales of CE consumables and instruments into hospital clinics and labs for diagnostic testing are particularly strong and have been a major driver of growth for the 3500 instrument. 
Lastly, the Next Generation Sequencing business demonstrated very strong double-digit growth during the quarter, driven by record sales of the SOLiD 4 system. Molecular Biology Systems had revenue of $415 million, flat to last year. However, excluding H1N1-related revenue, organic growth was approximately 4%, driven by strong demand for Genomic Assays and the recently launched ViiA 7 PCR instrument.
Customer reaction to the ViiA 7 has been very positive, and this is the first of several innovations that will refresh our entire qPCR franchise.
Shelf systems had revenue of $221 million, representing 15% organic growth. Growth was driven by strong demand across the portfolio. The Bioproduction, Dynal Beads and Stem Cell businesses all delivered double-digit growth in the quarter.
Organic growth by region in the quarter was as follows: The Americas grew 8%; Europe 5%; Asia-Pacific 7%; and Japan declined 1%. Excluding the impact of H1N1 and the Japanese police order, the Americas grew 10%, Europe 6%, Japan 13% and Asia-Pacific 11%.
Revenue growth in the Asia-Pacific region is slightly lower than in the past due to the timing of orders and a slowdown in order processing associated with an information systems implementation. This is similar to what we experienced when we implemented systems in Europe and the U.S. The project is now largely complete, and we expect fourth quarter growth for the region to return to historical levels.
In line with expectations, stimulus-related revenues for the third quarter were approximately $10 million. We also expect $10 million of stimulus-related revenue in the fourth quarter, the same level as prior year.
Moving on to other items. Third quarter non-GAAP gross margin was 66.8%, largely unchanged from the same period last year. Higher price and synergies were offset by mix, particularly increased sales of bioproduction and instruments.
On a sequential basis, gross margin declined by 90 basis points, primarily due to lower fixed cost absorption as a result of lower volume in the quarter.
Third quarter non-GAAP operating expenses increased 3% over prior year levels to $328 million. The increase was a result of acquisition-related headcount additions and an increase in depreciation, resulting from integration-related capital expenditures. Sequentially, operating expenses declined 4% as a result of cost controls implemented in the quarter, including a slowdown in spending on some commercial projects in our emerging markets.
These projects, such as building out our e-commerce platforms in Asia, are expected to ramp back up in the fourth quarter.
Non-GAAP operating income was $252 million, an increase of 15% over prior year, including the impact of currency, and 12% excluding currency. Third quarter operating margins were 29.0%, representing 170 basis points of improvement year-over-year. Operating margin expansion, primarily resulted from synergies and other operating expense reductions.
In terms of other income line items, we had $1 million of interest income, a loss of $5 million from currency, and interest expense for the quarter was $27 million.
Our non-GAAP tax rate was 25.8%. The tax rate is lower in the quarter due to the benefit of a one-time savings associated with the consolidation of foreign entities. This contributed approximately $0.02 to EPS.
Other items contributing to the lower tax rate are the settlement of prior year IRS audits and an adjustment to account for a higher portion of earnings in lower tax rate jurisdictions. These other items contributed an additional $0.02 to earnings per share.
Our diluted share count for the quarter was $190.1 million. As you will recall, our share count is impacted by our stock price due to our convertible debt and employee stock options.
GAAP diluted earnings per share were $0.56, which includes $0.22 per share of acquisition-related amortization expense, $0.03 per share of non-cash interest expense associated with the adoption of APB14-1 and $0.06 per share of business integration costs and other items. On a non-GAAP basis, which excludes these items, diluted earnings per share was $0.87.
Moving onto the balance sheet and cash flow. Our ending cash and short-term investments were $537 million. This compares to last quarter's balance of $706 million. Cash from operating activities was $215 million. Capital expenditures were $28 million, and free cash flow was $187 million.
Return on invested capital increased 20 basis points to 9.2%. We remain on track to achieve our goal of 10% ROIC by 2012.
Our ending debt as of September 30 was approximately $2.3 billion. This balance is made up of our convertible debt of $800 million and senior notes of $1.5 billion. During the quarter, we retired $350 million of convertible debt.
As for our ongoing integration efforts, during the quarter, we executed plans to generate an additional $25 million in annualized synergies. Specific actions included the completion of the European back-office consolidation, site consolidations in Asia and the placement of approximately 90 dual-branded supply centers worldwide.
At this point, we're on track to meet our goal of $175 million in annualized run rate synergies by the end of the fourth quarter, a year ahead of schedule.
Looking ahead to the fourth quarter, we expect organic revenue growth to be in the mid-single digits, but slightly lower than the third quarter due to a difficult year-over-year comparison. As a reminder, organic growth in the fourth quarter of last year was 11% as a result of several large one-time items. Revenue from acquisitions will add approximately 1.5 points to growth in the quarter. 
Due to the volatility of currency rates over the last couple of months, our estimate of the impact of currency on fourth quarter results has changed. As of September 30 rates, currency is expected to be neutral to the fourth quarter revenue growth and EPS.
Q4 gross margins are expected to be lower sequentially due to the impact of mix and lower price realization. Operating expenses in Q4 are expected to increase sequentially due to projects and activities that were delayed in the third quarter, acquisition-related expenses and increased depreciation from integration-related capital expenditures. Operating margins for the quarter are expected to expand approximately 150 basis points year-over-year.
The fourth quarter effective tax rate is expected to be approximately 29.5%, and the full year effective tax rate is expected to be approximately 29%, excluding any impact from the R&D tax credit. If the R&D tax credit is extended, then the full year tax rate will be reduced by approximately a point to 28%, and that would add $0.02 to earnings per share.  Our full year EPS guidance does not include any benefit from the tax credit.
Average diluted shares in the fourth quarter are expected to range from 191 million to 192 million, assuming an average stock price of between $46 and $50 a share. To date, we've repurchased 2.7 million shares at a cost of approximately $128 million, and are on track to complete the $350 million repurchase authorization and the repurchase of shares associated with the Ion Torrent transaction by the end of the year.
As Greg mentioned earlier, we're proud of our results so far this year and feel good about our ability to deliver on our financial goals. We are nearing the end of a successful integration, and despite minimal impact from the stimulus, we are on track to deliver between $3.48 and $3.52 earnings per share for the year.
And finally, since the dollar has weakened considerably over the last few months, I'll give you an update on the expected impact from currency on our 2011 results. As a reminder, we have currency hedges in place for the first seven months of 2011. We do not intend to hedge the remaining five months of the year.
As of September month-end rates, EPS is expected to be negatively impacted by approximately $0.12. In order to help you estimate the effect of currency for 2011, we've calculated the impact on earnings per share if all currencies moved by 5% versus the dollar. And our mix of foreign currencies stayed the same. In this case, the impact on earnings per share would be plus or minus $0.11.
And with that, I'll now hand the call back over to Eileen. Eileen?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, David. We have about 20 minutes for Q&A, so I'd like everyone to limit themselves to one question and one follow-up question. If you have additional questions after that, please get back in the queueu. Tony, we are now ready for the Q&A portion of",48,"Thanks, David. We have about 20 minutes for Q&A, so I'd like everyone to limit themselves to one question and one follow-up question. If you have additional questions after that, please get back in the queueu. Tony, we are now ready for the Q&A portion of the call.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","[Operator Instructions] And your first question comes from the line of Quintin Lai. [Robert W. Baird]",16,"[Operator Instructions] And your first question comes from the line of Quintin Lai. [Robert W. Baird]
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Looks like that it did get a little better from you from last quarter. So kindly give us a little color on what you're seeing now in terms of the market demand, given what you saw in Q2? And then as a quick follow-up, you put out a press release earlier t",79,"Looks like that it did get a little better from you from last quarter. So kindly give us a little color on what you're seeing now in terms of the market demand, given what you saw in Q2? And then as a quick follow-up, you put out a press release earlier this morning about the single-read accuracy for the SOLiD. Could you give us a little update or maybe a preview of what you're going to show next week?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, Quintin, we actually missed the first part of your question. Could you repeat the first part of that?",19,"Yes, Quintin, we actually missed the first part of your question. Could you repeat the first part of that?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","No problem. So the first part was really just Europe, that was one of the issues that came up on the last call. It looks like they may have been trailing down. And then this quarter, it looked like that you got back on schedule with 5% growth and then 6%",69,"No problem. So the first part was really just Europe, that was one of the issues that came up on the last call. It looks like they may have been trailing down. And then this quarter, it looked like that you got back on schedule with 5% growth and then 6% excluding H1N1. So just kind of a discussion of just how the trends have been going in Europe.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","This is Bernd. On the European market, as we shared in our last earnings call, we saw some changes in buying behavior. We also thought they were fairly short term, funding already at that point have stabilized in two to three core markets, being Germany a",113,"This is Bernd. On the European market, as we shared in our last earnings call, we saw some changes in buying behavior. We also thought they were fairly short term, funding already at that point have stabilized in two to three core markets, being Germany and France. Now with the U.K. funding announcement from lastly, I think we have the full picture in place again. So when you look at the European market, I think our outlook of low to mid-single digit growth, the execution is good. The portfolio is holding up against that well. The performance is there, and we see no change in that performance coming in the next foreseeable future.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","And just a follow up, Quintin, it's Mark here. on the second part of your question. So yes, we're very excited. As David mentioned, we had a record quarter with SOLiD. A lot of that traction was in contour applications where it matters with the accuracy.",85,"And just a follow up, Quintin, it's Mark here. on the second part of your question. So yes, we're very excited. As David mentioned, we had a record quarter with SOLiD. A lot of that traction was in contour applications where it matters with the accuracy. And so what we've made a great improvement of the level of accuracy to get [4,9] accuracy in a single-read, with new modification to our ligation chemistry and we're showing that data next week at the SHD [ph] meeting.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And is that something that can be immediately implementable now on SOLiD?",12,"And is that something that can be immediately implementable now on SOLiD?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","That will be implemented on SOLiD and we'll start shipping that new Chemistry with the systems, and we'll talk more about that at ASHG.",25,"That will be implemented on SOLiD and we'll start shipping that new Chemistry with the systems, and we'll talk more about that at ASHG.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Doug Schenkel. [Cowen and Company]",14,"And your next question comes from the line of Doug Schenkel. [Cowen and Company]
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","You guided operating margin flat year-over-year in Q3, I think, to about 27.3%. You came in at 29%. I was just hoping you would be willing to tease out really what changed. Was it better than you expected and maybe how much of it is attributable to some o",106,"You guided operating margin flat year-over-year in Q3, I think, to about 27.3%. You came in at 29%. I was just hoping you would be willing to tease out really what changed. Was it better than you expected and maybe how much of it is attributable to some of the projects that you referred to as being delayed? And then I guess the second question, kind of building off of a bit, my recollection is you talked about Q4 margin and growth being better than Q3. It sounds like that's no longer the case. So I was just hoping you can maybe explain what's changed.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Let me start, Doug, this is David. You're right about Q3. I think in terms of our guidance on Q3, I think what changed is it goes back to Quintin's question. When we look at Q3 at the end of Q2, there were some concerns about weakness in Europe, what the",186,"Let me start, Doug, this is David. You're right about Q3. I think in terms of our guidance on Q3, I think what changed is it goes back to Quintin's question. When we look at Q3 at the end of Q2, there were some concerns about weakness in Europe, what the impact would be in terms of sales elsewhere around the world. So we were cautious in terms of what our spending was. And we actually put some of the projects that we intended to begin on hold to get a better idea of what the revenue outlook was going to be. Good news is that revenues came in as we expected or better. And that, combined with lower spending, drove up our margins. What we're saying about Q4 is we're pretty confident in the outlook at this point. I think the markets and the funding around the world has stabilized from what it was at the end of Q2. And we plan to ramp back up some of those programs, particularly, some of the spending in commercial areas and on the web in emerging markets.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Your next question comes from the line of Tycho Peterson. [JPMorgan]",11,"Your next question comes from the line of Tycho Peterson. [JPMorgan]
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe I just want to jump in with a question on Ion Torrent since this is the first call you've done since you've announced the deal. Can you just talk a little bit about the go-to-market strategy here for the Personal Genome Machine, how we think about e",90,"Maybe I just want to jump in with a question on Ion Torrent since this is the first call you've done since you've announced the deal. Can you just talk a little bit about the go-to-market strategy here for the Personal Genome Machine, how we think about early access customers, if there are technical milestones that you'll be announcing along the way? And then are you to targeting kind of a mix at genome centers and in clinical markets initially or how do we think about the initial rollout?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Tycho, this is Greg, and I'll have Mark follow up  my point. As you know, we will be launching the Personal Genome Machine here in the fourth quarter. It has been in the hands of early access customers, working through the overall workflow and finishing u",110,"Tycho, this is Greg, and I'll have Mark follow up  my point. As you know, we will be launching the Personal Genome Machine here in the fourth quarter. It has been in the hands of early access customers, working through the overall workflow and finishing up the refinement of that. And that particular platform has lots of multi-generational growth in it as well. So it will be launched at a certain throughput, and then it will go up over time in basically the same box. In terms of the target customers, Mark, I'll let you give some a color commentary on how we see it being introduced in the market.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, so we really see, across that range of customers, the applications fit. So I think some of the genome centers are certainly seeing interest to QC some of their application work and do some smaller genomes with it. We'll certainly see it in the decent",152,"Yes, so we really see, across that range of customers, the applications fit. So I think some of the genome centers are certainly seeing interest to QC some of their application work and do some smaller genomes with it. We'll certainly see it in the decentralized application and some of the smaller genome centers or hospitals and application there is that will light the turnaround time and speech, just a number of experiments that you can do. And so really be quite a broad go-to-market approach for us. We're initially starting, we started taking orders across that breadth of customer base. And we'll be talking more again next week during SHD with that customer set and also at the Association Molecular Pathology meeting, one of the early access customers who we're presenting some data. So we'll begin to see more data here as we start shipping units at the end of December.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question will come from the line of John Wood. [Jefferies & Company]",15,"And your next question will come from the line of John Wood. [Jefferies & Company]
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","I think just probably for Mark. This might be too early as well, but talking to your customers last couple of weeks since the Europe budgets were announced. Is there a sense of relief or incremental concern versus their expectations going into those budge",44,"I think just probably for Mark. This might be too early as well, but talking to your customers last couple of weeks since the Europe budgets were announced. Is there a sense of relief or incremental concern versus their expectations going into those budgets.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","John, it's Bernd. No, I think to the sense of relief, obviously the only new one in recent history is the U.K. They both, Germany and France, they have announced some time ago in the U.K. the doomsday numbers were significantly worsened. I think, actually",81,"John, it's Bernd. No, I think to the sense of relief, obviously the only new one in recent history is the U.K. They both, Germany and France, they have announced some time ago in the U.K. the doomsday numbers were significantly worsened. I think, actually it was the best case scenario that was announced. And so I think in general, there's relief and people are feeling good about what the next few years hold from a research funding point of view.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And Bernd, do you think that there's been any pent-up demand just as people kind of held back in front of those numbers or is that a stretch at this point?",31,"And Bernd, do you think that there's been any pent-up demand just as people kind of held back in front of those numbers or is that a stretch at this point?
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","I think it's been a stretch. I think, materially, there won't be much change there. I think what you will see is much more consistency, right, as we saw in Q2 last time, a result in changes in volume toward the end of the quarter and I think you're going",58,"I think it's been a stretch. I think, materially, there won't be much change there. I think what you will see is much more consistency, right, as we saw in Q2 last time, a result in changes in volume toward the end of the quarter and I think you're going to see that balance out more now.
"
30253,114142881,81914,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Derik De Bruin. [UBS Investment Bank]",15,"And your next question comes from the line of Derik De Bruin. [UBS Investment Bank]

"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Good day, ladies and gentlemen, and welcome to the Life Technologies Third Quarter Earnings Conference Call. My name is Tony, and I'll be your coordinator for today. [Operator Instructions] I would now like to hand the call over to your host for today, Ms",52,"Good day, ladies and gentlemen, and welcome to the Life Technologies Third Quarter Earnings Conference Call. My name is Tony, and I'll be your coordinator for today. [Operator Instructions] I would now like to hand the call over to your host for today, Ms. Eileen Pattinson, Head of Investor Relations. Please proceed."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Tony, and good afternoon, everyone. Welcome to Life Technologies' Third Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer.In addition, Mark Ste",188,"Thank you, Tony, and good afternoon, everyone. Welcome to Life Technologies' Third Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer.
In addition, Mark Stevenson, our Chief Operating Officer; and Bernd Brust, our Chief Commercial Officer, will be available during the Q&A portion of the call. If you haven't received a copy of today's press release, you may obtain one from our website at lifetechnologies.com.
I want to remind our listeners that our discussion today will include forward-looking statements, including, but not limited to, statements about future expectations, plans and prospects for the company. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated. It is our intent that these forward-looking statements be protected under the Safe Harbor created by the Private Securities Litigation Reform Act of 1995. Additionally, we will be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP can be found in today's press release or on our website.
I'll now hand the call over to Greg Lucier."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Eileen, and thank you all for joining us. I hope you had a chance to review the press release that we issued earlier today. As you can see from our results, we delivered another quarter of strong top and bottom line growth.Revenue grew 6% organi",1311,"Thanks, Eileen, and thank you all for joining us. I hope you had a chance to review the press release that we issued earlier today. As you can see from our results, we delivered another quarter of strong top and bottom line growth.
Revenue grew 6% organically to $869 million. And excluding the impact from the H1N1 pandemic, as well as the very large forensics deal for the Japanese police, organic revenue grew 9% for the quarter, driven by strong demand for both instruments and consumables across all of our customer end markets. Operating margins expanded by 170 basis points to reach 29%, and earnings per share grew 19% to $0.87 for the quarter.
On a year-to-date basis, organic revenue has grown 7.5% over prior year, 9.5% excluding H1N1 and that Japanese police forensics deal. Operating margins have expanded by 270 basis points. These are terrific results for the third quarter and for the year-to-date and is a testament to the execution mindset of our teams from around the world.
Now this quarter marks the 16th quarter in a row that we have exceeded expectations on both the top and bottom line. I'm particularly proud of this achievement as it demonstrates our ability and commitment to deliver consistent, strong financial results to our shareholders.
Since 2007, EPS has grown at a compounded annual rate of 19% from $2.03 to the current consensus of $3.43, and free cash flow has more than doubled. Looking forward, you can expect the same focus on execution and commitment to great results as you've seen in the past.
This management team has built an incredibly unique business that is proven to be resilient enough to manage through the ups and the downs of the market that naturally occur over the years. With the opportunities for both revenue growth and margin expansion that we see on the horizon, there's just no reason to believe that we will do anything but strengthen our position, allowing us to deliver double-digit organic earnings growth per share in 2011 and the foreseeable future.
Let me share with you our thinking about how we will deliver on this promise by walking you through a little bit of history. Over the last two years, we've been taking very deliberate action to set the stage for our future. The planning process began actually several years ago when we set out to create the optimal portfolio of products. Today, we believe that we have the best mix by far in the Life Science tools industry. 20% of our revenue is derived from proprietary instruments, which drive demand for the high-margin consumables that make up the remaining 80% of our revenue stream. The consumables portion of our portfolio provides stability and adds to the resiliency of the company over time. In addition, specific investments we've made over the last few years have refreshened certain aspects of our portfolio, such as PCR, and laid the groundwork for Life Technologies to build leading positions in areas such as synthetic biology and genomic medicine. With the recent close of the Ion Torrent deal, our portfolio optimization is largely now complete. The stage is set for us to leverage this industry-leading portfolio for significant growth.
The balance of our product portfolio is only part of the story. Our revenues are also diversified by region, affording us a certain level of protection in periods where weakness in any one region could negatively impact a less resilient business. As a result, we've been able to grow through some relatively challenging periods in the last few years.
Since 2007, Life Technologies has grown organic revenue each and every quarter between 5% and 11%, even during some very difficult funding environments and when the overall market was flat or declining for our competitors. In order to manage regional expansion and the overall growth in volume we have experienced, we have reinvested in the business to build a scalable infrastructure so that new products and technologies could be easily incorporated into our network.
Since 2007, we have consolidated eight ERPs into two main systems and grown our e-commerce platforms to the point where over 50% of our global transactions are processed through this high-margin channel of the Web B2B connection in automated supply centers. Our investment in emerging markets, such as China and India, have enabled us to build out direct sales channels and distribution networks to build and meet the needs of these customers and their growing supply demands.
As a result of these efforts, Life Technologies has unparalleled scale and scope in its commercial, manufacturing and distribution capabilities around the globe.
So with the infrastructure now in place, we look to refine and optimize our operations. Again, since 2007, operating margins have increased 390 basis points from 24.9% to the 2010 consensus estimate of 28.8%. But there is still a lot of room for improvement here. Over the next three years, we will continue to drive significant margin expansion through very specific programs, designed to capture productivity in manufacturing, distribution and our supply chain.
The creation of multi-mix manufacturing sites is a very good example of the programs we're working on. Our substantial expansion of the Frederick, Maryland campus and the continued growth of our Singaporean operations this year are key to this thrust. Through these efforts and others like them, we can maximize operational productivity and expect to be able to deliver margins in excess of 31% in 2013.
While we are executing on the strategies that I have described to you today, we are also laying the groundwork for future revenue growth. Researchers in every field of science use our products to perform the fundamental research that advances scientific discovery. Over the next few years, we will leverage our strength in R&D and manufacturing to launch thousands of innovative products in the fastest-growing areas of research.
We also see a very bright future in applied markets, where for a relatively low cost, we can adapt the technologies used in biological research for use in fast-growing industries, such as forensics and food and water testing. Over the next few years, we will be focused on building out industry-leading franchises in high-growth technology areas, applied markets and emerging geographies, all of which will be key drivers of growth for the company going forward.
One of the greatest benefits of our portfolio is that our product mix heavily weighted towards high-volume, high-margin consumables allows us to generate significant free cash flow on a very consistent and predictable basis. Since the acquisition of Applied Biosystems, our priorities for the deployment of this cash have been to pay down debt, invest in the business and then return any excess cash to shareholders.
At the end of Q3, we reached our target debt levels, and with the recent acquisition of Ion Torrent, we believe our product portfolio is where it needs to be to drive significant future growth. In keeping with our philosophy of balanced capital deployment, the level of investment to acquire technologies will now come down in the next 24 months to approximately $100 million or so per year. After we have serviced our debt requirement, excess cash will be returned to shareholders.
So I've given you a little insight on what we've been working towards and more importantly, some thoughts on the future and what we can achieve. We'll go into more detail of our specific plans in the Q4 call in February, but suffice it to say, we are very optimistic about the future and confident in our ability to deliver on our financial goals in the very same consistent fashion that we have now done in the past. The track record is proven. 
Thanks. And with that, I'll hand it over to David to give you an update on the integration and more details on our  financial results for the third quarter."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Greg. This quarter, revenue grew 8% to $869 million. Currency had a positive half point impact on reported revenue growth, and acquisitions added 1 points. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6% and gr",1543,"Thanks, Greg. This quarter, revenue grew 8% to $869 million. Currency had a positive half point impact on reported revenue growth, and acquisitions added 1 points. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6% and grew 9% also excluding the impact of H1N1 and the Japanese police deal.
Moving on to the divisional results, the Genetic Systems division had revenues of $227 million, representing 12% organic growth. Overall, sales of CE instruments and consumables grew 5% for the quarter, driven by high-single digit growth in consumables and continued strong demand for our recently launched 3500 Genetic Analyzer.
Growth in this business was negatively impacted by a difficult year-over-year comparison, resulting from last year's Japanese police order. Excluding the impact of this order, overall sales of CE instruments and consumables grew 9% for the quarter.
The CE business has proven to be incredibly resilient and continues to be the gold standard for many sequencing applications, not only in research, but increasingly in forensics and other applied markets.
Sales of CE consumables and instruments into hospital clinics and labs for diagnostic testing are particularly strong and have been a major driver of growth for the 3500 instrument. 
Lastly, the Next Generation Sequencing business demonstrated very strong double-digit growth during the quarter, driven by record sales of the SOLiD 4 system. Molecular Biology Systems had revenue of $415 million, flat to last year. However, excluding H1N1-related revenue, organic growth was approximately 4%, driven by strong demand for Genomic Assays and the recently launched ViiA 7 PCR instrument.
Customer reaction to the ViiA 7 has been very positive, and this is the first of several innovations that will refresh our entire qPCR franchise.
Shelf systems had revenue of $221 million, representing 15% organic growth. Growth was driven by strong demand across the portfolio. The Bioproduction, Dynal Beads and Stem Cell businesses all delivered double-digit growth in the quarter.
Organic growth by region in the quarter was as follows: The Americas grew 8%; Europe 5%; Asia-Pacific 7%; and Japan declined 1%. Excluding the impact of H1N1 and the Japanese police order, the Americas grew 10%, Europe 6%, Japan 13% and Asia-Pacific 11%.
Revenue growth in the Asia-Pacific region is slightly lower than in the past due to the timing of orders and a slowdown in order processing associated with an information systems implementation. This is similar to what we experienced when we implemented systems in Europe and the U.S. The project is now largely complete, and we expect fourth quarter growth for the region to return to historical levels.
In line with expectations, stimulus-related revenues for the third quarter were approximately $10 million. We also expect $10 million of stimulus-related revenue in the fourth quarter, the same level as prior year.
Moving on to other items. Third quarter non-GAAP gross margin was 66.8%, largely unchanged from the same period last year. Higher price and synergies were offset by mix, particularly increased sales of bioproduction and instruments.
On a sequential basis, gross margin declined by 90 basis points, primarily due to lower fixed cost absorption as a result of lower volume in the quarter.
Third quarter non-GAAP operating expenses increased 3% over prior year levels to $328 million. The increase was a result of acquisition-related headcount additions and an increase in depreciation, resulting from integration-related capital expenditures. Sequentially, operating expenses declined 4% as a result of cost controls implemented in the quarter, including a slowdown in spending on some commercial projects in our emerging markets.
These projects, such as building out our e-commerce platforms in Asia, are expected to ramp back up in the fourth quarter.
Non-GAAP operating income was $252 million, an increase of 15% over prior year, including the impact of currency, and 12% excluding currency. Third quarter operating margins were 29.0%, representing 170 basis points of improvement year-over-year. Operating margin expansion, primarily resulted from synergies and other operating expense reductions.
In terms of other income line items, we had $1 million of interest income, a loss of $5 million from currency, and interest expense for the quarter was $27 million.
Our non-GAAP tax rate was 25.8%. The tax rate is lower in the quarter due to the benefit of a one-time savings associated with the consolidation of foreign entities. This contributed approximately $0.02 to EPS.
Other items contributing to the lower tax rate are the settlement of prior year IRS audits and an adjustment to account for a higher portion of earnings in lower tax rate jurisdictions. These other items contributed an additional $0.02 to earnings per share.
Our diluted share count for the quarter was $190.1 million. As you will recall, our share count is impacted by our stock price due to our convertible debt and employee stock options.
GAAP diluted earnings per share were $0.56, which includes $0.22 per share of acquisition-related amortization expense, $0.03 per share of non-cash interest expense associated with the adoption of APB14-1 and $0.06 per share of business integration costs and other items. On a non-GAAP basis, which excludes these items, diluted earnings per share was $0.87.
Moving onto the balance sheet and cash flow. Our ending cash and short-term investments were $537 million. This compares to last quarter's balance of $706 million. Cash from operating activities was $215 million. Capital expenditures were $28 million, and free cash flow was $187 million.
Return on invested capital increased 20 basis points to 9.2%. We remain on track to achieve our goal of 10% ROIC by 2012.
Our ending debt as of September 30 was approximately $2.3 billion. This balance is made up of our convertible debt of $800 million and senior notes of $1.5 billion. During the quarter, we retired $350 million of convertible debt.
As for our ongoing integration efforts, during the quarter, we executed plans to generate an additional $25 million in annualized synergies. Specific actions included the completion of the European back-office consolidation, site consolidations in Asia and the placement of approximately 90 dual-branded supply centers worldwide.
At this point, we're on track to meet our goal of $175 million in annualized run rate synergies by the end of the fourth quarter, a year ahead of schedule.
Looking ahead to the fourth quarter, we expect organic revenue growth to be in the mid-single digits, but slightly lower than the third quarter due to a difficult year-over-year comparison. As a reminder, organic growth in the fourth quarter of last year was 11% as a result of several large one-time items. Revenue from acquisitions will add approximately 1 points to growth in the quarter. 
Due to the volatility of currency rates over the last couple of months, our estimate of the impact of currency on fourth quarter results has changed. As of September 30 rates, currency is expected to be neutral to the fourth quarter revenue growth and EPS.
Q4 gross margins are expected to be lower sequentially due to the impact of mix and lower price realization. Operating expenses in Q4 are expected to increase sequentially due to projects and activities that were delayed in the third quarter, acquisition-related expenses and increased depreciation from integration-related capital expenditures. Operating margins for the quarter are expected to expand approximately 150 basis points year-over-year.
The fourth quarter effective tax rate is expected to be approximately 29.5%, and the full year effective tax rate is expected to be approximately 29%, excluding any impact from the R&D tax credit. If the R&D tax credit is extended, then the full year tax rate will be reduced by approximately a point to 28%, and that would add $0.02 to earnings per share. Our full year EPS guidance does not include any benefit from the tax credit.
Average diluted shares in the fourth quarter are expected to range from 191 million to 192 million, assuming an average stock price of between $46 and $50 a share. To date, we've repurchased 2.7 million shares at a cost of approximately $128 million and are on track to complete the $350 million repurchase authorization and the repurchase of shares associated with the Ion Torrent transaction by the end of the year.
As Greg mentioned earlier, we're proud of our results so far this year and feel good about our ability to deliver on our financial goals. We are nearing the end of a successful integration, and despite minimal impact from the stimulus, we are on track to deliver between $3.48 and $3.52 earnings per share for the year.
And finally, since the dollar has weakened considerably over the last few months, I'll give you an update on the expected impact from currency on our 2011 results. As a reminder, we have currency hedges in place for the first seven months of 2011. We do not intend to hedge the remaining five months of the year.
As of September month-end rates, EPS is expected to be negatively impacted by approximately $0.12. In order to help you estimate the effect of currency for 2011, we've calculated the impact on earnings per share if all currencies moved by 5% versus the dollar, and our mix of foreign currencies stayed the same. In this case, the impact on earnings per share would be plus or minus $0.11.
And with that, I'll now hand the call back over to Eileen. Eileen?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, David. We have about 20 minutes for Q&A, so I'd like everyone to limit themselves to one question and one follow-up question. If you have additional questions after that, please get back in the queue. Tony, we are now ready for the Q&A portion of",48,"Thanks, David. We have about 20 minutes for Q&A, so I'd like everyone to limit themselves to one question and one follow-up question. If you have additional questions after that, please get back in the queue. Tony, we are now ready for the Q&A portion of the call."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","[Operator Instructions] And your first question comes from the line of Quintin Lai. [Robert W. Baird]",16,"[Operator Instructions] And your first question comes from the line of Quintin Lai. [Robert W. Baird]"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Looks like that it did get a little better from you from the last quarter. So kindly give us a little color on what you're seeing now in terms of the market demand, given what you saw in Q2. And then as a quick follow-up, you put out a press release earli",80,"Looks like that it did get a little better from you from the last quarter. So kindly give us a little color on what you're seeing now in terms of the market demand, given what you saw in Q2. And then as a quick follow-up, you put out a press release earlier this morning about the single-read accuracy for the SOLiD. Could you give us a little update or maybe a preview of what you're going to show next week?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, Quintin, we actually missed the first part of your question. Could you repeat the first part of that?",19,"Yes, Quintin, we actually missed the first part of your question. Could you repeat the first part of that?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","No problem. So the first part was really just Europe, that was one of the issues that came up on the last call. It looked like they may have been trailing down. And then this quarter, it looked like that you got back on schedule with 5% growth and then 6%",69,"No problem. So the first part was really just Europe, that was one of the issues that came up on the last call. It looked like they may have been trailing down. And then this quarter, it looked like that you got back on schedule with 5% growth and then 6% excluding H1N1. So just kind of a discussion of just how the trends have been going in Europe."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Hi, Quintin, its Bernd. On the European market, as we shared in our last earnings call, we saw some changes in buying behavior. We also thought they were fairly short-term, as funding already at that point had stabilized in two to three core markets, b",116,"Hi, Quintin, its Bernd. On the European market, as we shared in our last earnings call, we saw some changes in buying behavior. We also thought they were fairly short-term, as funding already at that point had stabilized in two to three core markets, being Germany and France. Now with the U.K. funding announcement from last week, I think we have the full picture in place again. So when we look at the European market, I think our outlook of low- to mid-single digit growth, the execution is good. The portfolio is holding up against that well. The performance is there, and we see really no change in that performance coming in the next foreseeable future."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","And just to follow up, Quintin, it's Mark here, on the second part of your question. So yes, we're very excited. As David mentioned, we had a record quarter with SOLiD. A lot of that traction was in counter applications where it matters with the accuracy.",93,"And just to follow up, Quintin, it's Mark here, on the second part of your question. So yes, we're very excited. As David mentioned, we had a record quarter with SOLiD. A lot of that traction was in counter applications where it matters with the accuracy. And so what we've made a great improvement now to the level of accuracy to get 4 x 9s accuracy in a single read, with new modification to our ligation chemistry and we're showing that data next week at the ASHG [American Society of Human Genetics] meeting."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And is that something that can be immediately implementable now on SOLiD?",12,"And is that something that can be immediately implementable now on SOLiD?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","That will be implemented on SOLiD, and we'll start shipping that new chemistry with the systems, and we'll talk more about that at ASHG.",24,"That will be implemented on SOLiD, and we'll start shipping that new chemistry with the systems, and we'll talk more about that at ASHG."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Doug Schenkel. [Cowen and Company]",14,"And your next question comes from the line of Doug Schenkel. [Cowen and Company]"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","You guided operating margin flat year-over-year in Q3, I think, to about 27.3%. You came in at 29%. I was just hoping you would be willing to tease out really what changed. Was it better than you expected and maybe how much of this is attributable to some",105,"You guided operating margin flat year-over-year in Q3, I think, to about 27.3%. You came in at 29%. I was just hoping you would be willing to tease out really what changed. Was it better than you expected and maybe how much of this is attributable to some of the projects that you referred to as being delayed? And then I guess the second question, kind of building off of this, my recollection is you talked about Q4 margin and growth being better than Q3. It sounds like that's no longer the case. So I was just hoping you can maybe explain what's changed."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Let me start, Doug. This is David. You're right about Q3. I think in terms of our guidance on Q3, I think what changed is it goes back to Quintin's question. When we looked at Q3 at the end of Q2, there was some concern about weakness in Europe, what the",186,"Let me start, Doug. This is David. You're right about Q3. I think in terms of our guidance on Q3, I think what changed is it goes back to Quintin's question. When we looked at Q3 at the end of Q2, there was some concern about weakness in Europe, what the impact would be in terms of sales elsewhere around the world. So we were cautious in terms of what our spending was. And we actually put some of the projects that we intended to begin on hold to get a better idea of what the revenue outlook was going to be. Good news is that revenues came in as we expected or better. And that, combined with lower spending, drove up our margins. What we're saying about Q4 is we're pretty confident in the outlook at this point. I think the markets and the funding around the world has stabilized from what it was at the end of Q2. And we plan to ramp back up some of those programs, particularly, some of the spending in commercial areas and on the Web in emerging markets."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Your next question comes from the line of Tycho Peterson. [JPMorgan]",11,"Your next question comes from the line of Tycho Peterson. [JPMorgan]"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe I just want to jump in with a question on Ion Torrent since this is the first call you've done since you announced the deal. Can you just talk a little bit about the go-to-market strategy here for the Personal Genome Machine? How we think about earl",88,"Maybe I just want to jump in with a question on Ion Torrent since this is the first call you've done since you announced the deal. Can you just talk a little bit about the go-to-market strategy here for the Personal Genome Machine? How we think about early access customers? If there are technical milestones that you'll be announcing along the way? And then are you targeting kind of a mix of genome centers and clinical markets initially or how do we think about the initial rollout?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Tycho, this is Greg, and I'll have Mark follow up my point. As you know, we will be launching the Personal Genome Machine here in the fourth quarter. It has been in the hands of early access customers, working through the overall workflow and finishing up",110,"Tycho, this is Greg, and I'll have Mark follow up my point. As you know, we will be launching the Personal Genome Machine here in the fourth quarter. It has been in the hands of early access customers, working through the overall workflow and finishing up the refinement of that. And that particular platform has lots of multi-generational growth in it as well. So it will be launched at a certain throughput, and then it will go up over time in basically the same box. In terms of the target customers, Mark, I'll let you give some more color commentary on how we see it being introduced into the market."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, so we really see, across that range of customers, the applications fit. So I think some of the genome centers are certainly seeing interest to QC some of their application work and do some smaller genomes with it. We'll certainly see it in the decent",154,"Yes, so we really see, across that range of customers, the applications fit. So I think some of the genome centers are certainly seeing interest to QC some of their application work and do some smaller genomes with it. We'll certainly see it in the decentralized application in some of the smaller genome centers or hospitals. An application there is that will light the turnaround time and speed, just the number of experiments that you can do. And so it will really be quite a broad go-to-market approach for us. We're initially starting, we started taking orders across that breadth of customer base. And we'll be talking more again next week during ASHG with that customer set and also at the Association Molecular Pathology meeting, one of the early access customers will be presenting some data. So you'll begin to see more data here as we start shipping units at the end of December."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Jon Wood. [Jefferies & Company]",14,"And your next question comes from the line of Jon Wood. [Jefferies & Company]"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","I think this is probably for Mark. This might be too early as well, but talking to your customers the last couple of weeks since the Europe budgets were announced. Is there a sense of relief or incremental concern versus their expectations going into thos",46,"I think this is probably for Mark. This might be too early as well, but talking to your customers the last couple of weeks since the Europe budgets were announced. Is there a sense of relief or incremental concern versus their expectations going into those budgets?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Hi, Jon, it's Bernd. No, I think actually theres a sense of relief. Obviously the only new one in recent history is the U.K. They both, Germany and France, already had announced some time ago in the U.K. the doomsday numbers were significantly worsened",83,"Hi, Jon, it's Bernd. No, I think actually theres a sense of relief. Obviously the only new one in recent history is the U.K. They both, Germany and France, already had announced some time ago in the U.K. the doomsday numbers were significantly worsened. I think, actually it was the best case scenario that was announced. And so I think in general, there's relief and people are feeling good about what the next few years hold from a research funding point of view."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And Bernd, do you think that there's been any pent-up demand just as people kind of held back in front of those numbers or is that a stretch at this point?",31,"And Bernd, do you think that there's been any pent-up demand just as people kind of held back in front of those numbers or is that a stretch at this point?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","I think it's been a stretch. I think, materially, there won't be much change there. I think what you will see is much more consistency, right, as we saw in Q2 last time, when we saw some changes in volume through the end of the quarter and I think you're",59,"I think it's been a stretch. I think, materially, there won't be much change there. I think what you will see is much more consistency, right, as we saw in Q2 last time, when we saw some changes in volume through the end of the quarter and I think you're going to see that balance out more now."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Derik De Bruin. [UBS Investment Bank]",15,"And your next question comes from the line of Derik De Bruin. [UBS Investment Bank]"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","So first kind of a housekeeping. So what's the interest expense forecast for 2010? I guess, could you talk about -- I think you have some converts coming up in 2011, can you just talk about the debt claim plans and what your expectations are for the conve",48,"So first kind of a housekeeping. So what's the interest expense forecast for 2010? I guess, could you talk about -- I think you have some converts coming up in 2011, can you just talk about the debt claim plans and what your expectations are for the converts?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Sure. The first part of your question was the interest expense?",11,"Sure. The first part of your question was the interest expense?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Yes, for 2010. I mean, now that youve kind of paid down some things, I'm just questioning where the expense numbers going to come in at?",26,"Yes, for 2010. I mean, now that youve kind of paid down some things, I'm just questioning where the expense numbers going to come in at?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","So the interest expense is $110 million to $120 million. And then in terms of the converts, it obviously depends on the share price, but assuming the share price continues to rise, we would expect to retire or call those converts when they're due.",44,"So the interest expense is $110 million to $120 million. And then in terms of the converts, it obviously depends on the share price, but assuming the share price continues to rise, we would expect to retire or call those converts when they're due."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And I guess I'm a little bit -- I think I'm a little bit surprised and certainly, that I think some of the investors are going to be surprised the fact that you're reporting double-digit growth in your SOLiD franchise. And I guess a couple of questions. A",107,"And I guess I'm a little bit -- I think I'm a little bit surprised and certainly, that I think some of the investors are going to be surprised the fact that you're reporting double-digit growth in your SOLiD franchise. And I guess a couple of questions. Are you still on track to roll out the SOLiD, the upgraded SOLiD, the hq, by the end of the year? Is the throughput commentary that you still have on that the same? I think it was a 200 g throughput per run on that. And I guess, just where are those labs that you're placing new instruments in?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","First, just to confirm, actually it was a strong double-digit growth that we experienced in the quarter and it was the best quarter ever that we've have for SOLiD. So we've got great traction in that and you saw that in the overall growth actually of our",232,"First, just to confirm, actually it was a strong double-digit growth that we experienced in the quarter and it was the best quarter ever that we've have for SOLiD. So we've got great traction in that and you saw that in the overall growth actually of our sequencing franchise. It's not only SOLiD you see but also strong sales of CE, of the 3500. It's really across a range of labs. I mean, with regard to SOLiD, as I mentioned in the first question, the appreciation of the accuracy is there in terms of both finding these rare mutations as I've said in the quote sort of needle in the haystack that accuracy matters. And so that's very much appreciated. That also translates into lower throughput cost when you're doing how much coverage you need. So that's one thing. On the second part of your question, we're very much on track to launch the systems. We'll give much more detail about that and our plans next week at ASHG and update you on where we are both on the platforms and throughput, and very much its an upgradable part for all our customers. So they're coming with us on this journey. We've made tremendous improvement in the performance of the system, and they are coming with us on this journey as we carry on and get greater performance out of the system."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Marshall Urist. [Morgan Stanley]",13,"And your next question comes from the line of Marshall Urist. [Morgan Stanley]"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Just a big picture question on how you're kind of thinking about overall business trends. Typically, you guys talk about closing stronger sort of sequentially into the end of the year, both in terms of margin momentum and organic growth. So given the comm",139,"Just a big picture question on how you're kind of thinking about overall business trends. Typically, you guys talk about closing stronger sort of sequentially into the end of the year, both in terms of margin momentum and organic growth. So given the commentary that you've had, I guess, is there no change in sort of the sequential momentum that you're thinking about? Its purely a function of the tougher comp from last year? And I guess, on the margin side, sort of a similar question but sort of asking given some of the spending that you delayed this quarter, is some of that going to get pushed into next quarter so we can kind of think about underlying margin momentum sort of improving sequentially, if we kind of share some of that spend between the two quarters?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Right. So really, the commentary on the fourth quarter is nothing but the comparable issue. So as you know, fourth quarter is traditionally one of the larger ones of the overall year. It continues to be. And again, it just relates to the 2009 fourth quart",83,"Right. So really, the commentary on the fourth quarter is nothing but the comparable issue. So as you know, fourth quarter is traditionally one of the larger ones of the overall year. It continues to be. And again, it just relates to the 2009 fourth quarter comp that we have. The way you think about margins is right on. They will increase, but it will be modulated somewhat by the increased spending that we'll have in the quarter on some of these projects."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And then just one follow-up is just on the Molecular Biology Systems trends in the quarter, sort of flat organic, 4% without H1N1. Can you kind of talk about what the kind of biggest trends were there? And any sort of change from last quarter or over the",68,"And then just one follow-up is just on the Molecular Biology Systems trends in the quarter, sort of flat organic, 4% without H1N1. Can you kind of talk about what the kind of biggest trends were there? And any sort of change from last quarter or over the first half, in terms of the sort of excluding the H1N1 benefit but kind of the core business there?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","I think the only commentary about that piece of the business was it was probably more than any other part of our company impacted by the information technology project we had in Asia and the overall -- a little slower growth we had in Asia in the quarter.",77,"I think the only commentary about that piece of the business was it was probably more than any other part of our company impacted by the information technology project we had in Asia and the overall -- a little slower growth we had in Asia in the quarter. So again, fourth quarter, we expect Asia to snap back into the high-double digits again, and you'll see that business snap back up to higher organic growth as well."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Charles Butler. [Barclays Capital]",13,"And your next question comes from the line of Charles Butler. [Barclays Capital]"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Greg, a strategy question. You recently hired a medical officer to come on board. I'm curious just exactly to whom would he actually interface? Or is he just providing advice to you all in the board? And moreover, is he actually on board now? Just a very",49,"Greg, a strategy question. You recently hired a medical officer to come on board. I'm curious just exactly to whom would he actually interface? Or is he just providing advice to you all in the board? And moreover, is he actually on board now? Just a very interesting decision."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Dr. Paul Billings is on board now. He interfaces with myself, with Mark, with Bernd in terms of customers and the board as well. It is the first of several moves you'll see from us and that we will announce to continue to evolve the company to be not only",109,"Dr. Paul Billings is on board now. He interfaces with myself, with Mark, with Bernd in terms of customers and the board as well. It is the first of several moves you'll see from us and that we will announce to continue to evolve the company to be not only very strong in research, but increasingly strong in medicine. As I've said in the past, all of these molecular tools are getting pulled into the medical environment, and we have to get the company ready to become more hospital oriented, more genomically medicine oriented, and this is the first of several announcements that you'll hear over the next year."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Your next question comes from the line of Jon Groberg. [Macquarie Research]",12,"Your next question comes from the line of Jon Groberg. [Macquarie Research]"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","So just one quick clarification, on the FX for '11, Dave, is that a net number in terms of all the other activities you had in place for '11 as well or is that purely an FX number, the $0.12?",40,"So just one quick clarification, on the FX for '11, Dave, is that a net number in terms of all the other activities you had in place for '11 as well or is that purely an FX number, the $0.12?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Just FX, but its net of our hedges.",8,"Just FX, but its net of our hedges."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Right, right, but not the buybacks, before you gave a number kind of bracketed around some other things. So just FX right now is $0.12?",25,"Right, right, but not the buybacks, before you gave a number kind of bracketed around some other things. So just FX right now is $0.12?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Correct, I understand your question. No, it does not include any buybacks, that's just foreign currency.",16,"Correct, I understand your question. No, it does not include any buybacks, that's just foreign currency."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And then, Greg, how are you going to go about evaluating the R&D that you've been spending and the money that you spent on Ion Torrent. Can you maybe just talk about one, obviously, there are a lot of new technologies that are percolating out there, compa",97,"And then, Greg, how are you going to go about evaluating the R&D that you've been spending and the money that you spent on Ion Torrent. Can you maybe just talk about one, obviously, there are a lot of new technologies that are percolating out there, companies trying to go public, a lot of people involved in the space. Can you maybe talk about one, how it is that you decided on Ion Torrent. And two, how you're going to kind of evaluate all of the spend that's been going on in the sequencing business, going forward?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Well, Jon, we have been evaluating the technologies associated with sequencing for the last several years. We've had, and we still have, a standing team that is fully 100% dedicated to that effort. And our major requirement for sequencing to really explod",242,"Well, Jon, we have been evaluating the technologies associated with sequencing for the last several years. We've had, and we still have, a standing team that is fully 100% dedicated to that effort. And our major requirement for sequencing to really explode the market was a turnaround time, the ability to get fast results. And as we looked at that, we just really came to the conclusion that the current generations of technology wouldn't get you to the measurement of hours in that regard versus the current days. And so Ion Torrent, as we got to understand it better, test it better, understand where it was going, really presented to us the technology that would enable this technology to move into the clinical realm, and that's why we made the acquisition of Ion Torrent. We continue to monitor all sorts of different paths to read the genome. But again, we're quite bullish that we have the right platform here to complement the very high accuracy -- even higher accuracy than is even known today that Mark will talk about this next week of SOLiD. And yet, get to this turnaround time that I think will become quite essential to really unlock the big diagnostic markets. So that's why we did Ion Torrent. And, yet, I would just finish that we're not resting. We continue to monitor and watch, but we feel very confident that we have a great set of technologies here."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your final question comes from the line of Isaac Ro. [Goldman Sachs]",13,"And your final question comes from the line of Isaac Ro. [Goldman Sachs]"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","I want to ask a question about NIH funding. I understand the outlook here at a macroeconomic environment level is somewhat uncertain, but I'm just wondering what you guys are assuming for NIH funding growth over the next three to five years.",42,"I want to ask a question about NIH funding. I understand the outlook here at a macroeconomic environment level is somewhat uncertain, but I'm just wondering what you guys are assuming for NIH funding growth over the next three to five years."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Well, Isaac, next year should be pretty good. We think it'll go up a couple of percentage points, and the stimulus continues to meander along through the course of the next several quarters, which will be okay. So I would tell investors the next year shou",175,"Well, Isaac, next year should be pretty good. We think it'll go up a couple of percentage points, and the stimulus continues to meander along through the course of the next several quarters, which will be okay. So I would tell investors the next year should be fine. As we look to 2012 and beyond, those are the conversations that are taking place today. But as I've said in other settings, I'm actually hopeful that it will be okay. And I think it pertains back to an innovation agenda that a lot of our political leaders see is needed by the United States. And so there's not going to be a mad rush to balance the budget on the backs of the NIH. I mean, quite frankly, that's not where our overspending has been. And so the more that message, I think, is appreciated and shared by more and more folks, the more I feel better about that NIH will come through this pretty well okay. So that's kind of our current outlook right now."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Second one would be on the PCR business, maybe, David, if you could outline sort of the kind of growth you've seen in that business year-to-date. And then you said switch pricing in PCR has helped drive the growth?",39,"Second one would be on the PCR business, maybe, David, if you could outline sort of the kind of growth you've seen in that business year-to-date. And then you said switch pricing in PCR has helped drive the growth?"
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Well, maybe Mark...",3,"Well, maybe Mark..."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, I mean, we still see good growth overall in that qPCR market. It's really a breadth of portfolios. So now as we've introduced the ViiA 7, we have a refresh at the high end of our price point in the instrument side and all the way down to the lower pr",113,"Yes, I mean, we still see good growth overall in that qPCR market. It's really a breadth of portfolios. So now as we've introduced the ViiA 7, we have a refresh at the high end of our price point in the instrument side and all the way down to the lower price points on that system. And going forward, evermore, we're reinventing that game in terms of how we think about qPCR, both in terms of what you've seen us do in a couple of the acquisitions in getting to higher throughput and also moving into the world of digital PCR, which we think is going to be really big going forward here."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Great. This concludes our third quarter earnings conference call. If there are any additional questions, please feel free to contact me. The webcast will be available via a replay on our website for three weeks. Thank you, again, for joining us this after",43,"Great. This concludes our third quarter earnings conference call. If there are any additional questions, please feel free to contact me. The webcast will be available via a replay on our website for three weeks. Thank you, again, for joining us this afternoon."
30253,114142881,81958,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Thank you for your participation in today's presentation. You may now disconnect. Good day.",15,"Thank you for your participation in today's presentation. You may now disconnect. Good day."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Good day, ladies and gentlemen, and welcome to the Life Technologies Third Quarter Earnings Conference Call. My name is Tony, and I'll be your coordinator for today. [Operator Instructions] I would now like to hand the call over to your host for today, Ms",52,"Good day, ladies and gentlemen, and welcome to the Life Technologies Third Quarter Earnings Conference Call. My name is Tony, and I'll be your coordinator for today. [Operator Instructions] I would now like to hand the call over to your host for today, Ms. Eileen Pattinson, Head of Investor Relations. Please proceed."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thank you, Tony, and good afternoon, everyone. Welcome to Life Technologies' Third Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer.In addition, Mark Ste",188,"Thank you, Tony, and good afternoon, everyone. Welcome to Life Technologies' Third Quarter Earnings Conference Call. Joining me on the call today are Greg Lucier, our Chairman and CEO; and David Hoffmeister, Chief Financial Officer.
In addition, Mark Stevenson, our Chief Operating Officer; and Bernd Brust, our Chief Commercial Officer, will be available during the Q&A portion of the call. If you haven't received a copy of today's press release, you may obtain one from our website at lifetechnologies.com.
I want to remind our listeners that our discussion today will include forward-looking statements, including, but not limited to, statements about future expectations, plans and prospects for the company. We believe these statements are based on reasonable assumptions, but actual results may differ materially from those indicated. It is our intent that these forward-looking statements be protected under the Safe Harbor created by the Private Securities Litigation Reform Act of 1995. Additionally, we will be discussing GAAP and non-GAAP measures. A full reconciliation of the non-GAAP measures to GAAP can be found in today's press release or on our website.
I'll now hand the call over to Greg Lucier."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Eileen, and thank you all for joining us. I hope you had a chance to review the press release that we issued earlier today. As you can see from our results, we delivered another quarter of strong top and bottom line growth.Revenue grew 6% organi",1311,"Thanks, Eileen, and thank you all for joining us. I hope you had a chance to review the press release that we issued earlier today. As you can see from our results, we delivered another quarter of strong top and bottom line growth.
Revenue grew 6% organically to $869 million. And excluding the impact from the H1N1 pandemic, as well as the very large forensics deal for the Japanese police, organic revenue grew 9% for the quarter, driven by strong demand for both instruments and consumables across all of our customer end markets. Operating margins expanded by 170 basis points to reach 29%, and earnings per share grew 19% to $0.87 for the quarter.
On a year-to-date basis, organic revenue has grown 7.5% over prior year, 9.5% excluding H1N1 and that Japanese police forensics deal. Operating margins have expanded by 270 basis points. These are terrific results for the third quarter and for the year-to-date and is a testament to the execution mindset of our teams from around the world.
Now this quarter marks the 16th quarter in a row that we have exceeded expectations on both the top and bottom line. I'm particularly proud of this achievement as it demonstrates our ability and commitment to deliver consistent, strong financial results to our shareholders.
Since 2007, EPS has grown at a compounded annual rate of 19% from $2.03 to the current consensus of $3.43, and free cash flow has more than doubled. Looking forward, you can expect the same focus on execution and commitment to great results as you've seen in the past.
This management team has built an incredibly unique business that is proven to be resilient enough to manage through the ups and the downs of the market that naturally occur over the years. With the opportunities for both revenue growth and margin expansion that we see on the horizon, there's just no reason to believe that we will do anything but strengthen our position, allowing us to deliver double-digit organic earnings growth per share in 2011 and the foreseeable future.
Let me share with you our thinking about how we will deliver on this promise by walking you through a little bit of history. Over the last two years, we've been taking very deliberate action to set the stage for our future. The planning process began actually several years ago when we set out to create the optimal portfolio of products. Today, we believe that we have the best mix by far in the Life Science tools industry. 20% of our revenue is derived from proprietary instruments, which drive demand for the high-margin consumables that make up the remaining 80% of our revenue stream. The consumables portion of our portfolio provides stability and adds to the resiliency of the company over time. In addition, specific investments we've made over the last few years have refreshened certain aspects of our portfolio, such as PCR, and laid the groundwork for Life Technologies to build leading positions in areas such as synthetic biology and genomic medicine. With the recent close of the Ion Torrent deal, our portfolio optimization is largely now complete. The stage is set for us to leverage this industry-leading portfolio for significant growth.
The balance of our product portfolio is only part of the story. Our revenues are also diversified by region, affording us a certain level of protection in periods where weakness in any one region could negatively impact a less resilient business. As a result, we've been able to grow through some relatively challenging periods in the last few years.
Since 2007, Life Technologies has grown organic revenue each and every quarter between 5% and 11%, even during some very difficult funding environments and when the overall market was flat or declining for our competitors. In order to manage regional expansion and the overall growth in volume we have experienced, we have reinvested in the business to build a scalable infrastructure so that new products and technologies could be easily incorporated into our network.
Since 2007, we have consolidated eight ERPs into two main systems and grown our e-commerce platforms to the point where over 50% of our global transactions are processed through this high-margin channel of the Web B2B connection in automated supply centers. Our investment in emerging markets, such as China and India, have enabled us to build out direct sales channels and distribution networks to build and meet the needs of these customers and their growing supply demands.
As a result of these efforts, Life Technologies has unparalleled scale and scope in its commercial, manufacturing and distribution capabilities around the globe.
So with the infrastructure now in place, we look to refine and optimize our operations. Again, since 2007, operating margins have increased 390 basis points from 24.9% to the 2010 consensus estimate of 28.8%. But there is still a lot of room for improvement here. Over the next three years, we will continue to drive significant margin expansion through very specific programs, designed to capture productivity in manufacturing, distribution and our supply chain.
The creation of multi-mix manufacturing sites is a very good example of the programs we're working on. Our substantial expansion of the Frederick, Maryland campus and the continued growth of our Singaporean operations this year are key to this thrust. Through these efforts and others like them, we can maximize operational productivity and expect to be able to deliver margins in excess of 31% in 2013.
While we are executing on the strategies that I have described to you today, we are also laying the groundwork for future revenue growth. Researchers in every field of science use our products to perform the fundamental research that advances scientific discovery. Over the next few years, we will leverage our strength in R&D and manufacturing to launch thousands of innovative products in the fastest-growing areas of research.
We also see a very bright future in applied markets, where for a relatively low cost, we can adapt the technologies used in biological research for use in fast-growing industries, such as forensics and food and water testing. Over the next few years, we will be focused on building out industry-leading franchises in high-growth technology areas, applied markets and emerging geographies, all of which will be key drivers of growth for the company going forward.
One of the greatest benefits of our portfolio is that our product mix heavily weighted towards high-volume, high-margin consumables allows us to generate significant free cash flow on a very consistent and predictable basis. Since the acquisition of Applied Biosystems, our priorities for the deployment of this cash have been to pay down debt, invest in the business and then return any excess cash to shareholders.
At the end of Q3, we reached our target debt levels, and with the recent acquisition of Ion Torrent, we believe our product portfolio is where it needs to be to drive significant future growth. In keeping with our philosophy of balanced capital deployment, the level of investment to acquire technologies will now come down in the next 24 months to approximately $100 million or so per year. After we have serviced our debt requirement, excess cash will be returned to shareholders.
So I've given you a little insight on what we've been working towards and more importantly, some thoughts on the future and what we can achieve. We'll go into more detail of our specific plans in the Q4 call in February, but suffice it to say, we are very optimistic about the future and confident in our ability to deliver on our financial goals in the very same consistent fashion that we have now done in the past. The track record is proven. 
Thanks. And with that, I'll hand it over to David to give you an update on the integration and more details on our  financial results for the third quarter."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, Greg. This quarter, revenue grew 8% to $869 million. Currency had a positive half point impact on reported revenue growth, and acquisitions added 1 points. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6% and gr",1543,"Thanks, Greg. This quarter, revenue grew 8% to $869 million. Currency had a positive half point impact on reported revenue growth, and acquisitions added 1 points. Excluding the impact from currency, acquisitions and divestitures, revenue grew 6% and grew 9% also excluding the impact of H1N1 and the Japanese police deal.
Moving on to the divisional results, the Genetic Systems division had revenues of $227 million, representing 12% organic growth. Overall, sales of CE instruments and consumables grew 5% for the quarter, driven by high-single digit growth in consumables and continued strong demand for our recently launched 3500 Genetic Analyzer.
Growth in this business was negatively impacted by a difficult year-over-year comparison, resulting from last year's Japanese police order. Excluding the impact of this order, overall sales of CE instruments and consumables grew 9% for the quarter.
The CE business has proven to be incredibly resilient and continues to be the gold standard for many sequencing applications, not only in research, but increasingly in forensics and other applied markets.
Sales of CE consumables and instruments into hospital clinics and labs for diagnostic testing are particularly strong and have been a major driver of growth for the 3500 instrument. 
Lastly, the Next Generation Sequencing business demonstrated very strong double-digit growth during the quarter, driven by record sales of the SOLiD 4 system. Molecular Biology Systems had revenue of $415 million, flat to last year. However, excluding H1N1-related revenue, organic growth was approximately 4%, driven by strong demand for Genomic Assays and the recently launched ViiA 7 PCR instrument.
Customer reaction to the ViiA 7 has been very positive, and this is the first of several innovations that will refresh our entire qPCR franchise.
Shelf systems had revenue of $221 million, representing 15% organic growth. Growth was driven by strong demand across the portfolio. The Bioproduction, Dynal Beads and Stem Cell businesses all delivered double-digit growth in the quarter.
Organic growth by region in the quarter was as follows: The Americas grew 8%; Europe 5%; Asia-Pacific 7%; and Japan declined 1%. Excluding the impact of H1N1 and the Japanese police order, the Americas grew 10%, Europe 6%, Japan 13% and Asia-Pacific 11%.
Revenue growth in the Asia-Pacific region is slightly lower than in the past due to the timing of orders and a slowdown in order processing associated with an information systems implementation. This is similar to what we experienced when we implemented systems in Europe and the U.S. The project is now largely complete, and we expect fourth quarter growth for the region to return to historical levels.
In line with expectations, stimulus-related revenues for the third quarter were approximately $10 million. We also expect $10 million of stimulus-related revenue in the fourth quarter, the same level as prior year.
Moving on to other items. Third quarter non-GAAP gross margin was 66.8%, largely unchanged from the same period last year. Higher price and synergies were offset by mix, particularly increased sales of bioproduction and instruments.
On a sequential basis, gross margin declined by 90 basis points, primarily due to lower fixed cost absorption as a result of lower volume in the quarter.
Third quarter non-GAAP operating expenses increased 3% over prior year levels to $328 million. The increase was a result of acquisition-related headcount additions and an increase in depreciation, resulting from integration-related capital expenditures. Sequentially, operating expenses declined 4% as a result of cost controls implemented in the quarter, including a slowdown in spending on some commercial projects in our emerging markets.
These projects, such as building out our e-commerce platforms in Asia, are expected to ramp back up in the fourth quarter.
Non-GAAP operating income was $252 million, an increase of 15% over prior year, including the impact of currency, and 12% excluding currency. Third quarter operating margins were 29.0%, representing 170 basis points of improvement year-over-year. Operating margin expansion, primarily resulted from synergies and other operating expense reductions.
In terms of other income line items, we had $1 million of interest income, a loss of $5 million from currency, and interest expense for the quarter was $27 million.
Our non-GAAP tax rate was 25.8%. The tax rate is lower in the quarter due to the benefit of a one-time savings associated with the consolidation of foreign entities. This contributed approximately $0.02 to EPS.
Other items contributing to the lower tax rate are the settlement of prior year IRS audits and an adjustment to account for a higher portion of earnings in lower tax rate jurisdictions. These other items contributed an additional $0.02 to earnings per share.
Our diluted share count for the quarter was $190.1 million. As you will recall, our share count is impacted by our stock price due to our convertible debt and employee stock options.
GAAP diluted earnings per share were $0.56, which includes $0.22 per share of acquisition-related amortization expense, $0.03 per share of non-cash interest expense associated with the adoption of APB14-1 and $0.06 per share of business integration costs and other items. On a non-GAAP basis, which excludes these items, diluted earnings per share was $0.87.
Moving onto the balance sheet and cash flow. Our ending cash and short-term investments were $537 million. This compares to last quarter's balance of $706 million. Cash from operating activities was $215 million. Capital expenditures were $28 million, and free cash flow was $187 million.
Return on invested capital increased 20 basis points to 9.2%. We remain on track to achieve our goal of 10% ROIC by 2012.
Our ending debt as of September 30 was approximately $2.3 billion. This balance is made up of our convertible debt of $800 million and senior notes of $1.5 billion. During the quarter, we retired $350 million of convertible debt.
As for our ongoing integration efforts, during the quarter, we executed plans to generate an additional $25 million in annualized synergies. Specific actions included the completion of the European back-office consolidation, site consolidations in Asia and the placement of approximately 90 dual-branded supply centers worldwide.
At this point, we're on track to meet our goal of $175 million in annualized run rate synergies by the end of the fourth quarter, a year ahead of schedule.
Looking ahead to the fourth quarter, we expect organic revenue growth to be in the mid-single digits, but slightly lower than the third quarter due to a difficult year-over-year comparison. As a reminder, organic growth in the fourth quarter of last year was 11% as a result of several large one-time items. Revenue from acquisitions will add approximately 1 points to growth in the quarter. 
Due to the volatility of currency rates over the last couple of months, our estimate of the impact of currency on fourth quarter results has changed. As of September 30 rates, currency is expected to be neutral to the fourth quarter revenue growth and EPS.
Q4 gross margins are expected to be lower sequentially due to the impact of mix and lower price realization. Operating expenses in Q4 are expected to increase sequentially due to projects and activities that were delayed in the third quarter, acquisition-related expenses and increased depreciation from integration-related capital expenditures. Operating margins for the quarter are expected to expand approximately 150 basis points year-over-year.
The fourth quarter effective tax rate is expected to be approximately 29.5%, and the full year effective tax rate is expected to be approximately 29%, excluding any impact from the R&D tax credit. If the R&D tax credit is extended, then the full year tax rate will be reduced by approximately a point to 28%, and that would add $0.02 to earnings per share. Our full year EPS guidance does not include any benefit from the tax credit.
Average diluted shares in the fourth quarter are expected to range from 191 million to 192 million, assuming an average stock price of between $46 and $50 a share. To date, we've repurchased 2.7 million shares at a cost of approximately $128 million and are on track to complete the $350 million repurchase authorization and the repurchase of shares associated with the Ion Torrent transaction by the end of the year.
As Greg mentioned earlier, we're proud of our results so far this year and feel good about our ability to deliver on our financial goals. We are nearing the end of a successful integration, and despite minimal impact from the stimulus, we are on track to deliver between $3.48 and $3.52 earnings per share for the year.
And finally, since the dollar has weakened considerably over the last few months, I'll give you an update on the expected impact from currency on our 2011 results. As a reminder, we have currency hedges in place for the first seven months of 2011. We do not intend to hedge the remaining five months of the year.
As of September month-end rates, EPS is expected to be negatively impacted by approximately $0.12. In order to help you estimate the effect of currency for 2011, we've calculated the impact on earnings per share if all currencies moved by 5% versus the dollar, and our mix of foreign currencies stayed the same. In this case, the impact on earnings per share would be plus or minus $0.11.
And with that, I'll now hand the call back over to Eileen. Eileen?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Thanks, David. We have about 20 minutes for Q&A, so I'd like everyone to limit themselves to one question and one follow-up question. If you have additional questions after that, please get back in the queue. Tony, we are now ready for the Q&A portion of",48,"Thanks, David. We have about 20 minutes for Q&A, so I'd like everyone to limit themselves to one question and one follow-up question. If you have additional questions after that, please get back in the queue. Tony, we are now ready for the Q&A portion of the call."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","[Operator Instructions] And your first question comes from the line of Quintin Lai. [Robert W. Baird]",16,"[Operator Instructions] And your first question comes from the line of Quintin Lai. [Robert W. Baird]"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Looks like that it did get a little better from you from the last quarter. So kindly give us a little color on what you're seeing now in terms of the market demand, given what you saw in Q2. And then as a quick follow-up, you put out a press release earli",80,"Looks like that it did get a little better from you from the last quarter. So kindly give us a little color on what you're seeing now in terms of the market demand, given what you saw in Q2. And then as a quick follow-up, you put out a press release earlier this morning about the single-read accuracy for the SOLiD. Could you give us a little update or maybe a preview of what you're going to show next week?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, Quintin, we actually missed the first part of your question. Could you repeat the first part of that?",19,"Yes, Quintin, we actually missed the first part of your question. Could you repeat the first part of that?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","No problem. So the first part was really just Europe, that was one of the issues that came up on the last call. It looked like they may have been trailing down. And then this quarter, it looked like that you got back on schedule with 5% growth and then 6%",69,"No problem. So the first part was really just Europe, that was one of the issues that came up on the last call. It looked like they may have been trailing down. And then this quarter, it looked like that you got back on schedule with 5% growth and then 6% excluding H1N1. So just kind of a discussion of just how the trends have been going in Europe."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Hi, Quintin, its Bernd. On the European market, as we shared in our last earnings call, we saw some changes in buying behavior. We also thought they were fairly short-term, as funding already at that point had stabilized in two to three core markets, b",116,"Hi, Quintin, its Bernd. On the European market, as we shared in our last earnings call, we saw some changes in buying behavior. We also thought they were fairly short-term, as funding already at that point had stabilized in two to three core markets, being Germany and France. Now with the U.K. funding announcement from last week, I think we have the full picture in place again. So when we look at the European market, I think our outlook of low- to mid-single digit growth, the execution is good. The portfolio is holding up against that well. The performance is there, and we see really no change in that performance coming in the next foreseeable future."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","And just to follow up, Quintin, it's Mark here, on the second part of your question. So yes, we're very excited. As David mentioned, we had a record quarter with SOLiD. A lot of that traction was in counter applications where it matters with the accuracy.",92,"And just to follow up, Quintin, it's Mark here, on the second part of your question. So yes, we're very excited. As David mentioned, we had a record quarter with SOLiD. A lot of that traction was in counter applications where it matters with the accuracy. And so what we've made a great improvement now to the level of accuracy to get ""four nines"" accuracy in a single read, with new modification to our ligation chemistry and we're showing that data next week at the ASHG [American Society of Human Genetics] meeting."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And is that something that can be immediately implementable now on SOLiD?",12,"And is that something that can be immediately implementable now on SOLiD?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","That will be implemented on SOLiD, and we'll start shipping that new chemistry with the systems, and we'll talk more about that at ASHG.",24,"That will be implemented on SOLiD, and we'll start shipping that new chemistry with the systems, and we'll talk more about that at ASHG."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Doug Schenkel. [Cowen and Company]",14,"And your next question comes from the line of Doug Schenkel. [Cowen and Company]"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","You guided operating margin flat year-over-year in Q3, I think, to about 27.3%. You came in at 29%. I was just hoping you would be willing to tease out really what changed. Was it better than you expected and maybe how much of this is attributable to some",105,"You guided operating margin flat year-over-year in Q3, I think, to about 27.3%. You came in at 29%. I was just hoping you would be willing to tease out really what changed. Was it better than you expected and maybe how much of this is attributable to some of the projects that you referred to as being delayed? And then I guess the second question, kind of building off of this, my recollection is you talked about Q4 margin and growth being better than Q3. It sounds like that's no longer the case. So I was just hoping you can maybe explain what's changed."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Let me start, Doug. This is David. You're right about Q3. I think in terms of our guidance on Q3, I think what changed is it goes back to Quintin's question. When we looked at Q3 at the end of Q2, there was some concern about weakness in Europe, what the",186,"Let me start, Doug. This is David. You're right about Q3. I think in terms of our guidance on Q3, I think what changed is it goes back to Quintin's question. When we looked at Q3 at the end of Q2, there was some concern about weakness in Europe, what the impact would be in terms of sales elsewhere around the world. So we were cautious in terms of what our spending was. And we actually put some of the projects that we intended to begin on hold to get a better idea of what the revenue outlook was going to be. Good news is that revenues came in as we expected or better. And that, combined with lower spending, drove up our margins. What we're saying about Q4 is we're pretty confident in the outlook at this point. I think the markets and the funding around the world has stabilized from what it was at the end of Q2. And we plan to ramp back up some of those programs, particularly, some of the spending in commercial areas and on the Web in emerging markets."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Your next question comes from the line of Tycho Peterson. [JPMorgan]",11,"Your next question comes from the line of Tycho Peterson. [JPMorgan]"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Maybe I just want to jump in with a question on Ion Torrent since this is the first call you've done since you announced the deal. Can you just talk a little bit about the go-to-market strategy here for the Personal Genome Machine? How we think about earl",88,"Maybe I just want to jump in with a question on Ion Torrent since this is the first call you've done since you announced the deal. Can you just talk a little bit about the go-to-market strategy here for the Personal Genome Machine? How we think about early access customers? If there are technical milestones that you'll be announcing along the way? And then are you targeting kind of a mix of genome centers and clinical markets initially or how do we think about the initial rollout?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Tycho, this is Greg, and I'll have Mark follow up my point. As you know, we will be launching the Personal Genome Machine here in the fourth quarter. It has been in the hands of early access customers, working through the overall workflow and finishing up",110,"Tycho, this is Greg, and I'll have Mark follow up my point. As you know, we will be launching the Personal Genome Machine here in the fourth quarter. It has been in the hands of early access customers, working through the overall workflow and finishing up the refinement of that. And that particular platform has lots of multi-generational growth in it as well. So it will be launched at a certain throughput, and then it will go up over time in basically the same box. In terms of the target customers, Mark, I'll let you give some more color commentary on how we see it being introduced into the market."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, so we really see, across that range of customers, the applications fit. So I think some of the genome centers are certainly seeing interest to QC some of their application work and do some smaller genomes with it. We'll certainly see it in the decent",154,"Yes, so we really see, across that range of customers, the applications fit. So I think some of the genome centers are certainly seeing interest to QC some of their application work and do some smaller genomes with it. We'll certainly see it in the decentralized application in some of the smaller genome centers or hospitals. An application there is that will light the turnaround time and speed, just the number of experiments that you can do. And so it will really be quite a broad go-to-market approach for us. We're initially starting, we started taking orders across that breadth of customer base. And we'll be talking more again next week during ASHG with that customer set and also at the Association Molecular Pathology meeting, one of the early access customers will be presenting some data. So you'll begin to see more data here as we start shipping units at the end of December."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Jon Wood. [Jefferies & Company]",14,"And your next question comes from the line of Jon Wood. [Jefferies & Company]"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","I think this is probably for Mark. This might be too early as well, but talking to your customers the last couple of weeks since the Europe budgets were announced. Is there a sense of relief or incremental concern versus their expectations going into thos",46,"I think this is probably for Mark. This might be too early as well, but talking to your customers the last couple of weeks since the Europe budgets were announced. Is there a sense of relief or incremental concern versus their expectations going into those budgets?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Hi, Jon, it's Bernd. No, I think actually theres a sense of relief. Obviously the only new one in recent history is the U.K. They both, Germany and France, already had announced some time ago in the U.K. the doomsday numbers were significantly worsened",83,"Hi, Jon, it's Bernd. No, I think actually theres a sense of relief. Obviously the only new one in recent history is the U.K. They both, Germany and France, already had announced some time ago in the U.K. the doomsday numbers were significantly worsened. I think, actually it was the best case scenario that was announced. And so I think in general, there's relief and people are feeling good about what the next few years hold from a research funding point of view."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And Bernd, do you think that there's been any pent-up demand just as people kind of held back in front of those numbers or is that a stretch at this point?",31,"And Bernd, do you think that there's been any pent-up demand just as people kind of held back in front of those numbers or is that a stretch at this point?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","I think it's been a stretch. I think, materially, there won't be much change there. I think what you will see is much more consistency, right, as we saw in Q2 last time, when we saw some changes in volume through the end of the quarter and I think you're",59,"I think it's been a stretch. I think, materially, there won't be much change there. I think what you will see is much more consistency, right, as we saw in Q2 last time, when we saw some changes in volume through the end of the quarter and I think you're going to see that balance out more now."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Derik De Bruin. [UBS Investment Bank]",15,"And your next question comes from the line of Derik De Bruin. [UBS Investment Bank]"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","So first kind of a housekeeping. So what's the interest expense forecast for 2010? I guess, could you talk about -- I think you have some converts coming up in 2011, can you just talk about the debt claim plans and what your expectations are for the conve",48,"So first kind of a housekeeping. So what's the interest expense forecast for 2010? I guess, could you talk about -- I think you have some converts coming up in 2011, can you just talk about the debt claim plans and what your expectations are for the converts?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Sure. The first part of your question was the interest expense?",11,"Sure. The first part of your question was the interest expense?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Yes, for 2010. I mean, now that youve kind of paid down some things, I'm just questioning where the expense numbers going to come in at?",26,"Yes, for 2010. I mean, now that youve kind of paid down some things, I'm just questioning where the expense numbers going to come in at?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","So the interest expense is $110 million to $120 million. And then in terms of the converts, it obviously depends on the share price, but assuming the share price continues to rise, we would expect to retire or call those converts when they're due.",44,"So the interest expense is $110 million to $120 million. And then in terms of the converts, it obviously depends on the share price, but assuming the share price continues to rise, we would expect to retire or call those converts when they're due."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And I guess I'm a little bit -- I think I'm a little bit surprised and certainly, that I think some of the investors are going to be surprised the fact that you're reporting double-digit growth in your SOLiD franchise. And I guess a couple of questions. A",107,"And I guess I'm a little bit -- I think I'm a little bit surprised and certainly, that I think some of the investors are going to be surprised the fact that you're reporting double-digit growth in your SOLiD franchise. And I guess a couple of questions. Are you still on track to roll out the SOLiD, the upgraded SOLiD, the hq, by the end of the year? Is the throughput commentary that you still have on that the same? I think it was a 200 g throughput per run on that. And I guess, just where are those labs that you're placing new instruments in?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","First, just to confirm, actually it was a strong double-digit growth that we experienced in the quarter and it was the best quarter ever that we've have for SOLiD. So we've got great traction in that and you saw that in the overall growth actually of our",232,"First, just to confirm, actually it was a strong double-digit growth that we experienced in the quarter and it was the best quarter ever that we've have for SOLiD. So we've got great traction in that and you saw that in the overall growth actually of our sequencing franchise. It's not only SOLiD you see but also strong sales of CE, of the 3500. It's really across a range of labs. I mean, with regard to SOLiD, as I mentioned in the first question, the appreciation of the accuracy is there in terms of both finding these rare mutations as I've said in the quote sort of needle in the haystack that accuracy matters. And so that's very much appreciated. That also translates into lower throughput cost when you're doing how much coverage you need. So that's one thing. On the second part of your question, we're very much on track to launch the systems. We'll give much more detail about that and our plans next week at ASHG and update you on where we are both on the platforms and throughput, and very much its an upgradable part for all our customers. So they're coming with us on this journey. We've made tremendous improvement in the performance of the system, and they are coming with us on this journey as we carry on and get greater performance out of the system."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Marshall Urist. [Morgan Stanley]",13,"And your next question comes from the line of Marshall Urist. [Morgan Stanley]"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Just a big picture question on how you're kind of thinking about overall business trends. Typically, you guys talk about closing stronger sort of sequentially into the end of the year, both in terms of margin momentum and organic growth. So given the comm",139,"Just a big picture question on how you're kind of thinking about overall business trends. Typically, you guys talk about closing stronger sort of sequentially into the end of the year, both in terms of margin momentum and organic growth. So given the commentary that you've had, I guess, is there no change in sort of the sequential momentum that you're thinking about? Its purely a function of the tougher comp from last year? And I guess, on the margin side, sort of a similar question but sort of asking given some of the spending that you delayed this quarter, is some of that going to get pushed into next quarter so we can kind of think about underlying margin momentum sort of improving sequentially, if we kind of share some of that spend between the two quarters?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Right. So really, the commentary on the fourth quarter is nothing but the comparable issue. So as you know, fourth quarter is traditionally one of the larger ones of the overall year. It continues to be. And again, it just relates to the 2009 fourth quart",83,"Right. So really, the commentary on the fourth quarter is nothing but the comparable issue. So as you know, fourth quarter is traditionally one of the larger ones of the overall year. It continues to be. And again, it just relates to the 2009 fourth quarter comp that we have. The way you think about margins is right on. They will increase, but it will be modulated somewhat by the increased spending that we'll have in the quarter on some of these projects."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And then just one follow-up is just on the Molecular Biology Systems trends in the quarter, sort of flat organic, 4% without H1N1. Can you kind of talk about what the kind of biggest trends were there? And any sort of change from last quarter or over the",68,"And then just one follow-up is just on the Molecular Biology Systems trends in the quarter, sort of flat organic, 4% without H1N1. Can you kind of talk about what the kind of biggest trends were there? And any sort of change from last quarter or over the first half, in terms of the sort of excluding the H1N1 benefit but kind of the core business there?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","I think the only commentary about that piece of the business was it was probably more than any other part of our company impacted by the information technology project we had in Asia and the overall -- a little slower growth we had in Asia in the quarter.",77,"I think the only commentary about that piece of the business was it was probably more than any other part of our company impacted by the information technology project we had in Asia and the overall -- a little slower growth we had in Asia in the quarter. So again, fourth quarter, we expect Asia to snap back into the high-double digits again, and you'll see that business snap back up to higher organic growth as well."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your next question comes from the line of Charles Butler. [Barclays Capital]",13,"And your next question comes from the line of Charles Butler. [Barclays Capital]"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Greg, a strategy question. You recently hired a medical officer to come on board. I'm curious just exactly to whom would he actually interface? Or is he just providing advice to you all in the board? And moreover, is he actually on board now? Just a very",49,"Greg, a strategy question. You recently hired a medical officer to come on board. I'm curious just exactly to whom would he actually interface? Or is he just providing advice to you all in the board? And moreover, is he actually on board now? Just a very interesting decision."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Dr. Paul Billings is on board now. He interfaces with myself, with Mark, with Bernd in terms of customers and the board as well. It is the first of several moves you'll see from us and that we will announce to continue to evolve the company to be not only",109,"Dr. Paul Billings is on board now. He interfaces with myself, with Mark, with Bernd in terms of customers and the board as well. It is the first of several moves you'll see from us and that we will announce to continue to evolve the company to be not only very strong in research, but increasingly strong in medicine. As I've said in the past, all of these molecular tools are getting pulled into the medical environment, and we have to get the company ready to become more hospital oriented, more genomically medicine oriented, and this is the first of several announcements that you'll hear over the next year."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Your next question comes from the line of Jon Groberg. [Macquarie Research]",12,"Your next question comes from the line of Jon Groberg. [Macquarie Research]"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","So just one quick clarification, on the FX for '11, Dave, is that a net number in terms of all the other activities you had in place for '11 as well or is that purely an FX number, the $0.12?",40,"So just one quick clarification, on the FX for '11, Dave, is that a net number in terms of all the other activities you had in place for '11 as well or is that purely an FX number, the $0.12?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Just FX, but its net of our hedges.",8,"Just FX, but its net of our hedges."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Right, right, but not the buybacks, before you gave a number kind of bracketed around some other things. So just FX right now is $0.12?",25,"Right, right, but not the buybacks, before you gave a number kind of bracketed around some other things. So just FX right now is $0.12?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Correct, I understand your question. No, it does not include any buybacks, that's just foreign currency.",16,"Correct, I understand your question. No, it does not include any buybacks, that's just foreign currency."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","And then, Greg, how are you going to go about evaluating the R&D that you've been spending and the money that you spent on Ion Torrent. Can you maybe just talk about one, obviously, there are a lot of new technologies that are percolating out there, compa",97,"And then, Greg, how are you going to go about evaluating the R&D that you've been spending and the money that you spent on Ion Torrent. Can you maybe just talk about one, obviously, there are a lot of new technologies that are percolating out there, companies trying to go public, a lot of people involved in the space. Can you maybe talk about one, how it is that you decided on Ion Torrent. And two, how you're going to kind of evaluate all of the spend that's been going on in the sequencing business, going forward?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Well, Jon, we have been evaluating the technologies associated with sequencing for the last several years. We've had, and we still have, a standing team that is fully 100% dedicated to that effort. And our major requirement for sequencing to really explod",242,"Well, Jon, we have been evaluating the technologies associated with sequencing for the last several years. We've had, and we still have, a standing team that is fully 100% dedicated to that effort. And our major requirement for sequencing to really explode the market was a turnaround time, the ability to get fast results. And as we looked at that, we just really came to the conclusion that the current generations of technology wouldn't get you to the measurement of hours in that regard versus the current days. And so Ion Torrent, as we got to understand it better, test it better, understand where it was going, really presented to us the technology that would enable this technology to move into the clinical realm, and that's why we made the acquisition of Ion Torrent. We continue to monitor all sorts of different paths to read the genome. But again, we're quite bullish that we have the right platform here to complement the very high accuracy -- even higher accuracy than is even known today that Mark will talk about this next week of SOLiD. And yet, get to this turnaround time that I think will become quite essential to really unlock the big diagnostic markets. So that's why we did Ion Torrent. And, yet, I would just finish that we're not resting. We continue to monitor and watch, but we feel very confident that we have a great set of technologies here."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","And your final question comes from the line of Isaac Ro. [Goldman Sachs]",13,"And your final question comes from the line of Isaac Ro. [Goldman Sachs]"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","I want to ask a question about NIH funding. I understand the outlook here at a macroeconomic environment level is somewhat uncertain, but I'm just wondering what you guys are assuming for NIH funding growth over the next three to five years.",42,"I want to ask a question about NIH funding. I understand the outlook here at a macroeconomic environment level is somewhat uncertain, but I'm just wondering what you guys are assuming for NIH funding growth over the next three to five years."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Well, Isaac, next year should be pretty good. We think it'll go up a couple of percentage points, and the stimulus continues to meander along through the course of the next several quarters, which will be okay. So I would tell investors the next year shou",175,"Well, Isaac, next year should be pretty good. We think it'll go up a couple of percentage points, and the stimulus continues to meander along through the course of the next several quarters, which will be okay. So I would tell investors the next year should be fine. As we look to 2012 and beyond, those are the conversations that are taking place today. But as I've said in other settings, I'm actually hopeful that it will be okay. And I think it pertains back to an innovation agenda that a lot of our political leaders see is needed by the United States. And so there's not going to be a mad rush to balance the budget on the backs of the NIH. I mean, quite frankly, that's not where our overspending has been. And so the more that message, I think, is appreciated and shared by more and more folks, the more I feel better about that NIH will come through this pretty well okay. So that's kind of our current outlook right now."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Analysts","Second one would be on the PCR business, maybe, David, if you could outline sort of the kind of growth you've seen in that business year-to-date. And then you said switch pricing in PCR has helped drive the growth?",39,"Second one would be on the PCR business, maybe, David, if you could outline sort of the kind of growth you've seen in that business year-to-date. And then you said switch pricing in PCR has helped drive the growth?"
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Well, maybe Mark...",3,"Well, maybe Mark..."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Yes, I mean, we still see good growth overall in that qPCR market. It's really a breadth of portfolios. So now as we've introduced the ViiA 7, we have a refresh at the high end of our price point in the instrument side and all the way down to the lower pr",113,"Yes, I mean, we still see good growth overall in that qPCR market. It's really a breadth of portfolios. So now as we've introduced the ViiA 7, we have a refresh at the high end of our price point in the instrument side and all the way down to the lower price points on that system. And going forward, evermore, we're reinventing that game in terms of how we think about qPCR, both in terms of what you've seen us do in a couple of the acquisitions in getting to higher throughput and also moving into the world of digital PCR, which we think is going to be really big going forward here."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Executives","Great. This concludes our third quarter earnings conference call. If there are any additional questions, please feel free to contact me. The webcast will be available via a replay on our website for three weeks. Thank you, again, for joining us this after",43,"Great. This concludes our third quarter earnings conference call. If there are any additional questions, please feel free to contact me. The webcast will be available via a replay on our website for three weeks. Thank you, again, for joining us this afternoon."
30253,114142881,82052,"Life Technologies Corporation, Q3 2010 Earnings Call, Oct 26, 2010",2010-10-26,"Earnings Calls","Life Technologies Corporation","Operator","Thank you for your participation in today's presentation. You may now disconnect. Good day.",15,"Thank you for your participation in today's presentation. You may now disconnect. Good day."
